<SEC-DOCUMENT>0001657312-24-000031.txt : 20241104
<SEC-HEADER>0001657312-24-000031.hdr.sgml : 20241104
<ACCEPTANCE-DATETIME>20241104084712
ACCESSION NUMBER:		0001657312-24-000031
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241104
DATE AS OF CHANGE:		20241104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verona Pharma plc
		CENTRAL INDEX KEY:			0001657312
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38067
		FILM NUMBER:		241420971

	BUSINESS ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
		BUSINESS PHONE:		011-44-0-2032834200

	MAIL ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vrna-20240930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0ee8d2e7-f00d-490d-8b34-d8e4d0ae151e,g:42222ec7-8dc8-4139-853e-ab7cbe924947,d:fa7f77ae03ce400d93edbcfedf6d9f61-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrna="http://veronapharma.com/20240930" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrna-20240930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-30">0001657312</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-527" escape="true">Subsequent events<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">[OPEN]</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-126" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-532">357</ix:nonNumeric><ix:nonNumeric contextRef="c-127" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-533">359</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrna-20240930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>vrna:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>vrna:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vrna:SpecialtyPharmaciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vrna:SpecialtyPharmaciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-27</xbrli:startDate><xbrli:endDate>2023-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermELoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermELoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-28</xbrli:startDate><xbrli:endDate>2024-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:OaktreeFundAdministrationLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:OaktreeFundAdministrationLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">vrna:DavidZaccardelliMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">vrna:MarkHahnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OR </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM __________ TO __________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38067</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Verona Pharma plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-7">United Kingdom</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">98-1489389</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3 More London Riverside</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">London</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">SE1 2RE</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-12">United Kingdom</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric contextRef="c-1" name="dei:CountryRegion" id="f-13">44</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">203</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">283 4200</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:42.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.882%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Ordinary shares, nominal value &#163;0.05 per share*</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">VRNA</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Nasdaq Stock Market LLC (<ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Market</ix:nonNumeric>)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The ordinary shares are represented by American Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.812%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric>    No &#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of October 28, 2024, the registrant had  <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">654,649,358</ix:nonFraction> ordinary shares, nominal value &#163;0.05 per share, outstanding, which if all held in ADS form, would be represented by 81,831,170 American Depositary Shares, each representing eight (8) ordinary shares.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.516%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I - FINANCIAL INFORMATION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_25">Item 1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_25">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_91">Item 2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_91">16</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_106">Item 3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_106">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_109">Item 4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_109">29</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II - OTHER INFORMATION</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_115">Item 1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_115">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_118">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_118">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_121">Item 2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities and Use of Proceeds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_121">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_124">Item 3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_124">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_127">Item 4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_127">77</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_130">Item 5</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_130">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_139">Item 6</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_139">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_142">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa7f77ae03ce400d93edbcfedf6d9f61_142">79</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> </span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_19"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">SUMMARY RISK FACTORS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common shares. The principal risks and uncertainties affecting our business include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We have a limited operating history and have never generated any product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may need additional funding to complete development and commercialization of any future product candidates and to commercialize Ohtuvayre. If we are unable to raise capital when needed, or if a failure of any financial institution where we maintain our cash and cash equivalents prevents or delays us from accessing uninsured funds, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We depend solely on the success of ensifentrine, which was recently approved by the FDA as Ohtuvayre. If we are unable to commercialize Ohtuvayre, or successfully develop ensifentrine for other indications, our ability to generate revenue and our financial condition will be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The terms of our credit facility place restrictions on our operating and financial flexibility, and our existing and any future indebtedness could adversely affect our ability to operate our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The terms of the revenue interest purchase and sale agreement ("RIPSA&#8221;) place restrictions on our operating and financial flexibility, and if we fail to comply with certain covenants in the RIPSA, our results of operations and financial condition may be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Clinical drug development and regulatory approval involve a lengthy and expensive process, with uncertain outcomes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our product and product candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during product development or following approval, if any, we may need to abandon our development programs, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We depend on enrollment of patients in our clinical trials. If we are unable to enroll patients in our clinical trials, or enrollment is slower than anticipated, our research and development efforts could be adversely affected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may become exposed to costly and damaging liability claims, either when testing product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The regulatory approval processes of the FDA, the EMA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for ensifentrine for the maintenance treatment of COPD in adult patients in jurisdictions outside the U.S. or for ensifentrine for additional targeted indications and formulations, our business will be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may never obtain approval or commercialize ensifentrine in other major markets outside of the U.S., which would limit our ability to realize its full market potential.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize our products and may affect the prices we may set.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We operate in a highly competitive and rapidly changing industry, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">If our products, including Ohtuvayre, do not gain market acceptance or if we fail to accurately forecast demand or manage our inventories, our business will suffer because we might not be able to fund future operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our commercial capabilities and infrastructure, including sales, marketing, operations, distribution, and reimbursement infrastructure,  may not be adequate to successfully commercialize Ohtuvayre.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The collaboration and license agreement with Nuance Pharma is important to our business. If Nuance Pharma is unable to develop and commercialize products containing ensifentrine in Greater China, if we or Nuance Pharma fail to adequately perform under the Nuance Agreement, or if we or Nuance Pharma terminate the Nuance Agreement, our business would be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We rely on patents and other intellectual property rights to protect our products and product candidates, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our information technology systems, and those of our manufacturers, suppliers and other third parties that we use to perform services for us or otherwise collaborate with, may fail or suffer security breaches, which could distract our operations and cause delays in our research and development and commercialization activities, and may adversely affect our business, operations and financial performance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our future growth and ability to compete depends on our ability to retain our key personnel and recruit additional qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Certain of our shareholders, members of our board of directors, and senior management who own our ordinary shares (including ordinary shares represented by ADSs) may be able to exercise significant control over us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The price of our ADSs may be volatile and may fluctuate due to factors beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Business interruptions could adversely affect our operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_25"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1. Financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:71.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">336,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">271,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">6,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">7,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax incentive receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">5,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">10,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-39">4,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">3,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">3,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">364,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">289,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-45">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-46">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" scale="3" id="f-47">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" scale="3" id="f-48">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-51">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-52">2,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">17,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">18,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">381,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">308,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">6,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">18,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">3,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-61">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-63">952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-67">844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-68">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">27,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">8,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">120,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">48,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest purchase security agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrna:SecuritesPurchasedNoncurrentRevenueInterest" format="ixt:num-dot-decimal" scale="3" id="f-73">102,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrna:SecuritesPurchasedNoncurrentRevenueInterest" format="ixt:fixed-zero" scale="3" id="f-74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">223,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">50,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-79">251,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-80">58,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-81"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-82"/></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-83"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-84">0.05</ix:nonFraction></ix:nonFraction> par value shares; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-85">667,659,630</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-86">667,659,630</ix:nonFraction> issued, and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-87">654,649,358</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-88">643,536,094</ix:nonFraction> outstanding, at September 30, 2024 and December 31, 2023, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-89">42,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-90">42,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-91">621,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-92">601,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares held in treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="f-93">828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="f-94">1,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-95">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-96">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-97">528,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-98">388,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">130,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-100">249,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-101">381,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-102">308,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-103">5,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-105">5,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="f-107">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="f-109">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vrna:ResearchAndDevelopmentExpenseNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-111">10,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="vrna:ResearchAndDevelopmentExpenseNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-112">2,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:ResearchAndDevelopmentExpenseNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-113">36,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:ResearchAndDevelopmentExpenseNetOfAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-114">13,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">35,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">13,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">104,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">35,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-119">46,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-120">16,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-121">141,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-122">48,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">40,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">16,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">136,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">48,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-127">1,612</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" scale="3" id="f-128">309</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-129">3,044</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" scale="3" id="f-130">70</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-131">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-133">3,653</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-135">4,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-136">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-137">11,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-138">9,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-139">9,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-140">401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-141">13,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-142">1,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain/(loss)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-143">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-144">1,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-145">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" scale="3" id="f-146">660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other (expense)/income, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-147">2,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-148">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-149">1,285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-150">8,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-151">42,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-152">14,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-153">137,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-154">39,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-155">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-156">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-157">2,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-158">527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">42,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">14,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">139,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">40,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per ordinary share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-163"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-164">0.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-165"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-166">0.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-167"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-168">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-169"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-170">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-171"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-172">651,944</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-173"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-174"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-175"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-176">638,239</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-177"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-178">648,633</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-179"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-180"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-181"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-182">631,448</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except share data)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:19.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.921%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.412%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares held in treasury</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">667,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">42,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-185">601,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">1,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">388,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-189">249,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">25,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-191">25,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-192">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-193">170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-194">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-195">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-196">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares withheld for taxes on vested stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-197">3,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-198">3,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity settled share-based compensation reclassified as cash-settled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="f-199">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="f-200">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-201">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-202">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-203">667,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">42,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-205">602,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">1,282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">414,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">224,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,835)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,835)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares withheld for taxes on vested stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity settled share-based compensation reclassified as cash-settled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-210">667,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-211">42,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-212">616,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-213">1,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-214">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-215">485,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-216">168,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">42,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-218">42,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-219">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-220">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-221">3,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-222">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-223">3,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares withheld for taxes on vested stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-224">5,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-225">5,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity settled share-based compensation reclassified as cash-settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="f-226">543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="f-227">543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-228">7,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-229">7,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-230">667,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">42,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">621,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-233">828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">528,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">130,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares held in treasury</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-237">631,338,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-238">40,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">529,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">1,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-241">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">333,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">230,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">16,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-245">16,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares under at-the-market sales agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-246">20,321,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-247">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-248">55,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-249">56,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-250">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-251">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-252">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-253">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-254">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-255">4,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-256">4,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-257">651,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-258">41,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-259">590,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">1,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">350,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">276,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">8,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">8,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-266">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-267">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-268">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-269">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-270">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-271">5,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-272">5,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-273">651,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-274">41,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-275">596,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-276">975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-277">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-278">359,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-279">273,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-280">14,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-281">14,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-282">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-283">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-284">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-285">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-286">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-287">5,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-288">5,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-289">651,659,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-290">41,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-291">601,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-292">746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-293">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-294">374,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-295">263,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:71.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-296">139,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-297">40,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-298">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="f-299">660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issue costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-300">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-301">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of RIPSA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionExpense" format="ixt:num-dot-decimal" scale="3" id="f-302">5,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccretionExpense" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of redemption premium on debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-304">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-305">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-306">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-308">27,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-309">14,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-310">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-311">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-312">6,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-314">4,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-315">833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax incentive receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-316">5,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" scale="3" id="f-317">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-318">4,315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="f-320">832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-321">2,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-322">3,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-323">2,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-324">14,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-325">6,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:IncreaseDecreaseInLicenseAgreementObligations" scale="3" id="f-326">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:IncreaseDecreaseInLicenseAgreementObligations" format="ixt:fixed-zero" scale="3" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-328">573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-329">484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-330">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="3" id="f-331">954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-332">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-333">979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-334">93,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-335">39,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-336">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-338">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of ordinary shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-341">56,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from Term Loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-342">122,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-343">9,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from RIPSA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrna:ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" format="ixt:num-dot-decimal" scale="3" id="f-344">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vrna:ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" format="ixt:fixed-zero" scale="3" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-346">6,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of 2023 Term Loans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-348">52,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of withholding taxes from share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-350">11,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of share options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-352">4,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-353">1,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-354">156,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-355">68,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-356">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-357">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-358">64,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-359">29,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-360">271,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-361">227,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-362">336,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-363">257,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-364">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-365">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-366">6,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-367">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 1 - <ix:nonNumeric contextRef="c-1" name="vrna:OrganizationAndBusinessDescriptionTextBlock" id="f-368" continuedAt="f-368-1" escape="true">Organization and description of business operations </ix:nonNumeric></span></div><ix:continuation id="f-368-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc is incorporated and domiciled in the United Kingdom. Verona Pharma plc has <ix:nonFraction unitRef="subsidiary" contextRef="c-1" decimals="INF" name="vrna:NumberOfWhollyOwnedSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="f-369">one</ix:nonFraction> wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation (together with Verona Pharma plc, the &#8220;Company&#8221;). The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;VRNA&#8221;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On June 26, 2024, the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;) in adult patients and the Company launched Ohtuvayre in the U.S. through an exclusive network of accredited specialty pharmacies in August 2024. Ohtuvayre is the Company&#8217;s first commercial product and the first inhaled therapy with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Pipeline</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is developing a fixed-dose combination formulation with ensifentrine and glycopyrrolate, a Long-Acting Muscarinic Antagonist (&#8220;LAMA&#8221;), for the maintenance treatment of patients with COPD via delivery in a nebulizer. The Company has filed patent applications in multiple jurisdictions including the U.S. In the third quarter of 2024, the Company initiated a Phase 2 dose-ranging trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, based on the clinical results of ensifentrine observed in patients with COPD, including improvements in lung function and symptoms of cough and sputum, the Company believes ensifentrine could potentially be an effective treatment for non-cystic fibrosis bronchiectasis (&#8220;NCFBE&#8221;). In the third quarter of 2024, the Company commenced a Phase 2 clinical trial to assess the efficacy and safety of nebulized ensifentrine in patients with NCFBE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-370">528.5</ix:nonFraction>&#160;million as of September 30, 2024. The Company expects to incur additional losses and negative cash flows from operations until its products reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company expects that its cash and cash equivalents as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the Company may enter into out-licensing transactions from time to time but there can be no assurance that the Company can secure such transactions in the future. Accordingly, the Company may need to obtain substantial additional funds to achieve its business objectives including to further advance clinical and regulatory activities, to fund launch related costs and to create an effective sales and marketing organization to commercialize Ohtuvayre. Any such funding will need to be obtained through public or private financings, debt financing, collaboration or licensing arrangements or other arrangements. However, there is no guarantee the Company will be successful in securing additional capital on acceptable terms, or at all.</span></div></ix:continuation><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_46"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 2 - <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-371" continuedAt="f-371-1" escape="true">Basis of presentation and summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="f-371-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-372" continuedAt="f-372-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024 (the &#8220;2023 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2023, was derived from audited consolidated financial statements included in the 2023 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="f-372-1">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-373" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-374"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-375">one</ix:nonFraction></ix:nonFraction> operating and reportable segment, the development and commercialization of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the three and nine months ended September 30, 2024 the Company relied on four specialty pharmacies to purchase and supply Ohtuvayre to patients. These four specialty pharmacies accounted for <ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-376"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-377">100</ix:nonFraction></ix:nonFraction>% of all Ohtuvayre net product sales in the three and nine months ended September 30, 2024 and accounted for all of the Company's outstanding accounts receivable from product sales as of September 30, 2024. The loss, or a significant change in the buying patterns, of any one of these specialty pharmacies as a customer could negatively impact the sales of Ohtuvayre.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-378" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, gross-to-net revenue adjustments, amortization and carrying value of the revenue interest purchase and sale agreement (&#8220;RIPSA&#8221;), and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Inventory, including Pre-Launch Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company values its inventories at the lower of actual cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. When the Company expects to utilize the inventory beyond one year we record it in inventories, long-term on its consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining initial regulatory approval for Ohtuvayre, the Company expensed costs relating to production of pre-launch inventory as research and development (&#8220;R&amp;D&#8221;) expense in its consolidated statements of operations and comprehensive loss in the period incurred. Inventory acquired and the related costs after June 26, 2024, the date of the FDA&#8217;s approval of Ohtuvayre, are capitalized. Products used in clinical trials are expensed as research and development expense in the statement of operations and comprehensive loss.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess or obsolete inventory to its net realizable value in the period in which the impairment is identified through cost of product and other revenue in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the Company&#8217;s product is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of sales in the consolidated statements of operations and comprehensive loss. No inventory was written down as a result of excess, obsolescence, scrap, or other reasons during the three or nine months ended September 30, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-379" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-380">4,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-381">4,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Interest Purchase and Sale Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The RIPSA is eligible to be repaid based on royalties from net sales of Ohtuvayre (ensifentrine) and any other future products. Interest expense is calculated using the effective interest method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the RIPSA and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of the liability, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenues consist of product sales of Ohtuvayre. The Company accounts for contracts with its customers in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Pursuant to ASC 606, for arrangements or transactions between participants determined to be within the scope of the contracts with customers guidance, the Company performs the following five steps to determine the appropriate amount of revenue to be recognized as the Company fulfills its obligations: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Product Sales, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue from net product sales was generated in the United States following the FDA&#8217;s approval for marketing of Ohtuvayre for the treatment of COPD in June 2024. The Company sells Ohtuvayre principally through arrangements with specialty pharmacies (&#8220;SPs&#8221;), who are the Company&#8217;s customers. The customers subsequently resell the product to patients and health care providers. The Company applies the ASC 606 five step process discussed above to the contracts with SPs. The Company provides limited right of return to the customers in cases of shipment errors or expiring or defective products. Product revenues are recognized when the customers take control of the product, which occurs upon delivery to the customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company recognizes revenue from product sales at the net sales price which includes estimates of variable consideration for which reserves are established and reflects each of these as a reduction to revenue. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">results in the future vary from estimates, the Company may need to adjust its estimates, which would affect net revenue in the period of adjustment. The following are the Company&#8217;s significant categories of variable consideration:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Distribution Fees: The Company pays distribution fees to SPs in connection with the sales of its product. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Government rebates and chargebacks: The Company contracts with Medicaid, Medicare, and other government agencies (&#8220;Government Payors&#8221;) so that Ohtuvayre will be eligible for purchase by, or partial or full reimbursement from, such Government Payors. The Company estimates the rebates, chargebacks and discounts it will provide to Government Payors and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates these reserves based upon its contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Commercial Chargebacks: Chargebacks are discounts and fees related to contracts with various third-party payers and programs that purchase from SPs at a discounted price. SPs charge back to the Company the difference between the price initially paid by SPs and the discounted price paid to SPs by these entities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Product Returns: Consistent with industry practice, the Company offers SPs limited product return rights for shipment errors or expiring or defective products. The Company makes a reasonable estimate of future potential product returns based on inventory reports from SPs, visibility into the inventory distribution channel, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Co-pay assistance: Other incentives which the Company offers include voluntary patient assistance and assurance programs, such as a co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other fees: Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">License Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue may also at times consist of revenue from the Company&#8217;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements may include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-382" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 3 - <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-383" continuedAt="f-383-1" escape="true">Equity interest </ix:nonNumeric></span></div><ix:continuation id="f-383-1" continuedAt="f-383-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-384">40.0</ix:nonFraction>&#160;million consisting of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-385">25.0</ix:nonFraction>&#160;million in cash and an equity interest, valued at $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="f-386">15.0</ix:nonFraction>&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The equity interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company evaluates this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the nine months ended September 30, 2024.</span></div></ix:continuation><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_61"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 4 - <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-387" continuedAt="f-387-1" escape="true">Accrued expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-388" escape="true"><ix:continuation id="f-387-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-389">6,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" scale="3" id="f-390">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-391">4,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-392">2,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-393">7,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-394">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-395">18,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-396">3,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_64"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 5 - <ix:continuation id="f-383-2" continuedAt="f-383-3">Ligand license agreement obligations</ix:continuation></span></div><ix:continuation id="f-383-3"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006, the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#8220;Ligand Patents&#8221;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#8220;Ligand Licensed Products&#8221;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The contingent liability assumed included a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Due to the FDA approval of Ohtuvayre on June 26, 2024, the Company has recognized the following in the nine months ended September 30, 2024:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-397"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-398">6.3</ix:nonFraction></ix:nonFraction>&#160;million in research and development costs related to a milestone payment for first regulatory approval of ensifentrine; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">$<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-399"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-400">15.0</ix:nonFraction></ix:nonFraction>&#160;million related to a milestone payment for first commercial sale of ensifentrine. The Company has classified this as selling, general and administrative expense as it relates to the resolution of the 2021 dispute with Ligand. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is obligated to pay low single digit royalties based on the net sales of all Ligand Licensed Products and expenses all costs related to royalty amounts as a cost of sales within the income statement.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 6 - <ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-401" continuedAt="f-401-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-401-1" continuedAt="f-401-2"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">2023 Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On December 27, 2023 (the &#8220;2023 Effective Date&#8221;), Verona Pharma, Inc. entered into a term loan facility of up to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-402">400.0</ix:nonFraction>&#160;million (the &#8220;2023 Term Loan&#8221; or &#8220;Loan Agreement&#8221;), consisting of a term loan advance in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-403">50.0</ix:nonFraction>&#160;million funded on the 2023 Effective Date (the &#8220;Term A Loan&#8221;) and four additional term loan advances subject to certain terms and conditions. The 2023 Term Loan was repaid in full as of May 9, 2024. Verona Pharma, Inc. and the Company did not incur any penalties, but did incur a prepayment fee and final payment fee in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-404">2.3</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">2024 Term Loans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On May 9, 2024 (the &#8220;2024 Effective Date&#8221;), Verona Pharma, Inc. (the &#8220;Borrower&#8221;) entered into a term loan facility of up to $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-405">400.0</ix:nonFraction>&#160;million (the &#8220;2024 Term Loans&#8221; or &#8220;2024 Loan Agreement&#8221;), consisting of a term loan advance in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-406">55.0</ix:nonFraction>&#160;million funded on the 2024 Effective Date (the &#8220;Tranche A Term Loan&#8221;) and four additional term loan advances subject to certain terms and conditions, as discussed below, in the amounts of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-407">70.0</ix:nonFraction>&#160;million (the &#8220;Tranche B Term Loan&#8221;), $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-408">75.0</ix:nonFraction>&#160;million (the &#8220;Tranche C Term Loan&#8221;), $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-409">100.0</ix:nonFraction>&#160;million (the &#8220;Tranche D Term Loan&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-410">100.0</ix:nonFraction>&#160;million (the &#8220;Tranche E Term Loan&#8221;) with each tranche issued subject to an original issue discount of <ix:nonFraction unitRef="number" contextRef="c-89" decimals="4" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="f-411">2.0</ix:nonFraction>%. The 2024 Loan Agreement was entered into with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agent (in such capacity, the &#8220;Agent&#8221;), and certain funds managed by each of Oaktree Capital Management, L.P. (&#8220;Oaktree&#8221;) and OCM Life Sciences Portfolio LP (&#8220;OMERS&#8221;) party thereto (collectively, the &#8220;2024 Lenders&#8221;). The net proceeds of the 2024 Term Loans will be used for general corporate and working capital purposes and a portion of the proceeds from the Tranche A Term Loan was used by the Borrower on the 2024 Effective Date to repay, in full, the existing outstanding indebtedness owed under the 2023 Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Tranche B Term Loan was available, subject to customary terms and conditions, during the period commencing on the date the Company received approval from the FDA for its new drug application for ensifentrine through and including the earliest of (i) the date that is 30 days immediately following the date the Company receives such approval and (ii) September 30, 2024. The Tranche C Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche B Term Loan), during the period commencing on the first business day following the achievement of a specified net sales milestone for ensifentrine and ending on December 31, 2025. The Tranche D Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche C Term Loan), during the period commencing on the first business day following the achievement of a specified net sales milestone for ensifentrine and ending on June 30, 2026. The Tranche E Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche D Term Loan) at the 2024 Lenders sole discretion and upon the Company&#8217;s request. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company received $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" format="ixt:num-dot-decimal" scale="6" id="f-412">52.8</ix:nonFraction>&#160;million in net proceeds at closing of the 2024 Loan Agreement and draw of the Tranche A Term Loan, which consisted of the Tranche A Term Loan face value of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-413">55.0</ix:nonFraction>&#160;million less the original issue discount of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" format="ixt:num-dot-decimal" scale="6" id="f-414">1.1</ix:nonFraction>&#160;million and lender and third-party fees related to the 2024 Loan Agreement and RIPSA, as defined and discussed below, of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-415">1.1</ix:nonFraction>&#160;million. $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" format="ixt:num-dot-decimal" scale="6" id="f-416">52.4</ix:nonFraction>&#160;million of the net cash proceeds from the Tranche A Term Loan were used for the repayment in full of the existing outstanding indebtedness owed by the Company under the 2023 Term Loan of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-417">52.3</ix:nonFraction>&#160;million and interest amounts related to the 2023 Term Loan of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:InterestExpenseLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-418">0.1</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On June 28, 2024, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" format="ixt:num-dot-decimal" scale="6" id="f-419">68.6</ix:nonFraction>&#160;million in net proceeds related to the Tranche B Term Loan, which was available upon FDA approval for Ohtuvayre. The amount received consisted of the Tranche B Term Loan face value of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-420">70.0</ix:nonFraction>&#160;million less the original issue discount of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-421">1.4</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2024 Term Loans will mature on May 9, 2029 and each advance under the 2024 Loan Agreement accrues interest at a fixed per annum rate of <ix:nonFraction unitRef="number" contextRef="c-94" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-422">11.00</ix:nonFraction>%. The 2024 Loan Agreement provides for interest-only payments on a quarterly basis until maturity. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrower shall pay an exit fee to the 2024 Lenders in the amount of <ix:nonFraction unitRef="number" contextRef="c-95" decimals="4" name="vrna:DebtInstrumentExitFeePercentage" scale="-2" id="f-423">2.50</ix:nonFraction>% of the aggregate principal amount of the 2024 Term Loans to be paid (the &#8220;Exit Fee&#8221;). The Borrower may prepay the 2024 Term Loans in full or in part provided that the Borrower (i) provides at least two (2) business days&#8217; prior written notice to the Agent, (ii) pays on the date of such prepayment (A) all outstanding principal to be prepaid plus accrued and unpaid interest, (B) a prepayment fee of <ix:nonFraction unitRef="number" contextRef="c-96" decimals="3" name="vrna:DebtInstrumentEarlyRepaymentPenaltyPercent" scale="-2" id="f-424">7.00</ix:nonFraction>% of the 2024 Term Loans so prepaid if paid on or before the first anniversary of the 2024 Effective Date; <ix:nonFraction unitRef="number" contextRef="c-97" decimals="3" name="vrna:DebtInstrumentEarlyRepaymentPenaltyPercent" scale="-2" id="f-425">5.00</ix:nonFraction>% of the 2024 Term Loans so prepaid if paid after the first anniversary of the 2024 Effective Date and on or before the second anniversary of the 2024 Effective Date; <ix:nonFraction unitRef="number" contextRef="c-83" decimals="3" name="vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage" scale="-2" id="f-426">2.00</ix:nonFraction>% of the 2024 Term Loans so prepaid </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="f-401-2" continuedAt="f-401-3"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">if paid after the second anniversary of the 2024 Effective Date and on or before the third anniversary of the 2024 Effective Date or <ix:nonFraction unitRef="number" contextRef="c-98" decimals="3" name="vrna:DebtInstrumentEarlyRepaymentPenaltyPercent" scale="-2" id="f-427">1.00</ix:nonFraction>% of the 2024 Term Loans so prepaid if paid after the third anniversary of the 2024 Effective Date and on or before the fourth anniversary of the 2024 Effective Date, (C) the Exit Fee and (D) all other sums, if any, that shall become due and payable under the 2024 Loan Agreement, including interest at the default rate with respect to any past due amounts. Amounts outstanding during an event of default are due upon the Majority Lenders&#8217; (as defined in the 2024 Loan Agreement) demand (except during a payment or bankruptcy event of default, whereupon such default interest is automatically imposed) and shall accrue interest at an additional rate of <ix:nonFraction unitRef="number" contextRef="c-83" decimals="3" name="vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage" scale="-2" id="f-428">2.00</ix:nonFraction>% per annum, which interest shall be payable on demand in cash and (iii) any partial prepayment of the 2024 Term Loans shall be an aggregate amount at least equal to $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="6" id="f-429">5.0</ix:nonFraction>&#160;million in a denomination that is a whole number multiple of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="vrna:DebtInstrumentPartialPrepaymentDenominationMultiple" format="ixt:num-dot-decimal" scale="6" id="f-430">1.0</ix:nonFraction>&#160;million in excess thereof.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2024 Term Loans are secured by a lien on substantially all of the assets of the Borrower and the Company, including intellectual property, subject to customary exclusions and exceptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2024 Loan Agreement contains customary representations and warranties, covenants and events of default, including two financial covenants: (i) commencing on the 2024 Effective Date, the Borrower is required to maintain certain levels of cash, and, after the Account Control Agreement Completion Date (as defined in the Loan Agreement) subject to control agreements in favor of the Agent, and (ii) commencing on the fiscal quarter of Company ending on September 30, 2025, the Borrower and the Company are required to maintain quarterly trailing twelve-month net sales from the sale of ensifentrine in the United States; provided that such revenue covenant will be waived at any time (x) the Borrower and the Company&#8217;s unrestricted cash balance subject to control agreements in favor of the Agent on the last business day of the applicable fiscal quarter is equal to or greater than the product of <ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="vrna:DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" scale="0" id="f-431">1.25</ix:nonFraction> multiplied by the aggregate principal amount of outstanding 2024 Term Loans on such date or (y) the average daily closing price of the Company&#8217;s American Depositary Shares for each of the thirty (30) trading days preceding the last trading day of such fiscal quarter multiplied by the total number of issued and outstanding American Depositary Shares of the Company is at least $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-8" name="vrna:DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" format="ixt:num-dot-decimal" scale="9" id="f-432">1.0</ix:nonFraction>&#160;billion. The 2024 Loan Agreement also contains other customary provisions, such as expense reimbursement, as well as indemnification rights for the benefit of the Agent and the 2024 Lenders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of September 30, 2024, the effective interest rate was approximately <ix:nonFraction unitRef="number" contextRef="c-100" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-433">13</ix:nonFraction>% per annum and there was no material difference between the carrying value and the estimated fair value of the 2024 Term Loans.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="f-401-3"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Revenue Interest Purchase and Sale Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On May 9, 2024, the Company and Verona Pharma, Inc. (collectively the &#8220;Sellers&#8221;) entered into the RIPSA with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agent and certain funds managed by each of Oaktree and OMERS (collectively, the &#8220;Purchasers&#8221;). Under the terms of the RIPSA, in exchange for each of the Purchaser&#8217;s payment to the Sellers of a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="vrna:RevenuesPurchaseAndSaleAgreementPurchasePrice" format="ixt:num-dot-decimal" scale="6" id="f-434">100</ix:nonFraction>&#160;million, in the aggregate, upon approval of ensifentrine by the FDA by a specified date and subject to certain labeling conditions (the &#8220;Tranche A Purchase Price&#8221;), the Sellers agreed to a true sale of assigned interests to the Purchasers, including a right for the Purchasers to receive <ix:nonFraction unitRef="number" contextRef="c-102" decimals="3" name="vrna:RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" scale="-2" id="f-435">6.50</ix:nonFraction>% on the global net sales of ensifentrine by the Sellers (the &#8220;Royalty Interest Payments&#8221;) and <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="vrna:RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" scale="-2" id="f-436">5</ix:nonFraction>% on certain proceeds the Sellers receive from licensees engaged during the term of the RIPSA outside of the U.S. (the &#8220;Ex-U.S. Payments&#8221;). The Sellers will begin payment of the Royalty Interest Payments and Ex-U.S. Payments in the first fiscal quarter after receipt of the Tranche A Purchase Price. The Sellers will also have a right to receive an additional funding tranche equal to $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="vrna:RevenuesPurchaseAndSaleAgreementAdditionalFunding" format="ixt:num-dot-decimal" scale="6" id="f-437">150</ix:nonFraction>&#160;million (the &#8220;Tranche B Purchase Price&#8221;) upon achievement of a specified net sales milestone in any trailing six-month period after receipt of the Tranche A Purchase Price and subject to certain terms and conditions. The Royalty Interest Payments and Ex-U.S. Payments will cease upon reaching a multiple of <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="vrna:RevenuesPurchaseAndSaleAgreementMultiple" scale="0" id="f-438">1.75</ix:nonFraction> times the amounts actually funded by the Purchasers. The RIPSA includes a buy-out option, which provides the Sellers with the right to settle all outstanding liabilities at any time by paying a buy-out amount under various terms and conditions. As of any date of determination, the aggregate amount of payments received by the Purchasers under the RIPSA, divided by the amount funded as of such date (the &#8220;MOIC&#8221;) equals <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="vrna:RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" scale="0" id="f-439">1.20</ix:nonFraction>x, if such date is on or before the one-year anniversary of the funding of the first tranche of the RIPSA, the MOIC equals <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" scale="0" id="f-440">1.40</ix:nonFraction>x if such date is after the one-year anniversary of the Tranche A Funding Date and on or before the two-year anniversary of the Tranche A Funding Date, the MOIC equals <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" scale="0" id="f-441">1.55</ix:nonFraction>x if such date is after the two-year anniversary of the Tranche A Funding Date and on or before the three-year anniversary of the Tranche A Funding Date, and the MOIC equals <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" scale="0" id="f-442">1.75</ix:nonFraction>x if such date is after the three-year anniversary of the Tranche A Funding Date. The Purchasers have the right to terminate the RIPSA under certain conditions, including the Company&#8217;s insolvency, and the Company&#8217;s divestment of ensifentrine, in which case the Sellers must pay the Purchasers up to <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="vrna:RevenuesPurchaseAndSaleAgreementMultiple" scale="0" id="f-443">1.75</ix:nonFraction> times the amounts actually funded by the Purchasers as of such default determination date. Pursuant to a security agreement signed in connection with the RIPSA, the Sellers granted to the Purchasers a security interest in certain assets to secure obligations under the RIPSA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On June 28, 2024, the Company received the Tranche A Purchase Price of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="vrna:RevenuesPurchaseAndSaleAgreementPurchasePrice" format="ixt:num-dot-decimal" scale="6" id="f-444">100.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of September 30, 2024, the effective interest rate was approximately <ix:nonFraction unitRef="number" contextRef="c-3" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-445">25</ix:nonFraction>% per annum and there was no material difference between the carrying value and the estimated fair value of the RIPSA.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 7 - <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-446" continuedAt="f-446-1" escape="true">Share-based compensation</ix:nonNumeric></span></div><ix:continuation id="f-446-1" continuedAt="f-446-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-447" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-448">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-449">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-450">5,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-451">3,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-452">6,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-453">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-454">22,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-455">11,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-456">7,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-457">5,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-458">27,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-459">14,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following tables show the activity of each type of share-based compensation and are presented in ordinary shares. The Company&#8217;s ADSs that are listed on Nasdaq each represent <ix:nonFraction unitRef="number" contextRef="c-3" decimals="0" name="dei:EntityListingDepositoryReceiptRatio" format="ixt-sec:numwordsen" scale="0" id="f-460">eight</ix:nonFraction> ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share options activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-461" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-462">24,689,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-463">2,432,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-464">64,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-465">1,037,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-466">26,020,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-467">7,924,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-468">72,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-469">160,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-470">33,712,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-471">2,056,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-472">107,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-473">2,654,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-474">33,005,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units (&#8220;RSU&#8221;) activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-475" continuedAt="f-475-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.240%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-476">19,502,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-113" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-477">1,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-113" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-478">4,357,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-479">15,143,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-115" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-480">2,045,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-481">13,098,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-117" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-482">566,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-117" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-483">2,045,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-484">10,486,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="f-446-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Performance restricted stock units (&#8220;PRSU&#8221;) activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">PRSUs will begin to vest upon achievement of certain performance conditions and are subject to continued service. The fair value of PRSUs will be recognized over the remaining service period using the graded-vesting method once the performance conditions are determined to be probable of occurring. As of June 30, 2024, the performance conditions were assessed by the Company and considered probable of being met under the applicable accounting framework, and accordingly the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-485">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-486">12.1</ix:nonFraction>&#160;million in share-based compensation expense related to the PRSUs in the three and nine months ended September 30, 2024. The total compensation cost not yet recognized as of September 30, 2024 related to PRSUs was $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-487">5.0</ix:nonFraction> million, which will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-120" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-488">one year</ix:nonNumeric>.</span></div><ix:continuation id="f-475-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A summary of the Company&#8217;s PRSU activity for the period ended September 30, 2024 is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.240%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of PRSUs outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-489">10,730,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-490">5,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-491">10,724,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-492">10,724,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-119" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-493">420,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-119" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-494">3,569,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-495">6,734,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 8 - N<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-496" continuedAt="f-496-1" escape="true">et loss per share </ix:nonNumeric></span></div><ix:continuation id="f-496-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on Nasdaq each represent <ix:nonFraction unitRef="number" contextRef="c-3" decimals="0" name="dei:EntityListingDepositoryReceiptRatio" format="ixt-sec:numwordsen" scale="0" id="f-497">eight</ix:nonFraction> ordinary shares. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-498" continuedAt="f-498-1" escape="true">The following table shows the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands except per share amounts):</ix:nonNumeric></span></div><ix:continuation id="f-498-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-499">42,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-500">14,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-501">139,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-502">40,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-503"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-504">651,944</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-505"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-506"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-507"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-508">638,239</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-509"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-510">648,633</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-511"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-512"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-513"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-514">631,448</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-515"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-516">0.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-517"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-518">0.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-519"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-520">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-521"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-522">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three and nine months ended September 30, 2024 and 2023, outstanding share options, RSUs and PRSUs over <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-523"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-524">50.2</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-525"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-526">45.9</ix:nonFraction></ix:nonFraction>&#160;million ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s discussion and analysis of financial condition and results of operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on February 29, 2024 (the &#8220;2023 Form 10-K&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">In addition to historical information, this Quarterly Report on Form 10-Q contains statements that constitute forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including without limitation statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, the commercialization of Ohtuvayre and the increased costs related thereto, the development of our product candidates, including statements regarding the expected initiation, timing, progress and availability of data from our clinical trials, including our recently initiated Phase 2 clinical trials, and potential regulatory approvals, research and development costs, timing and likelihood of success, potential collaborations, the duration of our patent portfolio, our estimates regarding expenses, future revenues, capital requirements, debt service obligations and our need for additional financing, the funding we expect to become available under our various financing agreements and from cash receipts from U.K. tax credits, and the sufficiency of our cash and cash equivalents to fund operations, are forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our management&#8217;s current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, assumptions, and other important factors including, but not limited to, those set forth under Part II, Item 1A of this Quarterly Report on Form 10-Q under the heading &#8220;Risk Factors&#8221; and Part I, Item 1A of the 2023 Form 10-K under the heading &#8220;Risk Factors&#8221;. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Quarterly Report on Form 10-Q to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Our product candidate, ensifentrine, is a novel, inhaled, selective, small molecule and dual inhibitor of the enzymes phosphodiesterase 3 and 4 (&#8220;PDE3&#8221; and &#8220;PDE4&#8221;), combining bronchodilator and non-steroidal anti-inflammatory activities in one molecule. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On June 26, 2024, the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;) in adult patients. Ohtuvayre is our first commercial product and the first inhaled therapy with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. We believe Ohtuvayre is an important advancement in the treatment of COPD and will redefine the treatment paradigm for COPD. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We launched Ohtuvayre in the U.S. through an exclusive network of accredited specialty pharmacies in August 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The approval of Ohtuvayre in the United States (&#8220;U.S.&#8221;) was based on extensive data including the Phase 3 ENHANCE (&#8220;Ensifentrine as a Novel inHAled Nebulized COPD thErapy&#8221;) trials, the results of which were published in the American Journal of Respiratory and Critical Care Medicine. Ensifentrine met the primary endpoint in both the ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in measures of lung function. In addition, other endpoint data demonstrated that ensifentrine substantially reduced the rate and risk of COPD exacerbations in ENHANCE-1 and ENHANCE-2. Ensifentrine was well tolerated in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are commercializing Ohtuvayre for the maintenance treatment of COPD in the U.S. Ohtuvayre is not considered a drug device combination because patients use a readily available standard jet nebulizer to take Ohtuvayre. Outside the U.S., we intend to license Ohtuvayre to companies with expertise and experience in developing and commercializing products in those regions. To that end, we have entered into a strategic collaboration with Nuance Pharma Limited, a Shanghai-based specialty pharmaceutical company (&#8220;Nuance Pharma&#8221;), to develop and commercialize ensifentrine, including Ohtuvayre, in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In Phase 2 clinical trials, ensifentrine has demonstrated positive results in patients with COPD, asthma and cystic fibrosis (&#8220;CF&#8221;). Two additional formulations of ensifentrine have been evaluated in Phase 2 trials for the treatment of COPD: dry powder inhaler (&#8220;DPI&#8221;) and pressurized metered-dose inhaler (&#8220;pMDI&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, in the third quarter of 2024, we initiated two Phase 2 clinical trials:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">dose-ranging trial with a glycopyrrolate, a Long-Acting Muscarinic Antagonist (&#8220;LAMA&#8221;), supporting a fixed-dose combination program with ensifentrine for the maintenance treatment of COPD, and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">trial assessing the efficacy and safety of nebulized ensifentrine in patients with non-cystic fibrosis bronchiectasis (&#8220;NCFBE&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses and negative cash flows from operations since inception, and have an accumulated deficit of $528.5 million as of September 30, 2024. We expect to incur additional losses and negative cash flows from operations until our product or product candidates potentially reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We anticipate significant expenses in connection with our ongoing activities, if and as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">operate a sales, marketing and distribution infrastructure, continue to increase production to commercial scale with our manufacturing and other Chemistry, Manufacturing and Controls activities to commercialize Ohtuvayre as well as any additional products for which we may obtain regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">continue the clinical development of a fixed-dose combination of ensifentrine and a LAMA as well as our DPI and pMDI formulations of ensifentrine and research and development of other formulations of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct further clinical trials for ensifentrine for the treatment of NCFBE, acute COPD, CF or any other indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and progress pre-clinical studies relating to other potential indications of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek to discover and develop additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek regulatory approvals for any of our product candidates that successfully complete clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and to support our continuing operations as a U.S. public company; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">experience any delays or encounter any issues from any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On May 9, 2024, we entered into a term loan facility (the &#8220;2024 Term Loans&#8221;) of up to $400.0&#160;million with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agent, and certain funds managed by each of Oaktree Capital Management, L.P. and OCM Life Sciences Portfolio LP party thereto (collectively, the &#8220;2024 Lenders&#8221;). At closing, we received net proceeds of $52.8&#160;million and up to four additional advances of an aggregate $345.0 million were available subject to meeting certain commercial milestones and other specified conditions. On June 28, 2024, we received net proceeds of $68.6&#160;million related to the second tranche of the 2024 Term Loans, which was available upon FDA approval for Ohtuvayre, as well as proceeds from the $100.0 million first tranche of our revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;). Refer to Note 6 - Debt in our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q for additional information regarding the 2024 Term Loans and the RIPSA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of September 30, 2024, our product sales and funding expected to become available under the 2024 Term Loans and the RIPSA will enable us to fund our planned operating expenses and capital expenditure requirements through at least the end of 2026. The remaining advances under the 2024 Term Loans and the RIPSA are contingent upon the achievement of commercial milestones and other specified conditions, and in the case of the Tranche E Term Loan under the 2024 Term Loans, at the sole discretion of the 2024 Lenders. No additional advances are available under the 2023 Term Loan following our termination and repayment in full of the 2023 Term Loan on May 9, 2024. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Clinical development update</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Phase 3 ENHANCE program</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The U.S. approval of Ohtuvayre was based on extensive data including the Phase 3 ENHANCE trials, the results of which were published in the American Journal of Respiratory and Critical Care Medicine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We reported positive top-line results from ENHANCE-2 and ENHANCE-1 in August and December 2022, respectively. Ohtuvayre successfully met the primary endpoints in both trials, demonstrating statistically significant and clinically meaningful improvements in measures of lung function in moderate to severe COPD patients. Improvements in symptoms and quality of life measures were shown in both trials, which reached statistical significance in ENHANCE-1. Other endpoint data showed Ohtuvayre substantially reduced the rate and risk of moderate to severe COPD exacerbations and was well tolerated in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The ENHANCE trials were designed to evaluate Ohtuvayre as monotherapy and added onto a single bronchodilator. Each trial enrolled approximately 800 subjects, for a total of approximately 1,600 subjects, at sites primarily in the U.S. and Europe. The two trials provided replicate evidence of efficacy and safety data over 24 weeks and ENHANCE-1 also evaluated longer-term safety in approximately 400 subjects over 48 weeks.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject demographics and disease characteristics were well balanced between treatment groups in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-1 approximately 69% of subjects received background COPD therapy, either a LAMA or a long-acting beta-antagonist (&#8220;LABA&#8221;). Additionally, approximately 20% of all subjects received inhaled corticosteroids (&#8220;ICS&#8221;) with concomitant LAMA or LABA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-2 approximately 55% of subjects received background COPD therapy, either a LAMA or a LABA. Additionally, approximately 15% of all subjects received ICS with concomitant LAMA or LABA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="vrna-20240930_g1.jpg" alt="Screenshot 2024-10-24 182121.jpg" style="height:414px;margin-bottom:5pt;vertical-align:text-bottom;width:768px"/></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Clinical Development Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ensifentrine / Long-Acting Muscarinic Antagonist fixed-dose combination</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Fixed-dose combination therapies such as LABA / LAMA, LABA / ICS and LABA / LAMA / ICS are commonly used in the treatment of COPD and, based on our market research, an unmet need exists for a nebulized fixed-dose combination therapy. We believe the combination of ensifentrine with a LAMA could provide COPD patients with the first nebulized fixed-dosed combination with the potential to provide bronchodilation through a dual mechanism and also non-steroidal anti-inflammatory effects via PDE inhibition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are developing a fixed-dose combination formulation with ensifentrine and glycopyrrolate, a LAMA, for the maintenance treatment of patients with COPD via delivery in a nebulizer. We have filed patent applications in multiple jurisdictions including the U.S. In the third quarter of 2024, we initiated a Phase 2 dose-ranging trial. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Non-cystic fibrosis bronchiectasis</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">NCFBE is a chronic lung disease characterized by persistent cough, excess sputum production and frequent respiratory infections with more severe patients suffering exacerbations. The condition affects up to 500,000 adults in the U.S. and no therapies are specifically approved to treat it. Physicians currently use bronchodilators, antibiotics, steroids, mucus thinners and surgery.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on the clinical results of ensifentrine observed in patients with COPD, including improvements in lung function and symptoms of cough and sputum, we believe that ensifentrine could potentially be an effective treatment for NCFBE. In the third quarter of 2024, we commenced a Phase 2 clinical trial to assess the efficacy and safety of nebulized ensifentrine in patients with NCFBE.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Nuance Pharma</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2021, we entered into an agreement with Nuance Pharma for exclusive rights to develop and commercialize ensifentrine in Greater China, with future potential milestone payments up to $179 million plus royalties. In August 2022, Nuance Pharma received clearance from the Center of Drug Evaluation for its IND application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of COPD in mainland China. Nuance Pharma initiated a Phase 1 trial with ensifentrine in healthy volunteers in March 2023. In April 2023, Nuance Pharma dosed the first subject in its pivotal Phase 3 clinical trial evaluating ensifentrine for the maintenance treatment of COPD in mainland China and, in September 2024, the Company reported that enrollment had completed. Results from the trial are expected in 2025.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Critical accounting estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other than as described below, there were no material changes to the Company&#8217;s critical accounting estimates described in the Company&#8217;s 2023 Form 10-K during the nine months ended September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We generate revenue from the sale of Ohtuvayre. Revenue is recognized when we transfer control of Ohtuvayre to the specialty pharmacies, our customers, as our contracts have a single performance obligation which is the delivery of Ohtuvayre. These product sales are subject to various gross-to-net adjustments, which are deducted from our product sales to determine net product sales. For a description of our related accounting policies, see Note 2 - Basis of presentation and summary of significant accounting policies in our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Gross-to-net adjustments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Product sales are recorded at the estimated net sales price, which includes estimates of variable consideration for which reserves are established. Components of variable consideration include rebates and chargebacks, product returns and other allowances that are offered within contracts with our customer, payors, and other indirect customers relating to the sale of our product. These reserves are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">trends as well as industry data and other third party information. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Estimates associated with our gross-to-net adjustments are particularly susceptible to adjustment given the extensive time lag that may occur between our recording of an accrual and its ultimate invoicing by the government or commercial entity, which can occur up to several years after the sale of our product. Because of the time lag for these rebates and chargebacks, in any particular quarter, our adjustments may incorporate revisions of accruals related to prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Interest expense and royalty interest purchase and sale agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The RIPSA timing of repayment is based on royalties from net sales of Ohtuvayre as well as any future sales or monetization of ensifentrine prior to the repayment of the RIPSA. Interest expense is accrued using the effective interest method over the estimated period the RIPSA will be repaid. This requires us to estimate the total amount of future royalty payments to be made from product sales as well as the timing of those repayments. We impute interest on the carrying value of each of the royalty financing obligations and record interest expense using an imputed effective interest rate. We reassess the amount and timing of these payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact the RIPSA balance and interest expense.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Components of results of operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Product sales, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">With the FDA approval of Ohtuvayre and our commercial launch in the third quarter of 2024, we began to recognize product sales. We record product sales net of estimated distribution fees, government rebates and chargebacks, commercial chargebacks, product returns, co-pay assistance costs and other fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cost of sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We began to recognize cost of sales after the commercial launch of Ohtuvayre in the third quarter of 2024. Cost of sales includes the cost of producing inventory related to Ohtuvayre including manufacturing, freight and overhead as well as sales-based royalties due to Ligand.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs consist of salary and personnel related costs and third party costs for our research and development activities for ensifentrine. Personnel related costs include a share-based compensation charge relating to our share-based compensation. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Prior to obtaining regulatory approval for Ohtuvayre, we expensed costs relating to production of pre-launch inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss in the period incurred. All other research and development costs are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect our research and development costs to increase in future years related to our additional trials for a fixed-dose combination formulation for COPD patients and nebulized ensifentrine in patients with NCFBE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Due to the nature of research and development, the expected costs are inherently uncertain and may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs consist of salary and personnel related costs, including share-based compensation, expenses relating to the launch of Ohtuvayre and other commercial activities, expenses relating to operating as a public company, including professional fees, insurance and commercial related costs, as well as other operating expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect commercial costs to continue to increase due to the commercial launch of Ohtuvayre including costs related to our sales force, marketing and other commercial related costs. As we continue to develop our knowledge of the market and refine our commercial operations, expected costs may vary significantly from our current expectations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income/(expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income/(expense) are driven by interest income and expense, foreign exchange movements on cash and cash equivalents and taxes receivable, and the U.K. research and development tax credits (the &#8220;R&amp;D tax credit&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We participate in the U.K. Small and Medium Enterprises research and development tax relief program. The tax credits are calculated as a percentage of qualifying research and development expenditure and are payable in cash by the U.K. government to us. The credit recorded related to the 2022 financial year was received in the three months ended June 30, 2024, and the credit recorded in the 2023 financial year is expected to be received in 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Taxation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are subject to corporate taxation in the U.S. and the U.K. We have generated losses since inception and have therefore not paid U.K. corporation tax. The income taxes presented in our Condensed Consolidated Statements of Operations and Comprehensive Loss represent the tax impact from our financing and operating activities in the U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">U.K. losses may be carried forward indefinitely to be offset against future taxable profits, subject to various utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Results of operations for the three months ended September 30, 2024 and 2023</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows our statements of operations for the three months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,291&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,311&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,667)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,356)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other (expense)/income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,045)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,713)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,712)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,643)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,069)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,962)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,687)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,275)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Product sales, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ohtuvayre received FDA approval on June 26, 2024 and the product was commercially available on August 6, 2024. Product sales, net for Ohtuvayre was $5.6&#160;million for the three months ended September 30, 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cost of sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Cost of sales was $0.5&#160;million for the three months ended September 30, 2024 which includes Ohtuvayre manufacturing costs incurred after FDA approval, inventory overhead costs and sales-based royalties due to Ligand. Prior to obtaining initial regulatory approval for Ohtuvayre, we expensed costs relating to production of pre-launch inventory as R&amp;D expense in the period incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs were $10.6&#160;million for the three months ended September 30, 2024, compared to $3.0&#160;million for the three months ended September 30, 2023, an increase of $7.6&#160;million. This increase was primarily due to an $7.8 million increase in clinical trial and other development costs as we incurred costs related to the two Phase 2 studies which were initiated in the third quarter of 2024 related to the combination of ensifentrine and glycopyrrolate and nebulized ensifentrine in patients with NCFBE as well as a $0.9 million increase in people-related costs. The prior period clinical trial and other development costs also included the impact of $2.2 million of credits received related to the final financial reconciliation of a Phase 3 ENHANCE program supplier.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs were $35.2&#160;million for the three months ended September 30, 2024, compared to $13.4&#160;million for the three months ended September 30, 2023, an increase of $21.8&#160;million. This increase was driven primarily by a $9.7 million increase in people-related costs and $2.8 million in share-based compensation, each of which are primarily related to our field sales team which was hired in the lead up to the launch of Ohtuvayre. Additionally, as we launched Ohtuvayre, marketing and other commercial related activities, including travel, increased by $7.5 million. We also had an increase of $1.6 million related to professional and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">consulting fees, information technology costs and other support costs due to the continued buildout of our commercial organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income/(expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income/(expense), net for the three months ended September 30, 2024 was expense of $2.0&#160;million compared to income of $1.7&#160;million for the three months ended September 30, 2023, a change of $3.7&#160;million. This increase in net expense was primarily due to an increase in interest expense of $9.5&#160;million related to our higher average debt balance and increase in our effective interest rate. This was partially offset by an increase in our research and development tax credit of $1.9&#160;million primarily relating to the current period having higher qualifying clinical trial and other development costs while the prior year period included the impact of the Phase 3 ENHANCE program supplier final reconciliation credits discussed above as well as a $2.5&#160;million increase in foreign exchange impacts relating to the strengthening of the pound against the dollar and a $1.4&#160;million increase in interest income due to our higher average cash balance.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Results of operations for the nine months ended September 30, 2024 and 2023</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows our statements of operations for the nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,475&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,288)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,813)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,791)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other (expense)/income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,050)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,573)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,863)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(527)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,591)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,237)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,354)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Product sales, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ohtuvayre received FDA approval on June 26, 2024 and the product was commercially available on August 6, 2024. Product sales, net for Ohtuvayre was $5.6&#160;million for the nine months ended September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cost of sales </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Cost of sales was $0.5&#160;million for the nine months ended September 30, 2024, which includes Ohtuvayre manufacturing costs incurred after FDA approval, inventory overhead costs, and sales-based royalties due to Ligand. Prior to obtaining initial regulatory approval for Ohtuvayre, we expensed costs relating to production of pre-launch inventory as R&amp;D expense in the period incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs were $36.7&#160;million for the nine months ended September 30, 2024, compared to $13.1&#160;million for the nine months ended September 30, 2023, an increase of $23.6&#160;million. This increase was primarily due to a $11.9 million increase in clinical trial and other development costs as in the current period we incurred costs related to the two Phase 2 studies which were initiated in the quarter related to the combination of ensifentrine and glycopyrrolate and nebulized ensifentrine in patients with NCFBE, the accrual of the $6.3 million approval milestone due to Ligand, $2.1 million in share-based compensation largely driven by the recognition of PRSU expense, $2.1 million for people-related costs and $1.1 million related to pre-launch manufacturing costs for commercial supply. The increase in clinical trial and other development costs from the prior year also includes the impact on the prior year period of a reversal of $1.5 million of costs which were expensed in the year ended December 31, 2022 related to the resolution of the matter with the Phase 3 ENHANCE program supplier.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs were $104.7&#160;million for the nine months ended September 30, 2024 compared to $35.4&#160;million for the nine months ended September 30, 2023, an increase of $69.3&#160;million. This increase was driven primarily by an increase of $19.9 million in marketing and other commercial related activities, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">including travel related to the launch of Ohtuvayre, a charge of $15.0 million first sale milestone payment due to Ligand, and an increase of $5.1 million in professional and consulting fees, information technology costs and other support costs due to the continued buildout of our commercial organization. Additionally, we had an increase of $18.0 million in people-related costs as we built out our commercial organization including much of the field sales team as well as an increase of $10.8 million related to share-based compensation largely driven by the recognition of PRSU expense and the increase in our headcount due to the field sales team and other support staff.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other (expense)/income, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other (expense)/income, net for the nine months ended September 30, 2024 was expense of $1.3&#160;million compared to income of $8.8&#160;million for the nine months ended September 30, 2023, a change of $10.1&#160;million. This change was primarily due to the recognition of a loss on the extinguishment of our 2023 Term Loan of $3.7&#160;million as well as an increase in interest expense of $11.8&#160;million related to our higher average debt balance and increase in our effective interest rate. This was partially offset by an increase in our research and development tax credit of $3.0&#160;million primarily relating to the current period having higher qualifying clinical trial and other development costs while the prior year period included the impact of the Phase 3 ENHANCE program supplier final reconciliation credits discussed above and a $1.8&#160;million increase in interest income due to our higher average cash balance.</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_100"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table summarizes our cash flows for the nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,040&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,674&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Operating activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash used in operating activities was $93.4 million in the nine months ended September 30, 2024, compared to $39.8 million during the nine months ended September 30, 2023, an increase of $53.5 million. The increase in cash used in operating activities was primarily due to the increase of costs incurred for the commercial launch of Ohtuvayre and the related increase in people-related costs for the field sales team and commercial and corporate support functions as well as the milestone payments of $21.3 million to Ligand for regulatory approval and the first sale of Ohtuvayre. This was partially offset by the receipt of $8.7 million related to the 2022 R&amp;D tax credit from HMRC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Financing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net cash provided by financing activities was $156.6 million in the nine months ended September 30, 2024, compared to $68.9 million in the nine months ended September 30, 2023, an increase of $87.8 million. The increase in cash provided by financing activities was primarily due to net proceeds received of $163.4 million in the nine months ended September 30, 2024 from the 2024 Term Loans and the RIPSA, partially offset by the repayment of the 2023 Term Loans and debt issuance costs and the payment of withholding taxes from share-based awards of $11.2 million. In the nine months ended September 30, 2023, we received $56.9 million related to the issuance of ordinary shares as well as $10.0 million of proceeds from our prior term loan with Oxford Finance Luxembourg S.&#192; R.L.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To date, we have financed our operations primarily through the issuances of our equity securities, including warrants, from borrowings under term loan facilities, from payments under the RIPSA and from a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma effective June 9, 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses since inception, including net losses of $139.6 million for the nine months ended September 30, 2024, and $54.4&#160;million for the year ended December 31, 2023. As of September 30, 2024, we had an accumulated deficit of $528.5 million. We expect to incur additional losses and negative cash flows from operations until we reach profitability, if at all, and we may continue to incur significant operating losses for the foreseeable future as we have increased our headcount significantly in 2024 and have experienced increasing expenses to support our commercial launch of Ohtuvayre as well as our costs to expand our research and development efforts, advance our clinical development of ensifentrine in other formulations or for other indications, and seek to obtain regulatory approval for and commercialize ensifentrine in various formulations or indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than leases, the 2024 Term Loans and the RIPSA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">2024 Financing and Capital Transactions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">nine months ended September 30, 2024, we had the following financing transactions:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Entered into the 2024 Term Loans and RIPSA and drew on tranches of $225 million;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Repaid the 2023 Term Loans in full. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Refer also to Note 6 - Debt to the unaudited condensed consolidated financial statements for additional information on the 2024 Term Loans.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Funding requirements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of September 30, 2024, together with additional funding expected to become available under the 2024 Term Loans and the RIPSA, will enable us to fund planned operating expenses and capital expenditure requirements, including the commercial launch of Ohtuvayre, through at least the end of 2026. Future advances under the 2024 Term Loans and the RIPSA are contingent upon achievement of certain commercial milestones and other specified conditions, and in the case of the Tranche E Term Loan, at the sole discretion of the 2024 Lenders. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. In addition, our operating plan may change as a result of many factors unknown to us. These factors, among others, may necessitate that we seek additional capital sooner than currently planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at these institutions may exceed insured limits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may require additional capital to commercialize Ohtuvayre or to research and develop additional indications or additional formulations of or with ensifentrine. In addition, we may seek to initiate or conduct preclinical or clinical studies with ensifentrine in additional indications or to discover or in-license and develop additional product candidates. We may need to seek additional funding through public or private financings, debt financings, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of securities offerings, debt financings, license and collaboration agreements and research grants. If we raise capital through equity securities offerings, the ownership interest of our ADS holders and shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect these holders&#8217; rights as holders of our ADSs. Debt financing, if available, could result in fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, to acquire, sell or license intellectual property rights, to make capital expenditures, to declare dividends, or other operating restrictions. If we raise additional funds through collaboration or licensing agreements, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. In addition, we could also be required to seek </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. If we raise funds through research grants, we may be subject to certain requirements, which may limit our ability to use the funds or require us to share information from our research and development. Raising additional capital through any of these or other means could adversely affect our business and the holdings or rights of our ADS holders and shareholders, and may cause the market price of our ADSs to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost, progress and results of any studies required to support the commercial positioning of Ohtuvayre for the maintenance treatment of COPD in adult patients and any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the number of potential new product candidates we decide to in-license and develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost, progress and results of any clinical trials evaluating ensifentrine for the treatment of NCFBE, CF, asthma or other targeted indications, or for other formulations of ensifentrine, including fixed-dose combination products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost of manufacturing clinical and commercial supplies of the ensifentrine active ingredient and derived formulated drug products and for other formulations of ensifentrine in development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the scope, progress, results and costs of pre-clinical development, laboratory testing and clinical trials for ensifentrine in other target  indications and of the development of DPI and pMDI formulations of ensifentrine, or fixed-dose combination formulations of ensifentrine for the maintenance treatment of COPD and potentially NCFBE, CF, asthma and other respiratory diseases;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and commercialization of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs, timing and outcomes of current and future commercialization activities, including manufacturing, marketing, sales and distribution, for Ohtuvayre;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the sales price and availability of adequate third-party coverage and reimbursement for Ohtuvayre;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the effect of competing technological and market developments; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for our products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">any licensing or milestone fees we might have to pay during future development of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the commercialization of Ohtuvayre, potential commercialization of ensifentrine in other indications or any future product candidates, if approved, and costs involved in the creation of an effective sales and marketing organization; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the amount of revenue we may derive either directly or in the form of royalty payments from future sales of Ohtuvayre or any future product candidates, including ensifentrine in other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">fully develop a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize Ohtuvayre and any product candidates for which we may obtain regulatory approval; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to continue to operate as a public company.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Interest Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are exposed to market risk related to changes in interest rates. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">September 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, we had cash and cash equivalent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">s of $336.0 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$271.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, respectively, consisting primarily of money market funds. Our cash equivalents are subject to interest rate risk and the rate of return would be negatively impacted by a decrease in interest rates. Due to the short-term nature of our cash equivalents, a sudden change in interest rates would not be expected to have a material effect on our business, financial condition or results of operations. There has been no material change to our interest rate sensitivity during the three months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">September 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Foreign Exchange Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is exposed to foreign exchange risk as a result of transactions in currencies other than its functional currency, the U.S. dollar. The Company&#8217;s expenses in the three months ended September 30, 2024 were incurred primarily in U.S. dollars, but also included euros and pound sterling. As at September 30, 2024, approximately 5% of cash and cash equivalents and 12% of accounts payable were denominated in foreign currencies. In addition, the R&amp;D tax credit receivable is in pound sterling. Due to the relative magnitude of our foreign currency holdings, a change of 1% in foreign exchange rates would not have a material effect on our business, financial condition or results of operations.</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_109"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of September 30, 2024, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_112"></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_115"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are not currently subject to any material legal proceedings.</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_118"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1A. Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Investing in our ADSs involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The occurrence of any of the events or developments described below could adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our ADSs could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our Business and Industry</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We have a limited operating history and have not generated any significant product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a biopharmaceutical company with a limited operating history, and have incurred significant operating losses since our inception. We had net losses of $43.0&#160;million for the three months ended September 30, 2024, and $54.4&#160;million for the year ended December 31, 2023. As of September 30, 2024, we had an accumulated deficit of $528.5&#160;million. Our losses have resulted principally from expenses incurred in research and development of ensifentrine, and from general and administrative costs that we have incurred while building our business infrastructure. We may continue to incur significant operating losses for the foreseeable future as we expand our research and development efforts, advance our clinical development of ensifentrine in other formulations, and commercially launch ensifentrine under the brand name Ohtuvayre (ensifentrine), which was approved by the FDA on June 26, 2024 for the maintenance treatment of chronic obstructive pulmonary disease ("COPD&#8221;) in adult patients. We generally use &#8220;Ohtuvayre&#8221; when referring to our FDA-approved version of ensifentrine, and &#8220;ensifentrine&#8221; when referring to our investigational programs for ensifentrine. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct clinical trials of ensifentrine for the treatment of non-cystic fibrosis bronchiectasis (&#8220;NCFBE&#8221;), cystic fibrosis (&#8220;CF&#8221;), asthma or other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct other future clinical trials of ensifentrine in other formulations, including in combination with other active ingredients including fixed-dose combinations, for the treatment of COPD or other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct clinical pharmacology studies with any formulation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek to discover and develop or in-license additional respiratory product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">conduct pre-clinical studies to support ensifentrine and potentially other future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">develop the manufacturing processes and produce clinical and commercial supplies of the ensifentrine active pharmaceutical ingredient and formulated drug products derived from it;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek additional regulatory approvals of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain and potentially expand commercial infrastructure to support the commercialization of Ohtuvayre, including sales, marketing, operations, reimbursement, distribution and manufacturing capabilities to commercialize Ohtuvayre;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">secure, maintain or obtain freedom to operate for our in-licensed technologies and products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">expand our operations to support commercialization and research activities in the U.S. and elsewhere.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our expenses may also increase substantially if we experience any delays or encounter any issues with any of the above, including, but not limited to, failed pre-clinical studies or clinical trials, complex results, safety issues, manufacturing difficulties, inadequate quantity or quality of ensifentrine for our clinical trials or finished drug product, or regulatory challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have devoted substantially all of our financial resources and efforts to the research and development, pre-clinical studies and clinical trials, and commercialization of Ohtuvayre for the maintenance treatment of COPD of adults in the U.S. We are continuing the development of ensifentrine in other formulations and for other targeted indications, and to support commercialization in other territories, if and when approved in such territories.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To become and remain profitable, we must succeed in developing our product candidates and commercializing our product, Ohtuvayre, and any other products for which we may receive FDA approval that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials of ensifentrine in other formulations and other targeted indications, discovering and developing additional product candidates, obtaining additional regulatory approvals for ensifentrine and for any future product candidates that successfully complete clinical trials, establishing manufacturing, commercial and marketing capabilities and ultimately distributing and selling any products for which we obtain regulatory approval, including our approved product Ohtuvayre. We are only in the preliminary stages of some of these activities, such as the commercial launch of Ohtuvayre. We may never succeed in these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or other regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our planned clinical trials or the development of ensifentrine in additional formulations or for other targeted indications, or any other product candidates, our expenses could increase and revenue could be further delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ohtuvayre is our only product approved for marketing. It is approved in the U.S. but is not approved in any other jurisdiction, and may never receive approval in other jurisdictions.  We may not be successful in obtaining regulatory approval for any additional products, and Ohtuvayre may never generate revenues sufficient to achieve or sustain profitability. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. Our failure to achieve or sustain profitability would depress the market price of our ADSs and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our ADSs also could cause our ADS holders to lose all or a part of their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may need additional funding to complete development and commercialization of any future product candidates and to commercialize Ohtuvayre. If we are unable to raise capital when needed, or if a failure of any financial institution where we maintain our cash and cash equivalents prevents or delays us from accessing uninsured funds, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect our expenses to increase in connection with our ongoing and planned activities, particularly as we commercialize Ohtuvayre, and conduct clinical trials of ensifentrine in other formulations and for other targeted indications. We expect to incur significant commercialization expenses related to activities including product positioning studies, product manufacturing, medical affairs, marketing, sales and distribution. Furthermore, we expect to incur ongoing costs associated with operating as a public company in the U.S. and maintaining a listing on the Nasdaq Global Market, or Nasdaq. Accordingly, we may need to obtain additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We estimate that our existing cash resources and additional funding received and expected to become available under the 2024 Term Loans and the RIPSA will enable us to fund planned operating expenses and capital expenditure requirements through at least the end of 2026, including commercializing Ohtuvayre in the U.S. Future advances under the 2024 Term Loans and the RIPSA are contingent upon achievement of certain regulatory and commercial milestones and other specified conditions. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. In addition, our operating plan may change as a result of many factors unknown to us. These factors, among others, may necessitate that we seek additional capital sooner than currently planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. We maintain the majority of our cash and cash equivalents in accounts with major</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">U.S. and multi-national financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost, progress and results of any studies required to support the commercial positioning of Ohtuvayre for the maintenance treatment of COPD in adult patients and any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the number of potential new product candidates we decide to in-license and develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost, progress and results of any clinical trials evaluating ensifentrine for the treatment of NCFBE, CF, asthma or other targeted indications, or for other formulations of ensifentrine, including fixed-dose combination products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost of manufacturing clinical and commercial supplies of the ensifentrine active ingredient and derived formulated drug products and for other formulations of ensifentrine in development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the scope, progress, results and costs of pre-clinical development, laboratory testing and clinical trials for ensifentrine in other target indications and of the development of DPI and pMDI formulations of ensifentrine, or fixed-dose combination formulations of ensifentrine for the maintenance treatment of COPD and potentially NCFBE, CF, asthma and other respiratory diseases;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and commercialization of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs, timing and outcomes of current and future commercialization activities, including manufacturing, marketing, sales and distribution, for Ohtuvayre;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the sales price and availability of adequate third-party coverage and reimbursement for Ohtuvayre;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for our products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">any licensing or milestone fees we might have to pay during future development of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">selling and marketing activities undertaken in connection with the commercialization of Ohtuvayre, potential commercialization of ensifentrine in other indications or any future product candidates, if approved, and costs involved in the creation of an effective sales and marketing organization;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the amount of revenue we may derive either directly or in the form of royalty payments from future sales of Ohtuvayre or any future product candidates, including ensifentrine in other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost of fully developing a sales, marketing and distribution infrastructure and scale up of external manufacturing capabilities to commercialize Ohtuvayre and any product candidates for which we may obtain regulatory approval; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to continue to operate as a public company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize Ohtuvayre or our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect our business, the holdings or the rights of our shareholders, or the value of our ordinary shares or ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue our research and development programs relating to ensifentrine or any commercialization efforts, be unable to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">expand our operations, or be unable to otherwise capitalize on our business opportunities, as desired, which could harm our business and potentially cause us to discontinue operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We depend solely on the commercial success of Ohtuvayre. If we are unable to generate significant revenue from the sale of Ohtuvayre or successfully develop ensifentrine for other indications, our financial condition will be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA approved our New Drug Application (&#8220;NDA&#8221;) for Ohtuvayre for the maintenance treatment of COPD in adult patients on June 26, 2024, and we began generating revenue from the sale of Ohtuvayre in August 2024. We have invested substantially all of our efforts and financial resources on the development of Ohtuvayre and on preparation for its commercial launch, including costs related to commercial drug supply, sales, and marketing, and it is our sole source of revenue. Our ability to achieve profitability depends heavily on its successful commercialization. In addition, we have not submitted a marketing authorization application (&#8220;MAA&#8221;) to the EMA or comparable applications to other regulatory authorities for Ohtuvayre. The success of Ohtuvayre will depend on many factors, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the potential and perceived efficacy and potential advantages over alternative treatments, including over direct competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the ability to offer Ohtuvayre for sale at a competitive price;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">publicity concerning our product, or competing products and treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement for Ohtuvayre;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the possible occurrence of adverse clinical findings or decreased effectiveness of our product over time identified during continued monitoring and evaluation of patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">any restrictions on the use of our product together with other medications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the ability of our CMOs and supply chain to maintain sufficient quantity and quality, and uninterrupted supply, of Ohtuvayre;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the ability to timely scale up manufacturing capabilities through current or additional sources to support any increase in market demand;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected manufacturing issues, product performance issues or stability issues;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">interactions of our product with other medicines patients are taking; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the mix of private and governmental payers coverage, particularly if the percentage of patients receiving reimbursement from state Medicaid is high since such process can be slower to reimburse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Even if a product displays a favorable efficacy and safety profile in clinical studies, market acceptance of the product will not be known until some period after it is launched. Our efforts to educate the medical community and payers on the benefits of Ohtuvayre may require significant resources and may never be successful. Our efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors. Any of these factors may cause Ohtuvayre to be unsuccessful or less successful than anticipated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The success of any product candidates, including our planned and ongoing development programs for ensifentrine, will depend on many factors, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may not be able to demonstrate that a product candidate is safe and effective as a treatment for our targeted indications to the satisfaction of the applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may require additional pre-clinical or clinical trials, which would increase our costs and prolong our development;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the results of clinical trials of a product candidate may not meet the level of statistical or clinical significance required by the applicable regulatory authorities for marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the contract research organizations (&#8220;CROs&#8221;) that we retain to conduct clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate that the clinical and other benefits of a product candidate outweigh its safety risks or may disagree with our interpretation of data;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to demonstrate a non-clinical safety profile that is acceptable to the applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected operational or clinical issues may prevent completion or interpretation of clinical study results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected manufacturing issues, product performance issues or stability issues may delay or otherwise adversely affect the progress of our clinical development program;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if regulatory authorities determine that inspections of the manufacturing facilities or clinical sites for our product candidates are required in connection with a marketing application, and such regulatory authorities are unable to conduct such inspections, whether due to geopolitical conflict, including war and terrorism, such as the ongoing conflicts in Europe and the Middle East, or travel restrictions, such as those imposed during the COVID-19 pandemic;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may not accept data generated at our clinical trial sites due to Good Clinical Practice (&#8220;GCP&#8221;) compliance issues, misconduct, or other reasons;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may require development of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) or similar risk management measures as a condition of approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may identify deficiencies in the manufacturing processes or facilities of our third-party manufacturers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may change their approval policies or adopt new regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if we license a product candidate to others, the efforts of those parties in completing clinical trials of, receiving regulatory approval for, and commercializing that product candidate;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">through our clinical trials, we may discover factors that limit the commercial viability of a product candidate or make the commercialization of such product candidate unfeasible;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if we retain rights under a collaboration agreement for a product candidate, our efforts in completing pre-clinical studies and clinical trials of, receiving marketing approvals for, establishing commercial manufacturing capabilities for, and commercializing such product candidate; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if approved, acceptance of a product by patients, the medical community and third-party payors, effectively competing with other therapies, a continued acceptable safety profile following approval and qualifying for, maintaining, enforcing and defending our intellectual property rights and claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">An unfavorable outcome in any of these factors could result in our experiencing significant delays or an inability to successfully commercialize our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to manufacture and market our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have received FDA approval to commercialize ensifentrine in the U.S. for the maintenance treatment of COPD in adult patients under the brand name Ohtuvayre. We may in the future seek regulatory approval to commercialize ensifentrine in the European Union (&#8220;EU&#8221;) and additional countries. While the scope of regulatory approval is similar in many countries, to obtain separate regulatory approval in multiple countries requires us to comply with the numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">among other things, clinical trials and commercial sales, pricing and distribution of ensifentrine, and we cannot predict success in these jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our limited operating history may make it difficult for investors to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since our inception in 2005, we have devoted substantially all of our resources to developing ensifentrine, building our intellectual property portfolio, developing our supply chain, planning our business, raising capital and providing general and administrative support for these operations. We have completed multiple Phase 1 and 2 clinical trials with different formulations of ensifentrine and for different indications, and two registrational Phase 3 clinical trials for nebulized ensifentrine for the maintenance treatment of COPD. While we have received approval for marketing ensifentrine in the U.S. for the maintenance treatment of COPD in adults, we are in the very early stages of sales, marketing and distribution activities necessary for successful product commercialization. Additionally, we are not profitable and have incurred losses in each year since our inception, and we expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Consequently, any predictions investors make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The terms of our credit facility place restrictions on our operating and financial flexibility, and our existing and any future indebtedness could adversely affect our ability to operate our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On May 9, 2024 (the &#8220;2024 Effective Date&#8221;), Verona Pharma, Inc. entered into a term loan facility of up to $400.0 million (the &#8220;2024 Term Loans&#8221; or the &#8220;2024 Term Loan Agreement&#8221;), with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agent, (in such capacity, the &#8220;Agent&#8221;) and certain funds managed by each of Oaktree Capital Management, L.P. (&#8220;Oaktree&#8221;) and OCM Life Sciences Portfolio LP (&#8220;OMERS&#8221;) party thereto (collectively the &#8220;2024 Lenders&#8221;), We received net proceeds of $68.6 million related to the Tranche B Term Loan on June 28, 2024 following FDA approval of Ohtuvayre. Each advance under the 2024 Term Loans accrues interest at a per annum rate equal to 11.00%.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our outstanding indebtedness, including any additional indebtedness incurred beyond our borrowings under the 2024 Term Loans, combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital, capital expenditures, product candidate development and other general corporate purposes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We intend to satisfy our current and future debt service obligations with our then existing cash and cash equivalents. However, we may not have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under the 2024 Term Loans or any other debt instruments. Failure to satisfy our current and future debt obligations, including covenants to take or avoid specific actions, under the 2024 Term Loan Agreement could result in an event of default and, as a result, the 2024 Lenders could accelerate all of the amounts due. In the event of an acceleration of amounts due under the 2024 Term Loan Agreement as a result of an event of default, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness while still pursuing our current business strategy. In addition, the 2024 Lenders could seek to enforce their security interests in any collateral securing such indebtedness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, if we are liquidated, the 2024 Lenders&#8217; right to repayment would be senior to the rights of holders of our ADSs or our ordinary shares to receive any proceeds from the liquidation. Any declaration by the 2024 Lenders of an event of default could significantly harm our business and prospects and could cause the price of our ADS to decline. In addition, the covenants under the 2024 Term Loan Agreement, the pledge of our assets (including our intellectual property) as collateral could limit our ability to obtain additional debt financing. If we raise any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The terms of the RIPSA place restrictions on our operating and financial flexibility, and if we fail to comply with certain covenants in the RIPSA, our results of operations and financial condition may be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In May 2024, Verona Pharma plc and Verona Pharma, Inc. (collectively, the &#8220;Sellers&#8221;) entered into a revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) with Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by each of Oaktree and OMERS party thereto (collectively, the &#8220;Purchasers&#8221;). Under the terms of the RIPSA, in exchange for the Purchasers&#8217; payment to us of a purchase price of $100 million in the aggregate, upon approval of ensifentrine by the FDA by a specified date and subject to certain labeling conditions (the &#8220;Tranche A Purchase Price&#8221;), the Sellers agreed to a true sale of assigned interests to the Purchasers, including a right for the Purchasers to receive 6.50% on global net sales of ensifentrine by the Sellers and 5% on certain proceeds the Sellers receive from licenses engaged during the term of the RIPSA outside of the U.S. The Tranche A Purchase Price of $100.0 million was received on June 28, 2024 following FDA approval of Ohtuvayre. We are also eligible to receive an additional funding tranche equal to $150 million upon achievement of a specified net sales milestone in any trailing six-month period after receipt of the Tranche A Purchase Price. The RIPSA contains covenants that impose on us certain obligations with respect to payment, diligence, reporting, intellectual property, license agreements, and certain other actions, as well as indemnification obligations. Among other things, these covenants require us to use commercially reasonable efforts to develop and commercialize ensifentrine in the U.S. and each major jurisdiction in which a marketing authorization is obtained, and limit our ability to create or incur liens or dispose of certain assets related to ensifentrine. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might otherwise be advantageous to us and our shareholders, including the holders of our ADSs. Pursuant to the RIPSA and related security agreement, we granted to the Purchasers a second-priority lien in certain of our intellectual property assets and other related assets to secure our obligations under the RIPSA. If we are unable to comply with our obligations, the Purchasers could seek to enforce their security interest in such assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, the RIPSA and our payment obligations to the Purchasers could have important negative consequences to holders of our securities. For example, a portion of our cash flow from operations will be needed to make required payments to the Purchasers and will not be available to fund future operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Payment requirements under the RIPSA will increase our cash outflows. Our future operating performance is subject to market conditions and business factors that are beyond our control. If our cash inflows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay capital expenditures, sell assets or seek additional capital. If we raise funds by selling additional equity, such sale would result in dilution to our shareholders. There is no assurance that if we are required to secure funding we can do so on terms acceptable to us, or at all. Failure to pay amounts owed to the Purchasers when due would result in a default under the RIPSA and could result in foreclosure on all or substantially all of our assets, which would have a material adverse effect.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Raising additional capital may cause dilution to our holders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of securities offerings, debt financings, license and collaboration agreements and research grants. If we raise capital through securities offerings, the ownership interest of our ADS holders and shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect these holders&#8217; rights as holders of our ADSs. Debt financing, if available, could result in fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, to acquire, sell or license intellectual property rights, to make capital expenditures, to declare dividends, or other operating restrictions. If we raise additional funds through collaboration or licensing agreements, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. In addition, we could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. If we raise funds through research grants, we may be subject to certain requirements, which may limit our ability to use the funds or require us to share information from our research and development. Raising additional capital through any of these or other means could adversely affect our business and the holdings or rights of our ADS holders and shareholders, and may cause the market price of our ADSs to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our business may become subject to economic, political, regulatory and other risks associated with international operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a company based in the U.K. and whose securities are listed on Nasdaq, our business is subject to risks associated with conducting business internationally. Many of our suppliers and collaborative and clinical trial relationships are located outside the U.K. and the U.S. Accordingly, our future results could be harmed by a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing regulatory requirements for drug approvals in non-U.S. countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">potentially reduced protection for intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulties in compliance with non-U.S. laws and regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in non-U.S. regulations and customs, tariffs and trade barriers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in non-U.S. currency exchange rates of the euro and currency controls;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">       U.S. governments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain non-U.S. markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">negative consequences from changes in tax laws;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, such as the ongoing conflicts in Europe and the Middle East, or natural disasters including earthquakes, typhoons, floods and fires, or public health emergencies, such as the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Exchange rate fluctuations may materially affect our results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although we are based in the U.K., our financial statements are denominated in U.S. dollars and many of our business activities are carried out with partners outside the U.S. and U.K. and these transactions may be denominated in another currency. As a result, our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates not only between the pound sterling and the U.S. dollar, but also the currencies of other countries, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Development, Clinical Testing and Regulatory Approval</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Clinical drug development and regulatory approval involve a lengthy and expensive process, with uncertain outcomes. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and regulatory approval of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our product candidates, including our ensifentrine programs for additional targeted indications and formulations, are prolonged or delayed, or if such clinical trials fail to show the safety and efficacy required by regulatory authorities, we or our collaborators may be unable to obtain required regulatory approvals and be unable to commercialize our product candidates on a timely basis, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To obtain the requisite regulatory approvals to market and sell our product candidates, we or any collaborator must demonstrate through extensive pre-clinical studies and clinical trials that such product candidates are safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">stage clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. Regulators&#8217; interpretations of results may differ from our own, and expectations can change over time while a product is in clinical development.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. The FDA may require us to conduct additional pre-clinical studies or clinical trials that may not be successful, or may not be considered successful by regulators.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we wish to commercialize ensifentrine in territories other than the U.S., the regulatory authorities in such territories may require us to conduct additional pre-clinical studies or clinical trials beyond those we successfully completed to obtain FDA approval of Ohtuvayre, and if we wish to commercialize ensifentrine in other formulations or for other targeted indications, we will also be required to conduct further clinical studies in the U.S. to support potential FDA approvals for such targeted indications and formulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may experience delays in clinical trials of ensifentrine in different formulations, including fixed-dose combinations, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Our clinical trials can be delayed, suspended, or terminated, or the utility of data from these trials may be compromised, for a variety of reasons, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to generate sufficient preclinical, toxicology, drug product characterizations or other in vivo or in vitro data to support the initiation or continuation of clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain regulatory agreement on clinical trial design or implementation, including dose and frequency of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain regulatory authorization to commence a trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability of a CRO to meet their contracted obligations regarding subject enrollment, data collection, data monitoring, laboratory sample management, programming and analysis or other activities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain institutional review board (&#8220;IRB&#8221;), or ethics committee approval or positive opinion at each site;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to recruit suitable patients to participate in a trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">failure to have patients complete a trial or return for post-treatment follow-up;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial or committing gross misconduct or fraud;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays to the addition of new clinical trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to achieve or maintain double-blinding, when required by the applicable clinical trial protocol;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected technical issues during manufacture;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">variability in drug product performance and/or stability;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">discoveries that may reduce the commercial viability of the product candidate;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to manufacture sufficient quantities of the applicable product candidates for use in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the quality or stability of the product candidate falling below acceptable standards for either safety or efficacy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">third-party actions claiming infringement by the product candidate in clinical trials and obtaining injunctions interfering with our progress;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism, such as the ongoing conflicts in Europe and the Middle East, or natural disasters and other extreme weather-related events including earthquakes, hurricanes, typhoons, floods and fires;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">trade sanctions imposed by the U.S. or other governments impacting our ability to transfer money to certain countries, such as Russia, to pay clinical trials sites in those countries;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">safety or tolerability concerns causing us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">lower than anticipated retention rates of patients and volunteers in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">failure of our third-party research contractors to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner, or at all; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulty in certain countries in identifying the sub-populations that we are trying to evaluate in a particular trial, which may delay enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, failure of our clinical trials to demonstrate adequate efficacy and safety, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authority. The FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we experience delays in the completion of any clinical trial of ensifentrine for any indication, or of any other product candidate, or any clinical trial of ensifentrine or any other product candidate is terminated, the commercial prospects of such product candidates may be harmed, and our ability to generate product revenues, if any, will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down the development and approval process and jeopardize our ability to commence product sales and generate revenue, if any. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and could impair our ability to commercialize our product candidates. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of any product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Clinical trials must be conducted in accordance with the laws and regulations of the FDA, EU rules and regulations and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs (or other ethics committees) at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of the product candidate produced under current good manufacturing practice (&#8220;cGMP&#8221;) and similar foreign requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with GCP requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical trials that are conducted in countries outside the EU and the U.S. may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-EU and non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA or the EMA, and different standards of diagnosis, screening and medical care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (&#8220;CTR&#8221;), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">required a separate clinical trial application (&#8220;CTA&#8221;), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the EU Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">It is currently unclear to what extent the U.K. will seek to align its regulations with the EU. The U.K. regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into U.K. law, through secondary legislation).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On January 17, 2022, the U.K. Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), launched an eight-week consultation on reframing the U.K. legislation for clinical trials, which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The resulting legislative changes will be closely watched and will determine the extent to which the U.K. clinical trials framework aligns with or diverges from the (EU) CTR. Under the terms of the Protocol on Ireland/Northern Ireland, provisions of the (EU) CTR which relate to the manufacture and import of investigational medicinal products and auxiliary medicinal products apply in Northern Ireland. A decision by the U.K. Government not to closely align its regulations with the new approach that has been adopted in the EU may have an effect on the cost of conducting clinical trials in the U.K. compared with other countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our product and product candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during product development or following approval, if any, we may need to abandon our development programs, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Undesirable side effects that may be caused by a product or product candidate could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive or less desirable label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale clinical trials or, in some cases, after they are made available to patients on a commercial scale following approval. We have completed more than twenty Phase 1, 2 and 3 clinical trials of ensifentrine. In these trials, some patients have experienced mild to moderate adverse reactions, including urinary tract infection, back pain, hypertension, and diarrhea. An increase in psychiatric adverse events were reported with use of ensifentrine, although such events were rare and a causal relationship between ensifentrine and increased rates of psychiatric events could not be established at the time of FDA approval of Ohtuvayre.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Results of our future clinical trials could reveal a high and unacceptable severity and prevalence of adverse side effects. In such an event, our trials could be suspended or terminated and the FDA or other comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Additionally, if we or others identify </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">undesirable or unacceptable side effects following regulatory approval, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such products and require us to take them off the market;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS plan or similar risk management measures to ensure that the benefits of ensifentrine outweigh its risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be required to change the way a product is administered, conduct additional clinical trials or change the labeling of the product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be subject to limitations on how we may promote a product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">product sales may be adversely impacted;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any of these events could prevent us or any collaborators from achieving or maintaining market acceptance of any approved products, including Ohtuvayre, or could have significant negative consequences on the commercialization of such products, which in turn could delay or prevent us from generating significant revenue from the sale of such products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not be successful in our efforts to develop ensifentrine in different formulations, including fixed-dose combinations, and/or for other targeted indications, including NCFBE, CF, asthma or other respiratory diseases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Part of our strategy is to continue to develop ensifentrine in indications other than COPD, such as NCFBE, CF and asthma and other formulations including fixed-dose combinations, MDI and DPI. Although our research and development efforts to date have suggested that ensifentrine has the potential to treat NCFBE, CF and asthma, we may not be able to develop successfully ensifentrine to address these or any other diseases or conditions. In addition, the potential use of ensifentrine in other diseases may not be suitable for clinical development, including as a result of difficulties enrolling patients in any clinical studies we plan to initiate or the potential for harmful side effects or other characteristics that might suggest marketing approval and market acceptance are unlikely. We may find that it may not be feasible to develop an acceptable combination of ensifentrine with other products, including LAMAs, or that chemical stability or drug product stability does not support further development. If we do not continue to successfully develop, obtain regulatory approval for, and begin to commercialize ensifentrine for additional indications or formulations, we will face difficulty in obtaining product revenues in future periods, which could significantly harm our financial position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We depend on enrollment of patients in our clinical trials. If we are unable to enroll patients in our clinical trials, or enrollment is slower than anticipated, our research and development efforts could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal and other external factors. Patient enrollment depends on many factors, including the size and nature of the patient population, the severity of the disease under investigation, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the ability to obtain and maintain patient consents, the risk that enrolled patients will drop out of a trial, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Higher than expected numbers of patients could also discontinue participation in the clinical trials. Delays in the completion of any clinical trial will increase our costs, slow down our development and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may become exposed to costly and damaging liability claims, either when testing product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. The current and future use of product candidates by us and any collaborators in clinical trials, and the commercial sale of Ohtuvayre by us or partners, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, our collaborators or others selling Ohtuvayre. Any claims against us, regardless of their merit, could be difficult and costly to defend and could adversely affect the market for Ohtuvayre or any prospects for commercialization of other product candidates. In addition, regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">decreased demand for Ohtuvayre;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">injury to our reputation and the reputation of Ohtuvayre in the market;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">costs to defend related litigation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory investigation, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the inability to commercialize or promote any approved products, including Ohtuvayre.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with warnings that identify known potential adverse effects and patients who should not use a product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although we maintain product liability insurance for our product candidates and commercial products including Ohtuvayre, it is possible that our liabilities could exceed our insurance coverage. We may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The regulatory approval processes of the FDA, the EMA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for ensifentrine for the maintenance treatment of COPD in adult patients in jurisdictions outside the U.S. or for ensifentrine for additional targeted indications and formulations, our business will be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The time required to obtain approval by the FDA, the European Commission and comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for ensifentrine outside of the U.S. and it is possible that ensifentrine or any product candidates we may develop in the future will never obtain the necessary or desired regulatory approvals.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining approval to commercialize a product candidate in the U.S. or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidate is safe and effective for its intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidate are promising, such data may not be sufficient to support approval by the applicable regulatory authority. The FDA or foreign regulatory agencies may also require us to conduct additional preclinical studies or clinical trials prior to or post-approval, or it may object to elements of our clinical development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s benefits outweigh its safety risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials or may find the data to be unacceptable;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the data collected from clinical trials may, for various reasons, be insufficient to support the submission or approval of an NDA or supplemental NDA in the United States, a MAA in the EU, or other comparable submission to obtain regulatory approval in other countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">FDA or comparable regulatory authorities may identify issues of GCP noncompliance or unacceptable practices at clinical sites or CROs participating in our clinical studies, rendering clinical data insufficient to support approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our proposed product specifications and performance characteristics.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain the necessary or desired regulatory approvals for our product candidates. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for our products. Even if we believe the data collected from our clinical trials are promising, such data may not be sufficient to support approval by the FDA, the European Commission or any other regulatory authority.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, even if we receive regulatory approvals for our product candidates, regulatory authorities may approve our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for successful commercialization. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates, if approved at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, FDA and foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revision may however have a significant impact on the biopharmaceutical industry and our business in the long term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The ability of the FDA and comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">the FDA and other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs, or modifications to cleared or approved drugs, to be reviewed and/ or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Even though the FDA has approved Ohtuvayre, we remain subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, Ohtuvayre and any other approved products could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">With respect to any products approved by the FDA or a comparable foreign regulatory, including Ohtuvayre, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and record keeping for such product remains subject to extensive and ongoing regulatory requirements. These requirements include, among other things, payment of annual user fees, submissions of safety and other post-marketing information and reports, facility registration and drug listing, as well as continued compliance with cGMP and similar foreign requirements for the manufacture of the product and GCP requirements for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize any approved products, including Ohtuvayre. In addition, any approval we may obtain could include significant limitations related to use, restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We and our contract manufacturers will also be subject to periodic inspection by the FDA and other regulatory authorities to monitor compliance with these requirements. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or the rejection of product approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">restrictions on the products, manufacturers or manufacturing process;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">civil and criminal penalties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">injunctions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">product seizures, detentions or import bans;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">total or partial suspension of production; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The FDA and other foreign regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses which may result in significant liability if we are found to have violated such laws.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are found to have improperly promoted off-label uses for our products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. For example, the FDA has approved Ohtuvayre for the maintenance treatment of COPD in adult patients, and we are not permitted to promote Ohtuvayre for any other uses. Physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of Ohtuvayre and any other products for which we may obtain regulatory approval, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In Europe, off-label use is not per se regulated by the EU pharmaceutical legislation and a difference is made between the strict regulation of medicinal product and the use of medicinal products in medical practice. Off-label use is deferred to national regulation and may vary depending on the EU Member State(s).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may never obtain approval or commercialize ensifentrine in other major markets outside of the U.S., which would limit our ability to realize its full market potential.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such country or territory regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of ensifentrine in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. While we have received approval in the U.S. for Ohtuvayre for the maintenance treatment of COPD in adult patients, we currently do not have any product candidates approved for sale in any other jurisdiction, whether in the EU or any other international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be compromised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA, the EU and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our pre-clinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Interim, &#8220;top-line,&#8221; or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Healthcare Laws and Other Legal Compliance Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize our products and may affect the prices we may set.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, the EU and other foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, the ACA, was enacted, which substantially changes the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D (which, as discussed below, will be replaced by a new manufacturer discount program beginning in 2025);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected and not generally distributed through the retail channel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in force as it currently exists.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011 has, among other things, led to aggregate reductions of Medicare payments to providers, which, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional action is taken by Congress. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price. These laws and any laws enacted in the future may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Most significantly, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap (with resulting prices for the initial ten drugs first effective in 2026); imposes rebates under Medicare Part B and Medicare Part D continue to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning 2024); and replaces the Part D coverage gap discount program originally established under the ACA with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The impact of the IRA on our company and the pharmaceutical industry cannot yet be fully determined but, is likely to be significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for ensifentrine or additional pricing pressures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Individual states in the U.S. have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our products or put pressure on our product pricing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our products, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of health care in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our products, restrict or regulate post-approval activities and affect our ability to commercialize our products, if approved. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute ensifentrine, if approved. Such laws include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows, or should know, it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">in the EU, interactions between pharmaceutical companies, health care professionals, and health care organizations are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU member states. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of pharmaceutical products is prohibited in the EU. Relationships with healthcare professionals and associations are subject to stringent anti-gift statutes and anti-bribery laws, the scope of which differs across the EU. In addition, national &#8220;Sunshine Acts&#8221; may require pharmaceutical companies to report/publish transfers of value provided to health care professionals and associations on a regular (e.g. annual) basis. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations involves substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, a corporate integrity agreement or other agreement to resolve allegations of non-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">compliance with these laws, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder, or collectively HIPAA, imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the &#8220;CCPA&#8221;), requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Additional compliance investment and potential business process changes may be required. Similar laws have passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the U.S. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furthermore, the Federal Trade Commission (&#8220;FTC&#8221;) has authority to initiate enforcement actions against entities that make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5(a) of the FTC Act. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. The FTC and many state Attorneys General also continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive, including by regulating the presentation of website content.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are also subject to diverse laws and regulations relating to data privacy and security in the EU and the EEA, including the General Data Protection Regulation (&#8220;GDPR&#8221;). The GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. The GDPR imposes strict obligations on the ability to process health-related and other personal data of individuals within the EEA, including in relation to use, collection, analysis, and transfer (including cross-border transfer) of such personal data. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease/change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/ or civil claims (including class actions). Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S., and the efficacy and longevity of current transfer mechanisms between the EEA and the U.S. remains uncertain. Case law from the Court of Justice of the European Union (&#8220;CJEU&#8221;) states that reliance on the standard contractual clauses&#8212;a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism&#8212;alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-U.S. Data Privacy Framework (&#8220;DPF&#8221;), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the U.S. and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Relatedly, since the beginning of 2021, following the U.K.&#8217;s withdrawal from the EEA and the European Union, and the expiry of the transition period, companies have had to comply with both the GDPR and the GDPR as incorporated into U.K. national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. On October 12, 2023, the U.K. Extension to the DPF came into effect (as approved by the U.K. Government), as a data transfer mechanism from the U.K. to U.S. entities self-certified under the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Compliance with applicable data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure by us or our collaborators and third-party providers to comply with applicable data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose such information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The increasing focus on environmental sustainability and social initiatives could increase our costs, harm our reputation and adversely impact our financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There has been increasing public focus by investors, environmental activists, the media and governmental and nongovernmental organizations on a variety of environmental, social and other sustainability matters. We may experience pressure to make commitments relating to sustainability matters that affect us, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. If we are not effective in addressing environmental, social and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our reputation and financial results may suffer. In addition, we may experience </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">increased costs in order to execute upon our sustainability goals and measure achievement of those goals, which could have an adverse impact on our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, this emphasis on environmental, social and other sustainability matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements. If we fail to comply with new laws, regulations or reporting requirements, our reputation and business could be adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our sub-contracted operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could incur significant costs associated with civil or criminal fines, penalties or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which any of our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We also are subject to other laws and regulations governing any international operations, including regulations administered by the governments of the U.K. and the U.S., and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, or, collectively, the Trade Control laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by U.K., U.S. or other authorities, even if it is ultimately determined that we did not violate such laws, could be costly and time consuming, require significant personnel resources and harm our reputation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We will seek to build and continuously improve our systems of internal controls and to remedy any weaknesses identified. There can be no assurance, however, that the policies and procedures will be followed at all times or effectively detect and prevent violations of the applicable laws by one or more of our employees, consultants, agents or collaborators and, as a result, we could be subject to fines, penalties or prosecution.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Commercialization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We operate in a highly competitive and rapidly changing industry, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new products on a cost-effective basis and to market them successfully. We will face intense competition for our approved products from a variety of businesses, including large, fully integrated pharmaceutical companies, biopharmaceutical companies and specialty pharmaceutical companies, academic institutions, government agencies and other private and public research institutions in Europe, the U.S. and other jurisdictions. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Given the number of products already on the market and in development to treat COPD, asthma, CF and NCFBE, we expect to face intense competition for our products, including for Ohtuvayre, and for ensifentrine, if approved for these additional indications. Companies including GlaxoSmithKline, AstraZeneca, Novartis, Vertex, Viatris, Theravance, Gilead, Genentech, Regeneron and Sanofi currently have treatments on the market for COPD, CF and asthma, and we anticipate that new companies will enter these markets in the future. While no treatments for NCFBE currently have marketing approval in the U.S. or EU, there are products in late-stage clinical development that could be approved in the future. Our products will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of, and rapid technological changes in, the biopharmaceutical and pharmaceutical industries could render our products obsolete, less competitive or uneconomical. Our competitors may, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical and human resources than we do, and future mergers and acquisitions in the biopharmaceutical and pharmaceutical industries may result in even more resources being concentrated in our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">obtain quicker regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">establish superior proprietary positions covering our products and technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">implement more effective approaches to sales, marketing and distribution; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">form more advantageous strategic alliances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, any collaborators we may have may decide to market and sell products that compete with our products. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing or strengthening their market position before we are able to enter the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Forecasting potential sales for Ohtuvayre is difficult, and if our projections are inaccurate, our business may be harmed and our share price may be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business planning requires us to forecast or make assumptions regarding product demand and revenues for Ohtuvayre, despite numerous uncertainties. These uncertainties may be increased if we rely on third parties to conduct commercial activities in certain jurisdictions and provide us with accurate and timely information. Actual results may differ materially from projected results for various reasons, including the following, as well as risks identified in other risk factors: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the efficacy and safety of Ohtuvayre, including as relative to marketed products and product candidates in development by third parties; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">pricing (including discounting and other promotions), reimbursement, product returns or recalls, competition, labeling, adverse events and other items that impact commercialization; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the rate of adoption in the particular market, including fluctuations in demand for various reasons; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">potential market size; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">lack of patient and physician familiarity with Ohtuvayre; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">lack of patient use and physician prescribing history; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">lack of commercialization experience with Ohtuvayre; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">uncertainty relating to rate of adoption; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">products provided without compensation through patient support programs or other free drug programs, may not eventually result in or contribute to revenue-producing prescriptions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect that our revenues from sales of Ohtuvayre will be based in part on estimates, judgment and accounting policies. Any incorrect estimates or disagreements with regulators or others regarding such estimates, judgment or accounting policies may result in changes to our guidance, projections or previously reported results. Expected and actual product sales and quarterly and other results may greatly fluctuate, including in the near-term, and such fluctuations can adversely affect the price of our common stock, perceptions of our ability to forecast demand and revenues, and our ability to maintain and fund our operations. The metrics that we are tracking in order to evaluate the success of our sales efforts may not correlate to commercial success, particularly given the challenging market for Ohtuvayre.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The successful commercialization of Ohtuvayre will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies for it. Failure to obtain or maintain adequate coverage and reimbursement for Ohtuvayre could limit our ability to market it and decrease our ability to generate revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as Ohtuvayre. Our ability to achieve and maintain acceptable levels of coverage and reimbursement by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize ensifentrine. Assuming we obtain coverage for Ohtuvayre by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Moreover, for drugs and biologics administered under the supervision of a physician, obtaining appropriate documentation for usage may be difficult because of the higher prices often associated with such products. We cannot be sure that coverage and reimbursement in the U.S., the EU or elsewhere will be available for Ohtuvayre or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider Ohtuvayre as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with Ohtuvayre, pricing of existing drugs may limit the amount we will be able to charge for Ohtuvayre. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in ensifentrine. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize Ohtuvayre, and may not be able to obtain a satisfactory financial return on Ohtuvayre.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for Ohtuvayre.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Obtaining and maintaining reimbursement status is time consuming and costly. No uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time- consuming and costly process that will require us to provide scientific and clinical support for the use of Ohtuvayre to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">some cases at short notice, and we believe that changes in these rules and regulations are likely. Specifically, we believe that Ohtuvayre will be primarily reimbursed under a medical benefit through either Medicare Part B or Medicare Advantage programs, and changes within how products are reimbursed under these programs could occur and those changes may affect the overall coverage of Ohtuvayre in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of approved products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for ensifentrine. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of Ohtuvayre due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, even if a pharmaceutical product obtains a marketing authorization in the EU, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in which we participate, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Medicaid is a joint federal and state program administered by the states for low income and disabled beneficiaries. We participate in and have certain price reporting obligations under the Medicaid Drug Rebate Program, or the MDRP, as a condition of having covered outpatient drugs payable under Medicaid and, if applicable, under Medicare Part B. The MDRP requires us to pay a rebate to state Medicaid programs every quarter for each unit of our covered outpatient drugs dispensed to Medicaid beneficiaries and paid for by a state Medicaid program. The rebate is based on pricing data that we must report on a monthly and quarterly basis to the Centers for Medicare &amp; Medicaid Services, or CMS, the federal agency that administers the MDRP and other governmental healthcare programs. These data include the average manufacturer price (AMP) for each drug and, in the case of innovator products, the best price, which in general represents the lowest price available from the manufacturer to certain entities in the U.S. in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions. The Medicaid rebate consists of two components, the basic rebate and the additional rebate, which is triggered if the AMP for a drug increases faster than inflation. If we become aware that our MDRP government price reporting submission for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. If we fail to provide information timely or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP. In the event that CMS terminates our rebate agreement pursuant to which we participate in the MDRP, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs. Our failure to comply with our MDRP price reporting and rebate payment obligations could negatively impact our financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The ACA made significant changes to the MDRP, as described under the risk factor &#8220;Enacted and future legislation and regulation may increase the difficulty and cost for us to commercialize our products and may affect the prices we may set,&#8221; above. In addition, in March 2021, the American Rescue Plan Act of 2021 was signed into law, which, among other things, eliminated the statutory cap on drug manufacturers&#8217; MDRP rebate liability, effective January 1, 2024. Previously, under law enacted as part of the ACA, drug manufacturers&#8217; MDRP rebate liability was capped at 100% of the AMP for a covered outpatient drug. Congress could enact additional legislation that further increases Medicaid drug rebates or other costs and charges associated with participating in the MDRP. Additional legislation or the issuance of regulations relating to the MDRP could have a material adverse effect on our results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The recently-enacted IRA imposes rebates under Medicare Part B and Medicare Part D that are triggered by price increases that outpace inflation (first due in 2023), as described under the risk factor &#8220;Enacted and future legislation </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">and regulation may increase the difficulty and cost for us to commercialize our products and may affect the prices we may set,&#8221; above. The Medicare Part D rebate will be calculated on the basis of the AMP figures we report pursuant to the MDRP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Federal law requires that any company that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and, if applicable, Medicare Part B. We participate in the 340B program, which is administered by the Health Resources and Services Administration, or HRSA, and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP, and in general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes those prices to 340B covered entities. In addition, HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B-eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. Our failure to comply 340B program requirements could negatively impact our financial results. Any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or other legislation or regulation could affect our 340B ceiling price calculations and also negatively impact our financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In order for Ohtuvayre or any product candidates, if approved, to be paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we also participate in the U.S. Department of Veterans Affairs, or VA, Federal Supply Schedule, or FSS, pricing program. As part of this program, we are required to make our products available for procurement on an FSS contract under which we must comply with standard government terms and conditions and charge a price that is no higher than the statutory Federal Ceiling Price, or FCP, to four federal agencies (VA, U.S. Department of Defense, or DOD, Public Health Service, and U.S. Coast Guard). The FCP is based on the Non-Federal Average Manufacturer Price, or Non-FAMP, which we must calculate and report to the VA on a quarterly and annual basis. Pursuant to applicable law, knowing provision of false information in connection with a Non-FAMP filing can subject a manufacturer to significant civil monetary penalties for each item of false information. The FSS pricing and contracting obligations also contain extensive disclosure and certification requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We also participate in the Tricare Retail Pharmacy program, under which we are required to pay quarterly rebates on utilization of innovator products that are dispensed through the Tricare Retail Pharmacy network to Tricare beneficiaries. The rebates are calculated as the difference between the annual Non-FAMP and FCP. We are required to list our innovator products on a Tricare Agreement in order for them to be eligible for DOD formulary inclusion. If we overcharge the government in connection with our FSS contract or Tricare Agreement, whether due to a misstated FCP or otherwise, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges could result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation. Requirements of pharmaceutical manufacturers under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. CMS, the Department of Health &amp; Human Services Office of Inspector General, and other governmental agencies have pursued manufacturers that were alleged to have failed to report these data to the government in a timely or accurate manner. Governmental </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure you that any submissions we are required to make under the MDRP, the 340B program, the VA/FSS program, the Tricare Retail Pharmacy Program, and other governmental drug pricing programs will not be found to be incomplete or incorrect.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If our products, including Ohtuvayre, do not gain market acceptance or if we fail to accurately forecast demand or manage our inventories, our business will suffer because we might not be able to fund future operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Patients or the medical community may not accept or use Ohtuvayre in the U.S. If Ohtuvayre does not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of Ohtuvayre will depend on a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the timing of market introduction;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the price of our product relative to other products for the same or similar treatment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the number and clinical profile of competing products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the clinical indication for which Ohtuvayre is approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">relative convenience, frequency, and ease of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">cost effectiveness;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">marketing, sales, and distribution support;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">availability of adequate coverage, reimbursement and adequate payment from health maintenance organizations and other insurers, both public and private; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">other potential advantages over alternative treatment methods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If our products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for new product candidates and expanding our sales and marketing efforts for our approved products, which would cause our business to suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for Ohtuvayre and manage our inventory. To ensure adequate inventory supply, we must forecast inventory needs and place orders with our suppliers based on our estimates of future demand for Ohtuvayre. Our ability to accurately forecast demand for Ohtuvayre could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for Ohtuvayre or for products of our competitors, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters, and weakening of economic conditions or consumer confidence in future economic conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We seek to maintain sufficient levels of inventory to protect ourselves from supply interruptions. As a result, we are subject to the risk that a portion of our inventory will become obsolete or expire, which could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our commercial capabilities and infrastructure, including sales, marketing, operations, distribution, and reimbursement infrastructure, may not be adequate to successfully commercialize Ohtuvayre.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are continuing to develop sales, marketing, operations, distribution and reimbursement capabilities and infrastructure after receiving approval of Ohtuvayre in June 2024, and we have not marketed, sold or distributed pharmaceutical products prior to the approval of Ohtuvayre. The establishment of commercial capabilities and infrastructure, including sales, marketing, operations, distribution, and reimbursement with technical expertise and supporting distribution capabilities to commercialize Ohtuvayre, is expensive and time consuming. Some or all of these costs were incurred in preparation for approval and will continue as we commercialize Ohtuvayre for the maintenance treatment of COPD in adult patients. In addition, our sales force may not be sufficient in size or have adequate expertise in the medical markets that we intend to target, and we may have difficulty retaining our sales employees or attracting new employees. Any failure of our internal sales, marketing and distribution capabilities on our own or through collaborations would adversely impact the commercialization of Ohtuvayre.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are contracting third parties to perform certain services to support our sales, marketing, warehousing, distribution and reimbursement activities. To the extent that any of these third parties fail to perform their services in compliance with their obligations to us or other parties, we may not be successful in commercializing Ohtuvayre and our future product revenues may be adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold Ohtuvayre. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize Ohtuvayre. If we are not successful in commercializing Ohtuvayre, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we are unable to establish effective sales and marketing capabilities to market and sell our approved product, Ohtuvayre, we may be unable to generate adequate revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have no previous experience in marketing and selling drug products. We are continuing to establish our infrastructure for the sales, marketing and distribution of Ohtuvayre, and the cost of establishing and maintaining such an organization may exceed the benefits of doing so.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have established an in-house sales force to promote Ohtuvayre to appropriate healthcare providers including those that may be associated with hospital networks, Integrated delivery networks and third-party payers in the United States. There are significant expenses and risks involved with establishing our own sales and marketing capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We compete with other companies to recruit, hire, train and retain sales and marketing personnel. We cannot be sure that we will be able to hire or retain a sufficient number of qualified sales representatives or that they will be effective at promoting Ohtuvayre. In addition, we will need to commit significant additional management and other resources to build our sales organization to the desired size, and we may not be successful in a cost-effective manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Factors that may inhibit our efforts to establish and maintain our sales and marketing capabilities include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians in order to educate physicians about Ohtuvayre or our product candidates, once approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">higher fixed costs as compared to companies who market products using independent third parties, such as costs associated with employee benefits, training, and managing sales personnel; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, our business, results of operations, financial condition and prospects will be materially adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Beyond Ohtuvayre, we may leverage the sales and marketing capabilities that we establish for Ohtuvayre to commercialize additional product candidates or market Ohtuvayre for other indications, if approved by the FDA, in the United States. If we are unable to do so for any reason, we would need to expend additional resources to establish commercialization capabilities for those product candidates or Ohtuvayre for other indications, if approved.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approvals for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials and to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with Good Laboratory Practice (&#8220;GLP&#8221;) and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities with respect to the conduct of clinical trials, and in the case of GLP, certain animal studies. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections of CROs, trial sponsors, principal investigators and trial sites. If we fail to exercise adequate oversight over any of our CROs or if we or any of our CROs fail to comply with applicable GLP or GCP requirements, the non-clinical or clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional studies or clinical trials before approving our marketing applications. We cannot provide assurance that upon a regulatory inspection of us or our CROs or other third parties performing services in connection with our non-clinical studies or clinical trials, such regulatory authority will determine that any of our non-clinical or clinical trials complies with GLP or GCP regulations. In addition, our clinical trials must be conducted with product produced under applicable cGMP and similar foreign regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of our product candidates. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our existing and future CROs have or may have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding CROs involves additional cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could occur, which could materially impact our ability to meet our desired clinical development timelines. In addition, if our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approvals for, or commercialize, our product candidates. As a result, our results of operations and the commercial prospects would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The collaboration and license agreement with Nuance Pharma is important to our business. If Nuance Pharma is unable to develop and commercialize products containing ensifentrine in Greater China, if we or Nuance Pharma fail to adequately perform under the Nuance Agreement, or if we or Nuance Pharma terminate the Nuance Agreement, our business would be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We entered into a collaboration and license agreement with Nuance Pharma effective June 9, 2021 (the &#8220;Nuance Agreement&#8221;) under which we granted Nuance Pharma the exclusive rights to develop and commercialize products containing ensifentrine (the &#8220;Nuance Licensed Products&#8221;) in Greater China (China, Taiwan, Hong Kong and Macau).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Termination of the Nuance Agreement could cause significant setbacks in our ability to develop and commercialize the Nuance Licensed Products in Greater China. Any suitable alternative collaboration or license agreement would take considerable time to negotiate and could also be on less favorable terms to us. In addition, under the Nuance Agreement, Nuance Pharma agreed to assume all costs related to clinical development and commercialization of the Nuance Licensed Products in Greater China. If the Nuance Agreement were to be terminated, and whether or not we identify another suitable collaborator, we may need to seek additional financing to support the clinical development </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">and commercialization of the Nuance Licensed Products in Greater China, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the Nuance Agreement, we are dependent upon Nuance Pharma to successfully develop and commercialize Nuance Licensed Products. Although we have formed a joint steering committee with Nuance Pharma to oversee and coordinate the overall conduct of the clinical development and commercialization of the Nuance Licensed Products in Greater China, we do not control all aspects of Nuance Pharma&#8217;s development and commercialization or the resources it allocates to the development of the Nuance Licensed Products identified under the Nuance Agreement. Our interests and Nuance Pharma&#8217;s interests may differ or conflict from time to time, or we may disagree with Nuance Pharma&#8217;s level of effort or resource allocation. Nuance Pharma may internally prioritize programs under development within the collaboration differently than we would, or it may not allocate sufficient resources to effectively or optimally develop or commercialize the Nuance Licensed Products. If these events were to occur, our ability to receive revenue from the commercialization of the Nuance Licensed Products would be reduced, and our business would be adversely affected. In addition, under the Nuance Agreement, we have an obligation to supply Nuance Pharma with the ensifentrine drug product for their development and commercialization activities in Greater China and if our supply price is too high, the price at which Nuance Pharma sells the drug product in Greater China may not be competitive, which could have a material adverse effect on Nuance Pharma&#8217;s ability to successfully commercialize Nuance Licensed Products and the returns that we generate under the Nuance Agreement. Furthermore, the safety and/or efficacy data from Nuance Pharma&#8217;s clinical development activities could for various reasons differ from our data and could potentially impact our clinical development and commercialization activities, including our ability to obtain regulatory approval of ensifentrine in other countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to enter into new strategic relationships for ensifentrine, our business, research and development and commercialization prospects could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our development programs for our product candidates and, if approved, their commercialization will require substantial additional cash to fund expenses. Therefore, we may decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for their development and commercialization. For example, we may seek a collaborator for development of our DPI or pMDI formulation of ensifentrine for the maintenance treatment of COPD and potentially asthma and other respiratory diseases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If that were to occur, we may have to curtail the development of our product candidates, reduce or delay development programs, delay commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our products or product candidates to market and generate product revenue. If we do enter into collaboration agreements, we could be subject to the following risks, among others, any of which could adversely affect our ability to develop and commercialize our products and product candidates:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that the collaborator devotes to the development of the product candidate;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the collaborator may experience financial difficulties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be required to relinquish important rights such as marketing, distribution and intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">safety and/or efficacy data from a collaborator&#8217;s clinical development activities may conflict with our data and could potentially impact our global clinical development and commercialization activities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a collaborator may unlawfully use or disclose confidential information and materials in breach of confidentiality obligations to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect our willingness to complete our obligations under any arrangement;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we or a collaborator could fail to adequately perform our obligations under the agreement and/or the agreement could fall into dispute; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be involved in lawsuits to protect or enforce patents covering our products or product candidates, or relating to the terms of our collaborations, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We currently rely on third-party manufacturers and suppliers for production of the active pharmaceutical ingredient ensifentrine and its derived formulated products. Our dependence on these third parties may impair the advancement of our research and development programs. Moreover, we rely on third parties to produce commercial supplies of Ohtuvayre, and commercialization could be stopped, delayed or made less profitable if those third parties fail to maintain the necessary approvals from the FDA or comparable regulatory authorities, fail to provide us with sufficient quantities of product in a timely manner or fail to do so at acceptable quality levels or prices or fail to otherwise complete their duties in compliance with their obligations to us or other parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not own facilities for manufacturing ensifentrine and its derived formulated products. Instead, we rely on and expect to continue to rely on third-party CMOs, for the supply of cGMP- or GMP-grade clinical trial materials of ensifentrine and its derived formulated products, including commercial quantities of Ohtuvayre. While we may contract with other CMOs in the future, we currently have one CMO for the manufacture of ensifentrine drug substance and one CMO for each formulation of ensifentrine. The facilities used to manufacture ensifentrine and its derived formulated products must be approved for the manufacture of ensifentrine by the FDA, and by comparable foreign regulatory authorities for approvals outside the U.S.. While we provide sponsor oversight of manufacturing activities, we do not and will not directly control the manufacturing process of, and are or will be essentially dependent on, our CMOs for compliance with cGMP and similar foreign requirements for the manufacture of ensifentrine and its derived formulated products. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements of the FDA or a comparable foreign regulatory authority, it will not be able to secure or maintain regulatory approval for the manufacture of ensifentrine and its derived formulated products in its manufacturing facilities. In addition, we have little direct control over the ability of a CMO to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of ensifentrine and its derived formulated products or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, and obtain or maintain regulatory approval for or market ensifentrine and its derived formulated products. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of ensifentrine and its derived formulated products or that obtained approvals could be revoked. Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement because of their own financial difficulties or business priorities, at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In addition, the fact that we are dependent on our suppliers, CMOs and other third parties for the manufacture, storage and distribution of ensifentrine and its derived formulated products means that we are subject to the risk that ensifentrine and its derived formulated products may have manufacturing defects that we have limited ability to prevent, detect or control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the materials necessary to produce ensifentrine and its derived formulated products and the inhalation and nebulization devices to deliver ensifentrine. We do not and will not have any direct control over the process or timing of the acquisition and delivery of these supplies by any CMO or its third-party suppliers, or the quality or quantity of such supplies. These supplies could be interrupted from time to time and, if interrupted, we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost or quality, or at all. There are a limited number of suppliers for the raw materials that we may use to manufacture ensifentrine and for the drug delivery devices (e.g. nebulizers) that we use for clinical trials with ensifentrine, and we will need to assess alternate suppliers to prevent a possible disruption to our clinical trials and commercial sales. Although we generally do not begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of ensifentrine to complete the clinical trial, any significant delay in the supply of ensifentrine drug products, or the raw material components needed to produce, or devices needed to deliver, ensifentrine, for an ongoing clinical trial due to our CMOs or their third-party suppliers could considerably delay completion of our clinical trials, product testing and potential regulatory approval of ensifentrine. If our CMOs, their third-party supplies, or we are unable to purchase these supplies, the commercial launch of Ohtuvayre would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of Ohtuvayre. In addition, growth in the costs and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">expenses of these supplies may impair our ability to cost-effectively manufacture ensifentrine. Additionally, CMOs are experiencing labor constraints which could impact their ability to manufacture and deliver ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We rely and will continue to rely on CMOs and third-party suppliers to comply with and respect the proprietary rights of others in conducting their contractual obligations for us. If a CMO or third-party suppliers fails to acquire the proper licenses or otherwise infringes third-party proprietary rights in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers, or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or market ensifentrine and any of its derived formulated products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We rely on patents and other intellectual property rights to protect our products and product candidates, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for our products and product candidates, or on in-licensing such rights. The registrations of the assignment of each of these patents and patent applications with the relevant authorities in certain jurisdictions in which the patent and patent applications are registered have been granted, but there is no assurance that any additional registrations will be effected in a timely manner or at all. Failure to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could adversely affect our ability to develop and market Ohtuvayre or our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The patent prosecution process is expensive and time-consuming, and we or our licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, depending on the terms of any future in-licenses to which we may become a party, in some circumstances we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology in-licensed from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot provide assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover ensifentrine, third parties may initiate an opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to ensifentrine. Furthermore, if third parties have filed such patent applications on or before March 15, 2013, the date on which the U.S. patent filing system changed from a first-to-invent to a first-to-file standard, an interference proceeding can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop, manufacture and market our products and our product candidates, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the U.S. and abroad that is relevant to or necessary for the commercialization of our products in any jurisdiction. For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our products or product candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our products or product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products and, if approved, our product candidates. We may incorrectly determine that one of our products or product candidates is not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or, if approved, our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products and, if approved, our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our products or, if approved, our product candidates. We might, if possible, also be forced to redesign our products or product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be involved in lawsuits to protect or enforce patents covering our products or product candidates, which could be expensive, time consuming and unsuccessful, and issued patents could be found invalid or unenforceable if challenged in court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To protect our competitive position, we may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. As enforcement of intellectual property rights is difficult, unpredictable, time consuming and expensive, we may fail in enforcing our rights &#8212; in which case our competitors may be permitted to use our technology without being required to pay us any license fees. In addition, however, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize our products or product candidates, and then compete directly with us, without payment to us. If we in-license intellectual property rights, our agreements may give our licensors the first right to control claims of third-party infringement, or to defend validity challenges. Therefore, these patents and patent applications may not be enforced or defended in a manner consistent with the best interests of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S. or in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our products or product </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">candidates. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts, industry commentators or investors perceive these results to be negative, it could have an adverse effect on the price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial success depends, in part, upon our ability, and the ability of our future collaborators, to develop, manufacture, market and sell our products and, if approved, our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biopharmaceutical and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing ensifentrine. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products may be subject to claims of infringement of the intellectual property rights of third parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to Ohtuvayre and any existing or future product candidates, including interference or derivation proceedings, post grant review and inter partes review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Similarly, we or our licensors or collaborators may initiate such proceedings or litigation against third parties, for example, to challenge the validity or scope of intellectual property rights controlled by third parties. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product or product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. Such licenses may not be available on reasonable terms, or at all, or may be non-exclusive thereby giving our competitors access to the same technologies licensed to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail in any such dispute, we may be forced to pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully infringed certain intellectual property rights. We or our licensees may be temporarily or permanently prohibited from commercializing Ohtuvayre or from selling, incorporating, manufacturing or using our products or product candidates in the U.S. and/or other jurisdictions that use the subject intellectual property. We might, if possible, also be forced to redesign our products or product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign could be technically infeasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217; or collaborators&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize Ohtuvayre or any existing or future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although we are not currently experiencing any claims challenging the inventorship of our patents or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. For example, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, or we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, such perceptions could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to comply with our obligations under our existing and any future intellectual property licenses, the 2024 Loan Agreement, the RIPSA or any other future loan agreements with third parties, we could lose rights that are important to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are party to a license agreement with Ligand, under which we in-license certain intellectual property and were assigned certain patents and patent applications related to our business. We may enter into additional license agreements in the future. We expect that any future license agreements would impose various diligence, milestone payment, royalty, insurance and other obligations on us. We also entered into the 2024 Loan Agreement with the 2024 Lenders. The 2024 Term Loans is secured by a first-priority lien on substantially all of the assets of Verona Pharma, Inc. and the Company, including intellectual property. We also entered into the RIPSA with the Purchasers. The RIPSA is secured by a second-priority lien on certain of our intellectual property. For further description of the 2024 Term Loans and RIPSA, see Note 6 - Debt to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Any uncured, material breach under any of these agreements could result in our loss of rights to practice the patent rights and other intellectual property under these agreements, and could compromise our development and commercialization efforts for our products. Moreover, our future licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not be successful in maintaining the necessary rights to our products or product candidates or obtaining other intellectual property rights important to our business through acquisitions and in-licenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We currently own and have in-licensed rights to intellectual property, including patents, patent applications and know-how, and our success will likely depend on maintaining these rights. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, our products or product candidates may require specific formulations to work effectively and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights that we identify as necessary for our products or product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies also are pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to license or acquire third-party intellectual property rights on a timely basis, on terms that would allow us to make an appropriate return on our investment, or at all. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for a development program on acceptable terms, we may have to abandon that development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our competitive position may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have registered trademarks in some territories and made applications to register the trademarks in other territories for potential trade names for our business and products and product candidates. We may not be able to obtain trademark protection for our trade names in territories that we consider of significant importance to us. If we register trademarks, our trademark applications may be rejected during trademark registration proceedings. Although we will be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, any of our trademarks or trade names, whether registered or unregistered, may be challenged, opposed, infringed, cancelled, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential collaborators or customers in our markets of interest. Over the long-term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering Ohtuvayre and any of our product candidates, our ability to compete effectively could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. The issued patents covering the composition of matter for Ohtuvayre expired in 2020, and our other issued patents will expire in 2031 to 2041, subject to any patent extensions that may be available for such patents. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2034 to 2044. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Ohtuvayre are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">One of our U.S. patents for Ohtuvayre may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Generic drug manufacturers can also challenge the patents of a brand-name drug under the Hatch-Waxman Act. When a generic drug manufacturer files an Abbreviated New Drug Application (ANDA) with the FDA to seek approval for a generic version of a drug that is already on the market, they must make certain certifications regarding the patents listed for the drug in the Orange Book. The Orange Book lists patents that innovator drug companies assert cover their drug products or use of those products and a Paragraph IV certification is a legal challenge to the validity or enforceability of the patent(s) listed in the Orange Book. If the generic applicant makes a Paragraph IV certification, they must also notify the patent holder and the NDA (New Drug Application) holder that they have filed an ANDA with a Paragraph IV certification, providing detailed reasons why the patent is not valid or not infringed. The filing of a Paragraph IV certification can trigger a statutory stay of approval of the ANDA for 30 months while the parties engage in patent litigation, unless the litigation is resolved in favor of the generic applicant sooner or the court orders otherwise. This process can be a critical aspect of the generic drug approval pathway and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">may impact the timing of a generic drug&#8217;s entry into the market.  Our ability to assert or defend patents covering Ohtuvayre through this process will be adversely affected if we fail to seek listing of eligible patents in the Orange Book, or fail to otherwise maintain patents for which we have already obtained Orange Book listing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We enjoy only limited geographical protection with respect to certain patents and may face difficulties in certain jurisdictions, which may diminish the value of our intellectual property rights in those jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We generally file our first patent application, or priority filing, at the U.K. Intellectual Property Office or the U.S. Patent and Trademark Office. International applications under the Patent Cooperation Treaty, or PCT, are usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe a product candidate may be marketed or manufactured. We have so far not filed for patent protection for our products in all national and regional jurisdictions where such protection may be available. Filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S.. In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Competitors may use our or our licensors&#8217; or collaborators&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors or collaborators have patent protection, but enforcement is not as strong as that in the U.S.. These products may compete with our product candidates, and our and our licensors&#8217; or collaborators&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the U.S. and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Others may be able to make compounds that are the same as or similar to our products or product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The patents of third parties may impair our ability to develop or commercialize our products or product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We or our licensors or any future strategic collaborators might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We or our licensors or any future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">It is possible that our pending patent applications will not lead to issued patents;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may not develop additional technologies that are patentable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products or any existing or future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, the America Invents Act, or the AIA, which was passed on September 16, 2011, resulted in significant changes to the U.S. patent system.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">An important change introduced by the AIA is that, as of March 16, 2013, the U.S. transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO, after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This requires us to be cognizant of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; or collaboration partners&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; or collaboration partners&#8217; issued patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Finally, a Unitary Patent and Unified Patent Court (UPC) system were implemented in Europe on June 1, 2023. This new regime may present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. Under the UPC, all European patents in countries taking part in the UPC, including those issued prior to ratification of the European Patent Package, by default automatically fall under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents in UPC countries, and allows for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the UPC agreement, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We consider proprietary trade secrets and confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and confidential know-how are difficult to maintain as confidential.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of our information technology systems. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. We cannot guarantee that our trade secrets and other proprietary and confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets. However, current or former employees, consultants, contractors and advisors may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Failure to obtain or maintain trade secrets and confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our products or product candidates, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize Ohtuvayre or any existing or future product candidate.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Information Technology</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our information technology systems, and those of our manufacturers, suppliers and other third parties that we use to perform services for us or otherwise collaborate with, may fail or suffer security breaches, which could distract our operations and cause delays in our research and development and commercialization activities, and may adversely affect our business, operations and financial performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the ordinary course of our business, we and our manufacturers, suppliers and third parties that we use to perform services for us or otherwise collaborate with, collect and store sensitive data, including intellectual property, clinical trial data, sales, forecasting, and commercial performance data, proprietary business information and personally identifiable information (collectively, &#8220;Confidential Information&#8221;) of our clinical trial subjects and employees, in our and third-party data centers and on our and third-party networks. The secure processing, maintenance and transmission of Confidential Information is critical to our operations. Our information technology and other internal infrastructure systems, including cloud services, corporate firewalls, servers, leased lines and connection to the Internet, and that of our manufacturers, suppliers and other third parties that we use to perform services for us or otherwise collaborate with, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of these information technology and other internal infrastructure systems could cause interruptions in our collaborations and delays in our research and development and commercialization activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, our information technology systems and those of our third-party service providers, strategic partners and other contractors or consultants are vulnerable to damage, attack or interruption from computer viruses, malware (e.g. ransomware), misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, malicious code, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of a continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. There can also be no assurance that our and our manufacturers&#8217;, suppliers&#8217; and other critical third parties&#8217; cybersecurity risk management program and processes, including policies, controls or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Despite security measures that we and our critical third parties (e.g., collaborators) implement, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to human error, technical vulnerabilities, malfeasance or other disruptions. We and certain of our service providers are from time to time subject to cyberattacks and security incidents. Although to our knowledge we have not experienced any significant security breach to date, any such breach could compromise our information technology systems and the Confidential Information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal data, regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials and commercialize our product candidates, which could adversely affect our reputation and delay clinical development and commercialization of our product candidates. Any adverse impact to the availability, integrity or confidentiality of our or third-party systems or Confidential Information can result in legal claims or proceedings (such as class actions), regulatory investigations and enforcement actions, fines and penalties, negative reputational impacts that cause us to lose existing or future customers, and/or significant incident response, system restoration or remediation and future compliance costs. Any losses, costs or liabilities may not be covered by, or may exceed the coverage limits of, any or all applicable insurance policies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our future growth and ability to compete depends on our ability to retain our key personnel and recruit additional qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our success depends upon the contributions of our key management, scientific and technical personnel, many of whom have been instrumental for us and have substantial experience with ensifentrine and related technologies. Our key management individuals include our chief executive officer, David Zaccardelli, our chief financial officer, Mark Hahn, our general counsel, Andrew Fisher, our chief medical officer, Kathleen Rickard, our senior vice president, regulatory affairs, Caroline Diaz, our chief commercial officer, Christopher Martin, and our chief development officer, Tara Rheault. The loss of key personnel could impact our commercialization efforts and research and development activities. In addition, the competition for qualified personnel in the biopharmaceutical and pharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to achieve our commercialization goals for Ohtuvayre and our product candidate development objectives, raise additional capital and implement our business strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are continuing to expand our development, regulatory, commercial, sales, marketing, reimbursement and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have experienced significant growth in the number of our employees and the scope of our operations, particularly in the areas of commercial operations and sales, marketing, reimbursement and distribution. To manage this growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our ADSs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Certain of our shareholders, members of our board of directors, and senior management who own our ordinary shares (including ordinary shares represented by ADSs) may be able to exercise significant control over us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Depending on the level of attendance at our general meetings of shareholders, these shareholders either alone or voting together as a group may be in a position to determine or significantly influence the outcome of decisions taken at any such general meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any shareholder resolution requiring a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">simple majority, including the appointment of board members, certain decisions relating to our capital structure, and the approval of certain significant corporate transactions. Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our ADSs and ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Because we do not anticipate paying any cash dividends on our ADSs or ordinary shares in the foreseeable future, capital appreciation, if any, will be our ADS holders&#8217; and shareholders&#8217; sole source of gains and they may never receive a return on their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be paid. Therefore, we must have distributable profits before issuing a dividend. We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs or ordinary shares will be our ADS holders&#8217; and shareholders&#8217; sole source of gain for the foreseeable future, and they will suffer a loss on their investment if they are unable to sell their ADSs or ordinary shares at or above the price at which they were purchased. Investors seeking cash dividends should not purchase our ADSs or ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise their right to vote.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Holders of our ADSs are not able to exercise voting rights attaching to the ordinary shares evidenced by our ADSs on an individual basis. Holders of our ADSs have appointed a depositary as their representative to exercise the voting rights attaching to the ordinary shares represented by their ADSs. Holders of our ADSs may not receive voting materials in time to instruct the depositary to vote, and it is possible that they, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of our ADSs may not be able to exercise voting rights and may lack recourse if their ADSs are not voted as requested. In addition, holders of our ADSs will not be able to call a shareholders&#8217; meeting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may not receive distributions on our ordinary shares represented by our ADSs or any value for them if it is illegal or impractical to make them available to them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The depositary for our ADSs has agreed to pay to holders of our ADSs the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. Holders of our ADSs will receive these distributions in proportion to the number of our ordinary shares their ADSs represent. However, in accordance with the limitations set forth in the deposit agreement entered into with the depositary, it may be unlawful or impractical to make a distribution available to holders of our ADSs. We have no obligation to take any other action to permit the distribution of our ADSs, ordinary shares, rights or anything else to holders of our ADSs. This means that holders of our ADSs may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make the distributions available to them. These restrictions may have a material adverse effect on the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may be subject to limitations on transfer of their ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement. These limitations on transfer may have a material adverse effect on the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by English law, including the provisions of the Companies Act 2006, and by our Articles of Association. These rights differ in certain material respects from the rights of shareholders in typical U.S. corporations. As a result, investors in our ordinary shares or ADSs may not have the same protections or rights as they would if they had invested in a U.S. corporation. This may make our ADSs less attractive to such investors, which could harm the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Claims of U.S. civil liabilities may not be enforceable against us.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are incorporated under English law. Substantially all of our assets are located outside the U.S.. The majority of our senior management and board of directors reside outside the U.S.. As a result, it may not be possible for investors to effect service of process within the U.S. upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The U.S. and the U.K. do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the U.S., whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the U.K.. In addition, uncertainty exists as to whether U.K. courts would entertain original actions brought in the U.K. against us or our directors or senior management predicated upon the securities laws of the U.S. or any state in the U.S.. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of the U.K. as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the U.K. or countries other than the U.S. any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. As we continue to transition to a commercial company following the FDA&#8217;s approval of Ohtuvayre, our internal controls over financial reporting may become more complex, which could increase the probability of deficiencies in our internal controls in the future. Inadequate internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Taxation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">New income, sales use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, or interpreted, changed, modified or applied adversely to us, any of which could adversely affect our business operations and financial performance. We are currently unable to predict whether such changes will occur and, if so, the ultimate impact on our business. To the extent that such changes have a negative impact on us, including as a result of related uncertainty, these changes may materially and adversely impact our business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We carry out research and development activities including, but not limited to, developing ensifentrine for various indications and delivery methods, and as a result we currently benefit in the U.K. from the HM Revenue and Customs, or HMRC, small and medium sized enterprises research and development relief, or SME R&amp;D Relief, which currently provides relief against U.K. Corporation Tax.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Broadly, SME R&amp;D Relief comprises two elements, (a) allowing qualifying SMEs to deduct a total of 186% of their qualifying expenditure from their yearly profit for U.K. Corporation Tax purposes (the deduction is given by allowing an additional 86% deduction plus the usual 100% deduction), or the SME R&amp;D Additional Deduction and,(b) where there are not sufficient profits for U.K. Corporation Tax purposes to fully utilize the SME R&amp;D </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additional Deduction, the excess (&#8220;surrenderable losses&#8221;) can be carried forward to offset against future taxable profits, or a tax credit currently equal to 10% of such surrenderable loss can be claimed in cash, or the SME R&amp;D Tax Credit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on criteria established by HMRC a portion of expenditure incurred in relation to our research and development activities including, but not limited to, operating clinical trials, manufacturing, consultant and salary and related costs, is eligible for the SME R&amp;D Additional Deduction. Our consequential surrenderable losses are currently eligible for the SME R&amp;D Tax Credit, in accordance with HMRC criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the financial statements for the years ended December 31, 2023 and December 31, 2022, we recorded SME R&amp;D Tax Credits of $2.4 million and $8.6 million, respectively. We received the credit relating to the year ended December 31, 2022 in June 2024. Based on the HMRC criteria, we expect to receive the credit relating to the year ended December 31, 2023 in the year ending December 31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Changes to the U.K.&#8217;s SME R&amp;D Relief regime may adversely affect our financial condition. At the 2023 Autumn Statement, the U.K. Government confirmed that it would introduce a single R&amp;D relief regime which merges the current &#8220;RDEC&#8221; and SME R&amp;D Relief scheme. The proposed credit rate under the draft legislation is 20% of qualifying expenditure, with the credit itself subject to U.K. corporation tax. The credit will therefore be reduced by the applicable rate of U.K. corporation tax (the main rate of which is currently 25%), although the notional tax rate that applies to loss-making companies will be set at the lower rate of 19% for the purposes of the new R&amp;D relief regime. Therefore, under the proposed regime and current rates of U.K. corporation tax, profitable businesses subject to the main rate of U.K. corporation tax will effectively receive a credit of 15% of qualifying expenditure whilst loss-making businesses will receive a credit of 16.2%. The proposed legislation also contains restrictions on R&amp;D relief which can be claimed where a company contracts R&amp;D activity to a third party or makes payments for externally provided workers so that, broadly, a taxpayer will only be able to claim relief where the work is performed in the U.K. It is proposed that the only expenditure allowable outside the U.K. would be for activities which are necessary due to geographical, environmental or social conditions not present or replicable in the U.K. The proposed legislation also contains new rules relating to subcontracting of R&amp;D activities to a third party.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, it is proposed that for accounting periods beginning on or after 1 April 2024, the R&amp;D intensive loss-making SME scheme threshold (broadly, the proportion of qualifying R&amp;D expenditure compared to total expenditure) will be 30%. Therefore, loss-making SMEs with qualifying R&amp;D expenditure of 30% or more of its total expenditure may claim an enhanced deduction of 86% and a repayable credit of 14.5%.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">It is proposed that the new U.K. R&amp;D tax relief regime will apply to accounting periods starting on or after 1 April 2024. The legislation for the new regime is not yet finalized and therefore the impact on our financial position cannot be fully known, however the proposed changes to the scheme and/or any further changes could have a material adverse effect on our financial position, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we were classified as a passive foreign investment company, certain adverse U.S. federal income tax consequences could apply to U.S. holders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on the composition of our income and assets and the value of our assets in the taxable year ended December 31, 2023, we believe that we are a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes for such taxable year. However, no assurances regarding our PFIC status can be provided for any past taxable years, the taxable year ending December 31, 2024, or any future taxable years. If we are classified as a PFIC for any taxable year during which a U.S. Holder (as defined below) holds our ordinary shares or ADSs, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder, including (i) the treatment of all or a portion of any gain on disposition of our ordinary shares or ADSs as ordinary income, (ii) the application of a deferred interest charge on such gain and the receipt of certain dividends, and (iii) the obligation to comply with certain reporting requirements. We cannot provide any assurances that we will furnish to any U.S. Holder information that may be necessary to comply with the aforementioned reporting and tax payment obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A non-U.S. corporation will generally be considered a PFIC for any taxable year in which (i) 75% or more of its gross income consists of passive income or (ii) 50% or more of the value of its assets (generally determined on the basis of a quarterly average) consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of the assets and income of such corporation. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the income test, our status as a PFIC </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">depends on the composition of our income which will depend on the transactions we enter into and our corporate structure. The composition of our income and assets is also affected by the spending of the cash we raise in any offering. Each U.S. Holder should consult its tax advisors with respect to the potential adverse U.S. tax consequences to it if we are a PFIC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are classified as a PFIC in any year with respect to which a U.S. Holder owns our ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns our ordinary shares or ADSs, regardless of whether we continue to meet the PFIC tests described above, unless the U.S. Holder makes a specified election once we cease to be a PFIC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A &#8220;U.S. Holder&#8221; is any beneficial owner of our ordinary shares or ADSs that, for U.S. federal income tax purposes, is or is treated as any of the following: a citizen or individual resident of the U.S.; a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the U.S., any state therein or the District of Columbia; an estate the income of which is subject to U.S. federal income taxation regardless of its source; or a trust that (i) is subject to the supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the United States Internal Revenue Code of 1986, as amended (the &#8220;Internal Revenue Code&#8221;)), or (ii) has a valid election in effect to be treated as a United States person.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If a U.S. Holder is treated as owning at least 10% of our ordinary shares or ADSs, such holder may be subject to adverse U.S. federal income tax consequences.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If a U.S. Holder (as defined above) is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary shares or ADSs, such U.S. Holder would generally be treated as a &#8220;United States shareholder&#8221; (within the meaning of Section 951(b) of the Internal Revenue Code) with respect to each &#8220;controlled foreign corporation&#8221; (within the meaning of Section 957(a) of the Internal Revenue Code (a &#8220;CFC&#8221;)) in our group, if any. Because our group includes one or more U.S. subsidiaries, certain of our non-U.S. subsidiaries could be treated as CFCs, regardless of whether we are treated as a CFC. A United States shareholder of a CFC may be required to report annually and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by such CFC, regardless of whether such CFC makes any distributions. An individual that is a United States shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due. We cannot provide any assurances that we will assist investors in determining whether we or any of our non-U.S. subsidiaries are treated as CFCs or whether any such investor is treated as a United States shareholder with respect to any such CFCs. Further, we cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with the reporting and tax payment obligations described in this risk factor. U.S. Holders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares or ADSs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">General Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The price of our ADSs may be volatile and may fluctuate due to factors beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The trading market for publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our ADSs may fluctuate significantly due to a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">public concern relating to the commercial value or safety of ensifentrine, including for our approved product Ohtuvayre; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">developments in our competitors&#8217; businesses;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in entering into collaborations and strategic relationships with respect to commercialization of Ohtuvayre or development of ensifentrine in other target indications or formulations, or entry into collaborations and strategic relationships on terms that are not deemed to be favorable to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">technological innovations or commercial product introductions by us or competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in government regulations;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in healthcare payment systems;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">developments concerning proprietary rights, including patents and litigation matters;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">positive or negative results from, or delays in, clinical trials of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">financing or other corporate transactions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">actual or anticipated fluctuations in our financial condition or operating results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">limitations regarding the ownership of ADSs, including as related to their inclusion in U.S. market indices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">publication of research reports or comments by securities or industry analysts or commentators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">general market conditions in the pharmaceutical industry or in the economy as a whole;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the loss of any of our key scientific or senior management personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">sales of our ADSs by us, our senior management or board members, and significant holders of our ADSs; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">other events and factors, many of which are beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of our ADSs. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of the holders of our ADSs were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination in litigation could also subject us to significant liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Future sales, or the possibility of future sales, of a substantial number of our ADSs or ordinary shares could adversely affect the price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Future sales of a substantial number of our ADSs or ordinary shares, or the perception that such sales will occur, could cause a decline in the market price of our ADSs. Sales in the U.S. of our ADSs and ordinary shares held by our directors, officers and affiliated shareholders are subject to restrictions. If these shareholders sell substantial amounts of ordinary shares or ADSs in the public market, or the market perceives that such sales may occur, the market price of our ADSs and our ability to raise capital through an issue of equity securities in the future could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Unstable market and economic conditions may have serious adverse consequences on our business and financial condition and the price of our ADSs. The global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate or the U.K. or the U.S. enters a recession, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. In addition, there is a risk that one or more of our CROs, suppliers or other third-party providers may not survive an economic downturn or recession. As a result, our business, results of operations and price of our ADSs may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If securities or industry analysts or commentators publish inaccurate or unfavorable research, about our business, the price of our ADSs and ordinary shares and our trading volume could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The trading market for our ADSs and ordinary shares depends in part on the research and reports that securities or industry analysts or commentators publish about us, our business or our industry. If one or more of the analysts who cover us downgrade our ADSs or if they or other industry commentators publish inaccurate or unfavorable research or comments about our business, the price of our ADSs and ordinary shares would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our ADSs could decrease, which might cause the price of our ADSs and ordinary shares and trading volume to decline.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We have incurred and expect to continue to incur increased costs as a result of operating as a public company in the U.S., and our senior management are required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a U.S. public company, we have incurred and expect to continue to incur significant legal, accounting and other expenses that we did not incur prior to becoming a U.S. public company, including in connection with our transition to large accelerated filer as of December 31, 2023. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on non-U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our senior management and other personnel have devoted and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our senior management on our internal control over financial reporting and an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To prepare for and maintain compliance with Section 404(b), we have implemented a process of documenting and evaluating our internal control over financial reporting. In this regard, we have dedicated, and will need to continue to dedicate, internal resources, engage outside consultants and pursue a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting, which is both costly and challenging. Despite our efforts, there is a risk that we will not be able to conclude that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Business interruptions could adversely affect our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our operations are potentially vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity, public health crises and pandemic diseases, and other natural and man- made disasters or events beyond our control. Our facilities are located in regions that experience severe weather from time to time. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity, public health crisis, pandemic diseases or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_121"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_124"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_127"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 5. Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Rule 10b5-1 Trading Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading plans (as each such term is defined in Item 408 of Regulation S-K). The trading plans are intended to satisfy the affirmative defense in Rule 10b5-1(c). During the three months ended September 30, 2024, no director or officer of the Company <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-528"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-529">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-530"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-531">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading plan or a non-Rule 10b5-1 trading plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_139"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 6. Exhibits</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.999%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by Reference to Filings Indicated </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No. </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920140541/tm2039594d1_ex1.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920140541/tm2039594d1_ex1.htm">Articles of Association, as amended and as currently in effect</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q324.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q324.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q324.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q324.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q324.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q324.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q324.htm">32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q324.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ifa7f77ae03ce400d93edbcfedf6d9f61_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.664%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">VERONA PHARMA PLC</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: November&#160;4, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Zaccardelli</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David Zaccardelli, Pharm. D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: November&#160;4, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Mark W. Hahn</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mark W. Hahn</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311q324.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id3463ceb78bb41398b778059ff567b72_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Zaccardelli, Pharm.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; November&#160;4, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312q324.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iacd50196c0294d4fbe44166d81bc640f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark W. Hahn, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; November&#160;4, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321q324.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7c545d94db814cefbafd2e243df9511a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; November&#160;4, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322q324.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7191658706d043f599378a845595c9d1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended September&#160;30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; November&#160;4, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vrna-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0ee8d2e7-f00d-490d-8b34-d8e4d0ae151e,g:42222ec7-8dc8-4139-853e-ab7cbe924947-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrna="http://veronapharma.com/20240930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://veronapharma.com/20240930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://veronapharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000005 - Statement - Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organizationanddescriptionofbusinessoperations" roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations">
        <link:definition>0000007 - Disclosure - Organization and description of business operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentationandsummaryofsignificantaccountingpolicies" roleURI="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies">
        <link:definition>0000008 - Disclosure - Basis of presentation and summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInterest" roleURI="http://veronapharma.com/role/EquityInterest">
        <link:definition>0000009 - Disclosure - Equity Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accruedexpenses" roleURI="http://veronapharma.com/role/Accruedexpenses">
        <link:definition>0000010 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Ligandlicenseagreementobligations" roleURI="http://veronapharma.com/role/Ligandlicenseagreementobligations">
        <link:definition>0000011 - Disclosure - Ligand license agreement obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://veronapharma.com/role/Debt">
        <link:definition>0000012 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedcompensation" roleURI="http://veronapharma.com/role/Sharebasedcompensation">
        <link:definition>0000013 - Disclosure - Share based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalizationandnetlosspershare" roleURI="http://veronapharma.com/role/Capitalizationandnetlosspershare">
        <link:definition>0000014 - Disclosure - Capitalization and net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Subsequentevents" roleURI="http://veronapharma.com/role/Subsequentevents">
        <link:definition>0000015 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>9954471 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables">
        <link:definition>9954472 - Disclosure - Basis of presentation and summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesTables" roleURI="http://veronapharma.com/role/AccruedexpensesTables">
        <link:definition>9954473 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationTables" roleURI="http://veronapharma.com/role/SharebasedcompensationTables">
        <link:definition>9954474 - Disclosure - Share based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandnetlosspershareTables" roleURI="http://veronapharma.com/role/CapitalizationandnetlosspershareTables">
        <link:definition>9954475 - Disclosure - Capitalization and net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsDetails" roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails">
        <link:definition>9954476 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails" roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails">
        <link:definition>9954477 - Disclosure - Basis of presentation and summary of significant accounting policies - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInterestDetails" roleURI="http://veronapharma.com/role/EquityInterestDetails">
        <link:definition>9954478 - Disclosure - Equity Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesDetails" roleURI="http://veronapharma.com/role/AccruedexpensesDetails">
        <link:definition>9954479 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsDetails_1" roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1">
        <link:definition>9954480 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://veronapharma.com/role/DebtDetails">
        <link:definition>9954481 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareBasedCompensationExpenseDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails">
        <link:definition>9954482 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareOptionActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails">
        <link:definition>9954483 - Disclosure - Share based compensation - Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationRSUActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails">
        <link:definition>9954484 - Disclosure - Share based compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationNarrativeDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails">
        <link:definition>9954485 - Disclosure - Share based compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationandnetlosspershareComputationDetails" roleURI="http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails">
        <link:definition>9954486 - Disclosure - Capitalization and net loss per share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vrna_TaxCreditAndIncomeTaxesReceivableCurrent" abstract="false" name="TaxCreditAndIncomeTaxesReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SecuritesPurchasedNoncurrentRevenueInterest" abstract="false" name="SecuritesPurchasedNoncurrentRevenueInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" abstract="false" name="ResearchAndDevelopmentExpenseNetOfAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_GainLossFromResearchAndDevelopmentTaxCredit" abstract="false" name="GainLossFromResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" abstract="false" name="ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_AtTheMarketSalesAgreementMember" abstract="true" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" abstract="false" name="IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInLicenseAgreementObligations" abstract="false" name="IncreaseDecreaseInLicenseAgreementObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" abstract="false" name="ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_OrganizationAndBusinessDescriptionTextBlock" abstract="false" name="OrganizationAndBusinessDescriptionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vrna_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrna_SpecialtyPharmaciesMember" abstract="true" name="SpecialtyPharmaciesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_NuanceShanghaiPharmaCoLtdMember" abstract="true" name="NuanceShanghaiPharmaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrna_EquityInterestReceivable" abstract="false" name="EquityInterestReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_AccruedResearchAndDevelopmentFeesCurrent" abstract="false" name="AccruedResearchAndDevelopmentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" abstract="false" name="AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_LigandUKDevelopmentLimitedMember" abstract="true" name="LigandUKDevelopmentLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrna_A2023TermLoanMember" abstract="true" name="A2023TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_A2023TermALoanMember" abstract="true" name="A2023TermALoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_A2024TermLoanMember" abstract="true" name="A2024TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_A2024TermALoanMember" abstract="true" name="A2024TermALoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_A2024TermBMember" abstract="true" name="A2024TermBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_A2024TermCMember" abstract="true" name="A2024TermCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_A2024TermDMember" abstract="true" name="A2024TermDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_A2024TermELoanMember" abstract="true" name="A2024TermELoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_InterestRatePeriodAxis" abstract="true" name="InterestRatePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vrna_InterestRatePeriodDomain" abstract="true" name="InterestRatePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentInterestRatePeriodOneMember" abstract="true" name="DebtInstrumentInterestRatePeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodAxis" abstract="true" name="DebtPrepaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodDomain" abstract="true" name="DebtPrepaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodOneMember" abstract="true" name="DebtPrepaymentPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodTwoMember" abstract="true" name="DebtPrepaymentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrna_DebtPrepaymentPeriodFourMember" abstract="true" name="DebtPrepaymentPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_OaktreeFundAdministrationLLCMember" abstract="true" name="OaktreeFundAdministrationLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentExitFeePercentage" abstract="false" name="DebtInstrumentExitFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" abstract="false" name="DebtInstrumentEarlyRepaymentPenaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" abstract="false" name="DebtInstrumentDebtDefaultInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vrna_DebtInstrumentPartialPrepaymentDenominationMultiple" abstract="false" name="DebtInstrumentPartialPrepaymentDenominationMultiple" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" abstract="false" name="DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice" abstract="false" name="RevenuesPurchaseAndSaleAgreementPurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" abstract="false" name="RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" abstract="false" name="RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding" abstract="false" name="RevenuesPurchaseAndSaleAgreementAdditionalFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementMultiple" abstract="false" name="RevenuesPurchaseAndSaleAgreementMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" abstract="false" name="RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" abstract="false" name="RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" abstract="false" name="RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" abstract="false" name="RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vrna_PerformanceRestrictedStockUnitsPRSUsMember" abstract="true" name="PerformanceRestrictedStockUnitsPRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_DavidZaccardelliMember" abstract="true" name="DavidZaccardelliMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_MarkHahnMember" abstract="true" name="MarkHahnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vrna-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0ee8d2e7-f00d-490d-8b34-d8e4d0ae151e,g:42222ec7-8dc8-4139-853e-ab7cbe924947-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0ab81d05-871b-44f2-a348-4fcd59697b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9496f309-9907-4296-93b1-7d101416e43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ab81d05-871b-44f2-a348-4fcd59697b94" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9496f309-9907-4296-93b1-7d101416e43f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9d082506-8c3e-4f79-941a-0f2988d4fc51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ab81d05-871b-44f2-a348-4fcd59697b94" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9d082506-8c3e-4f79-941a-0f2988d4fc51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_ae4cdaa0-59c0-47f4-a024-fcd3466d9d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ab81d05-871b-44f2-a348-4fcd59697b94" xlink:to="loc_us-gaap_TaxesPayableCurrent_ae4cdaa0-59c0-47f4-a024-fcd3466d9d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f86effbf-1b10-44dd-be30-0106ddbc5d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ab81d05-871b-44f2-a348-4fcd59697b94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f86effbf-1b10-44dd-be30-0106ddbc5d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ce6cd5a8-4dd9-4f8b-ab3b-01c538cc0431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ab81d05-871b-44f2-a348-4fcd59697b94" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ce6cd5a8-4dd9-4f8b-ab3b-01c538cc0431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3e5a2068-271f-4f8b-babb-fd1dddfe2156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0ab81d05-871b-44f2-a348-4fcd59697b94" xlink:to="loc_us-gaap_AccountsPayableCurrent_3e5a2068-271f-4f8b-babb-fd1dddfe2156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1215942a-6a1a-4220-9974-921b768a4774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3d22df78-8082-4211-b99e-5f67cd49bdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1215942a-6a1a-4220-9974-921b768a4774" xlink:to="loc_us-gaap_InventoryNet_3d22df78-8082-4211-b99e-5f67cd49bdbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22f2a538-cac4-4a34-9f7f-f74e3ca4a8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1215942a-6a1a-4220-9974-921b768a4774" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22f2a538-cac4-4a34-9f7f-f74e3ca4a8cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9c4ea158-6971-42ca-95a3-2fbb9563962d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1215942a-6a1a-4220-9974-921b768a4774" xlink:to="loc_us-gaap_OtherAssetsCurrent_9c4ea158-6971-42ca-95a3-2fbb9563962d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_6d4e354e-3520-4f89-91fc-23b709b922b6" xlink:href="vrna-20240930.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1215942a-6a1a-4220-9974-921b768a4774" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_6d4e354e-3520-4f89-91fc-23b709b922b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f8bfa611-7134-40db-9360-9b436c84dfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1215942a-6a1a-4220-9974-921b768a4774" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f8bfa611-7134-40db-9360-9b436c84dfa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_a21cc972-fd0d-463d-8c56-5d9dfae96899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1215942a-6a1a-4220-9974-921b768a4774" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_a21cc972-fd0d-463d-8c56-5d9dfae96899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_51898ba6-9b59-4067-9bcc-fe5c611704c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4bcd44d2-11b5-4aaa-a0ed-aa4381087483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51898ba6-9b59-4067-9bcc-fe5c611704c9" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4bcd44d2-11b5-4aaa-a0ed-aa4381087483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f418aee6-4b3a-44fc-8b0c-b52019b4985b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_51898ba6-9b59-4067-9bcc-fe5c611704c9" xlink:to="loc_us-gaap_LiabilitiesCurrent_f418aee6-4b3a-44fc-8b0c-b52019b4985b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_182200d9-2e4f-4e36-96b5-360a2ab28d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_103e4740-f641-4d5d-9fdf-a5c36f958203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_182200d9-2e4f-4e36-96b5-360a2ab28d54" xlink:to="loc_us-gaap_Liabilities_103e4740-f641-4d5d-9fdf-a5c36f958203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_325e5d17-dc66-4200-bad3-b67fe3a96d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_182200d9-2e4f-4e36-96b5-360a2ab28d54" xlink:to="loc_us-gaap_CommitmentsAndContingencies_325e5d17-dc66-4200-bad3-b67fe3a96d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_50414a4c-4fb2-4ff0-96bd-a21bc7cf2258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_182200d9-2e4f-4e36-96b5-360a2ab28d54" xlink:to="loc_us-gaap_StockholdersEquity_50414a4c-4fb2-4ff0-96bd-a21bc7cf2258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa91d4f1-f61d-4eaf-8148-e0ef8e991fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d92a2249-2e5f-4c57-98af-509e34dd401f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa91d4f1-f61d-4eaf-8148-e0ef8e991fd5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d92a2249-2e5f-4c57-98af-509e34dd401f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_229b60f2-5f6a-478b-83d5-4e77d25ada11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa91d4f1-f61d-4eaf-8148-e0ef8e991fd5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_229b60f2-5f6a-478b-83d5-4e77d25ada11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5d844409-5052-4d3d-afb2-aac77e791ace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa91d4f1-f61d-4eaf-8148-e0ef8e991fd5" xlink:to="loc_us-gaap_TreasuryStockValue_5d844409-5052-4d3d-afb2-aac77e791ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_37f5af8b-23ee-4a28-9c3f-4b81613186ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa91d4f1-f61d-4eaf-8148-e0ef8e991fd5" xlink:to="loc_us-gaap_CommonStockValue_37f5af8b-23ee-4a28-9c3f-4b81613186ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36439985-f2a3-4bba-b0bb-3a052e3ba0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fa91d4f1-f61d-4eaf-8148-e0ef8e991fd5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36439985-f2a3-4bba-b0bb-3a052e3ba0f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_01fd8ce3-536f-4150-b07d-5563944a16fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_0cb92c92-eb33-4a90-b0f9-9f15c4a69672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01fd8ce3-536f-4150-b07d-5563944a16fa" xlink:to="loc_us-gaap_AssetsNoncurrent_0cb92c92-eb33-4a90-b0f9-9f15c4a69672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5bdeed1d-9262-4185-b3f8-d93b494266a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01fd8ce3-536f-4150-b07d-5563944a16fa" xlink:to="loc_us-gaap_AssetsCurrent_5bdeed1d-9262-4185-b3f8-d93b494266a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a9468e64-c103-4c81-b416-1022772f8a85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_331b80e2-7466-454f-a9c8-5ff46738e172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a9468e64-c103-4c81-b416-1022772f8a85" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_331b80e2-7466-454f-a9c8-5ff46738e172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SecuritesPurchasedNoncurrentRevenueInterest_bad6be6a-1755-4e1d-8c70-e10a9bd4ede1" xlink:href="vrna-20240930.xsd#vrna_SecuritesPurchasedNoncurrentRevenueInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a9468e64-c103-4c81-b416-1022772f8a85" xlink:to="loc_vrna_SecuritesPurchasedNoncurrentRevenueInterest_bad6be6a-1755-4e1d-8c70-e10a9bd4ede1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f81a86c8-5c23-4288-935c-70bda634dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a9468e64-c103-4c81-b416-1022772f8a85" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f81a86c8-5c23-4288-935c-70bda634dff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1167395a-4f42-440d-aca8-cb8a4a0b5a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_d7af383b-b7cb-4d64-8b51-27d8c99ce01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1167395a-4f42-440d-aca8-cb8a4a0b5a35" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_d7af383b-b7cb-4d64-8b51-27d8c99ce01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_17412f15-27e4-4e28-b4a8-ae22956eeb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1167395a-4f42-440d-aca8-cb8a4a0b5a35" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_17412f15-27e4-4e28-b4a8-ae22956eeb9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e3ba7399-10b2-4792-bf22-e2b7221b1d99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1167395a-4f42-440d-aca8-cb8a4a0b5a35" xlink:to="loc_us-gaap_Goodwill_e3ba7399-10b2-4792-bf22-e2b7221b1d99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f62d7842-5f32-418a-b9bd-eb3e3c5d182e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1167395a-4f42-440d-aca8-cb8a4a0b5a35" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f62d7842-5f32-418a-b9bd-eb3e3c5d182e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d55a41a5-3cfd-45e0-b0e6-7e13a8887cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_74dae924-7875-4b0e-b794-8cf9bef2ac70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d55a41a5-3cfd-45e0-b0e6-7e13a8887cff" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_74dae924-7875-4b0e-b794-8cf9bef2ac70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9f2bf661-0b8b-4e52-a15d-d68abeded55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d55a41a5-3cfd-45e0-b0e6-7e13a8887cff" xlink:to="loc_us-gaap_OperatingIncomeLoss_9f2bf661-0b8b-4e52-a15d-d68abeded55d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5fa470dd-47ee-403f-9304-4472fca19039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5f9fe7c4-8122-4e1c-934b-65e1eb57b762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5fa470dd-47ee-403f-9304-4472fca19039" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5f9fe7c4-8122-4e1c-934b-65e1eb57b762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_8a4d3ee7-2760-459a-a107-431266f0d429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5fa470dd-47ee-403f-9304-4472fca19039" xlink:to="loc_us-gaap_InvestmentIncomeNet_8a4d3ee7-2760-459a-a107-431266f0d429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_570c5fbe-38e1-4d0d-94e1-7b95a01c6867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5fa470dd-47ee-403f-9304-4472fca19039" xlink:to="loc_us-gaap_InterestExpense_570c5fbe-38e1-4d0d-94e1-7b95a01c6867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_8f260ade-5d83-4c1f-9fd9-731e8d8d088d" xlink:href="vrna-20240930.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5fa470dd-47ee-403f-9304-4472fca19039" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_8f260ade-5d83-4c1f-9fd9-731e8d8d088d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_a30bb4d9-6bbe-4118-b108-053967979cf8" xlink:href="vrna-20240930.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5fa470dd-47ee-403f-9304-4472fca19039" xlink:to="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_a30bb4d9-6bbe-4118-b108-053967979cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf464894-3300-4339-b398-5c6793aaef57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ff3e5485-481b-4920-80d3-c3b5d224d91e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cf464894-3300-4339-b398-5c6793aaef57" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ff3e5485-481b-4920-80d3-c3b5d224d91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ede3a58e-ff0c-4a9e-a9e4-63d4ec9ecef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cf464894-3300-4339-b398-5c6793aaef57" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ede3a58e-ff0c-4a9e-a9e4-63d4ec9ecef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4600185b-64bf-4243-96b5-b0d50872e1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06b670f6-dfea-4e66-bfd5-593b7b2791c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4600185b-64bf-4243-96b5-b0d50872e1a7" xlink:to="loc_us-gaap_Revenues_06b670f6-dfea-4e66-bfd5-593b7b2791c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d186b125-6cb2-4d96-b5e1-1d27c95cb49a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4600185b-64bf-4243-96b5-b0d50872e1a7" xlink:to="loc_us-gaap_OperatingExpenses_d186b125-6cb2-4d96-b5e1-1d27c95cb49a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1c2148f2-d848-4782-9351-32b66bce5f84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_fc56add5-52b9-4eca-860a-8cb2a8edc879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1c2148f2-d848-4782-9351-32b66bce5f84" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_fc56add5-52b9-4eca-860a-8cb2a8edc879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_16fce0a5-ef07-4a06-ab7d-a425884d8d4d" xlink:href="vrna-20240930.xsd#vrna_ResearchAndDevelopmentExpenseNetOfAdjustments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1c2148f2-d848-4782-9351-32b66bce5f84" xlink:to="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_16fce0a5-ef07-4a06-ab7d-a425884d8d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ca02be7d-baa5-48bc-9c2a-3ae95dceeb14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1c2148f2-d848-4782-9351-32b66bce5f84" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ca02be7d-baa5-48bc-9c2a-3ae95dceeb14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2795f91f-7507-4c46-aaa5-e174f635f316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c14f46d6-9218-4f2a-a110-fe84562feeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2795f91f-7507-4c46-aaa5-e174f635f316" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c14f46d6-9218-4f2a-a110-fe84562feeb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA_22edecf1-2e4a-49cc-bad4-323b8d73e89e" xlink:href="vrna-20240930.xsd#vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2795f91f-7507-4c46-aaa5-e174f635f316" xlink:to="loc_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA_22edecf1-2e4a-49cc-bad4-323b8d73e89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_130512e1-bd8c-4e44-8648-8c97636b7ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2795f91f-7507-4c46-aaa5-e174f635f316" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_130512e1-bd8c-4e44-8648-8c97636b7ee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e9fa264a-e4e3-4065-8442-4388f1be24c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2795f91f-7507-4c46-aaa5-e174f635f316" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e9fa264a-e4e3-4065-8442-4388f1be24c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b5f1ff81-3eb4-47f7-8604-d2103974b065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2795f91f-7507-4c46-aaa5-e174f635f316" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b5f1ff81-3eb4-47f7-8604-d2103974b065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_adfed556-0dfb-4328-a9e3-578ec21c02f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2795f91f-7507-4c46-aaa5-e174f635f316" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_adfed556-0dfb-4328-a9e3-578ec21c02f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9ecb6336-a90c-46b7-a914-33d97f747412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2795f91f-7507-4c46-aaa5-e174f635f316" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9ecb6336-a90c-46b7-a914-33d97f747412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52663bf7-edc4-4747-ae51-99231e98fee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6f607fef-ebbf-4778-9811-a99be7415981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52663bf7-edc4-4747-ae51-99231e98fee9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6f607fef-ebbf-4778-9811-a99be7415981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f20adfdb-1fa0-456d-b5ec-3e618fdad662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52663bf7-edc4-4747-ae51-99231e98fee9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f20adfdb-1fa0-456d-b5ec-3e618fdad662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44c1c710-255a-4543-9950-8d47947d4488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52663bf7-edc4-4747-ae51-99231e98fee9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44c1c710-255a-4543-9950-8d47947d4488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3fb5e6fb-17c5-460b-a403-dcfd3defa794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52663bf7-edc4-4747-ae51-99231e98fee9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3fb5e6fb-17c5-460b-a403-dcfd3defa794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00a24000-b4d8-4a4c-b07d-c9040e41fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_35ee1f2f-f04e-4a01-8296-17ed707629ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00a24000-b4d8-4a4c-b07d-c9040e41fb6d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_35ee1f2f-f04e-4a01-8296-17ed707629ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c1f9a6b4-bb81-48a7-8c69-b5f3fd49bc15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c1f9a6b4-bb81-48a7-8c69-b5f3fd49bc15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2615e195-0104-40ef-b4c9-b9926479c208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2615e195-0104-40ef-b4c9-b9926479c208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_1a24c272-a086-4fba-8dfa-c29703cf3d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_1a24c272-a086-4fba-8dfa-c29703cf3d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_04beb781-87d3-420a-a866-f1fa3a2ee2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_04beb781-87d3-420a-a866-f1fa3a2ee2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_fb615e24-fe32-4aad-9503-a513aa6f2618" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_fb615e24-fe32-4aad-9503-a513aa6f2618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_947db384-38ed-4eee-ab7e-8c41655baa89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_947db384-38ed-4eee-ab7e-8c41655baa89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_087671de-ea6a-4c50-8602-fcb330f79070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_087671de-ea6a-4c50-8602-fcb330f79070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_09a98c47-397b-4237-b413-db645c59e40c" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_09a98c47-397b-4237-b413-db645c59e40c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_43d5b273-09d9-4dcb-9be8-35f6fb3f88cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_43d5b273-09d9-4dcb-9be8-35f6fb3f88cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2f5066ee-1720-4fd8-ab4a-c9d97381e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2f5066ee-1720-4fd8-ab4a-c9d97381e9ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInLicenseAgreementObligations_8737cde7-f1c6-4c6c-b54a-2dc41bddf5f1" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInLicenseAgreementObligations"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_vrna_IncreaseDecreaseInLicenseAgreementObligations_8737cde7-f1c6-4c6c-b54a-2dc41bddf5f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6e7ed6c2-8b73-4b23-abdc-2ea49cf905a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_NetIncomeLoss_6e7ed6c2-8b73-4b23-abdc-2ea49cf905a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9c543826-514b-48b0-8cd6-b492f26ce888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_ShareBasedCompensation_9c543826-514b-48b0-8cd6-b492f26ce888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8d833dea-ba5e-4367-977d-90b1cfa8f30e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8d833dea-ba5e-4367-977d-90b1cfa8f30e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d3abe2b0-85e5-429c-bfef-73b7e30d5a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_d3abe2b0-85e5-429c-bfef-73b7e30d5a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a05d2a4f-904b-466d-8955-3cb035256178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a05d2a4f-904b-466d-8955-3cb035256178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense_85e339d6-8783-45b6-801d-2472fdeaa4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_AccretionExpense_85e339d6-8783-45b6-801d-2472fdeaa4f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_76e23c52-eda3-4eb9-bbd4-9060f799d58e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_76e23c52-eda3-4eb9-bbd4-9060f799d58e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3607ed57-b0df-4378-879c-d58eac52402e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00001ab3-8b26-4737-b561-037e2d32511b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3607ed57-b0df-4378-879c-d58eac52402e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#AccruedexpensesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6dbe50af-3b43-46ca-b3cc-f1a58b98b961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_b5b75b78-dd6f-4db3-b07d-0fde15209abb" xlink:href="vrna-20240930.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6dbe50af-3b43-46ca-b3cc-f1a58b98b961" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_b5b75b78-dd6f-4db3-b07d-0fde15209abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_22d2e386-c9c4-4882-a214-591a0499d4bc" xlink:href="vrna-20240930.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6dbe50af-3b43-46ca-b3cc-f1a58b98b961" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_22d2e386-c9c4-4882-a214-591a0499d4bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cd7e5245-4c10-4ce3-88b5-fbe6ebec3f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6dbe50af-3b43-46ca-b3cc-f1a58b98b961" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cd7e5245-4c10-4ce3-88b5-fbe6ebec3f2a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vrna-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0ee8d2e7-f00d-490d-8b34-d8e4d0ae151e,g:42222ec7-8dc8-4139-853e-ab7cbe924947-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e7ad25f-b3ce-4274-89e5-3e8df0ac51d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1e7ad25f-b3ce-4274-89e5-3e8df0ac51d4" xlink:to="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2069f178-6a5d-496e-90b6-b0e07bc9ee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2069f178-6a5d-496e-90b6-b0e07bc9ee6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2069f178-6a5d-496e-90b6-b0e07bc9ee6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2069f178-6a5d-496e-90b6-b0e07bc9ee6c" xlink:to="loc_us-gaap_EquityComponentDomain_2069f178-6a5d-496e-90b6-b0e07bc9ee6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2069f178-6a5d-496e-90b6-b0e07bc9ee6c" xlink:to="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b9c80819-447b-4148-aea0-0444b517b760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_CommonStockMember_b9c80819-447b-4148-aea0-0444b517b760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f8555aee-e000-4763-8bde-8190d70f9703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f8555aee-e000-4763-8bde-8190d70f9703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_cd0c4e50-1ef4-4a94-8f06-c50631b35263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_TreasuryStockCommonMember_cd0c4e50-1ef4-4a94-8f06-c50631b35263" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7094b38e-5398-4c8b-adde-91fe7a5391e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7094b38e-5398-4c8b-adde-91fe7a5391e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2f75fbef-8a6b-4159-bac3-06ea74c4f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_RetainedEarningsMember_2f75fbef-8a6b-4159-bac3-06ea74c4f4e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3c7d383c-e2e4-400e-9119-d90a339e1e41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3c7d383c-e2e4-400e-9119-d90a339e1e41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c7d383c-e2e4-400e-9119-d90a339e1e41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c7d383c-e2e4-400e-9119-d90a339e1e41" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c7d383c-e2e4-400e-9119-d90a339e1e41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ecdae7f-1a53-44d7-9ca8-1e02330234c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c7d383c-e2e4-400e-9119-d90a339e1e41" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ecdae7f-1a53-44d7-9ca8-1e02330234c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember_739da5fb-8fda-4b45-bd36-96d9d4820d2a" xlink:href="vrna-20240930.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ecdae7f-1a53-44d7-9ca8-1e02330234c8" xlink:to="loc_vrna_AtTheMarketSalesAgreementMember_739da5fb-8fda-4b45-bd36-96d9d4820d2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e7ad25f-b3ce-4274-89e5-3e8df0ac51d4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fe30bd29-ba96-4675-a510-8702dd950a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fe30bd29-ba96-4675-a510-8702dd950a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc516bbf-9c21-4d93-8060-2b9b8b515e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockholdersEquity_dc516bbf-9c21-4d93-8060-2b9b8b515e0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81da0b66-677a-4f3f-9106-f37f56c4e278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_NetIncomeLoss_81da0b66-677a-4f3f-9106-f37f56c4e278" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eb1e708-03d0-4fd5-989c-3b1c58dfecd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eb1e708-03d0-4fd5-989c-3b1c58dfecd8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_375da28b-7dc4-4602-8d3c-931a39ba320a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_375da28b-7dc4-4602-8d3c-931a39ba320a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_bbca2754-464b-4a37-82c3-3836e8807478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_bbca2754-464b-4a37-82c3-3836e8807478" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b2f8f78-73fe-4980-915c-604de1f9594d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b2f8f78-73fe-4980-915c-604de1f9594d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_204cfaf9-d088-41cd-a5f8-8979e7247c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_204cfaf9-d088-41cd-a5f8-8979e7247c7d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_8b8a5afa-b3f9-4db8-aee0-cd729a9353e6" xlink:href="vrna-20240930.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_8b8a5afa-b3f9-4db8-aee0-cd729a9353e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d40fdf8-395b-4955-a07f-2983f2e39643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d40fdf8-395b-4955-a07f-2983f2e39643" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_22bf3297-7afe-4430-b5ee-5c0e652c303f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ecdbfa88-9daa-4331-9f12-052377e06f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_66fc6b52-f6ff-4451-afbd-c477cf2ffba5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:to="loc_srt_MajorCustomersAxis_66fc6b52-f6ff-4451-afbd-c477cf2ffba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_66fc6b52-f6ff-4451-afbd-c477cf2ffba5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_66fc6b52-f6ff-4451-afbd-c477cf2ffba5" xlink:to="loc_srt_NameOfMajorCustomerDomain_66fc6b52-f6ff-4451-afbd-c477cf2ffba5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_528c24c8-5f29-4447-b28f-4a7b5daf8fa7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_66fc6b52-f6ff-4451-afbd-c477cf2ffba5" xlink:to="loc_srt_NameOfMajorCustomerDomain_528c24c8-5f29-4447-b28f-4a7b5daf8fa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SpecialtyPharmaciesMember_d0c2ddd5-d244-4239-b929-29335ac76abb" xlink:href="vrna-20240930.xsd#vrna_SpecialtyPharmaciesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_528c24c8-5f29-4447-b28f-4a7b5daf8fa7" xlink:to="loc_vrna_SpecialtyPharmaciesMember_d0c2ddd5-d244-4239-b929-29335ac76abb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e071e8f-3dc3-445d-b6b0-e185823adad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e071e8f-3dc3-445d-b6b0-e185823adad0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e071e8f-3dc3-445d-b6b0-e185823adad0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e071e8f-3dc3-445d-b6b0-e185823adad0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e071e8f-3dc3-445d-b6b0-e185823adad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_468d76e2-2e10-4f1d-a01a-c1a0e8b218ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e071e8f-3dc3-445d-b6b0-e185823adad0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_468d76e2-2e10-4f1d-a01a-c1a0e8b218ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_652a59e1-704c-4339-8c5e-a596fd10d373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_468d76e2-2e10-4f1d-a01a-c1a0e8b218ac" xlink:to="loc_us-gaap_SalesRevenueNetMember_652a59e1-704c-4339-8c5e-a596fd10d373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9dd640be-8f47-4515-8264-2a9f733499d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9dd640be-8f47-4515-8264-2a9f733499d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9dd640be-8f47-4515-8264-2a9f733499d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9dd640be-8f47-4515-8264-2a9f733499d9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9dd640be-8f47-4515-8264-2a9f733499d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_68d5910a-70ce-4ffd-9f4c-c537ba8d90d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9dd640be-8f47-4515-8264-2a9f733499d9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_68d5910a-70ce-4ffd-9f4c-c537ba8d90d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e693cda2-3571-4079-bcd0-956043413406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_68d5910a-70ce-4ffd-9f4c-c537ba8d90d1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e693cda2-3571-4079-bcd0-956043413406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_faec7815-8ec1-46a1-b523-3f3aad1e32c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:to="loc_us-gaap_NumberOfOperatingSegments_faec7815-8ec1-46a1-b523-3f3aad1e32c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3d7a66bd-3eec-4c4e-8a71-f89769ebf02f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:to="loc_us-gaap_NumberOfReportableSegments_3d7a66bd-3eec-4c4e-8a71-f89769ebf02f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c8f1bfdc-5e5f-428c-9c1a-81ae42051733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c8f1bfdc-5e5f-428c-9c1a-81ae42051733" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterestDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#EquityInterestDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/EquityInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_162c4d20-b21c-4012-b795-9a3fbc340bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_162c4d20-b21c-4012-b795-9a3fbc340bd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_05f87cd6-d77b-46ab-b72b-36d96ea8804e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_162c4d20-b21c-4012-b795-9a3fbc340bd8" xlink:to="loc_srt_CounterpartyNameAxis_05f87cd6-d77b-46ab-b72b-36d96ea8804e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05f87cd6-d77b-46ab-b72b-36d96ea8804e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_05f87cd6-d77b-46ab-b72b-36d96ea8804e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05f87cd6-d77b-46ab-b72b-36d96ea8804e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76307d44-aebe-46b3-bc37-5915264f9664" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_05f87cd6-d77b-46ab-b72b-36d96ea8804e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76307d44-aebe-46b3-bc37-5915264f9664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_f127c6c1-5e2f-4f5f-93b4-8ad432bb8f5e" xlink:href="vrna-20240930.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76307d44-aebe-46b3-bc37-5915264f9664" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_f127c6c1-5e2f-4f5f-93b4-8ad432bb8f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_9008d79e-4921-4796-a06e-c984473459e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_9008d79e-4921-4796-a06e-c984473459e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_68d082ea-1e49-4f98-9e21-89f2d5ef6cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_68d082ea-1e49-4f98-9e21-89f2d5ef6cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_7fb66ea5-f417-4a1a-9ffc-8b8f4ad4df95" xlink:href="vrna-20240930.xsd#vrna_EquityInterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:to="loc_vrna_EquityInterestReceivable_7fb66ea5-f417-4a1a-9ffc-8b8f4ad4df95" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1" xlink:type="simple" xlink:href="vrna-20240930.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22835647-e015-415c-b26b-98471c626781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b49e0b2-00ba-4cdc-b9ba-377b53d32cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22835647-e015-415c-b26b-98471c626781" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b49e0b2-00ba-4cdc-b9ba-377b53d32cbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4e3c2b2f-c76f-4105-b36e-b50be3c8d618" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b49e0b2-00ba-4cdc-b9ba-377b53d32cbb" xlink:to="loc_srt_CounterpartyNameAxis_4e3c2b2f-c76f-4105-b36e-b50be3c8d618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e3c2b2f-c76f-4105-b36e-b50be3c8d618_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4e3c2b2f-c76f-4105-b36e-b50be3c8d618" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e3c2b2f-c76f-4105-b36e-b50be3c8d618_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495bbe2b-1182-4fb9-9650-6398626b8594" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4e3c2b2f-c76f-4105-b36e-b50be3c8d618" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495bbe2b-1182-4fb9-9650-6398626b8594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember_725b715e-ca02-4e9a-bcc8-307d590d8ca6" xlink:href="vrna-20240930.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495bbe2b-1182-4fb9-9650-6398626b8594" xlink:to="loc_vrna_LigandUKDevelopmentLimitedMember_725b715e-ca02-4e9a-bcc8-307d590d8ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bf016f84-d540-4a8a-988b-b118bbdc3f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22835647-e015-415c-b26b-98471c626781" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bf016f84-d540-4a8a-988b-b118bbdc3f27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d11bde7c-922e-4d55-a17f-4fd50e5d8330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22835647-e015-415c-b26b-98471c626781" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d11bde7c-922e-4d55-a17f-4fd50e5d8330" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/DebtDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_11059edb-d7ec-45b8-93ed-999b43809cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_DebtInstrumentAxis_11059edb-d7ec-45b8-93ed-999b43809cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_11059edb-d7ec-45b8-93ed-999b43809cfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_11059edb-d7ec-45b8-93ed-999b43809cfe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_11059edb-d7ec-45b8-93ed-999b43809cfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_11059edb-d7ec-45b8-93ed-999b43809cfe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2023TermLoanMember_a815af65-310c-456e-9ee3-d239d787850e" xlink:href="vrna-20240930.xsd#vrna_A2023TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2023TermLoanMember_a815af65-310c-456e-9ee3-d239d787850e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2023TermALoanMember_aae4fee0-7f60-44cd-acb3-d36f837e9966" xlink:href="vrna-20240930.xsd#vrna_A2023TermALoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2023TermALoanMember_aae4fee0-7f60-44cd-acb3-d36f837e9966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermLoanMember_37a64c9e-c8dd-474d-bfc4-a11c2197eff8" xlink:href="vrna-20240930.xsd#vrna_A2024TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermLoanMember_37a64c9e-c8dd-474d-bfc4-a11c2197eff8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermALoanMember_6f304d73-ee57-40d8-a6bf-c40d1053d824" xlink:href="vrna-20240930.xsd#vrna_A2024TermALoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermALoanMember_6f304d73-ee57-40d8-a6bf-c40d1053d824" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermBMember_c484db44-63f7-4748-941d-90ad68e1db23" xlink:href="vrna-20240930.xsd#vrna_A2024TermBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermBMember_c484db44-63f7-4748-941d-90ad68e1db23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermCMember_e0540e52-e415-4ec9-983d-80b81703ac2c" xlink:href="vrna-20240930.xsd#vrna_A2024TermCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermCMember_e0540e52-e415-4ec9-983d-80b81703ac2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermDMember_e46b21e2-e8c2-4cdb-b6c0-89c6a3b3120a" xlink:href="vrna-20240930.xsd#vrna_A2024TermDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermDMember_e46b21e2-e8c2-4cdb-b6c0-89c6a3b3120a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermELoanMember_79b704e3-1ddc-4a5e-ba0a-a5bc538c572b" xlink:href="vrna-20240930.xsd#vrna_A2024TermELoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermELoanMember_79b704e3-1ddc-4a5e-ba0a-a5bc538c572b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_930d2e25-8da9-49c8-8df8-ef9577b39cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_930d2e25-8da9-49c8-8df8-ef9577b39cfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_930d2e25-8da9-49c8-8df8-ef9577b39cfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_930d2e25-8da9-49c8-8df8-ef9577b39cfd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_930d2e25-8da9-49c8-8df8-ef9577b39cfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c458f3bc-ae26-4068-b97b-3386d51a6a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_930d2e25-8da9-49c8-8df8-ef9577b39cfd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c458f3bc-ae26-4068-b97b-3386d51a6a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_6dbdfe27-1763-4d62-85ca-29654a29c475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c458f3bc-ae26-4068-b97b-3386d51a6a39" xlink:to="loc_us-gaap_SecuredDebtMember_6dbdfe27-1763-4d62-85ca-29654a29c475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_19262397-a3c6-4847-a12b-43d5e8beb675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_CreditFacilityAxis_19262397-a3c6-4847-a12b-43d5e8beb675" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_19262397-a3c6-4847-a12b-43d5e8beb675_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_19262397-a3c6-4847-a12b-43d5e8beb675" xlink:to="loc_us-gaap_CreditFacilityDomain_19262397-a3c6-4847-a12b-43d5e8beb675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0e0e38bc-5229-4416-8c30-f2e9e82aa01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_19262397-a3c6-4847-a12b-43d5e8beb675" xlink:to="loc_us-gaap_CreditFacilityDomain_0e0e38bc-5229-4416-8c30-f2e9e82aa01a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6cf390e2-62a7-46d3-8bc0-ea015eac2824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0e0e38bc-5229-4416-8c30-f2e9e82aa01a" xlink:to="loc_us-gaap_LineOfCreditMember_6cf390e2-62a7-46d3-8bc0-ea015eac2824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis_95d4bd12-9790-4b33-8952-3ca702cb5388" xlink:href="vrna-20240930.xsd#vrna_InterestRatePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_vrna_InterestRatePeriodAxis_95d4bd12-9790-4b33-8952-3ca702cb5388" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_95d4bd12-9790-4b33-8952-3ca702cb5388_default" xlink:href="vrna-20240930.xsd#vrna_InterestRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vrna_InterestRatePeriodAxis_95d4bd12-9790-4b33-8952-3ca702cb5388" xlink:to="loc_vrna_InterestRatePeriodDomain_95d4bd12-9790-4b33-8952-3ca702cb5388_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_fb64782d-cc9f-42e1-8959-245c842870a3" xlink:href="vrna-20240930.xsd#vrna_InterestRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vrna_InterestRatePeriodAxis_95d4bd12-9790-4b33-8952-3ca702cb5388" xlink:to="loc_vrna_InterestRatePeriodDomain_fb64782d-cc9f-42e1-8959-245c842870a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_0be010be-ba5f-48f1-8329-e7f96f635fd9" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_InterestRatePeriodDomain_fb64782d-cc9f-42e1-8959-245c842870a3" xlink:to="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_0be010be-ba5f-48f1-8329-e7f96f635fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_VariableRateAxis_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553" xlink:to="loc_us-gaap_VariableRateDomain_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9b1237d2-5441-4239-af9e-a64821829ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553" xlink:to="loc_us-gaap_VariableRateDomain_9b1237d2-5441-4239-af9e-a64821829ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_f89fb7af-98cc-4c6d-9ceb-857c0773907e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_9b1237d2-5441-4239-af9e-a64821829ff8" xlink:to="loc_us-gaap_BaseRateMember_f89fb7af-98cc-4c6d-9ceb-857c0773907e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodAxis_559c6f56-c46f-4540-b6a6-da44e61ddfe5" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_vrna_DebtPrepaymentPeriodAxis_559c6f56-c46f-4540-b6a6-da44e61ddfe5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodDomain_559c6f56-c46f-4540-b6a6-da44e61ddfe5_default" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vrna_DebtPrepaymentPeriodAxis_559c6f56-c46f-4540-b6a6-da44e61ddfe5" xlink:to="loc_vrna_DebtPrepaymentPeriodDomain_559c6f56-c46f-4540-b6a6-da44e61ddfe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vrna_DebtPrepaymentPeriodAxis_559c6f56-c46f-4540-b6a6-da44e61ddfe5" xlink:to="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodOneMember_16a7bc48-6fd0-41dc-9ec4-5d68b842dc23" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:to="loc_vrna_DebtPrepaymentPeriodOneMember_16a7bc48-6fd0-41dc-9ec4-5d68b842dc23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodTwoMember_f6ccaca1-2c67-4b20-9075-b4067e76523c" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:to="loc_vrna_DebtPrepaymentPeriodTwoMember_f6ccaca1-2c67-4b20-9075-b4067e76523c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodFourMember_8d3fb07f-23be-4177-80a3-c203029955bf" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:to="loc_vrna_DebtPrepaymentPeriodFourMember_8d3fb07f-23be-4177-80a3-c203029955bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e2c33ef2-ccca-4a53-a561-1609ebab871f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_srt_RangeAxis_e2c33ef2-ccca-4a53-a561-1609ebab871f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e2c33ef2-ccca-4a53-a561-1609ebab871f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e2c33ef2-ccca-4a53-a561-1609ebab871f" xlink:to="loc_srt_RangeMember_e2c33ef2-ccca-4a53-a561-1609ebab871f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57ef4167-c07d-464e-8136-3680f1d01b8f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e2c33ef2-ccca-4a53-a561-1609ebab871f" xlink:to="loc_srt_RangeMember_57ef4167-c07d-464e-8136-3680f1d01b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87422450-4898-4739-97cf-4c8e8ba86b13" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57ef4167-c07d-464e-8136-3680f1d01b8f" xlink:to="loc_srt_MinimumMember_87422450-4898-4739-97cf-4c8e8ba86b13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8683bf92-eb27-4834-a2eb-65eb583e356b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_srt_CounterpartyNameAxis_8683bf92-eb27-4834-a2eb-65eb583e356b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8683bf92-eb27-4834-a2eb-65eb583e356b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8683bf92-eb27-4834-a2eb-65eb583e356b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8683bf92-eb27-4834-a2eb-65eb583e356b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15457596-b05a-4918-abdf-d32a3e5f0fee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8683bf92-eb27-4834-a2eb-65eb583e356b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15457596-b05a-4918-abdf-d32a3e5f0fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OaktreeFundAdministrationLLCMember_c2b8ccea-f94f-482f-9cd6-426e8e5128ad" xlink:href="vrna-20240930.xsd#vrna_OaktreeFundAdministrationLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15457596-b05a-4918-abdf-d32a3e5f0fee" xlink:to="loc_vrna_OaktreeFundAdministrationLLCMember_c2b8ccea-f94f-482f-9cd6-426e8e5128ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_078fe279-ba9d-4949-a420-71b48f66d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_078fe279-ba9d-4949-a420-71b48f66d2b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fe564d6b-459e-45d2-9a69-b3d6fdf0b5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fe564d6b-459e-45d2-9a69-b3d6fdf0b5dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_36a3a7a6-5cce-458a-8751-0cfc9c0b2de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_36a3a7a6-5cce-458a-8751-0cfc9c0b2de6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4b368db7-b912-4bf8-bb97-402383e49b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4b368db7-b912-4bf8-bb97-402383e49b71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_b8390414-81d0-418d-826d-e17d8a452474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_b8390414-81d0-418d-826d-e17d8a452474" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_9ebc47b5-c664-47d8-8fb5-376931860620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_9ebc47b5-c664-47d8-8fb5-376931860620" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_206cb740-b6a0-45e5-8010-f43001dd03c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_206cb740-b6a0-45e5-8010-f43001dd03c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f478064b-e7ea-4d69-9bfd-73ca6d7778a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_LongTermDebt_f478064b-e7ea-4d69-9bfd-73ca6d7778a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_a26f11c9-d3b1-443b-a184-b9e2bcf6a155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_a26f11c9-d3b1-443b-a184-b9e2bcf6a155" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_47c7e1df-9c0f-46db-b745-7a3b0292de01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_47c7e1df-9c0f-46db-b745-7a3b0292de01" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f152962c-702d-4a4d-8137-885b2ff7745a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f152962c-702d-4a4d-8137-885b2ff7745a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentExitFeePercentage_ac4a701d-94ab-464d-90ce-dbc5b0f352fe" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentExitFeePercentage_ac4a701d-94ab-464d-90ce-dbc5b0f352fe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_231c2817-6b2c-49b4-a8fd-47e475e6301a" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_231c2817-6b2c-49b4-a8fd-47e475e6301a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_db6bc6dd-0b49-417a-b663-823c249a418e" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_db6bc6dd-0b49-417a-b663-823c249a418e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7c3d0ba3-06ff-463f-8ee5-81524f678f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7c3d0ba3-06ff-463f-8ee5-81524f678f4a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple_8cf7d0cd-91b2-4de3-9efd-d43d07bd51f2" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentPartialPrepaymentDenominationMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple_8cf7d0cd-91b2-4de3-9efd-d43d07bd51f2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum_13648dfa-71ed-4b43-8834-dc33c906c65f" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum_13648dfa-71ed-4b43-8834-dc33c906c65f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion_37501be9-59ce-4da1-9796-7473fca19701" xlink:href="vrna-20240930.xsd#vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion_37501be9-59ce-4da1-9796-7473fca19701" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d5eb578f-3594-451a-886a-1b24bd8f8e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d5eb578f-3594-451a-886a-1b24bd8f8e03" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice_0a4d09c1-2d43-4c0b-9714-8707b6408aba" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice_0a4d09c1-2d43-4c0b-9714-8707b6408aba" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales_27ec6f68-fe61-42ac-bd1c-7fff9621e71d" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales_27ec6f68-fe61-42ac-bd1c-7fff9621e71d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees_7042ff41-1868-40ab-b9d7-89bc40a3b923" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees_7042ff41-1868-40ab-b9d7-89bc40a3b923" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding_ae49bbf9-b157-4493-bc85-a284f913f17f" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding_ae49bbf9-b157-4493-bc85-a284f913f17f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultiple_441cbd28-833c-42d9-8f37-0c7cd9fb0690" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultiple_441cbd28-833c-42d9-8f37-0c7cd9fb0690" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne_d4db8aca-257f-435a-bcc2-74b522ba4406" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne_d4db8aca-257f-435a-bcc2-74b522ba4406" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo_470edaa5-a100-4360-a41c-47ed34e0ecc5" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo_470edaa5-a100-4360-a41c-47ed34e0ecc5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree_a00ea840-2cf5-4eac-ad0e-989ad4f23a4c" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree_a00ea840-2cf5-4eac-ad0e-989ad4f23a4c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree_fe937afa-6833-4f5c-98f1-50fc1c21bb4c" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree_fe937afa-6833-4f5c-98f1-50fc1c21bb4c" xlink:type="arc" order="27"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_393a848b-fd0b-4081-83fc-8251be5dcd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_332eddb1-9e9a-4191-aec0-71aef48dd638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_393a848b-fd0b-4081-83fc-8251be5dcd1b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_332eddb1-9e9a-4191-aec0-71aef48dd638" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e505cfcd-57a9-4942-8f6a-fddb32574cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_332eddb1-9e9a-4191-aec0-71aef48dd638" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e505cfcd-57a9-4942-8f6a-fddb32574cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e505cfcd-57a9-4942-8f6a-fddb32574cb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e505cfcd-57a9-4942-8f6a-fddb32574cb4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e505cfcd-57a9-4942-8f6a-fddb32574cb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_41cd571f-6982-4c37-8f4c-10af794dd061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e505cfcd-57a9-4942-8f6a-fddb32574cb4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_41cd571f-6982-4c37-8f4c-10af794dd061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_47e18677-e108-4c15-9024-a4127d0339d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_41cd571f-6982-4c37-8f4c-10af794dd061" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_47e18677-e108-4c15-9024-a4127d0339d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_493fe8c3-1e34-4f16-ae2f-cf86ac050091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_41cd571f-6982-4c37-8f4c-10af794dd061" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_493fe8c3-1e34-4f16-ae2f-cf86ac050091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc0c7a2f-8b82-4b92-b8c7-c985a6f77f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_393a848b-fd0b-4081-83fc-8251be5dcd1b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc0c7a2f-8b82-4b92-b8c7-c985a6f77f56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bee653fc-74bb-44ec-b9c2-ee2a54cd8924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0329d5-fd64-4084-8a79-3fb6bff2eb74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bee653fc-74bb-44ec-b9c2-ee2a54cd8924" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0329d5-fd64-4084-8a79-3fb6bff2eb74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4392f02-48ef-483b-b0fd-8263fb6ef431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0329d5-fd64-4084-8a79-3fb6bff2eb74" xlink:to="loc_us-gaap_AwardTypeAxis_d4392f02-48ef-483b-b0fd-8263fb6ef431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4392f02-48ef-483b-b0fd-8263fb6ef431_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d4392f02-48ef-483b-b0fd-8263fb6ef431" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4392f02-48ef-483b-b0fd-8263fb6ef431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_943e8963-a595-49f0-a473-b6eefbec1ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d4392f02-48ef-483b-b0fd-8263fb6ef431" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_943e8963-a595-49f0-a473-b6eefbec1ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4960b70f-9679-4ff2-b9b0-a8fad878e7db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_943e8963-a595-49f0-a473-b6eefbec1ba6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4960b70f-9679-4ff2-b9b0-a8fad878e7db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_18eec78d-c8ce-424e-bf9c-17200e3db5ce" xlink:href="vrna-20240930.xsd#vrna_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_943e8963-a595-49f0-a473-b6eefbec1ba6" xlink:to="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_18eec78d-c8ce-424e-bf9c-17200e3db5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bee653fc-74bb-44ec-b9c2-ee2a54cd8924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3dd057bc-c8bf-4036-9656-5cc95261a694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3dd057bc-c8bf-4036-9656-5cc95261a694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1a6eec89-acec-4afc-a5dc-237e79b60ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1a6eec89-acec-4afc-a5dc-237e79b60ce2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b017e49d-fdeb-4338-9439-dac9547754e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b017e49d-fdeb-4338-9439-dac9547754e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e3b6d5f2-e10c-4dab-a2bc-c5bfc20150eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306a3d56-d359-4962-b621-3cc48e2036a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306a3d56-d359-4962-b621-3cc48e2036a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7797d752-21b6-406e-912b-daa6a7b122c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306a3d56-d359-4962-b621-3cc48e2036a8" xlink:to="loc_us-gaap_AwardTypeAxis_7797d752-21b6-406e-912b-daa6a7b122c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7797d752-21b6-406e-912b-daa6a7b122c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7797d752-21b6-406e-912b-daa6a7b122c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7797d752-21b6-406e-912b-daa6a7b122c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84a63fc8-d4a8-4135-8c6c-4ca0b3ebbea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7797d752-21b6-406e-912b-daa6a7b122c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84a63fc8-d4a8-4135-8c6c-4ca0b3ebbea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_3030d63d-76c3-4dd5-9cf7-736ccbba27ba" xlink:href="vrna-20240930.xsd#vrna_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84a63fc8-d4a8-4135-8c6c-4ca0b3ebbea2" xlink:to="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_3030d63d-76c3-4dd5-9cf7-736ccbba27ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_242fa443-c949-4fca-84e2-6fde9a4e9310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_242fa443-c949-4fca-84e2-6fde9a4e9310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fb3f412a-db25-4763-8b3a-cd215110c603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fb3f412a-db25-4763-8b3a-cd215110c603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2291f340-5da3-41cc-a8c9-fe252148c1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2291f340-5da3-41cc-a8c9-fe252148c1b5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_e678e3a6-c1cf-4ba2-b5b9-960e045660d2" xlink:href="vrna-20240930.xsd#vrna_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_e678e3a6-c1cf-4ba2-b5b9-960e045660d2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DavidZaccardelliMember_03e207eb-9b62-45f9-8e22-8413540421e0" xlink:href="vrna-20240930.xsd#vrna_DavidZaccardelliMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_vrna_DavidZaccardelliMember_03e207eb-9b62-45f9-8e22-8413540421e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MarkHahnMember_875fa471-e303-4ed9-8bef-702526f25f1c" xlink:href="vrna-20240930.xsd#vrna_MarkHahnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_vrna_MarkHahnMember_875fa471-e303-4ed9-8bef-702526f25f1c" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vrna-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0ee8d2e7-f00d-490d-8b34-d8e4d0ae151e,g:42222ec7-8dc8-4139-853e-ab7cbe924947-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_ad9b53ac-6ef8-4d4f-ab82-7d45e30c0081_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_593e1168-3c9c-4bb1-9a99-fbb6016bf208_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5c3daef1-3c1f-44f9-b857-7e9ee48330ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_cfee72c5-986a-446b-9239-0c0b180a296b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_31c7c47c-0f85-4076-9ea1-bff68f71122e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_50e3e99a-d636-44f9-9b17-b2e8de312ac1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ef56d0d2-24b3-4994-ba60-2aff643189d6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_66227316-3019-4896-9167-4f085af43f14_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_675f8437-59fb-4e7f-9ff6-6b2bfe11bb19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_9e31116b-17fc-4482-881d-973cc087f2ec_negatedTerseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax incentive receivable</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:to="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_da409d12-75f4-4911-a569-96efaaa88886_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_53feddb1-3522-4e91-9cef-19453b7ff8f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_8037ef52-5d1c-42d2-9584-3e5f2f9a85cc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt and Capital Securities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales_aa458a65-6588-4f39-b5e0-cfb9e0962b95_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of global net sales</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Purchaser Percentage, Global Net Sales</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Purchaser Percentage, Global Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c87fdcc4-2edd-47c8-9a95-e1465db7e2ca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2024TermBMember_a015d72a-14c2-409f-ac4c-0471db7edb00_terseLabel_en-US" xlink:label="lab_vrna_A2024TermBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Term B</link:label>
    <link:label id="lab_vrna_A2024TermBMember_label_en-US" xlink:label="lab_vrna_A2024TermBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Term B [Member]</link:label>
    <link:label id="lab_vrna_A2024TermBMember_documentation_en-US" xlink:label="lab_vrna_A2024TermBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Term B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermBMember" xlink:href="vrna-20240930.xsd#vrna_A2024TermBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2024TermBMember" xlink:to="lab_vrna_A2024TermBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_155e5b12-7271-4266-8972-b63b00657279_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_e69bb328-d061-414c-b8ab-2b91ece1af9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice_27dbcdcf-a2cb-46bb-a30b-a45411115b4c_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Purchase Price</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d50a0009-0a91-4a2d-a91d-e0ec09d6bc8f_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other (expense)/income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_696e9f2f-4af0-44df-81d5-0a97efe0b375_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f0f3da09-9d50-4689-ad8b-4ce6860ae398_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_dfac001b-ff86-408a-a5e6-c9c42445f0ee_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_9b0be6e9-01a0-4b77-88a2-9c0160943eaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a2c68b2b-ec71-46f4-b297-4860e8cc80e9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2a3821ac-3fbe-46a0-9361-a2f728d7a9aa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d36e06e9-5c4f-4107-b165-cb3406135e8e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit/(loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_af5c5a09-fc72-4cbd-ba01-c4a3b113a018_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_fde71ce9-1148-4e4e-82f6-a7d3b85cc2d2_terseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_b3b9aeee-632a-422f-a899-235a234b6b27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_834f706e-3fcd-4db5-a8ab-60d6aa340497_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_582109aa-b6f7-4a22-abdd-ca9c9350d368_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2fe4c30c-c710-4bb4-858a-d277738d4b7a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_df9c3299-8b5c-431c-ae0d-85d115630dae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_e5c30264-69cb-4fa6-8042-bab7d27cd430_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2185d134-77af-4026-9b2b-02dad4a87628_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1cec8cc2-4132-4684-ad0a-241d16809635_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_67efdaea-f002-4810-8e5a-9a69eeac3e7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9aff26b5-6ed9-42bc-913f-26f8ec454735_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4b70c948-7380-41eb-be09-16eb3fc5fd5b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_341a573c-8227-42fb-87e0-e8e1e26ad9e9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_edabb5b6-f24f-4037-9b39-1dd80766582a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion_8ab7213f-82c6-48b0-8860-18550b87fb5d_terseLabel_en-US" xlink:label="lab_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum american depository shares value</link:label>
    <link:label id="lab_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion_label_en-US" xlink:label="lab_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant, Average Daily VWAP And American Depository Shares Value Calcualtion</link:label>
    <link:label id="lab_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion_documentation_en-US" xlink:label="lab_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant, Average Daily VWAP And American Depository Shares Value Calcualtion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" xlink:href="vrna-20240930.xsd#vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" xlink:to="lab_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f041672d-5281-423a-b040-c95b4ded2966_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SpecialtyPharmaciesMember_de9312b4-1d2e-4572-99d8-cecc12f42cda_terseLabel_en-US" xlink:label="lab_vrna_SpecialtyPharmaciesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Specialty Pharmacies</link:label>
    <link:label id="lab_vrna_SpecialtyPharmaciesMember_label_en-US" xlink:label="lab_vrna_SpecialtyPharmaciesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Specialty Pharmacies [Member]</link:label>
    <link:label id="lab_vrna_SpecialtyPharmaciesMember_documentation_en-US" xlink:label="lab_vrna_SpecialtyPharmaciesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Specialty Pharmacies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SpecialtyPharmaciesMember" xlink:href="vrna-20240930.xsd#vrna_SpecialtyPharmaciesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SpecialtyPharmaciesMember" xlink:to="lab_vrna_SpecialtyPharmaciesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_83792bdb-f54f-4bee-aef3-039e66dff4c4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of redemption premium on debt</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_dc8d460b-69aa-4876-8c3a-81a8544241f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_663dcab0-881a-4e5c-bb58-ceafc108798e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18cf20d3-2706-4a3c-bdfb-1c8012a388f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d8ac8ace-2b11-45ad-8424-b8b5bdd064da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_ccc3a80e-993c-4f23-b984-168cbe856589_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt default stated percentage</link:label>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_label_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:to="lab_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_f532dba4-7350-407e-b298-61d13a2382c1_terseLabel_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and description of business operations</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_label_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Business Description [Text Block]</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_documentation_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Business Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:href="vrna-20240930.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:to="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ca821d0f-73e4-4765-beee-2fe0a20b1268_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_52a6fb66-1c92-4f09-a31e-1d38552c5150_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1d405922-1784-4eea-8c58-e7b8065c1ee3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5a15883d-d085-4506-be4b-135b8230bd9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3d65fc78-1bb9-47cd-bfc4-497037ca1973_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f8ab5cf2-8a76-479e-beef-6f22609606d8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ef9429f9-4a73-4afc-bdff-f8723f80b647_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInLicenseAgreementObligations_703d1dd8-fd02-4edd-bdad-f7c8dcc9699a_terseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInLicenseAgreementObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties payable</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInLicenseAgreementObligations_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInLicenseAgreementObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in License Agreement Obligations</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInLicenseAgreementObligations_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInLicenseAgreementObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in License Agreement Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInLicenseAgreementObligations" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInLicenseAgreementObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInLicenseAgreementObligations" xlink:to="lab_vrna_IncreaseDecreaseInLicenseAgreementObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2024TermDMember_3e3e06a7-4e70-4459-8168-e049a3d9259d_terseLabel_en-US" xlink:label="lab_vrna_A2024TermDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Term D</link:label>
    <link:label id="lab_vrna_A2024TermDMember_label_en-US" xlink:label="lab_vrna_A2024TermDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Term D [Member]</link:label>
    <link:label id="lab_vrna_A2024TermDMember_documentation_en-US" xlink:label="lab_vrna_A2024TermDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Term D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermDMember" xlink:href="vrna-20240930.xsd#vrna_A2024TermDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2024TermDMember" xlink:to="lab_vrna_A2024TermDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6faacb50-6b45-4b34-ba61-8773fe892ccb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodFourMember_2e56180c-911a-46f6-8c29-38d369e5de59_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period Four</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodFourMember_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period Four [Member]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodFourMember_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodFourMember" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodFourMember" xlink:to="lab_vrna_DebtPrepaymentPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ffc74c4c-5e28-4ed3-853d-4458e72d8d82_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3989422b-7a7e-4f1b-bc99-a74d0c20d75c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SecuritesPurchasedNoncurrentRevenueInterest_b50f1075-9f9c-4233-ad16-a10528b597d6_terseLabel_en-US" xlink:label="lab_vrna_SecuritesPurchasedNoncurrentRevenueInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue interest purchase security agreement</link:label>
    <link:label id="lab_vrna_SecuritesPurchasedNoncurrentRevenueInterest_label_en-US" xlink:label="lab_vrna_SecuritesPurchasedNoncurrentRevenueInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securites Purchased, Noncurrent Revenue Interest</link:label>
    <link:label id="lab_vrna_SecuritesPurchasedNoncurrentRevenueInterest_documentation_en-US" xlink:label="lab_vrna_SecuritesPurchasedNoncurrentRevenueInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securites Purchased, Noncurrent Revenue Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SecuritesPurchasedNoncurrentRevenueInterest" xlink:href="vrna-20240930.xsd#vrna_SecuritesPurchasedNoncurrentRevenueInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SecuritesPurchasedNoncurrentRevenueInterest" xlink:to="lab_vrna_SecuritesPurchasedNoncurrentRevenueInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ed55116b-46eb-4ef8-82a9-7f973b18166a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0f906887-e0c0-48f3-91cd-01fe9e086e89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_6bb456cf-6652-480b-ab49-b5b9f109a192_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender and third-party fees</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_36a60dcb-ae9c-4f10-a760-fc41dffbcd4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_e968242e-e26c-4041-b596-41a6abbcea22_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1b98e1a0-57f2-4495-b694-b2387d438a81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common shares withheld for taxes on vested stock awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_50d46464-22d4-4211-83a4-ef9ecaecf4e4_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_EquityInterestReceivable_dcda477e-5f6a-4890-8acb-80bccc3e64e4_terseLabel_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest receivable</link:label>
    <link:label id="lab_vrna_EquityInterestReceivable_label_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Interest Receivable</link:label>
    <link:label id="lab_vrna_EquityInterestReceivable_documentation_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable" xlink:href="vrna-20240930.xsd#vrna_EquityInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_EquityInterestReceivable" xlink:to="lab_vrna_EquityInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9d4c6c51-9dbe-441b-9723-fe2bfb1cd938_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_90af0fd6-17ae-45ea-a836-640b0154b37d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4ba5bc3b-29e6-4b83-90e9-2729da511b3c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b8bb9d61-029c-40da-9830-0fd17cab4e59_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2e4754c8-8e13-43da-a7be-937a461a592f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b8aa0343-bc3b-4c6c-8776-f1d4c62f1c3e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_d1e7b917-a2c2-4553-a7ba-813e293972ad_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_79e0d19c-9482-4ccf-84e2-51385717ff64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_da5feb43-5024-4585-851f-96a3a3659b6f_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1baf807a-daa8-4ca7-80fb-a8efa2f23602_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6a384a09-b9c9-46c3-ae72-2ab62234e611_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_InterestRatePeriodDomain_91479998-937c-4a74-9580-1d10f54a9204_terseLabel_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodDomain_label_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodDomain_documentation_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain" xlink:href="vrna-20240930.xsd#vrna_InterestRatePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_InterestRatePeriodDomain" xlink:to="lab_vrna_InterestRatePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_72d18d53-1a8b-460a-8142-8ba90489a1f4_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_11b99e1f-8012-4fe3-8d14-fe3d1ef86dda_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b8344133-0d60-48db-8567-323d8b9014fe_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_87594de4-edf0-4a55-8f32-6c34e449dd16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_9387f310-a768-4530-92fd-00d3c3a163a4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2799dfff-f83e-4a3f-86d8-90adc406b848_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_81211f29-05d5-46a0-84df-9079f400c3a9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently adopted accounting standards and recent accounting standards not yet adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_50895fd3-36a3-4c65-85ef-f357c6babb09_terseLabel_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees and general corporate costs</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_label_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:href="vrna-20240930.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:to="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_bda1aab3-987d-407d-a64b-a81183372291_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2024TermELoanMember_5482f004-5489-41a0-8a4e-987f33974f7d_terseLabel_en-US" xlink:label="lab_vrna_A2024TermELoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Term E Loan</link:label>
    <link:label id="lab_vrna_A2024TermELoanMember_label_en-US" xlink:label="lab_vrna_A2024TermELoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Term E Loan [Member]</link:label>
    <link:label id="lab_vrna_A2024TermELoanMember_documentation_en-US" xlink:label="lab_vrna_A2024TermELoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Term E Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermELoanMember" xlink:href="vrna-20240930.xsd#vrna_A2024TermELoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2024TermELoanMember" xlink:to="lab_vrna_A2024TermELoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ea1acf1f-8a5c-43bb-ab58-683c96d1f22b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f42347d2-36f5-477c-b95b-d99f5f7aa7b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1e008573-6cd3-4cf7-8860-0debfe21de7d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingDepositoryReceiptRatio_f32ac3f3-aa7c-4701-97df-b4cf94872c15_terseLabel_en-US" xlink:label="lab_dei_EntityListingDepositoryReceiptRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of ordinary shares per ADS</link:label>
    <link:label id="lab_dei_EntityListingDepositoryReceiptRatio_label_en-US" xlink:label="lab_dei_EntityListingDepositoryReceiptRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listing, Depository Receipt Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingDepositoryReceiptRatio" xlink:to="lab_dei_EntityListingDepositoryReceiptRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2f1de44b-881f-44a7-b088-01a11c6ad855_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b050e538-eb05-4ba3-86c5-65190b425384_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_299da67d-0d7e-4d5b-9ee6-9f5bb777f9b1_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_0c251ebf-17ad-47c1-9f85-7fc8bc93db72_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne_15f8d7a2-f6bf-49b4-8e00-b15a81057b97_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple before year one</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple Before Year One</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple Before Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_609f4009-796c-4b29-b7cc-39043faec72d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties payable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e93802cf-2766-4d22-9eef-8fe4c6eed500_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_4134d0fd-2790-4b21-9dcf-c542f618af83_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3fbcecfd-efb4-4407-be80-21ecf4e2a1f6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c634303f-3939-4375-91e8-ea287f8f0c9c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9f683bb9-3c40-4fc3-8154-0b2790c91fd3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3922dad3-f85f-4dc8-be91-8f79dd4379f9_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ligand license agreement obligations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5190ef8-170d-4ff8-a4d2-5ec2aedc4261_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8cb55aec-d7f2-44b4-9405-498d0faa3448_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost related to share options and PRSUs granted but not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OaktreeFundAdministrationLLCMember_1e3550be-72e4-4b3b-a741-246dde95190b_terseLabel_en-US" xlink:label="lab_vrna_OaktreeFundAdministrationLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oaktree Fund Administration, LLC</link:label>
    <link:label id="lab_vrna_OaktreeFundAdministrationLLCMember_label_en-US" xlink:label="lab_vrna_OaktreeFundAdministrationLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oaktree Fund Administration, LLC [Member]</link:label>
    <link:label id="lab_vrna_OaktreeFundAdministrationLLCMember_documentation_en-US" xlink:label="lab_vrna_OaktreeFundAdministrationLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oaktree Fund Administration, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OaktreeFundAdministrationLLCMember" xlink:href="vrna-20240930.xsd#vrna_OaktreeFundAdministrationLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OaktreeFundAdministrationLLCMember" xlink:to="lab_vrna_OaktreeFundAdministrationLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c9ddd44a-2e86-4d99-b330-c039906898cc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultiple_055753ea-77ac-4eb7-b898-a4dc1c090b80_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultiple_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultiple_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultiple" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementMultiple" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_InterestRatePeriodAxis_33357c74-c9a7-42f1-a6c5-81fab97ac369_terseLabel_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate Period [Axis]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodAxis_label_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Period [Axis]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodAxis_documentation_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis" xlink:href="vrna-20240930.xsd#vrna_InterestRatePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_InterestRatePeriodAxis" xlink:to="lab_vrna_InterestRatePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_e69102f3-b4a1-4d97-967b-babc76302582_terseLabel_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_label_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Net Of Adjustments</link:label>
    <link:label id="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_documentation_en-US" xlink:label="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Net Of Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:href="vrna-20240930.xsd#vrna_ResearchAndDevelopmentExpenseNetOfAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:to="lab_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_13ffaf34-d8f3-45f9-8612-6d4aaf5c27a0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees_07ac35ba-4a76-47f9-b4eb-dcf0c0283ca2_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensees</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Purchaser Percentage, Licensees</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Purchaser Percentage, Licensees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_280771fb-e3a1-4496-9ad0-b70d4bd3eea2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_ebe0bb23-8e36-4533-81a8-7aeff4cdf87d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_cc4d7220-7ffb-4de6-b00c-f79d6e112e67_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_6e1dc719-b1cd-4f96-b0bb-a00b13770d0a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_735816c0-23a4-42fa-903e-c9ccddc87ec3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8cff2330-268d-4c09-a3dc-cdd05e69a2f3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4db4e3ef-e24f-4cb5-a89f-f1d14ff41137_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_14c4b50d-bd25-41df-a80f-a3c4a314e3e3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo_908c157c-cd6b-4906-ba34-895815a0fbc0_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple after year one, before year two</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple After Year One, Before Year Two</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple After Year One, Before Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_8b43e6cb-7b1c-459b-845a-2d0dd1b79d14_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_32f59b88-504f-4eeb-a2b1-338d2ba9bce9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e889b6fa-98a2-4f76-9bcd-e6623c2bd91b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest receivable</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_847811e2-e17a-4e8b-939f-927eeb8e6acd_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_c389cfbf-3f37-4c6b-90e7-c2c2d864c196_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_31775f6b-3b15-44dd-bd8c-5c12dd04e764_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_77fe617f-8b00-4fb7-a795-f1eff89e6046_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_39d4664a-48c0-417d-9be7-947bc41d0c3c_negatedTerseLabel_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity settled share-based compensation reclassified as cash-settled</link:label>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_label_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</link:label>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_documentation_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:href="vrna-20240930.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:to="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d45d5abc-ef37-4777-bc24-2bff92424734_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_205e53e8-2a92-4f43-b11e-18c912a492b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_a8591e34-5eed-46cc-9b39-b76d5b94d40e_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early repayment penalty</link:label>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_label_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instrument, Early Repayment Penalty, Percent</link:label>
    <link:label id="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument, Early Repayment Penalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:to="lab_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b526290e-16d5-4260-b651-890cc908afee_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_4774a7c8-e485-4445-9fc9-a16d2e3592e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1e19b9ff-10e7-4f22-8f4b-025ac48d273c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ce26fd66-53e2-40f9-8e3f-d0a7106fd256_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ed7c55ad-3659-45e8-bc93-1796c50798bb_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ebbd43c6-a599-4584-b534-d35c081fbc3c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f7eaf731-55df-4664-b313-dbcaca18e71e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5d41e4bc-ce92-4b0f-8d5c-0e8b3e7eabc4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f153ee47-34b8-4761-be37-407dcc5a1c4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DavidZaccardelliMember_label_en-US" xlink:label="lab_vrna_DavidZaccardelliMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">David Zaccardelli [Member]</link:label>
    <link:label id="lab_vrna_DavidZaccardelliMember_documentation_en-US" xlink:label="lab_vrna_DavidZaccardelliMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">David Zaccardelli</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DavidZaccardelliMember" xlink:href="vrna-20240930.xsd#vrna_DavidZaccardelliMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DavidZaccardelliMember" xlink:to="lab_vrna_DavidZaccardelliMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_a8bce1f9-0fc5-4e4e-98a3-666a3206ad26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income/(expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_9814483f-febe-4cae-9415-0624fba65773_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_73099f7e-211a-4604-bf10-dee5aff24e42_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e33c2456-6a02-482c-b8b0-7648204fe009_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in pounds sterling per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_95d109d1-46c5-4116-bcaa-5cfa641483ba_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_96730c04-67b5-4479-a450-91e4501cc692_terseLabel_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ligand UK Development Limited</link:label>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_label_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ligand UK Development Limited [Member]</link:label>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_documentation_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ligand UK Development Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember" xlink:href="vrna-20240930.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_LigandUKDevelopmentLimitedMember" xlink:to="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_54100daa-1ea7-4644-a523-eac3a23d801b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_da73b30f-6bb0-4cfe-98e4-1054a56cfb9b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7be78b8c-4995-4f43-8ff6-b00f1b09e173_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44ffbfaa-e6e0-4104-875f-3f3d79929486_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_69080425-f38a-4ce2-b733-63631c804c07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7ed98511-4a59-4994-a4cb-c4420b98e7b6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5ad26d0b-1e4c-47e1-b37f-b10ac3f04bd6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_021bc7ed-60b3-478a-add0-882aa69762bf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodDomain_7b8f1949-48cc-4cd2-bc62-78f384dbed39_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period [Domain]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodDomain_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period [Domain]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodDomain_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodDomain" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain" xlink:to="lab_vrna_DebtPrepaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0a9f2e9d-0858-477d-8493-8dbaafd223e6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_9f2cb363-36a3-4fd3-b131-d2bd173485d6_terseLabel_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of wholly owned subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:href="vrna-20240930.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_839ce7b3-6f4d-4545-9934-4216d51f312c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d0f62fe3-1dd3-43ee-8eca-442e2a2f37a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b94b03d8-e2e8-4676-a6d1-46b6fd5cb2f2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_03898e41-5c3b-4a5b-8ec8-dfcafdc18d95_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_476288c9-a9c2-429e-90a2-ed23138b12c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary &#163;0.05 par value shares; 667,659,630 and 667,659,630 issued, and 654,649,358 and 643,536,094 outstanding, at September 30, 2024 and December 31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9baed645-53ca-4358-8eb3-b57bc3bd4dc2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA_144be8fe-d999-401a-b1a0-5ac87bc428e7_terseLabel_en-US" xlink:label="lab_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Revenue Interest Purchase And Sale Agreement ("RIPSA&#8221;)</link:label>
    <link:label id="lab_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA_label_en-US" xlink:label="lab_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Revenue Interest Purchase And Sale Agreement ("RIPSA&#8221;)</link:label>
    <link:label id="lab_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA_documentation_en-US" xlink:label="lab_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Revenue Interest Purchase And Sale Agreement ("RIPSA&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" xlink:href="vrna-20240930.xsd#vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" xlink:to="lab_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_b493333b-e89f-4af6-b9b0-f39704762272_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_31450380-5d4b-4cba-96b0-4317d2e6f5a5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_7f6fd1ed-d7b3-4e42-82c6-6b19c0b4a309_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_70aec924-f1f9-4d02-a4ff-34dbd71d93b6_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0391796f-eaad-4272-bfcc-4eabcb791829_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_9b85b165-cb5a-4d3a-8d6c-291c298ddd3e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">issuance discount</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_889ae07a-2a41-4eef-af11-877e6dfa69f1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e6bc7623-f5ae-4f6c-8b25-20d3e3558c3b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_17516e0a-23c4-4db5-aa3d-c8325fcd605e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseLongTermDebt" xlink:to="lab_us-gaap_InterestExpenseLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple_5f9fc741-4e3a-4197-a850-a049fc8f01e4_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denomination multiple</link:label>
    <link:label id="lab_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple_label_en-US" xlink:label="lab_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Partial Prepayment, Denomination Multiple</link:label>
    <link:label id="lab_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Partial Prepayment, Denomination Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentPartialPrepaymentDenominationMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple" xlink:to="lab_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_2be54dad-5dda-471b-bfa3-b45db644e69b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree_1de54bd8-7316-4a8c-8716-4e16c0b5be18_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple after year three</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple After Year Three</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple After Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_a15e9166-7c81-4fab-a96e-706a5d7c9c73_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_98eb5c3e-01bb-4efc-ab4c-50e6c6589dac_terseLabel_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial and other development costs</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_label_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:href="vrna-20240930.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:to="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c822ac39-0b9b-497a-a189-96b92eafa6b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf24db73-1082-49f0-8db9-1f5629497a8a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_68e796b1-1ff8-478f-b044-a154b198e253_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, fee amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9b35351e-7acc-4428-8b97-89e1a163087c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_b23b19ca-f436-4f68-8a16-57e2bef858dc_terseLabel_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:href="vrna-20240930.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:to="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_49c47dc1-6b23-409f-a354-a14a1480c1d8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7f283d50-c619-4c10-a483-790e1915bdfb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0703fad4-cdf6-4e91-8098-ba66bbb7bfff_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0641a272-5121-4d82-9c55-18b0a0b1ceed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_a3ac9393-3be6-43d7-9499-4e667b7aaab7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_92b7ec50-c462-4b0b-9f10-e1dd45d27d81_terseLabel_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Sales Agreement</link:label>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Sales Agreement [Member]</link:label>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember" xlink:href="vrna-20240930.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AtTheMarketSalesAgreementMember" xlink:to="lab_vrna_AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b59f915-4cd1-44c0-a864-e611dc63e991_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1a3a6a3e-3dab-491e-b60c-1bee8d195932_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d4a58b6b-6447-46e3-8ce7-cf67e8c8bc0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fd809cf6-6c44-460d-93ee-8dea35b5bb16_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a6964903-b37c-44e6-a43c-ab225d3fee8d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9f692362-f86d-460a-a74f-7606293da7a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9452c75b-beee-4c8d-b8de-a7e5114a9dcf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1dd8a346-677d-4e66-90e8-7655ed46d102_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0dce4dce-e699-4de2-9faf-1413f23ad33b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6d1d6ba8-a533-459f-b695-bc1cf2f43b15_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization and net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c09f8c75-fff0-4c87-8c6e-0a0f0551ebbe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8fdb8a63-b1c2-4a44-ae7f-a7cfddf66709_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0235781d-6256-48e6-8013-426630ef9474_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ca52cea7-717f-4dea-8d10-9590de2ea052_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b172709a-56f3-46d9-a732-27e43db06343_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ecf987e3-d551-4ad1-ad22-bfa57c210363_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_40e19fd1-57c6-4ac2-9ca6-6c78fab51661_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Term Loans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1dae1eb9-18be-4af2-beef-bdf766cece65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gain</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cff9ff68-fc59-4c5c-ab46-038f01676842_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of withholding taxes from share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_3e94f915-6e9f-4341-b8ac-438308f909a9_terseLabel_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd</link:label>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_label_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd [Member]</link:label>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_documentation_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:href="vrna-20240930.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:to="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PerformanceRestrictedStockUnitsPRSUsMember_60d6084d-ee70-481f-8f9d-fd582bec8950_terseLabel_en-US" xlink:label="lab_vrna_PerformanceRestrictedStockUnitsPRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance restricted stock units (PRSUs)</link:label>
    <link:label id="lab_vrna_PerformanceRestrictedStockUnitsPRSUsMember_label_en-US" xlink:label="lab_vrna_PerformanceRestrictedStockUnitsPRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units (PRSUs) [Member]</link:label>
    <link:label id="lab_vrna_PerformanceRestrictedStockUnitsPRSUsMember_documentation_en-US" xlink:label="lab_vrna_PerformanceRestrictedStockUnitsPRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units (PRSUs)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember" xlink:href="vrna-20240930.xsd#vrna_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember" xlink:to="lab_vrna_PerformanceRestrictedStockUnitsPRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_46a3f036-01c5-4243-8fea-7ea04acdac72_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e20d3f1d-bc1e-485e-8725-6756b807f883_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_19a9e0fa-4a44-4576-b9ab-09d88022db5a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_da5412e5-20bb-47ee-b7bc-06f06205a18f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of Share Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodTwoMember_2aa0ea0a-6f8a-4c61-814c-b7cf2dd81f00_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period Two</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodTwoMember_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period Two [Member]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodTwoMember_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodTwoMember" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodTwoMember" xlink:to="lab_vrna_DebtPrepaymentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_459e8def-fae9-4f0b-acf2-e7989cd0b8c3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_75205189-1f8b-45bc-8e96-dbf9bfafeb24_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit/(loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_79c82e18-9205-4f11-bfac-c510bf3400e1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4eab58d4-56ee-4ca5-b70b-b3ed39507d3f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4827c43e-1a72-4a13-a975-d680abf38a7c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a136c13d-99bc-413f-8879-3948cb3f91fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b025aff9-290e-408b-84d0-7feccaa73dbd_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_e33b5642-fb5a-4b41-87e8-8c9f748649dd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_032605e7-65c7-41bc-89e7-bf5e04978131_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2618b351-2324-45b1-850f-faec50e90bed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2024TermCMember_b1bfc1e4-cd13-4aa7-8059-a1a873a690e4_terseLabel_en-US" xlink:label="lab_vrna_A2024TermCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Term C</link:label>
    <link:label id="lab_vrna_A2024TermCMember_label_en-US" xlink:label="lab_vrna_A2024TermCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Term C [Member]</link:label>
    <link:label id="lab_vrna_A2024TermCMember_documentation_en-US" xlink:label="lab_vrna_A2024TermCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Term C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermCMember" xlink:href="vrna-20240930.xsd#vrna_A2024TermCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2024TermCMember" xlink:to="lab_vrna_A2024TermCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_d5c453d7-6fed-4743-a8e6-ab36b93fa511_terseLabel_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gain/(loss)</link:label>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_label_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</link:label>
    <link:label id="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_documentation_en-US" xlink:label="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:href="vrna-20240930.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:to="lab_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_47a1c9c1-5460-4180-8ff0-24be638d5bc5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d9acf6d7-4a3d-4add-a8e7-88e07aa52061_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_26df08a5-39ac-4a41-a601-2c9fde3cbbbe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_247468d3-0127-4bc7-bacb-fd97ce67e74c_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Rate, Period One</link:label>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_label_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Rate, Period One [Member]</link:label>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Rate, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:to="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f8ad1991-935b-4e9e-b9b3-ddb10c07391b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding_59c1fa15-2d42-49c4-a34a-8d5da33c8122_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional funding</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Additional Funding</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_61e8f99b-8337-4f70-99b4-a791b552808f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b6e0e433-1c0b-450c-a6d9-34e6157125ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_36abed39-5890-440b-b134-7aff0b833f74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_9bb1c81a-2494-42c6-a129-a76a32881660_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_deaae224-b946-464d-be43-1961590c7a08_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2023TermALoanMember_f1c41b53-6bf0-49f5-bb65-f0fab386a98c_terseLabel_en-US" xlink:label="lab_vrna_A2023TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Term A Loan</link:label>
    <link:label id="lab_vrna_A2023TermALoanMember_label_en-US" xlink:label="lab_vrna_A2023TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Term A Loan [Member]</link:label>
    <link:label id="lab_vrna_A2023TermALoanMember_documentation_en-US" xlink:label="lab_vrna_A2023TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Term A Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2023TermALoanMember" xlink:href="vrna-20240930.xsd#vrna_A2023TermALoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2023TermALoanMember" xlink:to="lab_vrna_A2023TermALoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_9661e944-4340-4d7a-ac96-5ac3cd48f840_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8079eb71-1f7d-42b4-8c4e-d0fd56b38e10_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_cc518589-34aa-4f40-a112-35c2ec22f99f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share units vested</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_abb065f9-479f-4c0c-b20a-9ada727f5743_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of 2023 Term Loans</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum_4fa0041b-3e14-45ec-a971-5e7d1b7528ff_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple of aggregate principle amount</link:label>
    <link:label id="lab_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum_label_en-US" xlink:label="lab_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio, Minimum</link:label>
    <link:label id="lab_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" xlink:to="lab_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_f62c93fd-ffe2-4e3e-a192-978b397b30de_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ea8e9a77-bfd9-43c7-a670-ccbd0a864a3b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_ee5a7428-249a-4408-8965-212ae1dde4fb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a0d98b99-cc7a-4076-8519-fe955ded1b23_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a5a5f35f-00d7-4a8b-a5c3-8a078d07fbfb_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_3f067e85-4541-436e-87c0-b1a508b7eb46_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c32e532a-2062-40a0-8bde-bed2814a053f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d216947e-9b2f-403b-b469-add69176bc46_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">People related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f36c20e0-59ec-4d41-8ee0-6f365a18f80b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_219dce28-acdd-40c6-a2a3-9c168523d998_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_8ecf9d41-36af-4b02-8e93-4374117c7a8b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5334bd88-471c-4a7c-abab-5f4c50ff4518_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_6057415e-6fc9-4899-b83e-60ee1eea7eb7_verboseLabel_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax incentive receivable</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_label_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_documentation_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:href="vrna-20240930.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:to="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2c05e674-6c06-4c07-8b87-e5d60fb9aef9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c255de7c-77b1-4725-9a55-e1250f4e8cb2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ad99062-a53d-4f6c-ab43-8a011012631e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1e35abf9-389b-4f1f-be30-fd524c7aafef_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_51c0f783-5e17-4895-a341-1725a82917c0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f30cfab8-068e-4371-a233-27e87c5096f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_2e835d68-0b5a-4bc9-a9c4-722b92bfa8e7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2024TermALoanMember_62286cab-7de0-4548-a975-ad964d075c70_terseLabel_en-US" xlink:label="lab_vrna_A2024TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Term A Loan</link:label>
    <link:label id="lab_vrna_A2024TermALoanMember_label_en-US" xlink:label="lab_vrna_A2024TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Term A Loan [Member]</link:label>
    <link:label id="lab_vrna_A2024TermALoanMember_documentation_en-US" xlink:label="lab_vrna_A2024TermALoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Term A Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermALoanMember" xlink:href="vrna-20240930.xsd#vrna_A2024TermALoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2024TermALoanMember" xlink:to="lab_vrna_A2024TermALoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_141ed987-b45b-4131-a895-246c0e9ec936_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b493be9d-c2f3-4d3a-8b47-77e324e7397d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_54c2e5a9-768e-45ec-93d2-a4b011b598c5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of furniture and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_211fecd8-7d5b-4dc9-b545-ebea9f12d326_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentExitFeePercentage_d7f967a7-ccea-47ca-9ba6-c6f03ff5e376_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit fee percentage</link:label>
    <link:label id="lab_vrna_DebtInstrumentExitFeePercentage_label_en-US" xlink:label="lab_vrna_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee Percentage</link:label>
    <link:label id="lab_vrna_DebtInstrumentExitFeePercentage_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentExitFeePercentage" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentExitFeePercentage" xlink:to="lab_vrna_DebtInstrumentExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4277e78d-5f67-4bee-a549-5342775f574f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_MarkHahnMember_label_en-US" xlink:label="lab_vrna_MarkHahnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mark Hahn [Member]</link:label>
    <link:label id="lab_vrna_MarkHahnMember_documentation_en-US" xlink:label="lab_vrna_MarkHahnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mark Hahn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MarkHahnMember" xlink:href="vrna-20240930.xsd#vrna_MarkHahnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_MarkHahnMember" xlink:to="lab_vrna_MarkHahnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodOneMember_ff2656c3-59a0-4e48-b5c9-366e8ffbefbc_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period One</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodOneMember_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period One [Member]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodOneMember_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodOneMember" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodOneMember" xlink:to="lab_vrna_DebtPrepaymentPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_61dc0f19-96ef-45bf-8c70-c2e637273ea1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9c537b02-27ef-40f4-960f-597ea1a87a60_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_9016fb16-e17e-4043-aa5f-123ee094ef0f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issue costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_83c6fa23-900a-4b40-aac5-5b979b661c1c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d444930c-b50e-4517-b535-0a2eda90e958_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2024TermLoanMember_e0d382f6-d594-4d85-ae25-8a5895eb2123_terseLabel_en-US" xlink:label="lab_vrna_A2024TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Term Loan</link:label>
    <link:label id="lab_vrna_A2024TermLoanMember_label_en-US" xlink:label="lab_vrna_A2024TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Term Loan [Member]</link:label>
    <link:label id="lab_vrna_A2024TermLoanMember_documentation_en-US" xlink:label="lab_vrna_A2024TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermLoanMember" xlink:href="vrna-20240930.xsd#vrna_A2024TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2024TermLoanMember" xlink:to="lab_vrna_A2024TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ec89f774-0bf4-4dd8-b503-f4588aebb32c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_225deea6-2d09-4a5a-a39d-25e59c515607_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_66df2220-6dcf-4786-bb59-6e6325bf64cd_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d652c95d-064d-43c3-be8b-40fb0cb5907b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa05ee38-32b7-4be4-b4a0-4cb3ce497ffa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2023TermLoanMember_90dccf51-b0fc-4c91-9275-dced4cbb9fd0_terseLabel_en-US" xlink:label="lab_vrna_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Term Loan</link:label>
    <link:label id="lab_vrna_A2023TermLoanMember_label_en-US" xlink:label="lab_vrna_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Term Loan [Member]</link:label>
    <link:label id="lab_vrna_A2023TermLoanMember_documentation_en-US" xlink:label="lab_vrna_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2023TermLoanMember" xlink:href="vrna-20240930.xsd#vrna_A2023TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2023TermLoanMember" xlink:to="lab_vrna_A2023TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_26367dc0-596e-4b0e-ac54-fe5c2ec35061_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8391eda1-35f9-4a7b-8dee-6b6f33846ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_dc86607e-2451-4707-8c54-7effc534cc6f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_5ebe602e-9825-4401-bb6f-0ca95724ac60_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtPrepaymentPeriodAxis_4a01ab3f-599c-4160-a6be-06884438818f_terseLabel_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period [Axis]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodAxis_label_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period [Axis]</link:label>
    <link:label id="lab_vrna_DebtPrepaymentPeriodAxis_documentation_en-US" xlink:label="lab_vrna_DebtPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Prepayment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodAxis" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtPrepaymentPeriodAxis" xlink:to="lab_vrna_DebtPrepaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5a6c3cf3-e80c-454f-873b-37de5e57e4d5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fac52e86-c2dc-4fd2-b237-f06662e44f37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionExpense_bd3aa899-06ae-432f-adb1-3abb763c5af0_terseLabel_en-US" xlink:label="lab_us-gaap_AccretionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of RIPSA</link:label>
    <link:label id="lab_us-gaap_AccretionExpense_label_en-US" xlink:label="lab_us-gaap_AccretionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpense" xlink:to="lab_us-gaap_AccretionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree_b784507d-70cd-4b80-95db-e3164916a33a_terseLabel_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple after year two, before year three</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree_label_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple After Year Two, Before Year Three</link:label>
    <link:label id="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree_documentation_en-US" xlink:label="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues, Purchase and Sale Agreement, Multiple After Year Two, Before Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" xlink:to="lab_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vrna-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0ee8d2e7-f00d-490d-8b34-d8e4d0ae151e,g:42222ec7-8dc8-4139-853e-ab7cbe924947-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:type="simple" xlink:href="vrna-20240930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ccb11141-525f-40b2-b43b-b72708b76c64" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_DocumentType_ccb11141-525f-40b2-b43b-b72708b76c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_06b2ec6b-cd8a-4acf-a0c1-461b848ea162" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_DocumentQuarterlyReport_06b2ec6b-cd8a-4acf-a0c1-461b848ea162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cbb7e997-e260-43ac-a25c-6f832c17d847" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_DocumentPeriodEndDate_cbb7e997-e260-43ac-a25c-6f832c17d847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d728c50a-8fa5-47a7-b839-d803d18b34ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_DocumentTransitionReport_d728c50a-8fa5-47a7-b839-d803d18b34ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2112cf48-e196-4204-bbad-05a91f8b2119" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityFileNumber_2112cf48-e196-4204-bbad-05a91f8b2119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9f5b9bb1-c339-4272-9ecb-d6dff12d9976" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityRegistrantName_9f5b9bb1-c339-4272-9ecb-d6dff12d9976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b08d85e1-370e-4e2c-becd-d1229ed04e45" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b08d85e1-370e-4e2c-becd-d1229ed04e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dd580e2c-f1e2-487e-8623-b83ff981006a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityTaxIdentificationNumber_dd580e2c-f1e2-487e-8623-b83ff981006a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ae973ce3-bb2e-4196-96b7-1a36d7e45bfb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityAddressAddressLine1_ae973ce3-bb2e-4196-96b7-1a36d7e45bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5382d81d-9186-4e8a-811d-acde24ebbe43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityAddressCityOrTown_5382d81d-9186-4e8a-811d-acde24ebbe43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f9f7774c-2873-4120-8fbd-ff379f3c198a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityAddressPostalZipCode_f9f7774c-2873-4120-8fbd-ff379f3c198a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_885c59af-3ca2-4a21-8133-b2de627de908" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityAddressCountry_885c59af-3ca2-4a21-8133-b2de627de908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_0c9afca4-66a9-4a8a-8d12-75330047a631" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_CountryRegion_0c9afca4-66a9-4a8a-8d12-75330047a631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0c88e6a9-6ee4-4864-997d-9a276912f7dd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_CityAreaCode_0c88e6a9-6ee4-4864-997d-9a276912f7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2758fd3d-e37f-46e2-9a0b-f86272441b38" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_LocalPhoneNumber_2758fd3d-e37f-46e2-9a0b-f86272441b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8244217d-fd2c-422c-bebf-3853be3babdc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_Security12bTitle_8244217d-fd2c-422c-bebf-3853be3babdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7ca3b9e7-a989-4e2a-abf1-c88c980646c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_TradingSymbol_7ca3b9e7-a989-4e2a-abf1-c88c980646c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ed4a19a3-cc43-4124-9b3d-3337cbcc5ba9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_SecurityExchangeName_ed4a19a3-cc43-4124-9b3d-3337cbcc5ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2b6e116d-2480-481e-84c4-108e91569781" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityCurrentReportingStatus_2b6e116d-2480-481e-84c4-108e91569781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e3661c4e-d016-4eff-88d4-2d1a33adb8d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityInteractiveDataCurrent_e3661c4e-d016-4eff-88d4-2d1a33adb8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_33932490-5981-4158-994b-ad0c15fdddbe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityFilerCategory_33932490-5981-4158-994b-ad0c15fdddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_22fe3220-977e-47b0-95a6-b84e353a0a82" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntitySmallBusiness_22fe3220-977e-47b0-95a6-b84e353a0a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_82b3232f-787e-499b-b623-5e7a69388141" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityEmergingGrowthCompany_82b3232f-787e-499b-b623-5e7a69388141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_79944845-1afc-45f4-814f-58f0a156eb42" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityShellCompany_79944845-1afc-45f4-814f-58f0a156eb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7d0a6fca-7580-442f-a87e-f8942b09d776" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7d0a6fca-7580-442f-a87e-f8942b09d776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_487144f4-3800-4bb0-ae43-85e10131aa1c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_AmendmentFlag_487144f4-3800-4bb0-ae43-85e10131aa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_515b914e-2a80-4aa9-ae69-597b1c4677c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_DocumentFiscalYearFocus_515b914e-2a80-4aa9-ae69-597b1c4677c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e980d944-1431-4497-a255-1e1c5dfdc0c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_CurrentFiscalYearEndDate_e980d944-1431-4497-a255-1e1c5dfdc0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b35e4f6c-6392-4e8e-9283-45ff6c2c1741" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b35e4f6c-6392-4e8e-9283-45ff6c2c1741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cea78d7c-4131-4993-8e18-2abc939a6fa8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf8dfb19-7e41-48fe-952c-43ba035db3ed" xlink:to="loc_dei_EntityCentralIndexKey_cea78d7c-4131-4993-8e18-2abc939a6fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_58ac885a-c49d-4472-acda-2a0cd7d95647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8649c9de-7879-4b97-b080-20916038a7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_58ac885a-c49d-4472-acda-2a0cd7d95647" xlink:to="loc_us-gaap_AssetsAbstract_8649c9de-7879-4b97-b080-20916038a7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8649c9de-7879-4b97-b080-20916038a7f8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccc687dd-3be7-40a3-93ea-440e14c6bf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ccc687dd-3be7-40a3-93ea-440e14c6bf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_13cee0d1-661c-4eaf-9ab7-f99e1f4b4063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_13cee0d1-661c-4eaf-9ab7-f99e1f4b4063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d28548bb-3685-4c62-b41f-7b311844c008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d28548bb-3685-4c62-b41f-7b311844c008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_e7d59b68-4708-47f6-b98d-65f8b683a89c" xlink:href="vrna-20240930.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_e7d59b68-4708-47f6-b98d-65f8b683a89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9627d60f-d5aa-4cb2-967d-0cf6832505b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:to="loc_us-gaap_InventoryNet_9627d60f-d5aa-4cb2-967d-0cf6832505b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a9165b6e-ddb1-4685-ab17-d20895d0e950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:to="loc_us-gaap_OtherAssetsCurrent_a9165b6e-ddb1-4685-ab17-d20895d0e950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fd93fadc-fe73-4959-9679-b89e6f4a1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c030c71b-5a6a-4981-a28f-f4b5b88cc991" xlink:to="loc_us-gaap_AssetsCurrent_fd93fadc-fe73-4959-9679-b89e6f4a1f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_a9660e9b-7d46-402e-8f67-0c895f87d3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8649c9de-7879-4b97-b080-20916038a7f8" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_a9660e9b-7d46-402e-8f67-0c895f87d3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eeb9a62b-dbf0-4788-b5c8-f56623a7993a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a9660e9b-7d46-402e-8f67-0c895f87d3f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_eeb9a62b-dbf0-4788-b5c8-f56623a7993a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31126eb8-f59f-4531-9624-c6988d10e00e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a9660e9b-7d46-402e-8f67-0c895f87d3f0" xlink:to="loc_us-gaap_Goodwill_31126eb8-f59f-4531-9624-c6988d10e00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_7904f409-b6e0-4d11-bbb7-02ea94206b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a9660e9b-7d46-402e-8f67-0c895f87d3f0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_7904f409-b6e0-4d11-bbb7-02ea94206b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c0bbe233-11fe-496e-9dbe-37f3f3c00cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a9660e9b-7d46-402e-8f67-0c895f87d3f0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c0bbe233-11fe-496e-9dbe-37f3f3c00cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_d2b7faaf-a7d7-465e-8ce3-ed039155bf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a9660e9b-7d46-402e-8f67-0c895f87d3f0" xlink:to="loc_us-gaap_AssetsNoncurrent_d2b7faaf-a7d7-465e-8ce3-ed039155bf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_10e5ffa6-f11e-4ae4-9cb5-d51be2dc5012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8649c9de-7879-4b97-b080-20916038a7f8" xlink:to="loc_us-gaap_Assets_10e5ffa6-f11e-4ae4-9cb5-d51be2dc5012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02a5c9f7-54cd-4a67-aeef-5bbac4f7a694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_58ac885a-c49d-4472-acda-2a0cd7d95647" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02a5c9f7-54cd-4a67-aeef-5bbac4f7a694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02a5c9f7-54cd-4a67-aeef-5bbac4f7a694" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0640d5d2-569c-4fc9-a90f-857ebb61a9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:to="loc_us-gaap_AccountsPayableCurrent_0640d5d2-569c-4fc9-a90f-857ebb61a9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5060ef43-d31b-4bba-b57e-ed37815485bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5060ef43-d31b-4bba-b57e-ed37815485bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7c125d74-7380-4db2-8854-ec5dd204c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7c125d74-7380-4db2-8854-ec5dd204c18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_29a50521-8a88-4f91-885f-ef30266520b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_29a50521-8a88-4f91-885f-ef30266520b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_7f251819-9b61-4823-9d71-cbc8c37bb16a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:to="loc_us-gaap_TaxesPayableCurrent_7f251819-9b61-4823-9d71-cbc8c37bb16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_289b53db-0207-409d-8ac8-8f1c7a27dc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_289b53db-0207-409d-8ac8-8f1c7a27dc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3fab0e23-85e0-4c0f-bcf0-25eb9d8dd0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f0391589-83f3-485c-87a9-9c5f6df8250b" xlink:to="loc_us-gaap_LiabilitiesCurrent_3fab0e23-85e0-4c0f-bcf0-25eb9d8dd0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_d1375690-d818-4b22-a5b1-1df93763c674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02a5c9f7-54cd-4a67-aeef-5bbac4f7a694" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_d1375690-d818-4b22-a5b1-1df93763c674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8805f790-7b3d-41c5-abbb-d20739b4bf4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d1375690-d818-4b22-a5b1-1df93763c674" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8805f790-7b3d-41c5-abbb-d20739b4bf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SecuritesPurchasedNoncurrentRevenueInterest_c7e714ca-2bd8-473e-b1a2-38854e4e7592" xlink:href="vrna-20240930.xsd#vrna_SecuritesPurchasedNoncurrentRevenueInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d1375690-d818-4b22-a5b1-1df93763c674" xlink:to="loc_vrna_SecuritesPurchasedNoncurrentRevenueInterest_c7e714ca-2bd8-473e-b1a2-38854e4e7592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f63f5140-3303-44ec-81f2-947fccf68ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d1375690-d818-4b22-a5b1-1df93763c674" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f63f5140-3303-44ec-81f2-947fccf68ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9c29fa7d-63bf-463f-9904-8889b5cb61f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_d1375690-d818-4b22-a5b1-1df93763c674" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9c29fa7d-63bf-463f-9904-8889b5cb61f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9bc4ff5e-a43e-41c7-b175-335d39ae43c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02a5c9f7-54cd-4a67-aeef-5bbac4f7a694" xlink:to="loc_us-gaap_Liabilities_9bc4ff5e-a43e-41c7-b175-335d39ae43c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2433cb10-5b2f-4e46-a5af-9efc7fbfecaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02a5c9f7-54cd-4a67-aeef-5bbac4f7a694" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2433cb10-5b2f-4e46-a5af-9efc7fbfecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e730d243-b934-4e35-aa85-b12d3fcbbc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02a5c9f7-54cd-4a67-aeef-5bbac4f7a694" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e730d243-b934-4e35-aa85-b12d3fcbbc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a4d50ea8-e1d9-4bcb-93d2-dd3d7beca80c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e730d243-b934-4e35-aa85-b12d3fcbbc1b" xlink:to="loc_us-gaap_CommonStockValue_a4d50ea8-e1d9-4bcb-93d2-dd3d7beca80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4b4809c5-2959-42ff-9635-901c71fc6d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e730d243-b934-4e35-aa85-b12d3fcbbc1b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4b4809c5-2959-42ff-9635-901c71fc6d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0a366510-852c-49ac-ba88-05eb1b14215a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e730d243-b934-4e35-aa85-b12d3fcbbc1b" xlink:to="loc_us-gaap_TreasuryStockValue_0a366510-852c-49ac-ba88-05eb1b14215a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4071a471-96f2-4668-869b-b8e435bccf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e730d243-b934-4e35-aa85-b12d3fcbbc1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4071a471-96f2-4668-869b-b8e435bccf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f944f610-ed7b-421f-a344-6e5bf332f71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e730d243-b934-4e35-aa85-b12d3fcbbc1b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f944f610-ed7b-421f-a344-6e5bf332f71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b3757a85-5306-484c-9c81-2cd1e0e38468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e730d243-b934-4e35-aa85-b12d3fcbbc1b" xlink:to="loc_us-gaap_StockholdersEquity_b3757a85-5306-484c-9c81-2cd1e0e38468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a3d57216-23c9-4d28-ae77-e30a718b32d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02a5c9f7-54cd-4a67-aeef-5bbac4f7a694" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a3d57216-23c9-4d28-ae77-e30a718b32d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e7f3736f-1223-499a-8e96-4670d23178bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0b1b0296-8ff3-496a-8ddf-bc5d647b6458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7f3736f-1223-499a-8e96-4670d23178bc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0b1b0296-8ff3-496a-8ddf-bc5d647b6458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f9e9662f-976c-44aa-aa10-adb385d85881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7f3736f-1223-499a-8e96-4670d23178bc" xlink:to="loc_us-gaap_CommonStockSharesIssued_f9e9662f-976c-44aa-aa10-adb385d85881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e046684b-0378-4f3c-9114-de0d765fc7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e7f3736f-1223-499a-8e96-4670d23178bc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e046684b-0378-4f3c-9114-de0d765fc7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_df2ca810-5a5f-42c7-8ff2-27b07e34c408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_Revenues_df2ca810-5a5f-42c7-8ff2-27b07e34c408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5a9ad983-b26c-4769-980d-066741d9bd66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5a9ad983-b26c-4769-980d-066741d9bd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_29c73f04-5cbf-4ddc-b4d7-2125f27444aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a9ad983-b26c-4769-980d-066741d9bd66" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_29c73f04-5cbf-4ddc-b4d7-2125f27444aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_20570afd-3675-4c57-941b-65e39379644d" xlink:href="vrna-20240930.xsd#vrna_ResearchAndDevelopmentExpenseNetOfAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a9ad983-b26c-4769-980d-066741d9bd66" xlink:to="loc_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments_20570afd-3675-4c57-941b-65e39379644d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f101a4bb-2755-436a-9cfa-c0f7dfe34ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a9ad983-b26c-4769-980d-066741d9bd66" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f101a4bb-2755-436a-9cfa-c0f7dfe34ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8895e625-c45c-4301-b606-bdcd807638b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a9ad983-b26c-4769-980d-066741d9bd66" xlink:to="loc_us-gaap_OperatingExpenses_8895e625-c45c-4301-b606-bdcd807638b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2d0a4d51-2458-4c2c-8660-02dfd105c830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a9ad983-b26c-4769-980d-066741d9bd66" xlink:to="loc_us-gaap_OperatingIncomeLoss_2d0a4d51-2458-4c2c-8660-02dfd105c830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_2b89c238-4690-4986-9b12-3f0955c6ec88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_2b89c238-4690-4986-9b12-3f0955c6ec88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_2f72aa6c-b055-4085-9b63-94fa3e252507" xlink:href="vrna-20240930.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2b89c238-4690-4986-9b12-3f0955c6ec88" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_2f72aa6c-b055-4085-9b63-94fa3e252507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c9eae5d-e997-443c-abe6-b85e9edda33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2b89c238-4690-4986-9b12-3f0955c6ec88" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c9eae5d-e997-443c-abe6-b85e9edda33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_13478104-8885-4478-a2b6-265739a41ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2b89c238-4690-4986-9b12-3f0955c6ec88" xlink:to="loc_us-gaap_InvestmentIncomeNet_13478104-8885-4478-a2b6-265739a41ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_30211218-f6ac-4e4d-b66c-a40207f96fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2b89c238-4690-4986-9b12-3f0955c6ec88" xlink:to="loc_us-gaap_InterestExpense_30211218-f6ac-4e4d-b66c-a40207f96fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_c4020409-73ac-4d2e-99bb-fb508f7654e3" xlink:href="vrna-20240930.xsd#vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2b89c238-4690-4986-9b12-3f0955c6ec88" xlink:to="loc_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases_c4020409-73ac-4d2e-99bb-fb508f7654e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_196410d7-2d54-4771-97f3-228f57aa1bae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2b89c238-4690-4986-9b12-3f0955c6ec88" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_196410d7-2d54-4771-97f3-228f57aa1bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71027213-bc04-4e62-b351-742ce976b65b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71027213-bc04-4e62-b351-742ce976b65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70e17da6-4b13-4718-96bd-db0d9e399f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70e17da6-4b13-4718-96bd-db0d9e399f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8a61adf-f7b9-4939-a646-70fcdd95e496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_NetIncomeLoss_f8a61adf-f7b9-4939-a646-70fcdd95e496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_055423e9-e19d-4749-a20d-6d4f22020d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_EarningsPerShareBasic_055423e9-e19d-4749-a20d-6d4f22020d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a19326e9-d519-4f84-bd42-c6da1efe2697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a19326e9-d519-4f84-bd42-c6da1efe2697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7f9404d2-7e30-403a-8483-007f260aa308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7f9404d2-7e30-403a-8483-007f260aa308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5be5a44-153c-49d9-b42b-bc3fc8749be8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34919ce4-e466-43fd-8a08-e9fd4629e17f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5be5a44-153c-49d9-b42b-bc3fc8749be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cd9187e1-4804-4fd6-a37b-00c46246f794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cd9187e1-4804-4fd6-a37b-00c46246f794" xlink:to="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2069f178-6a5d-496e-90b6-b0e07bc9ee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2069f178-6a5d-496e-90b6-b0e07bc9ee6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2069f178-6a5d-496e-90b6-b0e07bc9ee6c" xlink:to="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b9c80819-447b-4148-aea0-0444b517b760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_CommonStockMember_b9c80819-447b-4148-aea0-0444b517b760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f8555aee-e000-4763-8bde-8190d70f9703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f8555aee-e000-4763-8bde-8190d70f9703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_cd0c4e50-1ef4-4a94-8f06-c50631b35263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_TreasuryStockCommonMember_cd0c4e50-1ef4-4a94-8f06-c50631b35263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7094b38e-5398-4c8b-adde-91fe7a5391e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7094b38e-5398-4c8b-adde-91fe7a5391e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2f75fbef-8a6b-4159-bac3-06ea74c4f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3e929d9e-31f8-4adf-959a-96e56f23c2a9" xlink:to="loc_us-gaap_RetainedEarningsMember_2f75fbef-8a6b-4159-bac3-06ea74c4f4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3c7d383c-e2e4-400e-9119-d90a339e1e41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3c7d383c-e2e4-400e-9119-d90a339e1e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ecdae7f-1a53-44d7-9ca8-1e02330234c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c7d383c-e2e4-400e-9119-d90a339e1e41" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ecdae7f-1a53-44d7-9ca8-1e02330234c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember_739da5fb-8fda-4b45-bd36-96d9d4820d2a" xlink:href="vrna-20240930.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ecdae7f-1a53-44d7-9ca8-1e02330234c8" xlink:to="loc_vrna_AtTheMarketSalesAgreementMember_739da5fb-8fda-4b45-bd36-96d9d4820d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e7ad25f-b3ce-4274-89e5-3e8df0ac51d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fc797ab7-e722-4144-ab9a-0d4fa1e0c0c5" xlink:to="loc_us-gaap_StatementLineItems_1e7ad25f-b3ce-4274-89e5-3e8df0ac51d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e7ad25f-b3ce-4274-89e5-3e8df0ac51d4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fe30bd29-ba96-4675-a510-8702dd950a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fe30bd29-ba96-4675-a510-8702dd950a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc516bbf-9c21-4d93-8060-2b9b8b515e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockholdersEquity_dc516bbf-9c21-4d93-8060-2b9b8b515e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81da0b66-677a-4f3f-9106-f37f56c4e278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_NetIncomeLoss_81da0b66-677a-4f3f-9106-f37f56c4e278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eb1e708-03d0-4fd5-989c-3b1c58dfecd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eb1e708-03d0-4fd5-989c-3b1c58dfecd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_375da28b-7dc4-4602-8d3c-931a39ba320a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_375da28b-7dc4-4602-8d3c-931a39ba320a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_bbca2754-464b-4a37-82c3-3836e8807478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_bbca2754-464b-4a37-82c3-3836e8807478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b2f8f78-73fe-4980-915c-604de1f9594d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b2f8f78-73fe-4980-915c-604de1f9594d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_204cfaf9-d088-41cd-a5f8-8979e7247c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_204cfaf9-d088-41cd-a5f8-8979e7247c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_8b8a5afa-b3f9-4db8-aee0-cd729a9353e6" xlink:href="vrna-20240930.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_8b8a5afa-b3f9-4db8-aee0-cd729a9353e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d40fdf8-395b-4955-a07f-2983f2e39643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d40fdf8-395b-4955-a07f-2983f2e39643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_22bf3297-7afe-4430-b5ee-5c0e652c303f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_22bf3297-7afe-4430-b5ee-5c0e652c303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ecdbfa88-9daa-4331-9f12-052377e06f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2c038a92-4743-4877-ad57-bfa5f47eb99b" xlink:to="loc_us-gaap_StockholdersEquity_ecdbfa88-9daa-4331-9f12-052377e06f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20240930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_620a0eef-4b73-4ccb-b684-c430aa8de66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_620a0eef-4b73-4ccb-b684-c430aa8de66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d92803fe-5fda-41c8-9f30-d06a08137ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_620a0eef-4b73-4ccb-b684-c430aa8de66c" xlink:to="loc_us-gaap_NetIncomeLoss_d92803fe-5fda-41c8-9f30-d06a08137ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_620a0eef-4b73-4ccb-b684-c430aa8de66c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c5a23341-b808-40ea-b4c2-493dbc51838a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c5a23341-b808-40ea-b4c2-493dbc51838a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_137f21e4-35b1-4df6-a50d-00c7b1ac0801" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_137f21e4-35b1-4df6-a50d-00c7b1ac0801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense_26149942-8fc2-44b1-887c-5426c2642ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:to="loc_us-gaap_AccretionExpense_26149942-8fc2-44b1-887c-5426c2642ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_85994e0a-1c51-423c-aef4-55ea9ce5a010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_85994e0a-1c51-423c-aef4-55ea9ce5a010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c1f53e33-6191-4088-930b-ed24b5fe7cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c1f53e33-6191-4088-930b-ed24b5fe7cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0809e9ca-2406-4596-8c04-78035bcdcb98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:to="loc_us-gaap_ShareBasedCompensation_0809e9ca-2406-4596-8c04-78035bcdcb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_939f3303-f82f-4b7c-82e5-4dfca41fc7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_939f3303-f82f-4b7c-82e5-4dfca41fc7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_843231fc-775b-43fa-a1e8-c634ff34b37e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_072e8f52-6f64-45b0-841e-d43bd6989f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_072e8f52-6f64-45b0-841e-d43bd6989f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_2343478a-97df-4ca4-ae87-de35980fa91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_2343478a-97df-4ca4-ae87-de35980fa91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_74d095b7-a0be-4899-b904-7366383b6193" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_74d095b7-a0be-4899-b904-7366383b6193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4a496cc8-afa3-496c-85e0-d10354031817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4a496cc8-afa3-496c-85e0-d10354031817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_56abd76e-c357-4d31-869b-799cc6b0819e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_56abd76e-c357-4d31-869b-799cc6b0819e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4661b5ed-3748-4c26-84d5-6968131b635a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4661b5ed-3748-4c26-84d5-6968131b635a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f8b5ca77-5b0e-4fe5-8594-513549209f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f8b5ca77-5b0e-4fe5-8594-513549209f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInLicenseAgreementObligations_7b2742dc-6dd6-4f96-a8b3-1c43e6be677c" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInLicenseAgreementObligations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_vrna_IncreaseDecreaseInLicenseAgreementObligations_7b2742dc-6dd6-4f96-a8b3-1c43e6be677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_111edd4f-71fb-4c05-ac69-ac6c7d42281f" xlink:href="vrna-20240930.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_111edd4f-71fb-4c05-ac69-ac6c7d42281f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_180517ff-1e10-4608-bf3f-219e32c00bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_180517ff-1e10-4608-bf3f-219e32c00bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b8e68388-1f79-4142-9977-150b589b9d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bce93809-6613-4a5f-97cc-12f534fc0136" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b8e68388-1f79-4142-9977-150b589b9d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ec006f54-ff61-4e26-b145-4c01e7882195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_620a0eef-4b73-4ccb-b684-c430aa8de66c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ec006f54-ff61-4e26-b145-4c01e7882195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b21dd9e3-d47d-4c2f-9969-a0ace378c438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b21dd9e3-d47d-4c2f-9969-a0ace378c438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2abe3136-6dad-4d0d-87a7-824f73a44c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b21dd9e3-d47d-4c2f-9969-a0ace378c438" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2abe3136-6dad-4d0d-87a7-824f73a44c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f7cde16-41bc-412c-b75e-6a5f4794d076" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b21dd9e3-d47d-4c2f-9969-a0ace378c438" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f7cde16-41bc-412c-b75e-6a5f4794d076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2dccf240-14d7-44b5-8359-1848d6134c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2dccf240-14d7-44b5-8359-1848d6134c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7666e85c-811b-44c1-a0a6-c0d1f95bd43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7666e85c-811b-44c1-a0a6-c0d1f95bd43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA_ce882b3a-7914-46e1-b109-1be94523a7e8" xlink:href="vrna-20240930.xsd#vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:to="loc_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA_ce882b3a-7914-46e1-b109-1be94523a7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_48ac4bb1-9c24-49f7-8848-67a463912805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_48ac4bb1-9c24-49f7-8848-67a463912805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d2d983c6-933f-4370-9596-24dede1d5b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d2d983c6-933f-4370-9596-24dede1d5b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8317ac41-e8ad-4ea6-ac78-97d01198520c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8317ac41-e8ad-4ea6-ac78-97d01198520c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1029d458-e9a8-4045-9bdf-af7f3b596c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1029d458-e9a8-4045-9bdf-af7f3b596c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b9e9f65-8a45-48c0-a6fb-09d3d78b48d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bf77a13-83cf-4790-a0e7-81528f4d215c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b9e9f65-8a45-48c0-a6fb-09d3d78b48d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c6b9c43-7381-4d44-a2db-1ccf80ca739a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c6b9c43-7381-4d44-a2db-1ccf80ca739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_260ff1d8-1ef9-4f23-9ce6-5df062fde94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_260ff1d8-1ef9-4f23-9ce6-5df062fde94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95515c6c-b06d-4e13-a50c-16c393725149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95515c6c-b06d-4e13-a50c-16c393725149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c4f06d3-4436-49b5-bcf8-259030651a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c4f06d3-4436-49b5-bcf8-259030651a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f088c5b2-7005-481a-a4bc-e2b7826a5b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa955fb3-4b61-4f88-9eae-9d8148b7e491" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f088c5b2-7005-481a-a4bc-e2b7826a5b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_cefc92cf-4a30-4609-88a6-8d0afb0ada24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f088c5b2-7005-481a-a4bc-e2b7826a5b23" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_cefc92cf-4a30-4609-88a6-8d0afb0ada24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e2de923d-3fa7-4ef7-b3b2-b3ef8548f94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f088c5b2-7005-481a-a4bc-e2b7826a5b23" xlink:to="loc_us-gaap_InterestPaidNet_e2de923d-3fa7-4ef7-b3b2-b3ef8548f94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="simple" xlink:href="vrna-20240930.xsd#Organizationanddescriptionofbusinessoperations"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65de772a-51c9-405f-be25-363ccfef36cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_a701449e-0929-4f1a-8832-b02a12260dd5" xlink:href="vrna-20240930.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65de772a-51c9-405f-be25-363ccfef36cc" xlink:to="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_a701449e-0929-4f1a-8832-b02a12260dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="vrna-20240930.xsd#Basisofpresentationandsummaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e4977a6-7a6a-4a31-b244-4559d900a922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c7da1d5b-67ce-4930-84a3-3790417f6d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e4977a6-7a6a-4a31-b244-4559d900a922" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c7da1d5b-67ce-4930-84a3-3790417f6d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterest" xlink:type="simple" xlink:href="vrna-20240930.xsd#EquityInterest"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/EquityInterest" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_023d8056-d613-48a5-b66c-5c0b3bed8786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b5403787-350e-4566-9848-af04a0b02581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_023d8056-d613-48a5-b66c-5c0b3bed8786" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b5403787-350e-4566-9848-af04a0b02581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Accruedexpenses" xlink:type="simple" xlink:href="vrna-20240930.xsd#Accruedexpenses"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Accruedexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_17c7c7e2-0687-4324-a0e0-354885761c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6f331290-4c79-492d-8616-9f9f0f6c707a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_17c7c7e2-0687-4324-a0e0-354885761c54" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6f331290-4c79-492d-8616-9f9f0f6c707a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Ligandlicenseagreementobligations" xlink:type="simple" xlink:href="vrna-20240930.xsd#Ligandlicenseagreementobligations"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Ligandlicenseagreementobligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f48d28d-4129-4529-ad62-93d157e29d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f870b654-f24a-4584-b21b-68b250f53c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f48d28d-4129-4529-ad62-93d157e29d1e" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f870b654-f24a-4584-b21b-68b250f53c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Debt" xlink:type="simple" xlink:href="vrna-20240930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_97cb303b-2cb5-43b3-9763-efb815326b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_dea06a39-a5b1-488d-b2f5-79c97cc222fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97cb303b-2cb5-43b3-9763-efb815326b24" xlink:to="loc_us-gaap_LongTermDebtTextBlock_dea06a39-a5b1-488d-b2f5-79c97cc222fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="simple" xlink:href="vrna-20240930.xsd#Sharebasedcompensation"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da4fef70-21d7-49b7-b03a-8a0769878c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3ad25687-bb8e-4281-bb66-3594d7d38f53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da4fef70-21d7-49b7-b03a-8a0769878c47" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3ad25687-bb8e-4281-bb66-3594d7d38f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Capitalizationandnetlosspershare" xlink:type="simple" xlink:href="vrna-20240930.xsd#Capitalizationandnetlosspershare"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Capitalizationandnetlosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0590ab9f-f0d1-4a85-b344-06b476d52940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_28ff07c3-a08f-477d-9cbe-a2fa9fee1449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0590ab9f-f0d1-4a85-b344-06b476d52940" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_28ff07c3-a08f-477d-9cbe-a2fa9fee1449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Subsequentevents" xlink:type="simple" xlink:href="vrna-20240930.xsd#Subsequentevents"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Subsequentevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8540464e-e8d7-4cca-9d74-6edd0a2b8f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c7b5be4d-9190-451a-8623-0e2cbb9c2fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8540464e-e8d7-4cca-9d74-6edd0a2b8f80" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c7b5be4d-9190-451a-8623-0e2cbb9c2fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="vrna-20240930.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3d7bda1c-fb48-4608-ac25-a21204e1a397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_c8ea3d1a-3506-4f88-9e96-befc7efa767c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3d7bda1c-fb48-4608-ac25-a21204e1a397" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_c8ea3d1a-3506-4f88-9e96-befc7efa767c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c84d83be-7d3d-40c4-ba26-1a992f58feda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3d7bda1c-fb48-4608-ac25-a21204e1a397" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c84d83be-7d3d-40c4-ba26-1a992f58feda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_46879e5b-2fc8-4bf3-a695-005cdb5e1250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3d7bda1c-fb48-4608-ac25-a21204e1a397" xlink:to="loc_us-gaap_UseOfEstimates_46879e5b-2fc8-4bf3-a695-005cdb5e1250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5f32b94c-b15a-4dc5-8513-e3ed07404c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3d7bda1c-fb48-4608-ac25-a21204e1a397" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5f32b94c-b15a-4dc5-8513-e3ed07404c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="vrna-20240930.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f7e796d4-e9ac-4606-b8d2-82e4509a1670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_20f39666-9b23-4625-9577-488749bcc39d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f7e796d4-e9ac-4606-b8d2-82e4509a1670" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_20f39666-9b23-4625-9577-488749bcc39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="vrna-20240930.xsd#AccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3de9ed2a-535e-49ed-bae3-cc1ab1b4338b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9fd4b047-f6b1-420c-ac67-5a2c8e8f828e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3de9ed2a-535e-49ed-bae3-cc1ab1b4338b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9fd4b047-f6b1-420c-ac67-5a2c8e8f828e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="simple" xlink:href="vrna-20240930.xsd#SharebasedcompensationTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9989c751-7b54-44af-a241-cd76e377d74e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1b7bbd1c-6ac6-40e9-97dd-b1cafbf59ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9989c751-7b54-44af-a241-cd76e377d74e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1b7bbd1c-6ac6-40e9-97dd-b1cafbf59ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f4a5c9ca-4574-4bec-8ee8-1d28c1379273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9989c751-7b54-44af-a241-cd76e377d74e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f4a5c9ca-4574-4bec-8ee8-1d28c1379273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_42ebae26-40f6-40b1-8d0a-c49d12d1e02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9989c751-7b54-44af-a241-cd76e377d74e" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_42ebae26-40f6-40b1-8d0a-c49d12d1e02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/CapitalizationandnetlosspershareTables" xlink:type="simple" xlink:href="vrna-20240930.xsd#CapitalizationandnetlosspershareTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/CapitalizationandnetlosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7adcb5f5-0172-421f-9e32-a4f7adc2a710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_42fcf300-da6c-4a5f-99db-a35761a10b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7adcb5f5-0172-421f-9e32-a4f7adc2a710" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_42fcf300-da6c-4a5f-99db-a35761a10b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc409441-0acf-44c6-bf99-eb348433becc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries_881b8852-016d-4b93-8433-bfb7cf63e2e1" xlink:href="vrna-20240930.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc409441-0acf-44c6-bf99-eb348433becc" xlink:to="loc_vrna_NumberOfWhollyOwnedSubsidiaries_881b8852-016d-4b93-8433-bfb7cf63e2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_028ca472-f8bb-4ce6-bc89-336b757cfefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc409441-0acf-44c6-bf99-eb348433becc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_028ca472-f8bb-4ce6-bc89-336b757cfefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18d25553-1177-46ce-bd7c-f10cd4a3b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18d25553-1177-46ce-bd7c-f10cd4a3b1c3" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_66fc6b52-f6ff-4451-afbd-c477cf2ffba5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:to="loc_srt_MajorCustomersAxis_66fc6b52-f6ff-4451-afbd-c477cf2ffba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_528c24c8-5f29-4447-b28f-4a7b5daf8fa7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_66fc6b52-f6ff-4451-afbd-c477cf2ffba5" xlink:to="loc_srt_NameOfMajorCustomerDomain_528c24c8-5f29-4447-b28f-4a7b5daf8fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SpecialtyPharmaciesMember_d0c2ddd5-d244-4239-b929-29335ac76abb" xlink:href="vrna-20240930.xsd#vrna_SpecialtyPharmaciesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_528c24c8-5f29-4447-b28f-4a7b5daf8fa7" xlink:to="loc_vrna_SpecialtyPharmaciesMember_d0c2ddd5-d244-4239-b929-29335ac76abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e071e8f-3dc3-445d-b6b0-e185823adad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e071e8f-3dc3-445d-b6b0-e185823adad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_468d76e2-2e10-4f1d-a01a-c1a0e8b218ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2e071e8f-3dc3-445d-b6b0-e185823adad0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_468d76e2-2e10-4f1d-a01a-c1a0e8b218ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_652a59e1-704c-4339-8c5e-a596fd10d373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_468d76e2-2e10-4f1d-a01a-c1a0e8b218ac" xlink:to="loc_us-gaap_SalesRevenueNetMember_652a59e1-704c-4339-8c5e-a596fd10d373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9dd640be-8f47-4515-8264-2a9f733499d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9dd640be-8f47-4515-8264-2a9f733499d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_68d5910a-70ce-4ffd-9f4c-c537ba8d90d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9dd640be-8f47-4515-8264-2a9f733499d9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_68d5910a-70ce-4ffd-9f4c-c537ba8d90d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e693cda2-3571-4079-bcd0-956043413406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_68d5910a-70ce-4ffd-9f4c-c537ba8d90d1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e693cda2-3571-4079-bcd0-956043413406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_8968171b-ccc3-4891-81de-b85d9f8b4300" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_faec7815-8ec1-46a1-b523-3f3aad1e32c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:to="loc_us-gaap_NumberOfOperatingSegments_faec7815-8ec1-46a1-b523-3f3aad1e32c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3d7a66bd-3eec-4c4e-8a71-f89769ebf02f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:to="loc_us-gaap_NumberOfReportableSegments_3d7a66bd-3eec-4c4e-8a71-f89769ebf02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c8f1bfdc-5e5f-428c-9c1a-81ae42051733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_a0954142-c9e4-4c09-b6f3-13884e8c64a9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c8f1bfdc-5e5f-428c-9c1a-81ae42051733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/EquityInterestDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#EquityInterestDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/EquityInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf99fcbf-74b1-4f9f-8453-02b2469ca037" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_162c4d20-b21c-4012-b795-9a3fbc340bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf99fcbf-74b1-4f9f-8453-02b2469ca037" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_162c4d20-b21c-4012-b795-9a3fbc340bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_05f87cd6-d77b-46ab-b72b-36d96ea8804e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_162c4d20-b21c-4012-b795-9a3fbc340bd8" xlink:to="loc_srt_CounterpartyNameAxis_05f87cd6-d77b-46ab-b72b-36d96ea8804e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76307d44-aebe-46b3-bc37-5915264f9664" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_05f87cd6-d77b-46ab-b72b-36d96ea8804e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76307d44-aebe-46b3-bc37-5915264f9664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_f127c6c1-5e2f-4f5f-93b4-8ad432bb8f5e" xlink:href="vrna-20240930.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76307d44-aebe-46b3-bc37-5915264f9664" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_f127c6c1-5e2f-4f5f-93b4-8ad432bb8f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_162c4d20-b21c-4012-b795-9a3fbc340bd8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_9008d79e-4921-4796-a06e-c984473459e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_9008d79e-4921-4796-a06e-c984473459e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_68d082ea-1e49-4f98-9e21-89f2d5ef6cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_68d082ea-1e49-4f98-9e21-89f2d5ef6cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_7fb66ea5-f417-4a1a-9ffc-8b8f4ad4df95" xlink:href="vrna-20240930.xsd#vrna_EquityInterestReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1870beb1-bdc4-4176-80fe-3a0932834569" xlink:to="loc_vrna_EquityInterestReceivable_7fb66ea5-f417-4a1a-9ffc-8b8f4ad4df95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#AccruedexpensesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d52d35d2-68a3-4e1a-869f-f877c79f148d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_ab763b0a-04e0-41d2-80e6-090f747c34bc" xlink:href="vrna-20240930.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d52d35d2-68a3-4e1a-869f-f877c79f148d" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_ab763b0a-04e0-41d2-80e6-090f747c34bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_e3107c53-3019-4771-ac6c-164a54a4ca9b" xlink:href="vrna-20240930.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d52d35d2-68a3-4e1a-869f-f877c79f148d" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_e3107c53-3019-4771-ac6c-164a54a4ca9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b2300a32-c6fb-4234-a1b4-d13f15a8142f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d52d35d2-68a3-4e1a-869f-f877c79f148d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b2300a32-c6fb-4234-a1b4-d13f15a8142f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_79bfa5f1-3ae3-4d2e-8946-c9809e377fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d52d35d2-68a3-4e1a-869f-f877c79f148d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_79bfa5f1-3ae3-4d2e-8946-c9809e377fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1" xlink:type="simple" xlink:href="vrna-20240930.xsd#OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d218729b-9c10-4e57-af0d-667a81579ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b49e0b2-00ba-4cdc-b9ba-377b53d32cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d218729b-9c10-4e57-af0d-667a81579ec0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b49e0b2-00ba-4cdc-b9ba-377b53d32cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4e3c2b2f-c76f-4105-b36e-b50be3c8d618" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b49e0b2-00ba-4cdc-b9ba-377b53d32cbb" xlink:to="loc_srt_CounterpartyNameAxis_4e3c2b2f-c76f-4105-b36e-b50be3c8d618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495bbe2b-1182-4fb9-9650-6398626b8594" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4e3c2b2f-c76f-4105-b36e-b50be3c8d618" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495bbe2b-1182-4fb9-9650-6398626b8594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember_725b715e-ca02-4e9a-bcc8-307d590d8ca6" xlink:href="vrna-20240930.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_495bbe2b-1182-4fb9-9650-6398626b8594" xlink:to="loc_vrna_LigandUKDevelopmentLimitedMember_725b715e-ca02-4e9a-bcc8-307d590d8ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22835647-e015-415c-b26b-98471c626781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9b49e0b2-00ba-4cdc-b9ba-377b53d32cbb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22835647-e015-415c-b26b-98471c626781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bf016f84-d540-4a8a-988b-b118bbdc3f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22835647-e015-415c-b26b-98471c626781" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bf016f84-d540-4a8a-988b-b118bbdc3f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d11bde7c-922e-4d55-a17f-4fd50e5d8330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22835647-e015-415c-b26b-98471c626781" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d11bde7c-922e-4d55-a17f-4fd50e5d8330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/DebtDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_40c97eb7-98d4-44b3-9d28-c37647ae7793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_40c97eb7-98d4-44b3-9d28-c37647ae7793" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_11059edb-d7ec-45b8-93ed-999b43809cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_DebtInstrumentAxis_11059edb-d7ec-45b8-93ed-999b43809cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_11059edb-d7ec-45b8-93ed-999b43809cfe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2023TermLoanMember_a815af65-310c-456e-9ee3-d239d787850e" xlink:href="vrna-20240930.xsd#vrna_A2023TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2023TermLoanMember_a815af65-310c-456e-9ee3-d239d787850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2023TermALoanMember_aae4fee0-7f60-44cd-acb3-d36f837e9966" xlink:href="vrna-20240930.xsd#vrna_A2023TermALoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2023TermALoanMember_aae4fee0-7f60-44cd-acb3-d36f837e9966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermLoanMember_37a64c9e-c8dd-474d-bfc4-a11c2197eff8" xlink:href="vrna-20240930.xsd#vrna_A2024TermLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermLoanMember_37a64c9e-c8dd-474d-bfc4-a11c2197eff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermALoanMember_6f304d73-ee57-40d8-a6bf-c40d1053d824" xlink:href="vrna-20240930.xsd#vrna_A2024TermALoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermALoanMember_6f304d73-ee57-40d8-a6bf-c40d1053d824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermBMember_c484db44-63f7-4748-941d-90ad68e1db23" xlink:href="vrna-20240930.xsd#vrna_A2024TermBMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermBMember_c484db44-63f7-4748-941d-90ad68e1db23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermCMember_e0540e52-e415-4ec9-983d-80b81703ac2c" xlink:href="vrna-20240930.xsd#vrna_A2024TermCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermCMember_e0540e52-e415-4ec9-983d-80b81703ac2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermDMember_e46b21e2-e8c2-4cdb-b6c0-89c6a3b3120a" xlink:href="vrna-20240930.xsd#vrna_A2024TermDMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermDMember_e46b21e2-e8c2-4cdb-b6c0-89c6a3b3120a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2024TermELoanMember_79b704e3-1ddc-4a5e-ba0a-a5bc538c572b" xlink:href="vrna-20240930.xsd#vrna_A2024TermELoanMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4c56476f-33c3-445e-85a2-b703ec4cb0d0" xlink:to="loc_vrna_A2024TermELoanMember_79b704e3-1ddc-4a5e-ba0a-a5bc538c572b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_930d2e25-8da9-49c8-8df8-ef9577b39cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_930d2e25-8da9-49c8-8df8-ef9577b39cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c458f3bc-ae26-4068-b97b-3386d51a6a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_930d2e25-8da9-49c8-8df8-ef9577b39cfd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c458f3bc-ae26-4068-b97b-3386d51a6a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_6dbdfe27-1763-4d62-85ca-29654a29c475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c458f3bc-ae26-4068-b97b-3386d51a6a39" xlink:to="loc_us-gaap_SecuredDebtMember_6dbdfe27-1763-4d62-85ca-29654a29c475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_19262397-a3c6-4847-a12b-43d5e8beb675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_CreditFacilityAxis_19262397-a3c6-4847-a12b-43d5e8beb675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0e0e38bc-5229-4416-8c30-f2e9e82aa01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_19262397-a3c6-4847-a12b-43d5e8beb675" xlink:to="loc_us-gaap_CreditFacilityDomain_0e0e38bc-5229-4416-8c30-f2e9e82aa01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6cf390e2-62a7-46d3-8bc0-ea015eac2824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0e0e38bc-5229-4416-8c30-f2e9e82aa01a" xlink:to="loc_us-gaap_LineOfCreditMember_6cf390e2-62a7-46d3-8bc0-ea015eac2824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis_95d4bd12-9790-4b33-8952-3ca702cb5388" xlink:href="vrna-20240930.xsd#vrna_InterestRatePeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_vrna_InterestRatePeriodAxis_95d4bd12-9790-4b33-8952-3ca702cb5388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_fb64782d-cc9f-42e1-8959-245c842870a3" xlink:href="vrna-20240930.xsd#vrna_InterestRatePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_InterestRatePeriodAxis_95d4bd12-9790-4b33-8952-3ca702cb5388" xlink:to="loc_vrna_InterestRatePeriodDomain_fb64782d-cc9f-42e1-8959-245c842870a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_0be010be-ba5f-48f1-8329-e7f96f635fd9" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_InterestRatePeriodDomain_fb64782d-cc9f-42e1-8959-245c842870a3" xlink:to="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_0be010be-ba5f-48f1-8329-e7f96f635fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_VariableRateAxis_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9b1237d2-5441-4239-af9e-a64821829ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7c9aa4ad-2a13-47fb-a7c1-730a0cc5e553" xlink:to="loc_us-gaap_VariableRateDomain_9b1237d2-5441-4239-af9e-a64821829ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_f89fb7af-98cc-4c6d-9ceb-857c0773907e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_9b1237d2-5441-4239-af9e-a64821829ff8" xlink:to="loc_us-gaap_BaseRateMember_f89fb7af-98cc-4c6d-9ceb-857c0773907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodAxis_559c6f56-c46f-4540-b6a6-da44e61ddfe5" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_vrna_DebtPrepaymentPeriodAxis_559c6f56-c46f-4540-b6a6-da44e61ddfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_DebtPrepaymentPeriodAxis_559c6f56-c46f-4540-b6a6-da44e61ddfe5" xlink:to="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodOneMember_16a7bc48-6fd0-41dc-9ec4-5d68b842dc23" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:to="loc_vrna_DebtPrepaymentPeriodOneMember_16a7bc48-6fd0-41dc-9ec4-5d68b842dc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodTwoMember_f6ccaca1-2c67-4b20-9075-b4067e76523c" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:to="loc_vrna_DebtPrepaymentPeriodTwoMember_f6ccaca1-2c67-4b20-9075-b4067e76523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtPrepaymentPeriodFourMember_8d3fb07f-23be-4177-80a3-c203029955bf" xlink:href="vrna-20240930.xsd#vrna_DebtPrepaymentPeriodFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_DebtPrepaymentPeriodDomain_3d9a3f60-92bf-4f8a-bf49-a76bf012ea14" xlink:to="loc_vrna_DebtPrepaymentPeriodFourMember_8d3fb07f-23be-4177-80a3-c203029955bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e2c33ef2-ccca-4a53-a561-1609ebab871f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_srt_RangeAxis_e2c33ef2-ccca-4a53-a561-1609ebab871f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57ef4167-c07d-464e-8136-3680f1d01b8f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e2c33ef2-ccca-4a53-a561-1609ebab871f" xlink:to="loc_srt_RangeMember_57ef4167-c07d-464e-8136-3680f1d01b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87422450-4898-4739-97cf-4c8e8ba86b13" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57ef4167-c07d-464e-8136-3680f1d01b8f" xlink:to="loc_srt_MinimumMember_87422450-4898-4739-97cf-4c8e8ba86b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8683bf92-eb27-4834-a2eb-65eb583e356b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_srt_CounterpartyNameAxis_8683bf92-eb27-4834-a2eb-65eb583e356b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15457596-b05a-4918-abdf-d32a3e5f0fee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8683bf92-eb27-4834-a2eb-65eb583e356b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15457596-b05a-4918-abdf-d32a3e5f0fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OaktreeFundAdministrationLLCMember_c2b8ccea-f94f-482f-9cd6-426e8e5128ad" xlink:href="vrna-20240930.xsd#vrna_OaktreeFundAdministrationLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15457596-b05a-4918-abdf-d32a3e5f0fee" xlink:to="loc_vrna_OaktreeFundAdministrationLLCMember_c2b8ccea-f94f-482f-9cd6-426e8e5128ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_735c88ad-dfbe-4c03-a248-516b2d7d9fe0" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_078fe279-ba9d-4949-a420-71b48f66d2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_078fe279-ba9d-4949-a420-71b48f66d2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fe564d6b-459e-45d2-9a69-b3d6fdf0b5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fe564d6b-459e-45d2-9a69-b3d6fdf0b5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_36a3a7a6-5cce-458a-8751-0cfc9c0b2de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_36a3a7a6-5cce-458a-8751-0cfc9c0b2de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4b368db7-b912-4bf8-bb97-402383e49b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4b368db7-b912-4bf8-bb97-402383e49b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_b8390414-81d0-418d-826d-e17d8a452474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_b8390414-81d0-418d-826d-e17d8a452474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_9ebc47b5-c664-47d8-8fb5-376931860620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_9ebc47b5-c664-47d8-8fb5-376931860620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_206cb740-b6a0-45e5-8010-f43001dd03c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_206cb740-b6a0-45e5-8010-f43001dd03c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f478064b-e7ea-4d69-9bfd-73ca6d7778a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_LongTermDebt_f478064b-e7ea-4d69-9bfd-73ca6d7778a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_a26f11c9-d3b1-443b-a184-b9e2bcf6a155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_a26f11c9-d3b1-443b-a184-b9e2bcf6a155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_47c7e1df-9c0f-46db-b745-7a3b0292de01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_47c7e1df-9c0f-46db-b745-7a3b0292de01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f152962c-702d-4a4d-8137-885b2ff7745a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f152962c-702d-4a4d-8137-885b2ff7745a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentExitFeePercentage_ac4a701d-94ab-464d-90ce-dbc5b0f352fe" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentExitFeePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentExitFeePercentage_ac4a701d-94ab-464d-90ce-dbc5b0f352fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_231c2817-6b2c-49b4-a8fd-47e475e6301a" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentEarlyRepaymentPenaltyPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent_231c2817-6b2c-49b4-a8fd-47e475e6301a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_db6bc6dd-0b49-417a-b663-823c249a418e" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage_db6bc6dd-0b49-417a-b663-823c249a418e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7c3d0ba3-06ff-463f-8ee5-81524f678f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7c3d0ba3-06ff-463f-8ee5-81524f678f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple_8cf7d0cd-91b2-4de3-9efd-d43d07bd51f2" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentPartialPrepaymentDenominationMultiple"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple_8cf7d0cd-91b2-4de3-9efd-d43d07bd51f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum_13648dfa-71ed-4b43-8834-dc33c906c65f" xlink:href="vrna-20240930.xsd#vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum_13648dfa-71ed-4b43-8834-dc33c906c65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion_37501be9-59ce-4da1-9796-7473fca19701" xlink:href="vrna-20240930.xsd#vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion_37501be9-59ce-4da1-9796-7473fca19701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d5eb578f-3594-451a-886a-1b24bd8f8e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d5eb578f-3594-451a-886a-1b24bd8f8e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice_0a4d09c1-2d43-4c0b-9714-8707b6408aba" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice_0a4d09c1-2d43-4c0b-9714-8707b6408aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales_27ec6f68-fe61-42ac-bd1c-7fff9621e71d" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales_27ec6f68-fe61-42ac-bd1c-7fff9621e71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees_7042ff41-1868-40ab-b9d7-89bc40a3b923" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees_7042ff41-1868-40ab-b9d7-89bc40a3b923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding_ae49bbf9-b157-4493-bc85-a284f913f17f" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding_ae49bbf9-b157-4493-bc85-a284f913f17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultiple_441cbd28-833c-42d9-8f37-0c7cd9fb0690" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultiple"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultiple_441cbd28-833c-42d9-8f37-0c7cd9fb0690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne_d4db8aca-257f-435a-bcc2-74b522ba4406" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne_d4db8aca-257f-435a-bcc2-74b522ba4406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo_470edaa5-a100-4360-a41c-47ed34e0ecc5" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo_470edaa5-a100-4360-a41c-47ed34e0ecc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree_a00ea840-2cf5-4eac-ad0e-989ad4f23a4c" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree_a00ea840-2cf5-4eac-ad0e-989ad4f23a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree_fe937afa-6833-4f5c-98f1-50fc1c21bb4c" xlink:href="vrna-20240930.xsd#vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_be1b33ce-5f7d-4b92-932c-ffc2c4fe8e1a" xlink:to="loc_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree_fe937afa-6833-4f5c-98f1-50fc1c21bb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1270979c-eb7e-440e-bac3-a9a9bc0cf7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_332eddb1-9e9a-4191-aec0-71aef48dd638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1270979c-eb7e-440e-bac3-a9a9bc0cf7d3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_332eddb1-9e9a-4191-aec0-71aef48dd638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e505cfcd-57a9-4942-8f6a-fddb32574cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_332eddb1-9e9a-4191-aec0-71aef48dd638" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e505cfcd-57a9-4942-8f6a-fddb32574cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_41cd571f-6982-4c37-8f4c-10af794dd061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e505cfcd-57a9-4942-8f6a-fddb32574cb4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_41cd571f-6982-4c37-8f4c-10af794dd061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_47e18677-e108-4c15-9024-a4127d0339d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_41cd571f-6982-4c37-8f4c-10af794dd061" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_47e18677-e108-4c15-9024-a4127d0339d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_493fe8c3-1e34-4f16-ae2f-cf86ac050091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_41cd571f-6982-4c37-8f4c-10af794dd061" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_493fe8c3-1e34-4f16-ae2f-cf86ac050091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_393a848b-fd0b-4081-83fc-8251be5dcd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_332eddb1-9e9a-4191-aec0-71aef48dd638" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_393a848b-fd0b-4081-83fc-8251be5dcd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc0c7a2f-8b82-4b92-b8c7-c985a6f77f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_393a848b-fd0b-4081-83fc-8251be5dcd1b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc0c7a2f-8b82-4b92-b8c7-c985a6f77f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#SharebasedcompensationShareOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e40a0c5d-bd28-47c4-ab89-b6b83b523351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4bd957cb-2894-4677-aaf5-b9eed366eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e40a0c5d-bd28-47c4-ab89-b6b83b523351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4bd957cb-2894-4677-aaf5-b9eed366eb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b3a939c4-dc2a-430f-b7db-afdc85cf2b84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4bd957cb-2894-4677-aaf5-b9eed366eb72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b3a939c4-dc2a-430f-b7db-afdc85cf2b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9bf5abec-31a4-4f24-b1bc-04ebabb3795a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4bd957cb-2894-4677-aaf5-b9eed366eb72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9bf5abec-31a4-4f24-b1bc-04ebabb3795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c864ad98-6d17-4503-b69f-0f88ac005d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4bd957cb-2894-4677-aaf5-b9eed366eb72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c864ad98-6d17-4503-b69f-0f88ac005d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9015318d-8b72-4461-87a0-9251159d64a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4bd957cb-2894-4677-aaf5-b9eed366eb72" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9015318d-8b72-4461-87a0-9251159d64a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_74951e46-c7f2-4931-af8f-38549189b692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4bd957cb-2894-4677-aaf5-b9eed366eb72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_74951e46-c7f2-4931-af8f-38549189b692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_115890c3-522b-4e89-a2f6-a233b84b49ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4bd957cb-2894-4677-aaf5-b9eed366eb72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_115890c3-522b-4e89-a2f6-a233b84b49ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62e4fac2-3760-4749-8b23-328d7ad93e91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0329d5-fd64-4084-8a79-3fb6bff2eb74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62e4fac2-3760-4749-8b23-328d7ad93e91" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0329d5-fd64-4084-8a79-3fb6bff2eb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4392f02-48ef-483b-b0fd-8263fb6ef431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0329d5-fd64-4084-8a79-3fb6bff2eb74" xlink:to="loc_us-gaap_AwardTypeAxis_d4392f02-48ef-483b-b0fd-8263fb6ef431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_943e8963-a595-49f0-a473-b6eefbec1ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d4392f02-48ef-483b-b0fd-8263fb6ef431" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_943e8963-a595-49f0-a473-b6eefbec1ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4960b70f-9679-4ff2-b9b0-a8fad878e7db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_943e8963-a595-49f0-a473-b6eefbec1ba6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4960b70f-9679-4ff2-b9b0-a8fad878e7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_18eec78d-c8ce-424e-bf9c-17200e3db5ce" xlink:href="vrna-20240930.xsd#vrna_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_943e8963-a595-49f0-a473-b6eefbec1ba6" xlink:to="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_18eec78d-c8ce-424e-bf9c-17200e3db5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bee653fc-74bb-44ec-b9c2-ee2a54cd8924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b0329d5-fd64-4084-8a79-3fb6bff2eb74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bee653fc-74bb-44ec-b9c2-ee2a54cd8924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bee653fc-74bb-44ec-b9c2-ee2a54cd8924" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3dd057bc-c8bf-4036-9656-5cc95261a694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3dd057bc-c8bf-4036-9656-5cc95261a694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1a6eec89-acec-4afc-a5dc-237e79b60ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1a6eec89-acec-4afc-a5dc-237e79b60ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b017e49d-fdeb-4338-9439-dac9547754e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b017e49d-fdeb-4338-9439-dac9547754e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e3b6d5f2-e10c-4dab-a2bc-c5bfc20150eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ffd042c0-7239-476a-a8d0-98dfe878e4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e3b6d5f2-e10c-4dab-a2bc-c5bfc20150eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc58394b-1eca-499b-9bbf-c749ab4a785e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306a3d56-d359-4962-b621-3cc48e2036a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc58394b-1eca-499b-9bbf-c749ab4a785e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306a3d56-d359-4962-b621-3cc48e2036a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7797d752-21b6-406e-912b-daa6a7b122c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306a3d56-d359-4962-b621-3cc48e2036a8" xlink:to="loc_us-gaap_AwardTypeAxis_7797d752-21b6-406e-912b-daa6a7b122c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84a63fc8-d4a8-4135-8c6c-4ca0b3ebbea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7797d752-21b6-406e-912b-daa6a7b122c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84a63fc8-d4a8-4135-8c6c-4ca0b3ebbea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_3030d63d-76c3-4dd5-9cf7-736ccbba27ba" xlink:href="vrna-20240930.xsd#vrna_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84a63fc8-d4a8-4135-8c6c-4ca0b3ebbea2" xlink:to="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember_3030d63d-76c3-4dd5-9cf7-736ccbba27ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306a3d56-d359-4962-b621-3cc48e2036a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_242fa443-c949-4fca-84e2-6fde9a4e9310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_242fa443-c949-4fca-84e2-6fde9a4e9310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fb3f412a-db25-4763-8b3a-cd215110c603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fb3f412a-db25-4763-8b3a-cd215110c603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2291f340-5da3-41cc-a8c9-fe252148c1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e3770a0-ac44-492b-8a4d-f1de4698902d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2291f340-5da3-41cc-a8c9-fe252148c1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails" xlink:type="simple" xlink:href="vrna-20240930.xsd#CapitalizationandnetlosspershareComputationDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c4e0f4a7-5898-4d77-bb09-2ef96cbe22b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_016f9fa5-f47f-4de9-a979-f7c0c4d9ad89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4e0f4a7-5898-4d77-bb09-2ef96cbe22b2" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_016f9fa5-f47f-4de9-a979-f7c0c4d9ad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_07ed29ff-5968-49c5-a039-311531627103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4e0f4a7-5898-4d77-bb09-2ef96cbe22b2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_07ed29ff-5968-49c5-a039-311531627103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a62eeb9-47e0-46c7-b089-bd79355638b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_07ed29ff-5968-49c5-a039-311531627103" xlink:to="loc_us-gaap_NetIncomeLoss_3a62eeb9-47e0-46c7-b089-bd79355638b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_42cb2e82-30b7-4829-b7b1-da5503dcca34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4e0f4a7-5898-4d77-bb09-2ef96cbe22b2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_42cb2e82-30b7-4829-b7b1-da5503dcca34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8a63e640-d8ef-4c92-9507-5a0bf328ee24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_42cb2e82-30b7-4829-b7b1-da5503dcca34" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8a63e640-d8ef-4c92-9507-5a0bf328ee24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbe23ce3-ea82-44f3-96c9-873cb1cf55c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_42cb2e82-30b7-4829-b7b1-da5503dcca34" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbe23ce3-ea82-44f3-96c9-873cb1cf55c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c871c4c2-dccb-46ef-a134-79a90f67f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_42cb2e82-30b7-4829-b7b1-da5503dcca34" xlink:to="loc_us-gaap_EarningsPerShareBasic_c871c4c2-dccb-46ef-a134-79a90f67f50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b14730e-077c-475a-931c-7198ff28b6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_42cb2e82-30b7-4829-b7b1-da5503dcca34" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b14730e-077c-475a-931c-7198ff28b6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aa42d8c7-1f28-4e49-9361-14951900f9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c4e0f4a7-5898-4d77-bb09-2ef96cbe22b2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aa42d8c7-1f28-4e49-9361-14951900f9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember" xlink:href="vrna-20240930.xsd#vrna_PerformanceRestrictedStockUnitsPRSUsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_vrna_PerformanceRestrictedStockUnitsPRSUsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DavidZaccardelliMember" xlink:href="vrna-20240930.xsd#vrna_DavidZaccardelliMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_vrna_DavidZaccardelliMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MarkHahnMember" xlink:href="vrna-20240930.xsd#vrna_MarkHahnMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_vrna_MarkHahnMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>vrna-20240930_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20240930_g1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *6!,P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **_'?XZ_MY_M*P?M2>,?A9\/O$4'F+XCFTC1K2/2;)YO]<5CC#R
MQE2>BY;\3GFK_CWXP?\ !1+X(Z%-XI\8QS-H%BOFW4BZ;HMY%&@ZM+]D4NBC
MNV0!W- 'Z\T5\6?\$_?^"A _:SDU+PKXHTJUT3QWIMM]M_T M]EO[<,J,Z*Q
M+(ZLZY0D\,"#U"_ OP[M[L?\%7(]'OY[JXM++XC:@UO#<S,P15N)VB8#.!P$
M/% '[FT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17DO[7$+3?L
ML?%XQS26\D7A+5)TDB;:RM':R.,'MRHK\V_^"(\8N/BU\3;N7]Y<_P!C0#S6
M.6^:?+<^Y4'\* /U^HHHH ***^$O%'_!0+QC9_MW6?P%TSPQH::1_;-O87&K
M7;S/</"\$<SE%5E57 9P,[AG&>] 'W;1110 4444 %%%% !1110 4444 %%0
MWEJE]9SVTF[RYHVC;:<'!&#@_C7X7_\ !+FZU.3]NCPS;ZK=3W5S:VFIPMY\
MQDVD6T@(!)/&1VH _=:BBB@ HK\'_%BWUK_P52M=,N+F[GM5^+-K<);W$K.J
MB34XY.%/ &'X]J^_O^"LGQ3^)_PM^">@77P\O=3T2QO-1:'6=:T@LD]M'Y>8
MD\Q?FB5VW?."#E%&?FP0#[BHKY"_X)>^,?BAXX_9K_M'XG7.I:A/_:DJ:/J&
MLEFN[JR$<9#L[_-(OF&4*[9) ZD 5]>T %%%?AC^U)'=1_\ !4*XT6ZN+J33
MI/&>BR_9)IF*8E%J_"YP 1(<8[&@#]SJ*** "BBB@ HHHH **\E_:XA:;]EC
MXO&.:2WDB\):I.DD3;65H[61Q@]N5%?FW_P1'C%Q\6OB;=R_O+G^QH!YK'+?
M-/EN?<J#^% 'Z_445^<O_!7SXR?%KX7Z7X$MO VK:SX8\,WYN#J&L:'(\$KW
M*E/*A:=,-&-I8A01ORW7;P ?HU17SS^P+XB^(?BK]EGPAJ?Q.-Y)XEF$VV?4
MD*74]J)6$$DH(!+% /F/++M8Y)R?H:@ HHHH ***JZIJ=KHNFW>HW]PEK8VD
M+W$]Q*<)'&BEF8GL  3^% %JBOPS\??\%,_VDM:U;Q/XL\*>+)-$\ _VT]II
M\3:+ITBVRR>8\$!>2!G=_*C)))/(YQD5^M?[('Q1O_C1^S/\/?&6K7PU/5]2
MTU?M]VJ(GFW,;M%,=J*JK^\C?A0 .E 'L-%%% !1110 4444 %%%% !117$?
M&_Q-KW@SX.>-M>\+6/\ :?B33=&N[O3K3RS)YMPD3,@V#EN0/E')Z=Z .WHK
M\J?^"5/Q6^/'Q>^.GB?5O%GB;Q%XC\$+ITHOY-8F>2SBO#(GE) K?+&_WR5C
M  4'(^[7ZK4 %%%% !1110 4444 %%%% !117Y1_ME?MK_&_P1^VY?\ PN\
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M/VRW^R?O?CZFL2[O^/!<7T4;>9U_T7A$;_9..,FOU4_X)%?\F9Z3_P!AB_\
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M7-K!<?8X+7R[=(8-L>V%$4_.TC;B,_/C/ K\DOV9_'WCCX<?M42:O\-_"_\
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MLUOM^UA OS9/0#).*\#_ &X=6U[4?^"B7BI_L5KJVJV^OZ?!8:=J; 6LP2.
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M-56,JHCB5F='8/,YSD@ X&WZ:\1?\H@8O^R>VO\ Z+CKQ'_@AC_S6S_N"?\
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MQX)&>:^R?VGOVK/ _P"RCX)CU[Q?<337-XS1:;I%D UU?2* 2$!("JN1N=B
M,CJ2H/LE?B3^TI?W7[5W_!3VR\#ZX\A\/6/B"W\-QV>\J$LX7!N=I!X9R)FS
MU^9?04 >^2?MZ?M8_%CPKJ?C7X;_  5TG1O 5E;S7QU36-TA-O$K,[K++- D
MH"J3^[C/*X'I71_\$K?VE?BS^TIXQ^)%]\0?%LVO:=H]G9I!:"SMK>**6=Y2
M& BC7G; PYSU.>:]^_X* >/='^#7[&/CN!/(T^/4-*/AO3;*$*@)N$\@1QKP
M,+$7; Z*A]*^=_\ @B-HBV_P;^(FL!2'NM?BM"V#@B*W5@/3_EN?S^E '$?$
MC_@HY\2/A;^W'JO@_P 3^([6Q^%^B:^\%W;V.EPO*UF%+*I=E+EL,F=I!R./
M?/\ C1^V-^V5X@\#W'Q<\(^%&^'OPB#"6TN%LK*[N6MF8*DLRSAY"K9!\Q(U
M3!&"1R?$]4\"V/[1/_!5O6/#&H1)<:7=>-KN*]@V';-!9%VFC(/]Y+9E)]R:
M_57]O"^M]!_8T^*S&.-(/["DM4CV?*ID*Q( !TP6&/3B@#@_^";_ .V%K/[6
M7PSUW_A*X;2/Q=X;NHK>\FLE\N.ZAE5FAF,?\#$QRJ0.#LR,9P/KNOS%_P""
M'FA_9_!?Q7UG;_Q]ZAI]INR>?)CF?&.G_+?]?I7Z=4 %?B=\2-/'Q&_X+$0V
MQW3HGC/32ZL0<K:10%E/7C$!&/3TK]L:_%S]C';\;/\ @JIK_C"R9;K2[75=
M=UY73E3;MYL,!R/0W$//?\: /TZ_:N_:H\+?LF_#5O$_B%7O[ZZD-MI>CV[!
M9KZ?&< G[J*.6<\ 8')95/Y\:#^U3^W1^T]IE[XN^%7AV#1O"D4SI'_9UC8[
M&V]55[XLTS#."8QU!&!R*X?_ (+1>)K_ %']I;PYHDLQ.FZ9X;AEMX>RR33S
M&1_J1'&/H@K]@/A?X-T?X>_#CPSX:T!$31=*TZ"TM/+Z-&J !O<M]XGJ22:
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M6@^$.C^);6V\%Q^+8-/DM8=-MGD>UC*M/$970L"561200P[$$5]Z?L_:3;>
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MLVGU!([UY7_P13\&Z/8_ /QAXH@6.37=2\0-8W4P'S)#!!$T4?YSR-[[QZ4
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M+WPENO$'Q;\+1^#?$K:K-!#I,>FW%@8[58XMC-%.[R99S(<DC((P,<G\W/\
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M'_X*)_M%?%+XS>/-/T#XA>$?^$.TS0+J_ET*%],N[":]M)951)Y!.Y\SY;<
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M@G]N.R_; \):E;ZE80:)XYT,1G4;&V8F">)\A;B'<2P7((9225.WD[A7R/\
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MF/Q;XQT&]CL?$5N;:WTV22%909I+B-"-C J<(9&Y[*>]>:_\$S/C)\5_C_\
M"GQ)XV^)FLKJEM<ZK]DT:-+&"V5(XHQYK+Y2*64N^W+$D&-L5\L_\%#OC/J?
M[45I^SU\)_!Y%[JGBVRL/$EU$F=OGW402W5L#Y0@:X9_0$$XQ7Z;_!CX6:5\
M$OA7X8\"Z*,Z=H=DEJLA&&E<<R2L/[SN7<^[&@#M*^-?VM/^"DWAC]GOQ:/
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MF47BJ'X;^+W\,+\3K6^.M?V!=_8_LZZC&S3^=Y>SRPH+;\[=HSG'-?M9110
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M?Q ^'/Q2\<S^*? WB+PUI6H:'&8+[6-)N+2*61)UPB/(@5B59C@9/RU^K5%
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M4_%-G?6EO%=PZ+ UQ=V=U!\J-Y29=D9 A#*#@JV<<9_6.B@#\I/%G@O]J_\
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M%J;F2:.)4=YE>65=TF,[D)ZX'2O)_P!C[7-/7_@J)'J/BR\$<\WB/7,3WC!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM/YZ[=RP ;@AQNZ''/UA\9O@WX5^/?P]U/P7XQL#?Z+?@%@C[)89%.4EC?\
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MQ_A7WA^S?^S=X/\ V6_AW_PA_@Q+PV4ERU]=75_-YL]U<,B(TC$ *,K&@VJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;.:_5OX._&7PK\>? ]MXO\%WTVI:!<2/%%<S6LMN69#AP%D56P#D9Q@D'&:
M.WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#XA_:/^)7QBUC]NCP5\&?A[\3O^%<Z-K'A(ZO-<
M_P!@6>J8G26\W';,N[YE@1<!P!C..N;O[3'BCXT_LI_L<>-/$=]\7!XW\;Q:
ME9FPU\^&;*P^R0230QM#Y"AXW_Y:'>P)^?V!KPC]OI?A/_P\2^'Y^-H_XMW_
M ,(*HO#_ *7_ *S[3J'E?\>O[W[^W[O'KQ6G^TMK_P $M6_X)F^.+#X!S^;X
M*TO6[.&2/9?#RKE[N"1QF\'F'(D4YY'.!Z4 >K^ ?VI/'U]^R#\9G\2:E#:?
M&KX:V=]#>WB6L(\QO*:6SO5AV>7M=,8^7:QC)Q@XK"\7_M2?$W2O!_[%=[:^
M(UCNOB)J>FVWB>3[!;'^T(Y6M!(,&/$6?-DYBV8SQC KG?\ @H)X:U+X0^&I
M_BGHUM-+H?C'P7-X(\5VUNO D:W9M/NV'JL@\IG/12H'WL'SGXW>#[#QM\&?
M^"?OAK7;)KS1]7O=.T^_M2SQ^;;S?8DD3<I#+E&;E2".H(ZT ?5/[=7Q\\<_
M!?Q]\ M.\(:RNEV7BCQ2NG:O"UI#/]JM_-MU*9D1BG$C\H5//6M[]N;XS>-?
MA[H/@'P;\,-1BTOXD>//$,.DZ9>3013K;0*0UQ.4D1U*J&C5LJ<*Y(Y KY'_
M &R/V2_A=^SG\7OV;[GX;>$VT"XU;QE!%>,M_=W?FJEQ:E!B:5\8W-]W&:[K
MXAW7Q3^/7_!1#5]0^$T?A*Y;X0:4FGQOXT-U_9ZW5TC^<Z"V!<RX=DY( \@G
MKC(!]#_L _'_ %S]H#X!Q7WC"X$WCO0M1N=%U[,*0/\ :(WW*S1(%5"8W0'
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M\MB(\^W[MS]%-:/CJQBU'_@K!X/M[F!;BTF^%LT4L<B[D=3=W@92.X(.#]:
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M?$?3O"'B/QA'>6VNZSI6AV]];231F/9*D5RFX#!/RAEY8]<"OIKX&?#WXF^
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MFG?_ !5 'UC17R=_PS_^U1_T=;;?^&\T[_XJC_AG_P#:H_Z.MMO_  WFG?\
MQ5 'UC17R=_PS_\ M4?]'6VW_AO-._\ BJ/^&?\ ]JC_ *.MMO\ PWFG?_%4
M ?6-%?)W_#/_ .U1_P!'6VW_ (;S3O\ XJC_ (9__:H_Z.MMO_#>:=_\50!]
M8T5\G?\ #/\ ^U1_T=;;?^&\T[_XJC_AG_\ :H_Z.MMO_#>:=_\ %4 ?6-%?
M)W_#/_[5'_1UMM_X;S3O_BJ/^&?_ -JC_HZVV_\ #>:=_P#%4 ?6-%?)W_#/
M_P"U1_T=;;?^&\T[_P"*H_X9_P#VJ/\ HZVV_P##>:=_\50!]8T5\G?\,_\
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M_P#:H_Z.MMO_  WFG?\ Q5 'UC17R=_PS_\ M4?]'6VW_AO-._\ BJ/^&?\
M]JC_ *.MMO\ PWFG?_%4 ?6-%?)W_#/_ .U1_P!'6VW_ (;S3O\ XJC_ (9_
M_:H_Z.MMO_#>:=_\50!]8T5\G?\ #/\ ^U1_T=;;?^&\T[_XJC_AG_\ :H_Z
M.MMO_#>:=_\ %4 ?6-%?)W_#/_[5'_1UMM_X;S3O_BJ/^&?_ -JC_HZVV_\
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M=S,MQ<K&JRS*FP.P'+!<G:"<G&3BOE7_ (9__:H_Z.MMO_#>:=_\51_PS_\
MM4?]'6VW_AO-._\ BJ /K&BOD[_AG_\ :H_Z.MMO_#>:=_\ %4?\,_\ [5'_
M $=;;?\ AO-._P#BJ /K&BOD[_AG_P#:H_Z.MMO_  WFG?\ Q5'_  S_ /M4
M?]'6VW_AO-._^*H ^L:*^3O^&?\ ]JC_ *.MMO\ PWFG?_%4?\,__M4?]'6V
MW_AO-._^*H ^@_BYX+U#XD?"_P 4^%=*UO\ X1N^UK3YM/35OLOVDVPE4HSB
M/>FX[2V/F&"0>U9OP#^#>E?L_P#P?\,> -'E-S::+:B%KIHQ&US,S%Y9BH)P
M7D9VQDXSC)QFO#O^&?\ ]JC_ *.MMO\ PWFG?_%4?\,__M4?]'6VW_AO-._^
M*H ^L:*^3O\ AG_]JC_HZVV_\-YIW_Q5'_#/_P"U1_T=;;?^&\T[_P"*H ^L
M:*^3O^&?_P!JC_HZVV_\-YIW_P 51_PS_P#M4?\ 1UMM_P"&\T[_ .*H ^L:
M*^3O^&?_ -JC_HZVV_\ #>:=_P#%4?\ #/\ ^U1_T=;;?^&\T[_XJ@#ZQHKY
M._X9_P#VJ/\ HZVV_P##>:=_\51_PS_^U1_T=;;?^&\T[_XJ@#ZQHKY._P"&
M?_VJ/^CK;;_PWFG?_%4?\,__ +5'_1UMM_X;S3O_ (J@#ZQHKY._X9__ &J/
M^CK;;_PWFG?_ !5'_#/_ .U1_P!'6VW_ (;S3O\ XJ@#ZQHKY._X9_\ VJ/^
MCK;;_P -YIW_ ,51_P ,_P#[5'_1UMM_X;S3O_BJ /K&BOD[_AG_ /:H_P"C
MK;;_ ,-YIW_Q5'_#/_[5'_1UMM_X;S3O_BJ /K&BOD[_ (9__:H_Z.MMO_#>
M:=_\51_PS_\ M4?]'6VW_AO-._\ BJ /K&BOD[_AG_\ :H_Z.MMO_#>:=_\
M%4?\,_\ [5'_ $=;;?\ AO-._P#BJ /K&BOD[_AG_P#:H_Z.MMO_  WFG?\
MQ5'_  S_ /M4?]'6VW_AO-._^*H ^L:*^3O^&?\ ]JC_ *.MMO\ PWFG?_%4
M?\,__M4?]'6VW_AO-._^*H ^L:*^3O\ AG_]JC_HZVV_\-YIW_Q5'_#/_P"U
M1_T=;;?^&\T[_P"*H ^L:*^3O^&?_P!JC_HZVV_\-YIW_P 51_PS_P#M4?\
M1UMM_P"&\T[_ .*H ^L:*^3O^&?_ -JC_HZVV_\ #>:=_P#%4?\ #/\ ^U1_
MT=;;?^&\T[_XJ@#ZQHKY._X9_P#VJ/\ HZVV_P##>:=_\51_PS_^U1_T=;;?
M^&\T[_XJ@#ZQHKY._P"&?_VJ/^CK;;_PWFG?_%4?\,__ +5'_1UMM_X;S3O_
M (J@#ZQHKY._X9__ &J/^CK;;_PWFG?_ !5'_#/_ .U1_P!'6VW_ (;S3O\
MXJ@#ZQHKY._X9_\ VJ/^CK;;_P -YIW_ ,51_P ,_P#[5'_1UMM_X;S3O_BJ
M /K&BOD[_AG_ /:H_P"CK;;_ ,-YIW_Q5'_#/_[5'_1UMM_X;S3O_BJ /H+X
MO?#/3/C)\+_$_@C6"4T_7;"6RDE5<M"67Y)5'=D;:X]U%9WP"^&5]\&/@WX3
M\#:CK_\ PD]QH%DM@NJ?9/LOFQ(2(AY6]]NV/8GWCG9GC.!X=_PS_P#M4?\
M1UMM_P"&\T[_ .*H_P"&?_VJ/^CK;;_PWFG?_%4 ?6-%?)W_  S_ /M4?]'6
MVW_AO-._^*H_X9__ &J/^CK;;_PWFG?_ !5 'UC17R=_PS_^U1_T=;;?^&\T
M[_XJC_AG_P#:H_Z.MMO_  WFG?\ Q5 'UC17R=_PS_\ M4?]'6VW_AO-._\
MBJ/^&?\ ]JC_ *.MMO\ PWFG?_%4 ?5[[BC!"%;'!89 /TKQ3]E?]F>+]FOP
MSXE@N?$#>+?$OB;6KC7-8UU[(6AN)I#D*(@[[57DXW'EV/&<#SO_ (9__:H_
MZ.MMO_#>:=_\51_PS_\ M4?]'6VW_AO-._\ BJ /K&BOD[_AG_\ :H_Z.MMO
M_#>:=_\ %4?\,_\ [5'_ $=;;?\ AO-._P#BJ /K&BOD[_AG_P#:H_Z.MMO_
M  WFG?\ Q5'_  S_ /M4?]'6VW_AO-._^*H ^L:*^3O^&?\ ]JC_ *.MMO\
MPWFG?_%4?\,__M4?]'6VW_AO-._^*H ^L:*^3O\ AG_]JC_HZVV_\-YIW_Q5
M'_#/_P"U1_T=;;?^&\T[_P"*H ^L:*^3O^&?_P!JC_HZVV_\-YIW_P 51_PS
M_P#M4?\ 1UMM_P"&\T[_ .*H ^L:*^3O^&?_ -JC_HZVV_\ #>:=_P#%4?\
M#/\ ^U1_T=;;?^&\T[_XJ@#ZQHKYN^'_ ,%?VBM!\::1J'BG]H^#Q1X>MYQ)
M>Z,G@BQM#=QCK'YR-N3/]X<BOI&@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\]
M[W]L3XD6G[4%KXA;6(Q^S[+X\?X=?8?[/AR;Q;8+]J%P4\PI]H+'.[;MC( -
M?;OQ6O/$NG_#3Q1/X,TW^V/%JZ=/_9-EYT<(ENBA$0+R,J@!B"<D< U^?U[_
M ,$M]<_X9+32X_'WCZ?Q_'IPU9/!K>(8?["&KX\UHEB*; V\LGF^9C<=V[%
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M$1.I3&89\ J0-R^U?:&AVMY8Z+I]MJ%ZVI7\-O''<7K(J&>0* TA50%&X@G
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M-?@WX)?M$Z]'^S7H/B7X9Z5X=\/_  LURT%W?1>(+>ZN;R&-2OVI8U;:D81
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*U3Q_-J-NFI>&?#=I8,X$TUKXBN)Y47N5C:Q0,?8LOUKL:** "BBB@ HHHH
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MD_;2^-7BSP+X+U?0?AKJ,.F^-[?0;_Q3=ZE);)<C2]-LXGD:0QNK(7GE1;=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\4?&3]BF']H#]N6/Q3X^\'#7OA7'X.2T6Z.IF
MWQJ*7#%4V0S),<(['.-G/7-?:]% 'Q]^V7^Q?%\1?@#X1\'?#+PUH\5IX1UR
M'5H?"KS-9VVHP!9%FM_-4@H[^83O+ GYOF!((X#X._LF>+- \ _%>7PA\'=+
M_9Z\3ZYX<DTC2I(O&EUK-]).QW%FF$C1PQG:H#(/,4G.>*_0"B@#\Q?V7_V-
M?B+X"_:8^#OC>]^#D'@*PT.WU&W\2ZM_PER:O<:C<OI\L2WCHTI$:R2286.(
M,1N;?@ &K7PQ_8[^,'P/\5Z7\7O#?A;[9XWM?&&J1:KX9;4[0?VIX?N9 RO'
M(TOE1RJ=Y +*3E<_=PWZ844 >)?MJ?#CQ#\7/V7?'WA#PII_]J>(=4M(H[.S
M\Z.'S66>)R-\C*H^53U(Z5RT?[+VD>&_V2O$GAOPM\/_  [H?Q%UCX?3Z%<R
M:;8VMK/=WDE@8S'+<( 'S-C+,Q7/S$]Z^EJ* /A/]B?X>?$/X/S>"?#NO_LI
M^'_"MQ9V;V.I_$NVU[29+YEV,V]XX4,S[V"(5\P]022!6!^UQ^QY\4?'G[1.
MKW/P^L4_X5[\3+'2]/\ &UZM[# ]G]FNHRTJHTBNY\F)!A%;.9 1S7Z%T4 ?
M-O[7GC+Q_P#"'PKX$NOA_J.D^'?#4.MZ;IFI*]H)[N2.6[MH(K>!7!CCC\MY
MR[G+@K&$ RS#Z2K@/BQ\"O!_QNM["W\7VVJ7UM8RK/!;V6NW^GQ>:KJZ2,EM
M/&KNC*K*S E2/E(R:[32=-AT72K/3[=[B2WM(4MXWN[F2YF954*"\LC,\C8'
M+NQ9CDDDDF@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;@=K@,<,.1D\\T 0Z!H46B^&--T9@LT%I9QV95AN5U5 G.>H('>OFO\ 9M^
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M2^"F\&:;X#>^OKVYGU&VNHM3O9K5[5$LO)D:3R!YCR;YTA<@1CRP2P7Z(HH
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M+]/_ /D>C_A _%/_ $4K6O\ P7Z?_P#(] '=T5PG_"!^*?\ HI6M?^"_3_\
MY'H_X0/Q3_T4K6O_  7Z?_\ (] '=T5PG_"!^*?^BE:U_P""_3__ )'H_P"$
M#\4_]%*UK_P7Z?\ _(] '=T5PG_"!^*?^BE:U_X+]/\ _D>C_A _%/\ T4K6
MO_!?I_\ \CT =W17"?\ "!^*?^BE:U_X+]/_ /D>C_A _%/_ $4K6O\ P7Z?
M_P#(] '=T5PG_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z?_\ (] '
M=T5PG_"!^*?^BE:U_P""_3__ )'H_P"$#\4_]%*UK_P7Z?\ _(] '=T5PG_"
M!^*?^BE:U_X+]/\ _D>C_A _%/\ T4K6O_!?I_\ \CT =W17"?\ "!^*?^BE
M:U_X+]/_ /D>C_A _%/_ $4K6O\ P7Z?_P#(] '=T5PG_"!^*?\ HI6M?^"_
M3_\ Y'H_X0/Q3_T4K6O_  7Z?_\ (] '=T5PG_"!^*?^BE:U_P""_3__ )'H
M_P"$#\4_]%*UK_P7Z?\ _(] '=T5PG_"!^*?^BE:U_X+]/\ _D>C_A _%/\
MT4K6O_!?I_\ \CT =W17"?\ "!^*?^BE:U_X+]/_ /D>C_A _%/_ $4K6O\
MP7Z?_P#(] '=T5PG_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z?_\
M(] '=T5PG_"!^*?^BE:U_P""_3__ )'H_P"$#\4_]%*UK_P7Z?\ _(] '=T5
MPG_"!^*?^BE:U_X+]/\ _D>C_A _%/\ T4K6O_!?I_\ \CT =W17"?\ "!^*
M?^BE:U_X+]/_ /D>C_A _%/_ $4K6O\ P7Z?_P#(] '=T5PG_"!^*?\ HI6M
M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z?_\ (] '=T5PG_"!^*?^BE:U_P""_3__
M )'H_P"$#\4_]%*UK_P7Z?\ _(] '=T5PG_"!^*?^BE:U_X+]/\ _D>C_A _
M%/\ T4K6O_!?I_\ \CT =W17"?\ "!^*?^BE:U_X+]/_ /D>C_A _%/_ $4K
M6O\ P7Z?_P#(] '=T5PG_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z
M?_\ (] '=T5PG_"!^*?^BE:U_P""_3__ )'H_P"$#\4_]%*UK_P7Z?\ _(]
M'=T5PG_"!^*?^BE:U_X+]/\ _D>C_A _%/\ T4K6O_!?I_\ \CT =W17"?\
M"!^*?^BE:U_X+]/_ /D>C_A _%/_ $4K6O\ P7Z?_P#(] '=T5PG_"!^*?\
MHI6M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z?_\ (] '=T5PG_"!^*?^BE:U_P""
M_3__ )'H_P"$#\4_]%*UK_P7Z?\ _(] '=T5PG_"!^*?^BE:U_X+]/\ _D>C
M_A _%/\ T4K6O_!?I_\ \CT =W17"?\ "!^*?^BE:U_X+]/_ /D>C_A _%/_
M $4K6O\ P7Z?_P#(] '=T5PG_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4K6O_
M  7Z?_\ (] '=T5PG_"!^*?^BE:U_P""_3__ )'H_P"$#\4_]%*UK_P7Z?\
M_(] '=T5PG_"!^*?^BE:U_X+]/\ _D>C_A _%/\ T4K6O_!?I_\ \CT =W17
M"?\ "!^*?^BE:U_X+]/_ /D>C_A _%/_ $4K6O\ P7Z?_P#(] '=T5PG_"!^
M*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z?_\ (] '=T5PG_"!^*?^BE:U
M_P""_3__ )'H_P"$#\4_]%*UK_P7Z?\ _(] '=T5PG_"!^*?^BE:U_X+]/\
M_D>C_A _%/\ T4K6O_!?I_\ \CT =W17"?\ "!^*?^BE:U_X+]/_ /D>C_A
M_%/_ $4K6O\ P7Z?_P#(] '=T5PG_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4
MK6O_  7Z?_\ (] '=T5PG_"!^*?^BE:U_P""_3__ )'H_P"$#\4_]%*UK_P7
MZ?\ _(] '=T5PG_"!^*?^BE:U_X+]/\ _D>C_A _%/\ T4K6O_!?I_\ \CT
M=W17"?\ "!^*?^BE:U_X+]/_ /D>C_A _%/_ $4K6O\ P7Z?_P#(] '=T5PG
M_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z?_\ (] '=T5PG_"!^*?^
MBE:U_P""_3__ )'H_P"$#\4_]%*UK_P7Z?\ _(] '=T5PG_"!^*?^BE:U_X+
M]/\ _D>C_A _%/\ T4K6O_!?I_\ \CT =W17"?\ "!^*?^BE:U_X+]/_ /D>
MC_A _%/_ $4K6O\ P7Z?_P#(] '=T5PG_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q
M3_T4K6O_  7Z?_\ (] '=T5PG_"!^*?^BE:U_P""_3__ )'H_P"$#\4_]%*U
MK_P7Z?\ _(] '=T5PG_"!^*?^BE:U_X+]/\ _D>C_A _%/\ T4K6O_!?I_\
M\CT =W17"?\ "!^*?^BE:U_X+]/_ /D>C_A _%/_ $4K6O\ P7Z?_P#(] '=
MT5PG_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z?_\ (] '=T5PG_"!
M^*?^BE:U_P""_3__ )'H_P"$#\4_]%*UK_P7Z?\ _(] '=T5PG_"!^*?^BE:
MU_X+]/\ _D>C_A _%/\ T4K6O_!?I_\ \CT =W17"?\ "!^*?^BE:U_X+]/_
M /D>C_A _%/_ $4K6O\ P7Z?_P#(] '=T5PG_"!^*?\ HI6M?^"_3_\ Y'H_
MX0/Q3_T4K6O_  7Z?_\ (] '=T5PG_"!^*?^BE:U_P""_3__ )'H_P"$#\4_
M]%*UK_P7Z?\ _(] '=T5PG_"!^*?^BE:U_X+]/\ _D>C_A _%/\ T4K6O_!?
MI_\ \CT =W17"?\ "!^*?^BE:U_X+]/_ /D>C_A _%/_ $4K6O\ P7Z?_P#(
M] '=T5PG_"!^*?\ HI6M?^"_3_\ Y'H_X0/Q3_T4K6O_  7Z?_\ (] '=T5P
MG_"!^*?^BE:U_P""_3__ )'H_P"$#\4_]%*UK_P7Z?\ _(] '=T5PG_"!^*?
M^BE:U_X+]/\ _D>C_A _%/\ T4K6O_!?I_\ \CT =W17(:/X/\0Z?J4%Q=^/
M-6U.VC;+VDUE9(DHQT+) & ^A!KKZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPS\6>*/#VFOH/C;0-&\1W@L-$\5ZYH+6VCZG,S;56&<N2<GC+*,=\5A_L_\
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MCZ?:#S%:*YMXA-<3N-YE)DF&Q"(PH3AFRU?1M !1110 4444 %%%% !1110
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MX"8RU/\ V5T_M_QE\=/&T4>W3]=\:RV=E*&RL\5A;0V32J>A4S03@'OM],4
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M>,U#1?B'X!_:I\;^/-,^']UXP\):SX>TO3$.EZG90WOVB%[IR4CN)HD,:^8
MY9U;+IL63Y]O'^'OV>?'GP]\+?"GQ?#I%MKWC'PWXIU?Q'K'ABPNXE+PZM]H
M6XAMIIBD;2VZW"$;VC5_+<;AD9 /1?%W[2UI+X!^)D;:5XD\$>,?">GQW5SI
M5_\ 88[R"&9?W%XDP-U:F#(??+^]$?E2;TRH!7]COXF>(/B5X1\9MK_B33_%
MS:-XD?3++6M+O8;Z"YM_L5G/D7,-I:QS;9+B5=Z0(/EQ\VW>USX:^#O$_B/X
M_>)OBMXC\/S>#K6;0+3PSI6B7UQ;SWSQ132W$MQ<&WDEB3,DVQ$65_E0LVTM
MM'N% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$
M3? [X<7'BK_A)Y?A_P"%I/$OF>;_ &R^BVQO-_\ >\[9OS[YKMZ* "BBB@ H
MHHH *YCQM\+_  9\3(;>'QAX1T+Q7#;DM#'K>FPWBQ$]2HE5L'Z5T]% &?H/
MA_2_"NDV^EZ+IMGI&F6Z[8;*P@2"&(>BHH"@?05H444 %%%% !1110!YK<?L
M[^";KXIP_$:6'7&\7PJ8X[X>)=3$:1%E<P" 7'DB$LJL8=GEDC)4UZ5110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7/ZA\/O"VK6NL6U]X:T>]MM8GCN=2AN+"*1+Z6,((Y)@5Q
M(RB*(!FR1Y:8^Z,=!10 4444 %%%% !1110 4444 %4=$T+3?#.EP:9I&GVN
ME:;;@B&SL8%AAC!))"HH &22>!U)J]10 4444 175K#?6LUM<PQW%O,C1RPR
MJ&1U(P58'@@@X(-0:/HVG^'=)L]+TJQMM,TRSA6WMK*SA6&&"-1A41% 55
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M#&V?$W_GMX3_ ._-U_\ %4;/B;_SV\)_]^;K_P"*KNZ* .$V?$W_ )[>$_\
MOS=?_%4;/B;_ ,]O"?\ WYNO_BJ[NN=L_B!H%_X\U+P9!?\ F>)=.L8-2NK'
MR9!Y=O,[I&^\KL.6B<8#$C;R!D4 8VSXF_\ /;PG_P!^;K_XJC9\3?\ GMX3
M_P"_-U_\57=URGQ6\=?\*Q^&?BKQ=]A_M+^P],N-1^Q^;Y7G^5&7V;]K;<XQ
MG!QZ&@#/V?$W_GMX3_[\W7_Q5&SXF_\ /;PG_P!^;K_XJMWPCX^\,>/[>\G\
M,>(])\20V5PUK=2:1?172P3  F-S&QVN 1E3SS6]0!PFSXF_\]O"?_?FZ_\
MBJ-GQ-_Y[>$_^_-U_P#%5W=% '";/B;_ ,]O"?\ WYNO_BJ-GQ-_Y[>$_P#O
MS=?_ !5=W10!PFSXF_\ /;PG_P!^;K_XJC9\3?\ GMX3_P"_-U_\57=T4 <)
ML^)O_/;PG_WYNO\ XJC9\3?^>WA/_OS=?_%5W=% '";/B;_SV\)_]^;K_P"*
MHV?$W_GMX3_[\W7_ ,57=T4 <)L^)O\ SV\)_P#?FZ_^*HV?$W_GMX3_ ._-
MU_\ %5W=% '(Z*GCO^TX/[7E\.G3LGS1913B7&#C;N;'7'7MFNNHHH ****
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M"OO&GC&9K"+4[62UN9--MMT=J[0N R AWQGKUZ$$_5- !1110 4444 %%%%
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M(41$55141(XT1$50%4<Y .VHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;^T5XTUW]IKPSXVD35/$;7'A+XL:!J5PUII%H7S!!M1ML.U< J4=N" A W$
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MRUO/@OJWC.V\*GP]\2BMH--T6WN5N])N)+%[NW8W$DK)<(RPNKJ(8O++KAY
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MG8K2LH+8!.!S@4 =)17RTMKX6_:2_:HUS3O$$&D>// ?A_PEIFHZ+87 CO\
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M0 4444 %%%(S!%+'. ,\ D_E0 M%<)_PMRU_Z%GQ9_X(I_\ XFC_ (6Y:_\
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M VGM-9:GLLQ.=4TFX,9N[ DNOE^9Y,>)/FVX/RG-==_PMRU_Z%GQ9_X(I_\
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MGQ9_X(I__B: .[HKA/\ A;EK_P!"SXL_\$4__P 31_PMRU_Z%GQ9_P""*?\
M^)H [NBN$_X6Y:_]"SXL_P#!%/\ _$T?\+<M?^A9\6?^"*?_ .)H [NBN$_X
M6Y:_]"SXL_\ !%/_ /$T?\+<M?\ H6?%G_@BG_\ B: .[HKA/^%N6O\ T+/B
MS_P13_\ Q-'_  MRU_Z%GQ9_X(I__B: .[HKA/\ A;EK_P!"SXL_\$4__P 3
M1_PMRU_Z%GQ9_P""*?\ ^)H [NBN$_X6Y:_]"SXL_P#!%/\ _$T?\+<M?^A9
M\6?^"*?_ .)H [NBN$_X6Y:_]"SXL_\ !%/_ /$T?\+<M?\ H6?%G_@BG_\
MB: .[HKA/^%N6O\ T+/BS_P13_\ Q-'_  MRU_Z%GQ9_X(I__B: .[HKA/\
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MWF C+IN#PSRKRV =K8.T"MS_ (6Y:_\ 0L^+/_!%/_\ $T?\+<M?^A9\6?\
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MY:_]"SXL_P#!%/\ _$T =W17"?\ "W+7_H6?%G_@BG_^)H_X6Y:_]"SXL_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MROO'6O>%/#7BW4-8OM/L='BO5MI+J.&8QH8X9I6=V('.W()!P!TKVGQE\8/
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MM0'OWYKTWQ-\:/A]X)UR'1?$/COPSH.LS$"/3]3UBWMKA\XQMC=PQSD=!W%
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M8VCD1PV,%74@X(- '845GZ[X@TOPOI<NI:SJ5GI&G1,BR7E].D$*%W"("[$
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MX.GX.?%2QU_PW\0_#^I7D<6CQZ-<W,FJB29I$:V,:%6SNP"Q4$ $$@U^DM%
M'Y\S?$W3/V0?VYOBIXU^)MGJ.B^ _B'I>G7&F>)CILUQ'!-#%&C6TGE*[(V=
MX*X)^1#T(H^%MU<_'S]HSXY_'?0M)U"R^';^ IO"^DZAJ5H]NVK28CE:>)'
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MZO/_  :VG_Q='_":^,?^B=7G_@UM/_BZ .[HKA/^$U\8_P#1.KS_ ,&MI_\
M%T?\)KXQ_P"B=7G_ (-;3_XN@#NZ*X3_ (37QC_T3J\_\&MI_P#%T?\ ":^,
M?^B=7G_@UM/_ (N@#NZ*X3_A-?&/_1.KS_P:VG_Q='_":^,?^B=7G_@UM/\
MXN@#NZ*X3_A-?&/_ $3J\_\ !K:?_%T?\)KXQ_Z)U>?^#6T_^+H [NBN$_X3
M7QC_ -$ZO/\ P:VG_P 71_PFOC'_ *)U>?\ @UM/_BZ .[HKA/\ A-?&/_1.
MKS_P:VG_ ,71_P )KXQ_Z)U>?^#6T_\ BZ .[HKA/^$U\8_]$ZO/_!K:?_%T
M?\)KXQ_Z)U>?^#6T_P#BZ .[HKA/^$U\8_\ 1.KS_P &MI_\71_PFOC'_HG5
MY_X-;3_XN@#NZ*X3_A-?&/\ T3J\_P#!K:?_ !='_":^,?\ HG5Y_P"#6T_^
M+H [NBN$_P"$U\8_]$ZO/_!K:?\ Q='_  FOC'_HG5Y_X-;3_P"+H [NBN$_
MX37QC_T3J\_\&MI_\71_PFOC'_HG5Y_X-;3_ .+H [NBN$_X37QC_P!$ZO/_
M  :VG_Q='_":^,?^B=7G_@UM/_BZ .[HKA/^$U\8_P#1.KS_ ,&MI_\ %T?\
M)KXQ_P"B=7G_ (-;3_XN@#NZ*X3_ (37QC_T3J\_\&MI_P#%T?\ ":^,?^B=
M7G_@UM/_ (N@#NZ*X3_A-?&/_1.KS_P:VG_Q='_":^,?^B=7G_@UM/\ XN@#
MNZ*X3_A-?&/_ $3J\_\ !K:?_%T?\)KXQ_Z)U>?^#6T_^+H [NBN$_X37QC_
M -$ZO/\ P:VG_P 71_PFOC'_ *)U>?\ @UM/_BZ .[HKA/\ A-?&/_1.KS_P
M:VG_ ,71_P )KXQ_Z)U>?^#6T_\ BZ .[HKA/^$U\8_]$ZO/_!K:?_%T?\)K
MXQ_Z)U>?^#6T_P#BZ .[HKA/^$U\8_\ 1.KS_P &MI_\71_PFOC'_HG5Y_X-
M;3_XN@#NZ*X3_A-?&/\ T3J\_P#!K:?_ !='_":^,?\ HG5Y_P"#6T_^+H [
MNBN$_P"$U\8_]$ZO/_!K:?\ Q='_  FOC'_HG5Y_X-;3_P"+H [NBN$_X37Q
MC_T3J\_\&MI_\71_PFOC'_HG5Y_X-;3_ .+H [NBN$_X37QC_P!$ZO/_  :V
MG_Q='_":^,?^B=7G_@UM/_BZ .[HKA/^$U\8_P#1.KS_ ,&MI_\ %T?\)KXQ
M_P"B=7G_ (-;3_XN@#NZ*X3_ (37QC_T3J\_\&MI_P#%T?\ ":^,?^B=7G_@
MUM/_ (N@#NZ*X3_A-?&/_1.KS_P:VG_Q='_":^,?^B=7G_@UM/\ XN@#NZ*X
M3_A-?&/_ $3J\_\ !K:?_%T?\)KXQ_Z)U>?^#6T_^+H [NBN$_X37QC_ -$Z
MO/\ P:VG_P 71_PFOC'_ *)U>?\ @UM/_BZ .[HKA/\ A-?&/_1.KS_P:VG_
M ,71_P )KXQ_Z)U>?^#6T_\ BZ .[HKA/^$U\8_]$ZO/_!K:?_%T?\)KXQ_Z
M)U>?^#6T_P#BZ .[HKA/^$U\8_\ 1.KS_P &MI_\71_PFOC'_HG5Y_X-;3_X
MN@#NZ*X3_A-?&/\ T3J\_P#!K:?_ !='_":^,?\ HG5Y_P"#6T_^+H [NBN$
M_P"$U\8_]$ZO/_!K:?\ Q='_  FOC'_HG5Y_X-;3_P"+H [NBN$_X37QC_T3
MJ\_\&MI_\71_PFOC'_HG5Y_X-;3_ .+H [NBN$_X37QC_P!$ZO/_  :VG_Q=
M'_":^,?^B=7G_@UM/_BZ .[HKA/^$U\8_P#1.KS_ ,&MI_\ %T?\)KXQ_P"B
M=7G_ (-;3_XN@#NZ*X3_ (37QC_T3J\_\&MI_P#%T?\ ":^,?^B=7G_@UM/_
M (N@#NZ*X3_A-?&/_1.KS_P:VG_Q='_":^,?^B=7G_@UM/\ XN@#NZ*X3_A-
M?&/_ $3J\_\ !K:?_%T?\)KXQ_Z)U>?^#6T_^+H [NBN$_X37QC_ -$ZO/\
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M^\$W6F6CDA[MM0MI1'P<$JKY/.!QZUUU !1110 4444 %%%% !1110 4444
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M(3\O6OA?XF:]\./!G[:WCK7_ -I#PR^M>'/$/A;2X?!UQ?Z-)J-J2+>,7-O
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M;]EEF6&Q$L*W%J7?859(\QLS#Y<'(R*\^U3P7KT'P3_;B\#_  YTJ:WL=/\
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M6JJR.\&TEF:5VVJ2?+)4"O?=6^#_ (-\=:]^WSXB\0>&-/UO7-%M;AM+OKV
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M\2/CW8>%/A5'XW\):/>?$^UNLBRC\+21SQ2#RWD,LD^[RXH5$9W2$\$J "S
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MSGBKXD^$? NCV^K>)?%.B^'M*N,>3?:KJ$-M!)D9&UY&"G(YX-1?\+2\%_\
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MQ=?Z"VEL]V^H6D$447E7GGA4A+6]O(R&%R2C@.H;Y0#W6BBB@ HHHH ****
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M.Z/=\TB*22B-7Z&T4 ? G_!+_P 1V6H:U\1]+T+2/#VK>'M/M]-M;?X@^&M
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M?%.D7.CV.G7UQ+)(+*.76K+S3#&6\N.1Q\K2JH=E^0L5XKZPH X[6/C-\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_:WQ-_Z%3PG_ .%/=?\ ROKNZ* .$_M;XF_]"IX3_P#"GNO_ )7T?VM\3?\
MH5/"?_A3W7_ROKNZ* .$_M;XF_\ 0J>$_P#PI[K_ .5]']K?$W_H5/"?_A3W
M7_ROKNZ* .$_M;XF_P#0J>$__"GNO_E?1_:WQ-_Z%3PG_P"%/=?_ "OKNZ*
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M_:WQ-_Z%3PG_ .%/=?\ ROKNZ* .$_M;XF_]"IX3_P#"GNO_ )7T?VM\3?\
MH5/"?_A3W7_ROKNZ* .$_M;XF_\ 0J>$_P#PI[K_ .5]']K?$W_H5/"?_A3W
M7_ROKNZ* .$_M;XF_P#0J>$__"GNO_E?1_:WQ-_Z%3PG_P"%/=?_ "OKNZ*
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M_:WQ-_Z%3PG_ .%/=?\ ROKNZ* .$_M;XF_]"IX3_P#"GNO_ )7T?VM\3?\
MH5/"?_A3W7_ROKNZ* .$_M;XF_\ 0J>$_P#PI[K_ .5]']K?$W_H5/"?_A3W
M7_ROKNZ* .$_M;XF_P#0J>$__"GNO_E?1_:WQ-_Z%3PG_P"%/=?_ "OKNZ*
M.$_M;XF_]"IX3_\ "GNO_E?1_:WQ-_Z%3PG_ .%/=?\ ROKNZ* .$_M;XF_]
M"IX3_P#"GNO_ )7T?VM\3?\ H5/"?_A3W7_ROKNZ* .$_M;XF_\ 0J>$_P#P
MI[K_ .5]']K?$W_H5/"?_A3W7_ROKNZ* .$_M;XF_P#0J>$__"GNO_E?1_:W
MQ-_Z%3PG_P"%/=?_ "OKNZ* .$_M;XF_]"IX3_\ "GNO_E?1_:WQ-_Z%3PG_
M .%/=?\ ROKNZ* .$_M;XF_]"IX3_P#"GNO_ )7T?VM\3?\ H5/"?_A3W7_R
MOKNZ* .$_M;XF_\ 0J>$_P#PI[K_ .5]']K?$W_H5/"?_A3W7_ROKNZ* .$_
MM;XF_P#0J>$__"GNO_E?1_:WQ-_Z%3PG_P"%/=?_ "OKNZ* .$_M;XF_]"IX
M3_\ "GNO_E?1_:WQ-_Z%3PG_ .%/=?\ ROKNZ* .$_M;XF_]"IX3_P#"GNO_
M )7T?VM\3?\ H5/"?_A3W7_ROKNZ* .$_M;XF_\ 0J>$_P#PI[K_ .5]']K?
M$W_H5/"?_A3W7_ROKNZ* .$_M;XF_P#0J>$__"GNO_E?1_:WQ-_Z%3PG_P"%
M/=?_ "OKNZ* .$_M;XF_]"IX3_\ "GNO_E?1_:WQ-_Z%3PG_ .%/=?\ ROKN
MZ* .$_M;XF_]"IX3_P#"GNO_ )7T?VM\3?\ H5/"?_A3W7_ROKNZ* .$_M;X
MF_\ 0J>$_P#PI[K_ .5]']K?$W_H5/"?_A3W7_ROKNZ* .$_M;XF_P#0J>$_
M_"GNO_E?1_:WQ-_Z%3PG_P"%/=?_ "OKNZ* .$_M;XF_]"IX3_\ "GNO_E?1
M_:WQ-_Z%3PG_ .%/=?\ ROKNZ* .$_M;XF_]"IX3_P#"GNO_ )7T?VM\3?\
MH5/"?_A3W7_ROKNZ* .$_M;XF_\ 0J>$_P#PI[K_ .5]']K?$W_H5/"?_A3W
M7_ROKNZ* .$_M;XF_P#0J>$__"GNO_E?1_:WQ-_Z%3PG_P"%/=?_ "OKNZ*
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M.OQE^-^FZS:ZMK>@&+6O#,NEC3[/Q!JMAI^DWC/<-YGV:)2NHAHY+>,O<>6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSPO'(N]44.KK\J%"7 '/^V%X3O-#TK5M!T'Q)XIMKGP\/%5\NE6L'F:1II+
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MNCB40R--LR"=#X!_L=:=\"?$^F7UE-X6DL-'M+BRL)-.\&VEEJ]Q&[*(VO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M95W#X4A\67G@80>%]<T#5=?\+W4>K%Y[^.R@:X$=W$8!]D::%2Z%6G  (;#
M ]E#^RKX9M_%$6M)KOB21DU72]::UN;V.X66\L;7[+%+)++&T\C/$$#EI3N*
M C!))HP_L>^$4TJXT>;6O$%UH,6E:EHNBZ3+-;B#0+:^0QSBT*P!V(0[$-PT
MVQ?E7 + @&G\)/CIKGCKQLWAKQ+X2M/#-W=>';3Q/IS6.L'4/,M9I'C,<^;>
M(13(53*H94.\X<[>?8ZX;P_\(=&\-^-;'Q/;7-])?V?AV'PS''-(AB-M%)YB
MN0$!\S)Y.<8_A%=S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%+@!O6+CX8^&+S3_ !A97&E)<6OBXN=<CFD=_MH>V2V96);*KY,:)M7  !(
M))-?3?A'X4TFVM8+;3'6.UU--8B,EW/(PNUA$(E+,Y+'8 ,$D'J1GF@#!T3X
MH:AXM^"OB+Q-]@7P_KVFIJUG/:QSB[CM[RREG@<I(R+YB%X"RED7*D94'*CA
M?BE\3/$&E_ GX6ZU'XBUC1;[7KS28=3U/P_I$>H7[)-;L\ODVWV:<,S,!PL+
M$<X KU35O@[X6UKP7JOA2:UOK;0]4N[F^O(=/U:[LY)I;B9YI\S0RI(%=Y')
M0,%(8KC;Q6QJ?@?0]8M=$MKJP5K?1+J&\T^*-VC6WEB4K&0%(R%5B-IR/:@#
MYETG]K/Q+X<\$^';>/0KWXB:]JS:K?6-U)9WB23:5;WAAMY;E-,L+HQ73J\8
M:,P0JK*X?R7 BKLM7_:LO=)F\537/@Z/1++1_#DOB"SL?$FH3:;J^J^78+>.
MD%JUJT;K&6\F5DG=X74[XQE=W=:K^SGX"U:8W TW4-+O/MMYJ O-$UR_TVX6
M6Z97N@LMM/&ZQRNBR/$"$9P'*[N:H>//V;/#7C32?$:"\UE-7U31;O1[>]U+
M6K_4K>P\^U:V,T5I-<&)9-C'+*%=MSY;YV) .8U+X^^(8?$%OX?UWPZWA;4W
MOM#N;4Z3J\5XMS8WM\UOMF,EKB.12A$D: \,/+GSEEZGP-\9-=\3?#_Q3XTU
M3PE;:1HFG)=R:;%;ZL;J[OEMGF24R1^0B0[FA&S#R%@^6"$;3>\-?LZ^!/"\
M)6VTJXN)VGLKDW-]J=W=2AK.3S+5$>65VCAB<LR0*1$NYL+\QSVWAGPSIO@_
M1XM*TBV^R6$3R2)#YC/AI)&D<Y8D\L['KWXXH \-T_Q5XZ\ _"6V^*.L>*I_
M'\NH:;:W<GA6&UL[.Q6:ZDA\M;&98Q*B)YI4?:))MXVDLIR:Q_B7\8OBAH-Y
M=V>F:;I5OXBM]4\*P7>GR:X)-.BCOM0E@>.";^S?-;S B([NORK(6C :/$OI
MND_LS?#O0X9K>TT>^%@P"PZ=-K5]-9V:B9)@EK;O,8K5 \:?+ J+A0N-O%;W
MBSX/^$_&W]L'5]-EFEU86/VJ>WO;BWFW6<IFM7CDBD5H7CD8NKQE6SCG@4 <
MQ\4O$?B:Z\1^ /!.EZP/!VH>)?M-Q?ZO81Q7<UM':Q)(\-J;B,QEW=U&^2%A
MY:RD(&VE>,^(/[0&N? /6-%\,ZBD7Q&*"WEU/5%%U%J=M;3WC0QRS06FGR6B
M$(#AY9K5)6BD"J@%>P>,/A9X<\>:#INDZU;7EQ#ILL<]E=P:E<V]];2HA021
MW<4BSHY1F5G$@9E=PQ(8@\E?_LK_  UU1K9KK1]0E,4<4<O_ !/M0'VT13O<
M1->8G_TMTFEDD5[CS&#.Q!!- ''Z_P#M4ZWH&AZIJ\O@2.2S;Q/=^$]$2WO[
MN[N-1N[>>YC>22"UL9I(H?+M9'RBS/N!79M_>'0\8?&;Q'JW[*OBGQO9:9J/
M@3Q-:VEPL4=Y92J\$L<FP31I>6\;O&P^9#+ A((R@Z5Z)JOP9\(:SX6N?#UQ
MIDR:;/J<NM9M;ZXM[B*]DN&N'GAN(Y%EA<RNYS&ZX#%1A3BK#?"OP]<?#^X\
M%7D>HZKX?N8WBFCU75[R]N)59BQ#7,TK3'D\9?@8 P !0!\V?$#]HKQM_P *
METO3M%U5--^(FBO<#Q9?1V<4BQ"QN([:8B-T9$^U2RPO&IY\F1ROW<CK8_VS
MD_X2KQ!O\"ZY)X&T>75H)?$=K8:BY0Z<EP;B20M9+9B(R6LT2%+R1RSPAHT+
M2"+UG4/@;X%U35/&.I7/AZ%K_P 7I:1Z[<I+(CWJVR[8 Q5AMV#CY<9P,YIE
MG\#?!^G^*-1UVWM-2BFU*2>6]TU=:OO[*N'F0K,SZ=YWV5B^YF8F++,2Y^8[
MJ .(^%?CGQOXJ^-5[%XLT2'PS"_A2SOK73=/UMM2M2)+B7YV+0P[)QC:P"%<
M!-LCY(79_:3OO$&A^!9]7\/^-+_PM?VL$T=A8:986ES/K&I2!5LK7%S&X*M)
ME2B!&;>#YL:HQ.AX3_9S\"^"8YAHUIK%M/+!;6C7LGB+49KL6\$HEA@%Q)<-
M*L*L#B(,$P[J5*NX;1^(GP3\*?%+6=%U;7H]774]%69+"[TC7[_2Y(!,%$N&
MM)XB=P10<YX&.YH \2\1_$KXB+_PEGC!/$[:5'X3\4:/X<D\(PV=K)I]ZLRZ
M?]J:25XFN/,+7\@C,<J*/*BRK9?=U-AJ'CY?BEXW\/:9XWU#Q7:VN@S7-Z_]
MFV"#0]5ED5[*TLP%B#L;=I7,=U+*4 M6=PLV7[5OV=? 4GBJS\12Z7?3ZI;O
M:3$S:S?2074]JBI;7%S TQBN;B,)'MGF5Y 8XSNRBD4=!_9=^'_AFQU.QTZW
M\0PZ?J0N#<6+^+-6EM]\\AEEE2)[HI'*9"9!*@5U8EE8'F@#%^ GC#QOJG_"
M3Z/K<MWJ>I:3K\4$MKXK:UM=5L-.ELHI5:9K" V=Q*93(R+"=HC=0\HE1T'"
M^+OB'X_\!ZCXSL[#QU<^+;:/^QM'N=6NM-LDBT'6-0U*"V\JU2*-=X2"\6<P
MW#3,@6VW.WF-N]DTWX'Z7X:N-)_X1[4]6TF"#5AJ^IR2:E=7EYK#K;M#'%<W
M<\KRR1*"AV.6&(HU&T#!RM!_91^&_AWP[J7A^TL-<FT#4+>:VGTJ_P#%.JWE
MJ!+)YKR1Q37+I%-YG[P3(%D5R65@230!P&I:YXI\/Q_%2QU[XK^*8=,\"K;Z
ME#K6FZ?I!U*\AFM/,-I*CV+0NXD1O+\J*-F\Y%.XX)[*W\?>+/@O^S_+XH^)
M<]MJ=SHGAG^U-3U"6YCCN9=0PSM:>5%!'#M7,<:RJR[SUC7J>IT[X">"--T.
M721I=U>VL^J6VM7,FIZI=WMQ=WENT;027$\TKR3^68(=JR,R@1( ,* -OQ-\
M.="\972S:S!=7R*]K(+5M0N%M2]M<"YA<P+((RPE56+%<L%56W* * /F3P/\
M8_'WQ*^#OB+1/"?C:#X@>/O#6O:;%?Z]X)FT>26[TVX>*>9K<3'[&LB1M<VZ
MB3O;9.2=QUM#\?>*OBA='PIH'Q#\6>%;S0M%U&ZU/4-7TO2&U9M1CO&@6"Y"
MV[VGE1;'_P"/=!YBF)A+PQ?W;Q;\'?#'C36I]8OH]4L]6N+.*PEO]%UN^TN>
M2WBD>2.,R6LT;%5>60CG^-NQ-<_J7[+_ ,-]4TNPL)-%O;9+.*Z@%U8:W?VE
MW<1W,@DNDN;F*=9;D32*'D$SOO<;FR>: /!O!OQZ^(GC[X;6'Q>'B)M'MX=:
M\-Z7+X)AL;8V%Q'>KIJW6^5XVN1+OU"4QE)55?*B5D?YRV_^S7\8?&_C/XJ0
MV7B+6=:GTC4M'O=0A;6-,M(-,U)TO%CAFT*>")9);01"1C]J8RM'+:2*"LA>
MO9Y?V=?A[+XMA\1#0&AO8IH+C[';WUS#ITDT$8C@FDL4D%M))&BH$D>(LOEQ
MX(V+B3P)^S_X&^&NL0:GH&F7D%Q:V\EI917>KWEY;Z?#(REXK2">9X[5#L0;
M850815Q@ 4 >B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476783719552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verona Pharma plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1489389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3 More London Riverside<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SE1 2RE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283 4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.05 per share*<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654,649,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001657312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476786409216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 336,040<span></span>
</td>
<td class="nump">$ 271,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,904<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">7,964<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent', window );">Tax incentive receivable</a></td>
<td class="nump">5,587<span></span>
</td>
<td class="nump">10,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Equity interest receivable</a></td>
<td class="nump">4,315<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,443<span></span>
</td>
<td class="nump">3,365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">364,253<span></span>
</td>
<td class="nump">289,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Equity interest</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">2,847<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">17,565<span></span>
</td>
<td class="nump">18,416<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">381,818<span></span>
</td>
<td class="nump">308,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,831<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">18,143<span></span>
</td>
<td class="nump">3,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Royalties payable</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">1,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,950<span></span>
</td>
<td class="nump">8,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan</a></td>
<td class="nump">120,009<span></span>
</td>
<td class="nump">48,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SecuritesPurchasedNoncurrentRevenueInterest', window );">Revenue interest purchase security agreement</a></td>
<td class="nump">102,019<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">223,377<span></span>
</td>
<td class="nump">50,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">251,327<span></span>
</td>
<td class="nump">58,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary &#163;0.05 par value shares; 667,659,630 and 667,659,630 issued, and 654,649,358 and 643,536,094 outstanding, at September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">42,771<span></span>
</td>
<td class="nump">42,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">621,628<span></span>
</td>
<td class="nump">601,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Ordinary shares held in treasury</a></td>
<td class="num">(828)<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(528,479)<span></span>
</td>
<td class="num">(388,433)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">130,491<span></span>
</td>
<td class="nump">249,283<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 381,818<span></span>
</td>
<td class="nump">$ 308,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SecuritesPurchasedNoncurrentRevenueInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securites Purchased, Noncurrent Revenue Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SecuritesPurchasedNoncurrentRevenueInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit And Income Taxes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_TaxCreditAndIncomeTaxesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476879026384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in pounds sterling per share)</a></td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">667,659,630<span></span>
</td>
<td class="nump">667,659,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">654,649,358<span></span>
</td>
<td class="nump">643,536,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476789177376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product sales, net</a></td>
<td class="nump">$ 5,624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,624<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of sales</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments', window );">Research and development</a></td>
<td class="nump">10,552<span></span>
</td>
<td class="nump">2,958<span></span>
</td>
<td class="nump">36,704<span></span>
</td>
<td class="nump">13,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">35,196<span></span>
</td>
<td class="nump">13,353<span></span>
</td>
<td class="nump">104,665<span></span>
</td>
<td class="nump">35,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">46,291<span></span>
</td>
<td class="nump">16,311<span></span>
</td>
<td class="nump">141,912<span></span>
</td>
<td class="nump">48,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(40,667)<span></span>
</td>
<td class="num">(16,311)<span></span>
</td>
<td class="num">(136,288)<span></span>
</td>
<td class="num">(48,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit', window );">Research and development tax credit</a></td>
<td class="nump">1,612<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,653)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">4,750<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">11,268<span></span>
</td>
<td class="nump">9,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(9,882)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="num">(13,225)<span></span>
</td>
<td class="num">(1,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases', window );">Foreign exchange gain/(loss)</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense)/income, net</a></td>
<td class="num">(2,045)<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
<td class="num">(1,285)<span></span>
</td>
<td class="nump">8,765<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(42,712)<span></span>
</td>
<td class="num">(14,643)<span></span>
</td>
<td class="num">(137,573)<span></span>
</td>
<td class="num">(39,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(2,018)<span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (42,962)<span></span>
</td>
<td class="num">$ (14,687)<span></span>
</td>
<td class="num">$ (139,591)<span></span>
</td>
<td class="num">$ (40,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Profit/(loss) per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Profit/(loss) per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (in shares)</a></td>
<td class="nump">651,944,000<span></span>
</td>
<td class="nump">638,239,000<span></span>
</td>
<td class="nump">648,633,000<span></span>
</td>
<td class="nump">631,448,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (in shares)</a></td>
<td class="nump">651,944,000<span></span>
</td>
<td class="nump">638,239,000<span></span>
</td>
<td class="nump">648,633,000<span></span>
</td>
<td class="nump">631,448,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Research And Development Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GainLossFromResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ResearchAndDevelopmentExpenseNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Net Of Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ResearchAndDevelopmentExpenseNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476779867264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-The-Market Sales Agreement</div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th">
<div>Ordinary shares </div>
<div>At-The-Market Sales Agreement</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>At-The-Market Sales Agreement</div>
</th>
<th class="th"><div>Ordinary shares held in treasury</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,338,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 230,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 529,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,549)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (333,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,321,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Share options exercised</a></td>
<td class="nump">1,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">276,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(350,110)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,338,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">230,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,549)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(333,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">263,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(746)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(374,053)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">276,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(350,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Share options exercised</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">273,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(359,143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,687)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Share options exercised</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 263,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(746)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(374,053)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">643,536,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 249,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(388,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Share options exercised</a></td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common shares withheld for taxes on vested stock awards</a></td>
<td class="num">(3,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation', window );">Equity settled share-based compensation reclassified as cash-settled</a></td>
<td class="num">(237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 224,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,282)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(414,397)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">643,536,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 249,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(388,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (139,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">654,649,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 130,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(828)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(528,479)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2024</a></td>
<td class="nump">168,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,203)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(485,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(42,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Share options exercised</a></td>
<td class="nump">3,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common shares withheld for taxes on vested stock awards</a></td>
<td class="num">(5,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation', window );">Equity settled share-based compensation reclassified as cash-settled</a></td>
<td class="num">(543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 7,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">654,649,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,659,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 130,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 621,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (828)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (528,479)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476777235824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (139,591)<span></span>
</td>
<td class="num">$ (40,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issue costs</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of RIPSA</a></td>
<td class="nump">5,511<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of redemption premium on debt</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">3,653<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">27,506<span></span>
</td>
<td class="nump">14,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">799<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(6,904)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(4,347)<span></span>
</td>
<td class="num">(833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent', window );">Tax incentive receivable</a></td>
<td class="nump">5,590<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">4,315<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(832)<span></span>
</td>
<td class="num">(2,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,435<span></span>
</td>
<td class="num">(2,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">14,742<span></span>
</td>
<td class="num">(6,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_IncreaseDecreaseInLicenseAgreementObligations', window );">Royalties payable</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(573)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Income taxes</a></td>
<td class="nump">1,765<span></span>
</td>
<td class="num">(954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">409<span></span>
</td>
<td class="num">(979)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(93,367)<span></span>
</td>
<td class="num">(39,820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of furniture and equipment</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Term Loans</a></td>
<td class="nump">122,500<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA', window );">Proceeds From Revenue Interest Purchase And Sale Agreement ("RIPSA&#8221;)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(6,915)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of 2023 Term Loans</a></td>
<td class="num">(52,256)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of withholding taxes from share-based awards</a></td>
<td class="num">(11,191)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">4,484<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">156,622<span></span>
</td>
<td class="nump">68,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">64,268<span></span>
</td>
<td class="nump">29,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">271,772<span></span>
</td>
<td class="nump">227,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">336,040<span></span>
</td>
<td class="nump">257,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 6,452<span></span>
</td>
<td class="nump">$ 1,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481639/420-10-35-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInLicenseAgreementObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in License Agreement Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInLicenseAgreementObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Tax And Tax Credit Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Revenue Interest Purchase And Sale Agreement ("RIPSA&#8221;)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476789082448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and description of business operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_OrganizationAndBusinessDescriptionTextBlock', window );">Organization and description of business operations</a></td>
<td class="text">Organization and description of business operations <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc is incorporated and domiciled in the United Kingdom. Verona Pharma plc has one wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation (together with Verona Pharma plc, the &#8220;Company&#8221;). The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;VRNA&#8221;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On June 26, 2024, the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;) in adult patients and the Company launched Ohtuvayre in the U.S. through an exclusive network of accredited specialty pharmacies in August 2024. Ohtuvayre is the Company&#8217;s first commercial product and the first inhaled therapy with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Pipeline</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is developing a fixed-dose combination formulation with ensifentrine and glycopyrrolate, a Long-Acting Muscarinic Antagonist (&#8220;LAMA&#8221;), for the maintenance treatment of patients with COPD via delivery in a nebulizer. The Company has filed patent applications in multiple jurisdictions including the U.S. In the third quarter of 2024, the Company initiated a Phase 2 dose-ranging trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, based on the clinical results of ensifentrine observed in patients with COPD, including improvements in lung function and symptoms of cough and sputum, the Company believes ensifentrine could potentially be an effective treatment for non-cystic fibrosis bronchiectasis (&#8220;NCFBE&#8221;). In the third quarter of 2024, the Company commenced a Phase 2 clinical trial to assess the efficacy and safety of nebulized ensifentrine in patients with NCFBE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $528.5&#160;million as of September 30, 2024. The Company expects to incur additional losses and negative cash flows from operations until its products reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company expects that its cash and cash equivalents as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the Company may enter into out-licensing transactions from time to time but there can be no assurance that the Company can secure such transactions in the future. Accordingly, the Company may need to obtain substantial additional funds to achieve its business objectives including to further advance clinical and regulatory activities, to fund launch related costs and to create an effective sales and marketing organization to commercialize Ohtuvayre. Any such funding will need to be obtained through public or private financings, debt financing, collaboration or licensing arrangements or other arrangements. However, there is no guarantee the Company will be successful in securing additional capital on acceptable terms, or at all.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_OrganizationAndBusinessDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Business Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_OrganizationAndBusinessDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476789315248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text">Basis of presentation and summary of significant accounting policies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024 (the &#8220;2023 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2023, was derived from audited consolidated financial statements included in the 2023 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and reportable segment, the development and commercialization of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the three and nine months ended September 30, 2024 the Company relied on four specialty pharmacies to purchase and supply Ohtuvayre to patients. These four specialty pharmacies accounted for 100% of all Ohtuvayre net product sales in the three and nine months ended September 30, 2024 and accounted for all of the Company's outstanding accounts receivable from product sales as of September 30, 2024. The loss, or a significant change in the buying patterns, of any one of these specialty pharmacies as a customer could negatively impact the sales of Ohtuvayre.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, gross-to-net revenue adjustments, amortization and carrying value of the revenue interest purchase and sale agreement (&#8220;RIPSA&#8221;), and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Inventory, including Pre-Launch Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company values its inventories at the lower of actual cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. When the Company expects to utilize the inventory beyond one year we record it in inventories, long-term on its consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining initial regulatory approval for Ohtuvayre, the Company expensed costs relating to production of pre-launch inventory as research and development (&#8220;R&amp;D&#8221;) expense in its consolidated statements of operations and comprehensive loss in the period incurred. Inventory acquired and the related costs after June 26, 2024, the date of the FDA&#8217;s approval of Ohtuvayre, are capitalized. Products used in clinical trials are expensed as research and development expense in the statement of operations and comprehensive loss.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess or obsolete inventory to its net realizable value in the period in which the impairment is identified through cost of product and other revenue in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the Company&#8217;s product is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of sales in the consolidated statements of operations and comprehensive loss. No inventory was written down as a result of excess, obsolescence, scrap, or other reasons during the three or nine months ended September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Interest Purchase and Sale Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The RIPSA is eligible to be repaid based on royalties from net sales of Ohtuvayre (ensifentrine) and any other future products. Interest expense is calculated using the effective interest method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the RIPSA and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of the liability, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenues consist of product sales of Ohtuvayre. The Company accounts for contracts with its customers in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Pursuant to ASC 606, for arrangements or transactions between participants determined to be within the scope of the contracts with customers guidance, the Company performs the following five steps to determine the appropriate amount of revenue to be recognized as the Company fulfills its obligations: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Product Sales, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue from net product sales was generated in the United States following the FDA&#8217;s approval for marketing of Ohtuvayre for the treatment of COPD in June 2024. The Company sells Ohtuvayre principally through arrangements with specialty pharmacies (&#8220;SPs&#8221;), who are the Company&#8217;s customers. The customers subsequently resell the product to patients and health care providers. The Company applies the ASC 606 five step process discussed above to the contracts with SPs. The Company provides limited right of return to the customers in cases of shipment errors or expiring or defective products. Product revenues are recognized when the customers take control of the product, which occurs upon delivery to the customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company recognizes revenue from product sales at the net sales price which includes estimates of variable consideration for which reserves are established and reflects each of these as a reduction to revenue. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">results in the future vary from estimates, the Company may need to adjust its estimates, which would affect net revenue in the period of adjustment. The following are the Company&#8217;s significant categories of variable consideration:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Distribution Fees: The Company pays distribution fees to SPs in connection with the sales of its product. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Government rebates and chargebacks: The Company contracts with Medicaid, Medicare, and other government agencies (&#8220;Government Payors&#8221;) so that Ohtuvayre will be eligible for purchase by, or partial or full reimbursement from, such Government Payors. The Company estimates the rebates, chargebacks and discounts it will provide to Government Payors and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates these reserves based upon its contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Commercial Chargebacks: Chargebacks are discounts and fees related to contracts with various third-party payers and programs that purchase from SPs at a discounted price. SPs charge back to the Company the difference between the price initially paid by SPs and the discounted price paid to SPs by these entities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Product Returns: Consistent with industry practice, the Company offers SPs limited product return rights for shipment errors or expiring or defective products. The Company makes a reasonable estimate of future potential product returns based on inventory reports from SPs, visibility into the inventory distribution channel, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Co-pay assistance: Other incentives which the Company offers include voluntary patient assistance and assurance programs, such as a co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other fees: Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">License Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue may also at times consist of revenue from the Company&#8217;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements may include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476784818880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Interest<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Equity interest</a></td>
<td class="text">Equity interest <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The equity interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company evaluates this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the nine months ended September 30, 2024.</span></div>Ligand license agreement obligations<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006, the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#8220;Ligand Patents&#8221;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#8220;Ligand Licensed Products&#8221;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The contingent liability assumed included a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Due to the FDA approval of Ohtuvayre on June 26, 2024, the Company has recognized the following in the nine months ended September 30, 2024:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">$6.3&#160;million in research and development costs related to a milestone payment for first regulatory approval of ensifentrine; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">$15.0&#160;million related to a milestone payment for first commercial sale of ensifentrine. The Company has classified this as selling, general and administrative expense as it relates to the resolution of the 2021 dispute with Ligand. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is obligated to pay low single digit royalties based on the net sales of all Ligand Licensed Products and expenses all costs related to royalty amounts as a cost of sales within the income statement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476789055168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text">Accrued expenses<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476785377472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ligand license agreement obligations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Ligand license agreement obligations</a></td>
<td class="text">Equity interest <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The equity interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company evaluates this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the nine months ended September 30, 2024.</span></div>Ligand license agreement obligations<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006, the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#8220;Ligand Patents&#8221;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#8220;Ligand Licensed Products&#8221;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The contingent liability assumed included a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Due to the FDA approval of Ohtuvayre on June 26, 2024, the Company has recognized the following in the nine months ended September 30, 2024:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">$6.3&#160;million in research and development costs related to a milestone payment for first regulatory approval of ensifentrine; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">$15.0&#160;million related to a milestone payment for first commercial sale of ensifentrine. The Company has classified this as selling, general and administrative expense as it relates to the resolution of the 2021 dispute with Ligand. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is obligated to pay low single digit royalties based on the net sales of all Ligand Licensed Products and expenses all costs related to royalty amounts as a cost of sales within the income statement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476789309520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">2023 Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On December 27, 2023 (the &#8220;2023 Effective Date&#8221;), Verona Pharma, Inc. entered into a term loan facility of up to $400.0&#160;million (the &#8220;2023 Term Loan&#8221; or &#8220;Loan Agreement&#8221;), consisting of a term loan advance in an aggregate amount of $50.0&#160;million funded on the 2023 Effective Date (the &#8220;Term A Loan&#8221;) and four additional term loan advances subject to certain terms and conditions. The 2023 Term Loan was repaid in full as of May 9, 2024. Verona Pharma, Inc. and the Company did not incur any penalties, but did incur a prepayment fee and final payment fee in the aggregate amount of $2.3&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">2024 Term Loans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On May 9, 2024 (the &#8220;2024 Effective Date&#8221;), Verona Pharma, Inc. (the &#8220;Borrower&#8221;) entered into a term loan facility of up to $400.0&#160;million (the &#8220;2024 Term Loans&#8221; or &#8220;2024 Loan Agreement&#8221;), consisting of a term loan advance in an aggregate amount of $55.0&#160;million funded on the 2024 Effective Date (the &#8220;Tranche A Term Loan&#8221;) and four additional term loan advances subject to certain terms and conditions, as discussed below, in the amounts of $70.0&#160;million (the &#8220;Tranche B Term Loan&#8221;), $75.0&#160;million (the &#8220;Tranche C Term Loan&#8221;), $100.0&#160;million (the &#8220;Tranche D Term Loan&#8221;) and $100.0&#160;million (the &#8220;Tranche E Term Loan&#8221;) with each tranche issued subject to an original issue discount of 2.0%. The 2024 Loan Agreement was entered into with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agent (in such capacity, the &#8220;Agent&#8221;), and certain funds managed by each of Oaktree Capital Management, L.P. (&#8220;Oaktree&#8221;) and OCM Life Sciences Portfolio LP (&#8220;OMERS&#8221;) party thereto (collectively, the &#8220;2024 Lenders&#8221;). The net proceeds of the 2024 Term Loans will be used for general corporate and working capital purposes and a portion of the proceeds from the Tranche A Term Loan was used by the Borrower on the 2024 Effective Date to repay, in full, the existing outstanding indebtedness owed under the 2023 Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Tranche B Term Loan was available, subject to customary terms and conditions, during the period commencing on the date the Company received approval from the FDA for its new drug application for ensifentrine through and including the earliest of (i) the date that is 30 days immediately following the date the Company receives such approval and (ii) September 30, 2024. The Tranche C Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche B Term Loan), during the period commencing on the first business day following the achievement of a specified net sales milestone for ensifentrine and ending on December 31, 2025. The Tranche D Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche C Term Loan), during the period commencing on the first business day following the achievement of a specified net sales milestone for ensifentrine and ending on June 30, 2026. The Tranche E Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche D Term Loan) at the 2024 Lenders sole discretion and upon the Company&#8217;s request. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company received $52.8&#160;million in net proceeds at closing of the 2024 Loan Agreement and draw of the Tranche A Term Loan, which consisted of the Tranche A Term Loan face value of $55.0&#160;million less the original issue discount of $1.1&#160;million and lender and third-party fees related to the 2024 Loan Agreement and RIPSA, as defined and discussed below, of $1.1&#160;million. $52.4&#160;million of the net cash proceeds from the Tranche A Term Loan were used for the repayment in full of the existing outstanding indebtedness owed by the Company under the 2023 Term Loan of $52.3&#160;million and interest amounts related to the 2023 Term Loan of $0.1&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On June 28, 2024, the Company received $68.6&#160;million in net proceeds related to the Tranche B Term Loan, which was available upon FDA approval for Ohtuvayre. The amount received consisted of the Tranche B Term Loan face value of $70.0&#160;million less the original issue discount of $1.4&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2024 Term Loans will mature on May 9, 2029 and each advance under the 2024 Loan Agreement accrues interest at a fixed per annum rate of 11.00%. The 2024 Loan Agreement provides for interest-only payments on a quarterly basis until maturity. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrower shall pay an exit fee to the 2024 Lenders in the amount of 2.50% of the aggregate principal amount of the 2024 Term Loans to be paid (the &#8220;Exit Fee&#8221;). The Borrower may prepay the 2024 Term Loans in full or in part provided that the Borrower (i) provides at least two (2) business days&#8217; prior written notice to the Agent, (ii) pays on the date of such prepayment (A) all outstanding principal to be prepaid plus accrued and unpaid interest, (B) a prepayment fee of 7.00% of the 2024 Term Loans so prepaid if paid on or before the first anniversary of the 2024 Effective Date; 5.00% of the 2024 Term Loans so prepaid if paid after the first anniversary of the 2024 Effective Date and on or before the second anniversary of the 2024 Effective Date; 2.00% of the 2024 Term Loans so prepaid </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">if paid after the second anniversary of the 2024 Effective Date and on or before the third anniversary of the 2024 Effective Date or 1.00% of the 2024 Term Loans so prepaid if paid after the third anniversary of the 2024 Effective Date and on or before the fourth anniversary of the 2024 Effective Date, (C) the Exit Fee and (D) all other sums, if any, that shall become due and payable under the 2024 Loan Agreement, including interest at the default rate with respect to any past due amounts. Amounts outstanding during an event of default are due upon the Majority Lenders&#8217; (as defined in the 2024 Loan Agreement) demand (except during a payment or bankruptcy event of default, whereupon such default interest is automatically imposed) and shall accrue interest at an additional rate of 2.00% per annum, which interest shall be payable on demand in cash and (iii) any partial prepayment of the 2024 Term Loans shall be an aggregate amount at least equal to $5.0&#160;million in a denomination that is a whole number multiple of $1.0&#160;million in excess thereof.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2024 Term Loans are secured by a lien on substantially all of the assets of the Borrower and the Company, including intellectual property, subject to customary exclusions and exceptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2024 Loan Agreement contains customary representations and warranties, covenants and events of default, including two financial covenants: (i) commencing on the 2024 Effective Date, the Borrower is required to maintain certain levels of cash, and, after the Account Control Agreement Completion Date (as defined in the Loan Agreement) subject to control agreements in favor of the Agent, and (ii) commencing on the fiscal quarter of Company ending on September 30, 2025, the Borrower and the Company are required to maintain quarterly trailing twelve-month net sales from the sale of ensifentrine in the United States; provided that such revenue covenant will be waived at any time (x) the Borrower and the Company&#8217;s unrestricted cash balance subject to control agreements in favor of the Agent on the last business day of the applicable fiscal quarter is equal to or greater than the product of 1.25 multiplied by the aggregate principal amount of outstanding 2024 Term Loans on such date or (y) the average daily closing price of the Company&#8217;s American Depositary Shares for each of the thirty (30) trading days preceding the last trading day of such fiscal quarter multiplied by the total number of issued and outstanding American Depositary Shares of the Company is at least $1.0&#160;billion. The 2024 Loan Agreement also contains other customary provisions, such as expense reimbursement, as well as indemnification rights for the benefit of the Agent and the 2024 Lenders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of September 30, 2024, the effective interest rate was approximately 13% per annum and there was no material difference between the carrying value and the estimated fair value of the 2024 Term Loans.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Revenue Interest Purchase and Sale Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On May 9, 2024, the Company and Verona Pharma, Inc. (collectively the &#8220;Sellers&#8221;) entered into the RIPSA with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agent and certain funds managed by each of Oaktree and OMERS (collectively, the &#8220;Purchasers&#8221;). Under the terms of the RIPSA, in exchange for each of the Purchaser&#8217;s payment to the Sellers of a purchase price of $100&#160;million, in the aggregate, upon approval of ensifentrine by the FDA by a specified date and subject to certain labeling conditions (the &#8220;Tranche A Purchase Price&#8221;), the Sellers agreed to a true sale of assigned interests to the Purchasers, including a right for the Purchasers to receive 6.50% on the global net sales of ensifentrine by the Sellers (the &#8220;Royalty Interest Payments&#8221;) and 5% on certain proceeds the Sellers receive from licensees engaged during the term of the RIPSA outside of the U.S. (the &#8220;Ex-U.S. Payments&#8221;). The Sellers will begin payment of the Royalty Interest Payments and Ex-U.S. Payments in the first fiscal quarter after receipt of the Tranche A Purchase Price. The Sellers will also have a right to receive an additional funding tranche equal to $150&#160;million (the &#8220;Tranche B Purchase Price&#8221;) upon achievement of a specified net sales milestone in any trailing six-month period after receipt of the Tranche A Purchase Price and subject to certain terms and conditions. The Royalty Interest Payments and Ex-U.S. Payments will cease upon reaching a multiple of 1.75 times the amounts actually funded by the Purchasers. The RIPSA includes a buy-out option, which provides the Sellers with the right to settle all outstanding liabilities at any time by paying a buy-out amount under various terms and conditions. As of any date of determination, the aggregate amount of payments received by the Purchasers under the RIPSA, divided by the amount funded as of such date (the &#8220;MOIC&#8221;) equals 1.20x, if such date is on or before the one-year anniversary of the funding of the first tranche of the RIPSA, the MOIC equals 1.40x if such date is after the one-year anniversary of the Tranche A Funding Date and on or before the two-year anniversary of the Tranche A Funding Date, the MOIC equals 1.55x if such date is after the two-year anniversary of the Tranche A Funding Date and on or before the three-year anniversary of the Tranche A Funding Date, and the MOIC equals 1.75x if such date is after the three-year anniversary of the Tranche A Funding Date. The Purchasers have the right to terminate the RIPSA under certain conditions, including the Company&#8217;s insolvency, and the Company&#8217;s divestment of ensifentrine, in which case the Sellers must pay the Purchasers up to 1.75 times the amounts actually funded by the Purchasers as of such default determination date. Pursuant to a security agreement signed in connection with the RIPSA, the Sellers granted to the Purchasers a security interest in certain assets to secure obligations under the RIPSA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On June 28, 2024, the Company received the Tranche A Purchase Price of $100.0&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of September 30, 2024, the effective interest rate was approximately 25% per annum and there was no material difference between the carrying value and the estimated fair value of the RIPSA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476788815568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share based compensation</a></td>
<td class="text">Share-based compensation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following tables show the activity of each type of share-based compensation and are presented in ordinary shares. The Company&#8217;s ADSs that are listed on Nasdaq each represent eight ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share options activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,689,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,432,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,037,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,020,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,924,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,712,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,056,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,654,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,005,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units (&#8220;RSU&#8221;) activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,502,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,357,208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,143,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,045,384)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566,824)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,045,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,486,080&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Performance restricted stock units (&#8220;PRSU&#8221;) activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">PRSUs will begin to vest upon achievement of certain performance conditions and are subject to continued service. The fair value of PRSUs will be recognized over the remaining service period using the graded-vesting method once the performance conditions are determined to be probable of occurring. As of June 30, 2024, the performance conditions were assessed by the Company and considered probable of being met under the applicable accounting framework, and accordingly the Company recognized $2.2&#160;million and $12.1&#160;million in share-based compensation expense related to the PRSUs in the three and nine months ended September 30, 2024. The total compensation cost not yet recognized as of September 30, 2024 related to PRSUs was $5.0 million, which will be recognized over a weighted-average period of approximately one year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A summary of the Company&#8217;s PRSU activity for the period ended September 30, 2024 is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of PRSUs outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,730,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,724,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,724,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(420,864)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,569,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476879104128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and net loss per share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Capitalization and net loss per share</a></td>
<td class="text">et loss per share <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on Nasdaq each represent eight ordinary shares. The following table shows the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the three and nine months ended September 30, 2024 and 2023, outstanding share options, RSUs and PRSUs over 50.2 million and 45.9&#160;million ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476878842384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text">Subsequent events<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">[OPEN]</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476785240960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (42,962)<span></span>
</td>
<td class="num">$ (25,794)<span></span>
</td>
<td class="num">$ (14,687)<span></span>
</td>
<td class="num">$ (8,807)<span></span>
</td>
<td class="num">$ (16,743)<span></span>
</td>
<td class="num">$ (139,591)<span></span>
</td>
<td class="num">$ (40,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476785802976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=vrna_DavidZaccardelliMember', window );">David Zaccardelli [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">357 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=vrna_MarkHahnMember', window );">Mark Hahn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">359 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=vrna_DavidZaccardelliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=vrna_DavidZaccardelliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=vrna_MarkHahnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=vrna_MarkHahnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476785422288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K filed on February 29, 2024 (the &#8220;2023 Form 10-K&#8221;). The Consolidated Balance Sheet as of December 31, 2023, was derived from audited consolidated financial statements included in the 2023 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#8217;s significant accounting policies are described in Note 2 to those consolidated financial statements.</span></div>Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and reportable segment, the development and commercialization of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the three and nine months ended September 30, 2024 the Company relied on four specialty pharmacies to purchase and supply Ohtuvayre to patients. These four specialty pharmacies accounted for 100% of all Ohtuvayre net product sales in the three and nine months ended September 30, 2024 and accounted for all of the Company's outstanding accounts receivable from product sales as of September 30, 2024. The loss, or a significant change in the buying patterns, of any one of these specialty pharmacies as a customer could negatively impact the sales of Ohtuvayre.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, gross-to-net revenue adjustments, amortization and carrying value of the revenue interest purchase and sale agreement (&#8220;RIPSA&#8221;), and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Inventory, including Pre-Launch Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company values its inventories at the lower of actual cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. When the Company expects to utilize the inventory beyond one year we record it in inventories, long-term on its consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining initial regulatory approval for Ohtuvayre, the Company expensed costs relating to production of pre-launch inventory as research and development (&#8220;R&amp;D&#8221;) expense in its consolidated statements of operations and comprehensive loss in the period incurred. Inventory acquired and the related costs after June 26, 2024, the date of the FDA&#8217;s approval of Ohtuvayre, are capitalized. Products used in clinical trials are expensed as research and development expense in the statement of operations and comprehensive loss.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess or obsolete inventory to its net realizable value in the period in which the impairment is identified through cost of product and other revenue in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the Company&#8217;s product is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of sales in the consolidated statements of operations and comprehensive loss. No inventory was written down as a result of excess, obsolescence, scrap, or other reasons during the three or nine months ended September 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Interest Purchase and Sale Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The RIPSA is eligible to be repaid based on royalties from net sales of Ohtuvayre (ensifentrine) and any other future products. Interest expense is calculated using the effective interest method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the RIPSA and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of the liability, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenues consist of product sales of Ohtuvayre. The Company accounts for contracts with its customers in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Pursuant to ASC 606, for arrangements or transactions between participants determined to be within the scope of the contracts with customers guidance, the Company performs the following five steps to determine the appropriate amount of revenue to be recognized as the Company fulfills its obligations: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Product Sales, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue from net product sales was generated in the United States following the FDA&#8217;s approval for marketing of Ohtuvayre for the treatment of COPD in June 2024. The Company sells Ohtuvayre principally through arrangements with specialty pharmacies (&#8220;SPs&#8221;), who are the Company&#8217;s customers. The customers subsequently resell the product to patients and health care providers. The Company applies the ASC 606 five step process discussed above to the contracts with SPs. The Company provides limited right of return to the customers in cases of shipment errors or expiring or defective products. Product revenues are recognized when the customers take control of the product, which occurs upon delivery to the customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company recognizes revenue from product sales at the net sales price which includes estimates of variable consideration for which reserves are established and reflects each of these as a reduction to revenue. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates. If actual </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">results in the future vary from estimates, the Company may need to adjust its estimates, which would affect net revenue in the period of adjustment. The following are the Company&#8217;s significant categories of variable consideration:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Distribution Fees: The Company pays distribution fees to SPs in connection with the sales of its product. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Government rebates and chargebacks: The Company contracts with Medicaid, Medicare, and other government agencies (&#8220;Government Payors&#8221;) so that Ohtuvayre will be eligible for purchase by, or partial or full reimbursement from, such Government Payors. The Company estimates the rebates, chargebacks and discounts it will provide to Government Payors and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates these reserves based upon its contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix, resulting in a reduction of product revenue and the establishment of a current liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Commercial Chargebacks: Chargebacks are discounts and fees related to contracts with various third-party payers and programs that purchase from SPs at a discounted price. SPs charge back to the Company the difference between the price initially paid by SPs and the discounted price paid to SPs by these entities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Product Returns: Consistent with industry practice, the Company offers SPs limited product return rights for shipment errors or expiring or defective products. The Company makes a reasonable estimate of future potential product returns based on inventory reports from SPs, visibility into the inventory distribution channel, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Co-pay assistance: Other incentives which the Company offers include voluntary patient assistance and assurance programs, such as a co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other fees: Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">License Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue may also at times consist of revenue from the Company&#8217;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements may include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting standards and recent accounting standards not yet adopted</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476789344704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476881396320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476788749264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Share Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,689,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,432,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,037,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,020,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,924,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,712,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,056,000&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,654,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,005,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,502,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,357,208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,143,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,045,384)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,098,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566,824)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,045,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,486,080&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A summary of the Company&#8217;s PRSU activity for the period ended September 30, 2024 is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of PRSUs outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,730,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,724,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,724,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(420,864)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,569,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476788815568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earning Per Share</a></td>
<td class="text">The following table shows the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands except per share amounts):<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476878839536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | subsidiary</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="num">$ (528,479)<span></span>
</td>
<td class="num">$ (388,433)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Wholly Owned Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476885212688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies - Segment Reporting (Details) - segment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=vrna_SpecialtyPharmaciesMember', window );">Specialty Pharmacies | Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vrna_SpecialtyPharmaciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vrna_SpecialtyPharmaciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476785407040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 6,904<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember', window );">Nuance (Shanghai) Pharma Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_EquityInterestReceivable', window );">Equity interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_EquityInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Interest Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_EquityInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476880755312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AccruedResearchAndDevelopmentFeesCurrent', window );">Clinical trial and other development costs</a></td>
<td class="nump">$ 6,414<span></span>
</td>
<td class="nump">$ 752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent', window );">Professional fees and general corporate costs</a></td>
<td class="nump">4,463<span></span>
</td>
<td class="nump">2,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">People related costs</a></td>
<td class="nump">7,266<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 18,143<span></span>
</td>
<td class="nump">$ 3,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Fees, Listing, And General Corporate Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476885362144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Consolidation and Presentation of Financial Statements (Details) - Ligand UK Development Limited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476777482752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>Dec. 27, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,500<span></span>
</td>
<td class="nump">$ 9,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Lender and third-party fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,915<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_OaktreeFundAdministrationLLCMember', window );">Oaktree Fund Administration, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales', window );">Percentage of global net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees', window );">Licensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding', window );">Additional funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementMultiple', window );">Multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne', window );">Multiple before year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo', window );">Multiple after year one, before year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree', window );">Multiple after year two, before year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree', window );">Multiple after year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2023TermLoanMember', window );">2023 Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument, fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2023TermALoanMember', window );">2023 Term A Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember', window );">2024 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember', window );">2024 Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentExitFeePercentage', window );">Exit fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember', window );">2024 Term Loan | Line of Credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion', window );">Minimum american depository shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember', window );">2024 Term Loan | Line of Credit | Debt Instrument Interest Rate, Period One | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember', window );">2024 Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Lender and third-party fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage', window );">Debt default stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Prepayment cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple', window );">Denomination multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum', window );">Multiple of aggregate principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember', window );">2024 Term Loan | Secured Debt | Debt Prepayment Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent', window );">Early repayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember', window );">2024 Term Loan | Secured Debt | Debt Prepayment Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent', window );">Early repayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember', window );">2024 Term Loan | Secured Debt | Debt Prepayment Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent', window );">Early repayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermALoanMember', window );">2024 Term A Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermBMember', window );">2024 Term B | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermBMember', window );">2024 Term B | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Term Loans</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet', window );">Net proceeds</a></td>
<td class="nump">68,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">issuance discount</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermCMember', window );">2024 Term C | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermDMember', window );">2024 Term D | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermELoanMember', window );">2024 Term E Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Issuance discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from long-term debt, finance lease obligation, and mandatorily redeemable capital security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Average Daily VWAP And American Depository Shares Value Calcualtion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Service Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentEarlyRepaymentPenaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Early Repayment Penalty, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentEarlyRepaymentPenaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentPartialPrepaymentDenominationMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Partial Prepayment, Denomination Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentPartialPrepaymentDenominationMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase and Sale Agreement, Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase and Sale Agreement, Multiple After Year One, Before Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase and Sale Agreement, Multiple After Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase and Sale Agreement, Multiple After Year Two, Before Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase and Sale Agreement, Multiple Before Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase and Sale Agreement, Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase and Sale Agreement, Purchaser Percentage, Global Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Purchase and Sale Agreement, Purchaser Percentage, Licensees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_OaktreeFundAdministrationLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_OaktreeFundAdministrationLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_A2023TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_A2023TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_A2023TermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_A2023TermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_A2024TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_InterestRatePeriodAxis=vrna_DebtInstrumentInterestRatePeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_InterestRatePeriodAxis=vrna_DebtInstrumentInterestRatePeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtPrepaymentPeriodAxis=vrna_DebtPrepaymentPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_A2024TermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_A2024TermBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_A2024TermCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_A2024TermDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_A2024TermELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_A2024TermELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476777370768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 7,654<span></span>
</td>
<td class="nump">$ 5,079<span></span>
</td>
<td class="nump">$ 27,506<span></span>
</td>
<td class="nump">$ 14,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">5,470<span></span>
</td>
<td class="nump">3,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 6,864<span></span>
</td>
<td class="nump">$ 3,969<span></span>
</td>
<td class="nump">$ 22,036<span></span>
</td>
<td class="nump">$ 11,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476788862992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share Option Activity (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance outstanding</a></td>
<td class="nump">33,712,200<span></span>
</td>
<td class="nump">26,020,200<span></span>
</td>
<td class="nump">24,689,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">2,056,000<span></span>
</td>
<td class="nump">7,924,000<span></span>
</td>
<td class="nump">2,432,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(107,632)<span></span>
</td>
<td class="num">(72,000)<span></span>
</td>
<td class="num">(64,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(2,654,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,037,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance outstanding</a></td>
<td class="nump">33,005,608<span></span>
</td>
<td class="nump">33,712,200<span></span>
</td>
<td class="nump">26,020,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476777603120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - RSU Activity (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance</a></td>
<td class="nump">13,098,280<span></span>
</td>
<td class="nump">15,143,664<span></span>
</td>
<td class="nump">19,502,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(566,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(2,045,376)<span></span>
</td>
<td class="num">(2,045,384)<span></span>
</td>
<td class="num">(4,357,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">10,486,080<span></span>
</td>
<td class="nump">13,098,280<span></span>
</td>
<td class="nump">15,143,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vrna_PerformanceRestrictedStockUnitsPRSUsMember', window );">Performance restricted stock units (PRSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance</a></td>
<td class="nump">10,724,896<span></span>
</td>
<td class="nump">10,724,896<span></span>
</td>
<td class="nump">10,730,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(420,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(3,569,696)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">6,734,336<span></span>
</td>
<td class="nump">10,724,896<span></span>
</td>
<td class="nump">10,724,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vrna_PerformanceRestrictedStockUnitsPRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vrna_PerformanceRestrictedStockUnitsPRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476778687424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 7,654<span></span>
</td>
<td class="nump">$ 5,079<span></span>
</td>
<td class="nump">$ 27,506<span></span>
</td>
<td class="nump">$ 14,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vrna_PerformanceRestrictedStockUnitsPRSUsMember', window );">Performance restricted stock units (PRSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Cost related to share options and PRSUs granted but not yet recognized</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vrna_PerformanceRestrictedStockUnitsPRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vrna_PerformanceRestrictedStockUnitsPRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45476879091344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization and net loss per share - Computation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares per ADS</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (42,962)<span></span>
</td>
<td class="num">$ (25,794)<span></span>
</td>
<td class="num">$ (14,687)<span></span>
</td>
<td class="num">$ (8,807)<span></span>
</td>
<td class="num">$ (16,743)<span></span>
</td>
<td class="num">$ (139,591)<span></span>
</td>
<td class="num">$ (40,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (in shares)</a></td>
<td class="nump">651,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,633,000<span></span>
</td>
<td class="nump">631,448,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (in shares)</a></td>
<td class="nump">651,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,633,000<span></span>
</td>
<td class="nump">631,448,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share (in shares)</a></td>
<td class="nump">50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200,000<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-"&A42V1^B52OQG2QXQ)Q67X2AYY(J0RX>%22F:F2IFA42WQ!B7>H!G>G,M
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M]&=/"\"67\[@:!ASIZ#8?>YYOR6<;EF142Y^:C:G\M6:4/%9CS_/Y6T8=>\
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M 64#\'PEI7G:V&'5_YOROU!+ P04    " #D1619M3_2-4$&  #F'   &
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MBY&P! E+D3"!A&5(6 Z"23TF>.LQ@7&4_4<W5QN9^+P+M!?J"0LCWU/&4J.
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MKD>D7 V1,JAD3DA.CC5E.P_A'3>'=Q;/7'(] HJT<1F:UD%I,9264*VAKC-
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MM!A*2Z"T%$H34%H&I>4HFMQYAB#/__R-<H>J\F>P>[-@QM0A%AK'06DQE)9
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M!!2AQ/"A:76!@X6C',4CR;"?9!J^+?<G"C:I%-*$3IUH,;N(210Y)(X PWZ
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MW7 N_!Q.4V(=]J-]HM5'$7P))?4!8:-EQ6=<!;<S]DX,C4+AF!Y)@?M;B@7
MO3U;FAZE$8BP79C$RZSG7 _)P1$H++%?;,5DYC'T'A8A_HL5E:'<1BBD-0OV
M:7)P\ 5":0\A%JMEV4[5+Y[7-SY8>!4N$\62,K*=I3CRN0!N#WX-:2<F:5]&
M<Q@0>6=!$VO. WVO!7!R:-+SN8F,B1=1:%EE&$PN&2#'QNJ9;1# C8^NE;,H
MW0;2R!G9S_@)WJQX2&G9@SA,QG(4MQTCAN(GQ 4\U'/L'NZ+,8/B,T)I81['
MN8^),J,C_R<KB GCJ90<",'3$Z&;I-+"$; D*M@NMD4^10*@?(5+9<!*W$XH
MEGI_&KI3\F&'6]K>E.EM0D*"$'XORB/M'+L"Q?(B*<FS;(H0S4X,@F$KO4 T
MX/T34'_WYN;V*N'82580(X.\.B?Q4VJ <)0ERID8I.M! R[E<^B&0!?(L68C
M&FBH/\*FQ XM!F]=U:\HC%0DACD\4/1(HG&(C90=KH?[S6@K!!N@M ']RM;T
M3;(B?J.L3$!%O6]1SDUB; L](P3)WQ():@LW<1F_[0';O/,4=1]D'#JWG43+
MX"X!A/.#1AFS'*Z/\AH+TG-]:>,-A=< *V%W<D<AKNJ@.X1"L0?.9A13>9%Q
MOJR1[1$R6DHY7#=Y%O+./I,,#]F4?78ZI#(M9JR(/0?3%PT@T/2D#W'$[LZX
M)>JU"24]@$;K?#BU[21^(B0RHTI^JOX-A#A*EH*)."'V <'B=Q-!5Y+2S&SA
MC!S!"2FI3=(LF%",\PLVFJY=G!+'1(AE]17N&VMOQ?TP$',#@W"T<S>CDH$X
MP?^#9?4O>K!.!.@UTA1$R[DNQ_S)'A<Q7/@D-HY07<IQ,0G ]T\;,82!1>V/
M1X'LA5_HU?KIJUPLQQU9 KM\%L%IA-(3!BJ .F75/0<A;$Q(>S!57<4J< C/
M8AC"KYY#YNJ_>NCH\K$D[<E>N'_]ZBK[2Y9IF48G[+:57MM )DT4W(CPO.I]
M;$$TT!"BAPK1%IT9A'^?' MY<1(O2YJ/2FCL4Q&<TLT1LJ:%1#(5N8-D/FYR
M%1P52H\YS&@0NYO$)!)MG*585B,T*3$R*CBXGIQ!V8+CTW*P-+*#0Q'AG@#(
MN,8ZIA]U@$72"TB=Y/%+ /C%,D>,!-6(,*Z[BF2RWY+Y@Q8X55>U5(>4%R8'
M0VPB &3Z?O8K@Y8.&SF+3[\A*I*T"8>X3M(L@*REN,! 0?.#47,#>Q29:+-Q
M.,-6).DR@,/>C1:01W,$!+?3>!=1 5Q@$51JM>@8@;P1D9" @FQ>Q:[$3(=J
M:5B)?6N#+T5;=PP=5M0.2@PQ5IUS;<EE=AET-K9I4BS48BVG;"P1]*Z[0.J$
ML_3M2KOW1BJD/9M)R:L^;#U28/$NS%1T)*X_Q39&Y<2?LX.?NH(^:GT16V C
M>@&!=,G,@@=%3>(.OB) ,%$H<?6:*X5DI]K3E@5HE)*'$N@G5#S30U70ZY'&
MU7^H1Y.'%U\7$3/]\BYZR9L$N6Y*R'5+D.LJ0RZ*,@RWR%A112XLJ0%JXGXH
M/+56 K%HY-5M4<,02&!40JK;KTS4@[*ZE18KUT,LF7E/O8]D?VRWD<@<+:%D
MW52]!/O>)P$:KAJDTQ,?69FP1'2AV">W9*N*<:=,&ZDRB$8,]H@Y"K/6#]5,
M:>P00EI15-@%@M.,4XCER(M(!;8O -M'X4E/.K?@QG5G)KF!I%(8SSAX'/L1
M+WOI(T>VNVCU!_&VZ')PH.*Y)&&1*3*)K%P?$BU1/B:#;)H23Q12;BSML7\P
MO90UO/2Y:,T$O%/DI^R6:PQIP1Y4/'>6&/=!K!2O^'+$>SR^**JNE,<3+LT&
ME3G(M9' N'ELY,PD]8P*G<A-O,=B&X9W"8.Q%4GX+2UIIRJ6\,PHORCR#^LS
MF^V$0M'&4(_5C_J4;$N27L%VAUJ1*\PQ:<GF(S,$=*Y&30WD'2?IAAMK\IDZ
MTQWL2/L4JL5\A?8$SX=>!:M^E_ \?YKLFV+"=I#,P!!91];)-(>S=[#G16OS
M\&TW6T=P(,#4CB'$H09*:=PCR^2,SH4?]SP8Z\8NC3_4B[^ZO58_=VM;J<?G
M@**)7G;[Z_%:UWF=!++I83PV#&T0K$ES;/[QXD0<QCGREIC:W'B2-S-AP[,S
M#?56%DP%/U1B=8Q)1$-"HQ528]+5#L<#MXO>,J-C%)#1*!?E78-:D>QV3DX(
M2UES",R;2VPC]+UV9)M%!$UX+J4;5O#O JO+#>=],X<!2[':S9"E)*<_40_L
M5QE"5KGOQ>X!\5N?TR4$1D-N6XU@ W/]%*M@F41P7F6S-)RS/K):[#&DYG%)
M7X'FBL6VTE2'B>)R**DQ'\*N2I@X4+>"0R+;E+"_,  :AI*6AOT2+L)-MN6<
M<:<A?DKN[!]UQ$6T_MU7J4->R&]O]12/C_&:8<*0ACW"51S50E)/V=T?8#=7
MN')A!ANJU!^0J?NO1OJGQHZ?$_#@"'.8@B%2<$+/MD2K2A=W!\P.J^HC2_(P
M@N0P-S*ZT6-#*.R QPS9<Q!=I5#C&B O<8B:W "6CH#/!07K0<?N9JY+&;_A
MT9],N"\*#@AM' ()WP[() W)6VX<W@;.3H-#'RVA*1P)O.=63(G^TIPI((.$
M9*W7;V]>T692KN?^>E:$(=\>UHB3?<XL&1J4T8^CU,&>>@JKMS=^Z!]NEAV[
MW*$:+\<Z(6D(?73, OD<^W';D&A,D8#E64Q+V*Z7*&(H=FJ!MW?D83M5/.37
MV(B?8F@?@F8J ;G-W7MN+LR0VY/;[<1H,+C3(I ]?>X#N]3>= 8XM<WKE*D,
MF5WRHE_:V+1PKG,<X)"CK;3:"!$D##8@]V20.>^F#FCA=SL[!L)!(_O."Z9^
M8%=52("J7W>$V!IL*57C:*%=9!KWW+'^G5&/H*P!Q$A0V^E"#B -Y!V.F&SB
M\E@\.!5[0IZ*72G1!']SM]^7J$B*6"HH4X,.K$6BI^KM'9]BF<0[\^IIP'[(
M?F<,ITJJ.=WF%#LF';L-C9A<8% A&FQH3%'KL0\;2O(["2D"[+S!$2&E_L?N
M@9#]M!(GU3E9,3:5IG,QB!FOCFJ<&6;7I &?J7F=/](TG^_VW2.%L:R[XQ,)
MM%!^:)P^:+_6"+:2JF74VL@=[@V#Y3CT*L<IXQX9=5!R[2-"'B+QL>@U&DMB
MTX7T\(^JY8EZ9:E_->M9C*^- 88:11&]Y0@TW#,W,CM&P(D3P=;L'(W*Z-J&
MW#1+$^2\%IR&ER)6LI7I;%8]1_L"L<[M!RGD*SJ$MS"YZS-5?Z>2IXUG%V9Y
MU(9JTBWPO7J_P]1.Z/S1T#3(UI/XB=O N<>X&!;'KNTHJQ0;W^@MXF3NC?M.
M+'Y(8JGBRCT5"AMY^#7;,@A@N$X]:2<',YRQJQGBG^ \LKZ)G"S9VWD< LO:
MTB2A3$J)2'<:J44\R@8A,&8-4O#>%K&A+=UP"4D#M$NNR1Y">N>)88ZY>608
MAOIN- XL(=H]O)1A4*R&,T.</Y1:/:2W0:N=6^@V%O$0##4)R20MVYR<;AF$
MP_.^H9=$PE K^V$2(X4,;491O"@U,^>QM,UI(8$A0HF @FT82N0I,1^/B=!T
M<3#CZU*#4C441+)#%0.S'9%0#.AZDJ-U]2G9&CNXB:H%Q0NG5[$?D4V3-4K>
M3M@S;TB"H' ]Y4MB6(KH2LDY=\UX4D]AF'JCN3"55$_Q/LZ[FJV2[N)6-HOB
MVMU/;HKQ1\X&D1U2OK*F0"'O&.20Q*3Z)_E*^=[6"*J. !*EG=U:MB-*/:^>
M@-.@2<9-C*.D,_ 9*.GGY;@-)-F?VL,<G7.#<>@G#CWT,2%%A37TJZ7/YK/2
M)NK.>AL;+RC\NIW1YBBT4_NM-8(W5-_6=#8W#B-D.F!0$,7)4!9CK8/.,X*D
M_#TL;K #S<Q&^Z4UR-QACC2%)%51T?5$O64_!5P@YLG=]X%*U%4Z-WK7-3 4
M2M,1B!?KY;,7CK\E4X_15$[>[-*0[DJ)F_R-.E;<I)>Q*L?*X4A&\2RN\P"%
M)UG#H:]F>XJ:KG<<1V*UP&9)IPLK9[E'J6K7+R(]Z4CE< 16/'8:!33GE$V)
MFR[HV*QG#U=['BXUR;@DH>.*'34DB(J4W.F85XT-H?0"K7/UZ>B 6V!P>&>U
MG*1,=)8-AS1N.J"+)/VI^@'^1WV_5*G?5\$2OM(-$BOE$.2/46-O!/0/(J-
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MW8#K]%9L^D(;Y#_W\>+_ %!+ P04    " #D161949Y]MM@&  #%$   &
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M<BR\M.1X& ZM4#>9:0)9\M3;00"$7%U#R&I./G-5I3Q11?_ :@C5$DEZX O
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M#'8'[<)7/<\#+8Q/CRLY5]<J?*^N'-[&G994%ZKTVI;"J>QD<+9[>+Y/Y_G
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M&RZ=W9[1M]T1M(YJ)8>B1M$ZL<AUDHNP%N/<R9(,]]VA$^HN,;4G38Y8P N
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M<VAE970Q,BYX;6S-6VUO&S<2_BN$FQ8VH,B2;"5IW@#;27 YQ(@1-[T/A_M
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MJI->%S+:A<RYTZ=F!>'BNOU.]/LLVVGQ7/\R'OP87*!M:)'-4;\J@C!QZ2X
MC3-0/WC:D?9<[XF'#VT?X/0<^5W*(-I.HC'^2?/<"01S3!U&ZPA/$"Y:"R]S
M)6'\>H6N8732*;G6UP]?JU;0?:T*FK'H+*J+VZ.>0VT5H< 4K4(+#/ 2NQQ?
MH)X1LTER:K7G]>,'0E7>6.^G+M<VA1\4.?_"L9<GV\,<G/J<O'6?$6P93] S
M9PSO00K>JQ( @AA \!M+13TEUNTS7HGQ(X^3L]I'YF/.815L<6H5@8P'LSKZ
M;E8?==!N7KGR/I0"M@Z_F]E'G;235YH>U8L'DH G7KG.*(2RZV7>>6?G%&:;
M)5H]\,K3"(Y,EXDFT.P2(=.X7?!E5Z<.Y>]>TJ6E*9QCSUW/N.3-(Q2\K>)\
MAE(R%O-QKGSWQ4488B5AZ8$ZY<@[C[,#99JTT/Z(.*_E;R7EYG2V0*GC.$%+
MNM@GS G6+%EAZCY#ZQ>/%DDZG\CBFVFJ.EMO\4-U'AI@;CCA!#ZC9E!I9$/P
M'+D+*E^C6:61Q-2-7)P97*;I%L0B'2"&8NAB*!;)@#+BQF#5:$FPY06$#ACU
M^4Y7GWA[F%K3H"2I7WN</I#>-4^-V1QPWR73)RENIBDL^"C*)> '5\W0P4M(
M0/T$A*'F<0G5Z2I7'I)T*)"!') QJISM!BGD'<@6C7$P4XI<HVZP;2;D720K
M3"!;S"H!H.LX=HJU:F/$O^GS/.-J6&\EK$'(8&<_!IY12;@+8Y#$/M:YD=C"
M,TAU-.*S"178AN[!\+R.I%;2&)*'KABR$EXI*8CXD#OEA\+11Y,&$-66KAM0
M]7AXYC>^Y.*\W0WO3#@=16G7XVGCX#!=2_.$,DPJ<["3,S?D?3S%["79\B)S
M$/0*4ILR3_1 FL]=A^GF[]OQO!G*J0D\/1G>.K B[PB=S5+\$"<_NV8!%B$;
M@"/M"WU"V\!OS8O&O8.>Q"ZZ4V,M/JT-&@9G+97?J:=+NOM-I@NQ7Z./Q%9G
MP."5\[7@:?0MG$;95QNXC%.5(4]!V@E>$*<,*^F&>S6GB%JC0AS?GQP4*S;\
M34&)R.B,#N>$,Y$Y-P7?89U@B%QNSF1"]+K!(F6Z#6/!+V,NHG&Q4=+YG"S"
M['?:9)SMAOW1.&0>W?:GAS%V6JXVLU"L!1Y,'*^=\B3*N9P30M6P<IAM@'JF
M@D";ZKQ8*KR6-%]#U= UI8/;!7S(]3MA[!^ !\K@\=G@A#S(%5+"Q16UDG'\
MP[I,WD>HO*' ;874)8W4?:;&+G\#PQ@FT<8!EKM"<OX/A8.S_62K =UL'7-;
MMAG2@9LV3[*/6S?7=N-=.,%]A>B@D-/+26.LAS!X@]CB&U\:4"P+/0L#:D/?
M*[%QVC%1!;).W?7+X/UIRP8HPQ)N3Y#]\#^FT5BN'4RB$0'- ^[UTHVPAV=)
MC0]G&;>RH(R![92^IQHD#=W4@$OD"N5<.T-I6),EW#P@\(H#^8 I DV;=EBP
MH]CWQ1>?&SX&5F\:DRVD=>1N*>^T5NG>.7<G*K1\Y]UR>E&4WA/=4G%MKXBZ
MMW*TCH=A?\W]W*.NW/@&C:[&#ER"!2VF5V!?(]AVTUMO$C_S<\ '66NNMB(^
M4HOI(F XKRJO2S>GKH(%8\*AN]B L-I+Y9#VPK CC*HVZXS/"C3.8JC5SL&G
MH;79<<F=RXGBVI8.J!,-M2/(Z'$WQ&][#YH*Q@6$RZA$3FO:B@A8I^<.*C@'
MMD$GK0E27"1=V,>H;U>YNSR>Q8EG;@;C%#7/RPGEPUB6]R@H\)I*^:5<RQP>
MV(:7'U5U[F/'?%;07)P^ID0#9PP)4 HIURFZRIZSFR8W'OP=A-2W.&D#$H2'
M7_NW_8W9T%-^MLF;2\^! P\:YCP ZG00>X5DX3:I!_]S<XF-8N0 (PM;1?K[
M7&4'?UPW%I("VQLZL6JWU:(X9YUYZFU',QS_T3<L=KML&!H^ZMZ(O[B20$&K
M[ST.]%=7CU+)OFC<_V6I1QJ/M9PI.K!Q<U22EP,K[>F&_>=C!I0VF6[2I(V:
M*;J\=5_#\9'3!J'GB=W6!2V-$ $)UT_AQ:*L7,IWW7"<,=8=-X#J^/8BF!]]
M7PVN-D>"H3QH-Z2,"'C"\V0G4CC7PT$W+KF3L$MC]^C480/^MICOY:>*5OJ&
MN+<!.5N@&8?8\4)@2SO)O,97C:EV8#] 64?-:]=]RZU%J*DO7W_^>-667G)]
M2_AX<,_CHW:/MMMS*[CMT[629M?D*D15^,A!'D*L6_%XJ ,VVN//!_=;I[<M
MY*%CVWCXX!DX,")<E8^DLXO7\?@0KX\_8]\X$W7OT=P&)-CE^/EACK_C)!>M
MB7]RYNT$7W!]E=0CY\4A-:5?4NE>8&_V2&@%2K3)1;;N[6U+I_2=CSHDW[1,
M,_#Q]\.4OM*DL41K(<+E1QIO_+7&[TUFG0#TX\).,F S]&F';:1#<]*-M0BU
MQJ991(A#RBK\U^YCHDO"*<@SIY%1>V^9LM32;R>7+?;P4S+.FAG? $YR/??C
MJ(WL\^ [UH,%R\/3=@3XY[57H_%?W5XYO>SZ\OII\DL"],US_KV$%3P4<S\J
MB$_C3S(NW"\1VN7N]QS7TLRI*\[5#%L'<,XC%V_A0UU6_+N$25FC8>8_%TK"
M=K0 [V=E68</=$#\H<K;_P)02P,$%     @ Y$5D68QBOGSG!0  ^PX  !D
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MBGNZ6T"53T?YA33E^A?M2FVG8Z"PX()F%2Q7D"6D_,?/U7,X .Q3@%,!SEO
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MP (  &L*   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;+666V_;(!2
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MJ__H8:.+)T(<)GMP__;-98Z7K-,RE4\X;"N]MAVY-$EP+<H+J@^QJ$7F)?1
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MJX1^I"2'@K7"/JG]-SCHF3J\3 GCOV3?^=ZA<]8:J^I#,#*HN>S^[.50A[.
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M5<CEZQVNT%9[V\WU)7G.POSGT^#3!'$#=I2&F(;LS9BC))98.N3] 7Z^=J"
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M9\4<OS8@C0'>;X30>\4$:+]?LW]02P,$%     @ Y$5D6>\M[MFL @  Z08
M !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULM55=;],P%/TK5IC0D,:2
M)NW6C392/YC@85"M#!X0#VYRVUAS[& [S8;X\5P[:=9-71X0O#2V<\^YY]R;
M7H\JJ>YT!F#(?<Z%'GN9,<6E[^LD@YSJ4UF P#=KJ7)J<*LVOBX4T-2!<NZ'
M07#FYY0)+QZYLX6*1[(TG E8**++/*?J80I<5F.OY^T.;M@F,_; CT<%W< 2
MS&VQ4+CS6Y:4Y2 TDX(H6(^]2>]R-K#Q+N K@TKOK8EULI+RSFX^IF,OL(*
M0V(L \7'%F; N25"&3\;3J]-:8'[ZQW[E?..7E94PTSR;RPUV=@;>B2%-2VY
MN9'5!VC\.(&)Y-K]DJJ)#3R2E-K(O &C@IR)^DGOFSKL :+H!4#8 ,)G@#!\
M 1 U@,@9K94Y6W-J:#Q2LB+*1B.;7;C:.#2Z8<)V<6D4OF6(,_%GM:&"_:*V
MIB=D)H66G*6T+K%(R4*!!F'J [DF5TQ0D3#*R1(/ ?MI-#F>@Z&,ZS?DB#!!
MOF2RU C6(]^@1)O(3QHYTUI.^(*<"W(MA<DT>2]22)_B?;36^@MW_J9A)^$2
MBE,2!2<D#,(^N5W.R?'1&_QF5YJE##_; Q)GW8QS2)"QYQBC'6.'TJCM1.1X
MH__9B>^3E38*_QL_#M6^%M _+,#.BTM=T 3&7F%SJ2UX\>M7O;/@W:$J_2.R
M)[7JM[7J=[''G\I\!<I6H<HDYP]$5@+2Q[8RT.1W=Y>G=8:!RV!GW3;NC?SM
MOL-.#7_I<- Z''0ZG"1)F9<<&YO:J<029M#1T2$C-='9GI&W@W#8/[]X9N=
M7#0<]J.HC:N5^GO3) >U<4-6DT26PM2#I3UMY_C$C2__,;R^!*ZIVC"A"8<U
M0H/3<]2@ZL%:;XPLW&Q:28.3SBTSO(M V0!\OY;2[#8V07N[Q7\ 4$L#!!0
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M:' YQ TDW=O!-;0H[?6[$AK7UGYF^-P":0)P?"V$/C3,!/4#+OH#4$L#!!0
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M2!.-;F:0P\S5F#[CYFN?:HEW&>JT_^$Q8_J9W' -$I0FQP%HRF)U0MZ1AVE
MCH].R!%AG-Q'(E.4S]7(UKBN4=MAN<95L8:[9XTII!W2<TZ)Z[A>C?RZ61Y
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M>5K6_Y/7YK.C 9EM2Y&OF\)R"]9)MOL:_VAVQ$$!QS]2P&T*N.T"WI$"7E/
M.[<&ORG@MPL$1PH$38'@W!K"ID!8[_O=SJKW=!2+>'I;Y*^DJ#XM:=4W=5QU
M:;F#DZSZR_HB"OG31)83TXB_"/)SQ$6<I.4OY%?R^Y>(_/S3+^0GDF3DZRK?
MEG$V+V^'0E96%1G.&C#=@=TCX EYRC.Q*@G-YGRNEQ_*C=QOJ?N^I0^N%?B/
M;79%W.L/Q!VYOF%['NW%G^(W,IH<+1W92T=\)BL?U\4]T\ZP%__"-U?$&QVM
MG9U?W+/L2F\?NE?SO".\3_(UR1?DL>#S1! 6SY(T$6_D/_4//@J^+O]KV,J'
M'=4W4ZLV\*;<Q#-^-Y"-7,F+[WPP_>M?G'#T-U-<2%B$A%$DC(%@6L[^/F??
M1I\^%_F,\WE)%D6^)E]YL2:?\C@S'<T/5E+?;)&P" FC.UA8PZJS[O>IX[K!
M:'0[_'Z86O=CD\DDW'](2R/8IQ%8T_C$94M8$-F<$K%*BOFOF[B0!]V"<V,@
M5EC?0)"P" FC06=/AQ,G:,71_=#(G$6XSR*T9D$7"UY?T\BSG.!R,P4I8L%-
M.5A!?7- PB(DC.Y@D\-=?.6V<P#5J$4VWD<VMD;V6_Q-%)P3MI4'T/U<7@LE
MI9"AR>O3#^33IT=3=E9BW^R0L @)HT@8 \&TC*_W&5]?Y,+D&IDS$A8A810)
M8R"8EO-DG_/$?F&R+68KV1\DFR*9&5M=:_F^B4ZZ)_U1]4]OW2)DG10)8R"8
MEI4S4EW$D3TM7LQX)N)E?6PNT_PE3DG&!2GCU'SM8@?VC:^A55\.3DZCL'5V
MBJ"U4BB-H6AZA >]?,=^[2D/LZP\<J5I+]L[+<=P)3'J9(6LDT)I#$73LW)5
M5JXUJ_NY//?)JQIYD"WDM4Z2+8VA62&]0W.[361@:"*AM5(HC:%H>FS*J3C6
MKOST:9N*9),:SV;VHKW#VM$<YS"MJW'G$(-*$2B-H6AZ5LJ+.'8Q\IX5>>&+
MO.#DC<<%R3-S=E STM!:V;GMZ*#. TIC*)H>G9(HCMVB[*.+%[+COD_N@Q:E
M>,V-44*=2D-K1>FWHX3:$BB-H6AZE,K!.'8)8XI2)M>*<B4[_<8PH6*FH;7"
M##IM*M2Y0&D,1=/35'K&L?L98YI'PX.:F89V\H0(E2Y0&D/1]/"4=W&LW?UI
M=6-)W2 @?Y O?+8M^)Q4]P>- 4*5"Y0606D42F,HFIZS\B[.Y"*"S8'Z&"@M
M@M(HE,90-/V.N3(WKMW<U'?WDZP4Q7;-,_&!+&1=)%[GV\QX5-MQ?6.&TJ*&
M=MA%]0T6CT)K92B:'J#R-J[=VW0#Y-;\H":GH1WN<=?K* %HG11*8RB:GIXR
M.:[=Y#P7239+-G%*\JTH17Q4YM@YO7/;T8*#W )3<%"7 Z4Q%$T/3KD<U^YR
M/K[?%.8_-I4W-68&=3H-[3 SIYL8U.A :0Q%TQ-31L>U&QUU 7M_[B6LG=@[
M0.B8%RB-0FD,1=.35@+(#2YR">M"Y0^4%D%I%$IC*)H>MY)$KET2]1G#9D?U
MCA@Z6*>A'5Y,&6ZP4&BE#$73LU-*R+4KH7]R039-?L:\H!:HH6GWL SG4*@$
M@M(8BJ;'I220>U("^>H(,P8&M3Y06@2E42B-H6AZL,KZN)>Q/B[4^D!I$91&
MH32&HNF#^Y7U\>S6I\?@5CNI]Y!^J/"!TFA#TX>E.%YK@"NJ3CTYI7L\N^[1
M6V#9A]&/7&."4.4#I450&H72&(JF)ZW4D.=>I$GVH*8(2HN@- JE,11-C_M@
MPI5=*-$?,N3*W6[V8RF-Z6)G6#7CA%KC)MNC^B-HK11*8RB:GIO22MY)K61K
MD.4;3TF6K+=K8YI0P02E15 :A=(8BJ9GK@23=QG!Y$$%$Y0606D42F,HFAZW
M$DS>B5%(NP.8Q&M>)#-YD,_Y)B\3D1=OI%S%LDKR/4ZWYO8:*IR\KB+:S5-H
M.PQHM11*8RB:GJ923IY=.9UNL.M;JA_WMU3)_E[/9]E'^D">Y5]!/B>_R5)_
MD(=JCLKG8WTGJ+V"TB(HC4)I#$73_T*4Y?(N,\?,@[HO*"V"TBB4QE T/6[E
MOCS[5#-Y""<EV2V[0O),MN5%$K^D_+@2@4JOAM;2#DZ[08?*+"B-H6CZ"@9*
M9OEVF=5IT$_=UK7S^N8'I450&H72&(JFYZS4E^]<I%GVH?X+2HN@- JE,11-
MCUOY+]\^-*KOR$0[KG?,W>ENIK&$$;16"J4Q%$T/4!DMWVZT3MW;M1?O'5AW
M>%3@7G?S@IHL*(VA:'I>!TL!V4U6S]5G[+3>\?GGW)J'UDFA-(:BZ>DI)^7;
M9[W5S66S8!XIA;QTG9]0R79@[P #PV7LJ#UM$5HGA=(8BJ8'J"R3?VH8$]_$
M;[5PF.6E^10'E4F^>;Q1.S&H28+2&(JF)Z9,DF\W21'/\G62U0L,D;5E<K>=
MTSLWPR@F0VY0OP.E,11-STWY'=\^BFD_#U%V)N+ELN!+V5I6"\U40_%3ZS4F
MU/ TM/9,[_;--VBE%$IC*)J>I%(WOEW=6+O^[R;WH&%5ZM:8+M3K0&D1E$:A
M-(:BZ6LF*O\3C"[B!0*H!H+2(BB-0FD,1=/C5AHHL(^ HG&1OA%U3&]X%J?B
MS9@PU/P$QF6+QB/M7]O;0C>!0FD,1=.#5((GL N>/]EX?S6OW&&OK'?6T&%/
M4!J%TAB*IO\1*$D47&:AZ0 JCZ"T"$JC4!I#T?2XE6,*[(ZI3^,-]4L-[<2:
M<] Z*93&4#0]N8.EJ>U^Z4^VUBS?%L9TL8M78U>OQBY?#954*)K^5Z D51!>
MIKF&FBLH+8+2*)3&4#0];F6X KOAZM-<0QU70VLUUYV+:ZCC@M(8BJ8GIQQ7
M<.Y,O;-GN]N)O1.$#E^"TBB4QE T/6GEP(++3-T+H+8+2HN@- JE,11-?RJ%
MLEWAB:6V>\QVMZ/Z1AQVEU<*##>,H)52*(VA:'IV2EV%=G5U:D2$O7COO!S#
MB B_FQ?44$%I#$73\U*&*CS74#V<-=/2CNN=']1!06D42F,HFAZS<E#A91Q4
M"'504%H$I5$HC:%H>MS*085V!_44_ZBG\[SDA2R;9$LRBV5UB;E?8X?U#MGO
MM,ECPZA":*442F,HFIZ>\E#AN1[JX8P^C1W6.SVH9H+2*)3&4#0]Y(-GKUU&
M,X781[%AG\6&?1@;5#.A:'K<2C.%=LW4JT_3'?UD:$$?[37VS@XJFJ TAJ+I
MV2G1%-I%T\D^S77GC!=>A]V\H+H(2J-0&D/1]+R4+@KM0Z:2LMS&V8R3>5+.
MCHUS"PW/0^OT'!_M-?7.#.I\H#2&HNF/M53.9WSN#+?'L_JA=ES?TR"4%D%I
M%$IC*)H>L])#X\M,<!M#M1&4%D%I%$IC*)H>M[)+8[M=ZM</M<-ZA]Q= 'QL
M<+G02BF4QE T/3TEC<;VV6VJ38[.:Y.AL@A*BZ T"J4Q%$V/6<FBL7^9-AFJ
MC:"T"$JC4!I#T?2XE5T:GWAV7+\V&6J7&EIK@7]#HPSU1E :0]'T^)0W&MOG
MT*E&F9Z_/J:=V3M%J#2"TBB4QE T/6LEC<;CR[3,T(%*4%H$I5$HC:%H>MS*
M,XU/3-KKUS)#QS(UM)./AX?62J$TAJ+I\2GM-+9KIX_G:"<[HW=JIH65.C/2
MH752*(VA:+O,AN6*<Q'%(I[>KGFQY(\\34M2IW$WJ+JM^W=)P1?5HP)O[MW!
ML/,^=6Z84[T_5)CI[29>\J>X6"9925*^D,C1574Y4"3+U?Z%R#=W ]GM?LF%
MR-?UMRL>SWE1?4#^?)'GXOU%5<%K7GRK-WOZ?U!+ P04    " #D16191D+J
M;I4#  !]$   &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6S%6-ENVS@4
M_15"4PQ:((EV.<[8 F)+10NT0!!W>2CF@;&N+:&2J"%I.YFO'Y*254M6A31#
MH"\QEW,.>1=<\69V(/0[2P$X>BSRDLV-E//JQC39.H4"LRM202EV-H06F(LI
MW9JLHH 312IRT[&LP"QP5AKA3*W=T7!&=CS/2KBCB.V* M.G!>3D,#=LX[AP
MGVU3+A?,<%;A+:R ?Z[NJ)B9K4J2%5"RC)2(PF9NW-HWL6U)@D)\R># 3L9(
MFO) R'<Y>9_,#4O>"')8<RF!Q<\>EI#G4DG<XY]&U&C/E,33\5']K3)>&/.
M&2Q)_C5+>#HWK@V4P ;O<GY/#N^@,<B7>FN2,_47'1JL9:#UCG%2-&1Q@R(K
MZU_\V#CBA"!TA@E.0W#Z!.\G!+<AN,\]P6L(WG-/\!N",MVL;5>.BS#'X8R2
M Z(2+=3D0'E?L86_LE(FRHI3L9L)'@]7*::@7)V@-2E$_C&L(GB)U-;E0FTM
M3[?B1SD&]#H"CK.<O1'@SZL(O7[U!KU"68D^I63'<)FPF<G%'>5)YKJYSZ*^
MC_.3^[CH(REYRE!<)I ,\*-Q_G2$;PK?M YRC@Y:.*."*ZBND&M=(,=RO('[
M+)]/=X?,^7^GQR\^O>,,M\T65^FY8]ER66?+'7X2!8.C6TIQN04YOCBF1H)$
M]-$25QG'>?8O)!?HMB [@?[V04BB]QP*]O=0=M3G>\/GRZIYPRJ\AKDARB(#
MN@<C_/,/.[#^&@J-3K%(IUBL2:P31*\-HC>F'GXB(BA#OJ]I@:+)#\P^G 2^
MR+K]J4_/0;XUF79!T3G(F?A6T$7%YRC;\SRW176L\UOK_%'K[H6_,%VG*@,3
MV(M/825S<\C@4:5?33:=8I%.L5B36"<<01N.X#=7C$!G$'6*13K%8DUBG2!.
MVB!.7E8Q:II_6C&F5J]@G&-LV^Z!HG.0[TUZH/@<Y+IN,%PNKEO3KD=-6XDG
M:E9N+] 62J X5VF($_'2RABG6+YBAPP?%?W5I-,I%ND4BS6)=2(S;2,S_<V5
M8ZHSB#K%(IUBL2:Q3A!MZT=_8;VL=C2\T\]_<!WTGQL#*'<:]-\; RC'L=S^
M@V, )FO1I%="S)-VJ@"Z57TL$^V12*KZK=RNMKWRK>H0>^L+^V9I#ZQ'LK=6
M[=L/^;HQ_XCI-BL9RF$CCK*N)J+:T;K7K2><5*J9>R!<M(9JF ).@$J V-\0
MPH\3>4#['X?P/U!+ P04    " #D1619$KB.N3L#   7"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6RM5M%NVS@0_!5"!0XMT$:R)$MVSA80QVWO
M#F@O2-#>,R.M;:(2J9*TG?S]+2E%M2U:28&\V"(U,\M9DJN=[87\H38 FCQ4
M)5=S;Z-U?>G[*M] 1=6%J('CFY60%=4XE&M?U1)H84E5Z8=!D/@59=S+9G;N
M1F8SL=4EXW CB=I6%96/"RC%?NZ-O*>)6[;>:#/A9[.:KN$.]+?Z1N+([U0*
M5@%73' B837WKD:7RZG!6\!W!GMU\$R,DWLA?IC!W\7<"\R"H(1<&P6*?SNX
MAK(T0KB,GZVFUX4TQ,/G)_5/UCMZN:<*KD7Y'ROT9NY-/%+ BFY+?2OV?T'K
M9VST<E$J^TOV#39!<+Y56E0M&5=0,=[\TX<V#P<$U'$3PI80GA+B,X2H)40O
M)<0M(;:9::S8/"RIIME,BCV1!HUJYL$FT[+1/N-FV^^TQ+<,>3J[VU )-G,%
MR46%ITE1NR$?2//JW]H.K\S^,/U(WBY!4U:J=XA0!J%FOL:%&#D_;X,NFJ#A
MF: 1^2*XWBCRD1=0'/-]--"Y")]<+,)!P3NH+T@4O"=A$,:.]5P/T__9\D'Z
M<IC^A4JDCUST(S=1MR>1U8O.Z'W=5O<@B5@U"2;";H$B>&N5IKQ@?.W*>2,:
MNT5-^;A4-<UA[F%]4"!WX&5_O!DEP9^NA+VFV/*5Q(Z2&7?)C(?4LP6L&>>8
M,CSD)>4Y/)?&1FYLY4S1W&51E(Y"K*,S?W>8HCXP3 (\ J? I0,8)Y-I8@[+
MSF%MW%D;#UK[+"G7I_>G,3'NAPS&2=#ST,>ETS#NX98.O3@*#W%'#I+.03+H
M $OW"M@9#TDOYH=1D"91>.+!@4O#O@4'+(G/.D@[!^F@@X\/('-FJN=;QMN"
M^,[E)NV'#Y-Q/$U.MV0PWN_>/$?441"E\;FC-^EL3YZQ73/YO.E!D=\M21.'
M%W.D3S?ZE8(>Y67:Y64ZG!=;5EY::J:.4A.8>SHY.1,NH*LF+?O 7DUJ?/D'
M+4,%<FU;+X4MP);KYKO;S7;=W95M:D[F%]CU-4W:+YFF9<3/(I9>14I8H61P
MD>*R9-.&-0,M:MN8W N-;8Y]W&#G"M( \/U*"/TT, &Z7CC['U!+ P04
M" #D16195MN;G<(#  "<$   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6RM6&N/HS84_2L6E:I=:7< \\PTB3036K655HTFFMW/'KA)T !.;6>R^^]K
M&X8$8M#,EB_A=<^Y/L?FXIOYB;)GO@<0Z'M95'QA[84XW-HV3_=0$GY##U#)
M)UO*2B+D)=O9_," 9!I4%C9VG- N25Y9R[F^MV;+.3V*(J]@S1 _EB5A/^ZA
MH*>%Y5JO-Q[RW5ZH&_9R?B [V(!X/*R9O+);EBPOH>(YK1"#[<*Z<V\3UU<
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M]T R8"I /M]2*EXO5(+V#XGE?U!+ P04    " #D1619FJT83Y\#  "J#P
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M",5HP7,**'ZV:(SB.&<2<?Q5D6JUSQS8O-ZS!T7R(IE7R-"8Q%]PQ-=#S==
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M.4F*RS6"$:*Y@7B^)(3O;W(']6GCZ#]02P,$%     @ Y$5D67RC..\Z P
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MHBA)_ A@?@=1A"'P-.((Y@ \8$@45>_!O?=1N'E/A=M?N,:_ 5!+ P04
M" #D1619EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MU)L%Z,VH-PO0FU%O%J WH]XL0&]&O5F WHQZLP"]&?5F 7H;U-L(T-N@WD:
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M<',O87!P+GAM;%!+ 0(4 Q0    ( .1%9%G'J?)\[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    " #D1619')7C/Y0"  "G!@  &
M    @($N%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MY$5D6;4_TC5!!@  YAP  !@              ("!^!<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .1%9%E4C:6DN@X  *RO   8
M          " @6\>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " #D1619]7EK+LD'  "[(@  &               @(%?+0  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ Y$5D6=2;ZZV2"   SQ,
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .1%9%EW2RPK) \  +0R   9
M      " @?5E  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ Y$5D68QBOGSG!0  ^PX  !D              ("!4'4  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #D1619N/$;49P#  """
M&0              @(%N>P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( .1%9%D#14Z1_0$  *0$   9              " @4%_  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ Y$5D6>KO+7/,
M @  9@H  !D              ("!=8$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " #D1619PRL85, "  !K"@  &0
M@(%XA   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .1%
M9%F0VO%Z*Q8  (M*   9              " @6^'  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ Y$5D6=D[\<]/ @  * 4  !D
M         ("!T9T  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " #D1619CC.H4K,"  #3!0  &0              @(%7H   >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .1%9%D> ".S<00  +$+
M   9              " @4&C  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ Y$5D6259%\K] @  RP8  !D              ("!Z:<
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #D1619[RWN
MV:P"  #I!@  &0              @($=JP  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( .1%9%F[&$UF\P(  ,P)   9
M  " @0"N  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MY$5D66&1!W/^ @  10P  !D              ("!*K$  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " #D16194R,KC*D"   1!P  &0
M            @(%?M   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( .1%9%D=ZE#LPP(   L'   9              " @3^W  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ Y$5D6=;=6O!.#
M2Y$  !D              ("!.;H  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " #D16191D+J;I4#  !]$   &0              @(&^
MQ@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .1%9%D2
MN(ZY.P,  !<+   9              " @8K*  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ Y$5D65;;FYW" P  G!   !D
M     ("!_,T  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M" #D1619FJT83Y\#  "J#P  &0              @('UT0  >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .1%9%F*3= V[@0  'D<   9
M              " @<O5  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!
M A0#%     @ Y$5D67RC..\Z P  [A(   T              ( !\-H  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #D1619EXJ[',     3 @  "P
M        @ %5W@  7W)E;',O+G)E;'-02P$"% ,4    " #D1619H B$6DH#
M  !X%@  #P              @ $^WP  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ Y$5D6> ]"5=H 0  2A0  !H              ( !M>(  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ Y$5D61R:"5V, 0
MYQ0  !,              ( !5>0  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     "D *0 6"P  $N8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>127</ContextCount>
  <ElementCount>198</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and description of business operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations</Role>
      <ShortName>Organization and description of business operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of presentation and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Equity Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/EquityInterest</Role>
      <ShortName>Equity Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Accruedexpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Ligand license agreement obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Ligandlicenseagreementobligations</Role>
      <ShortName>Ligand license agreement obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Share based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Sharebasedcompensation</Role>
      <ShortName>Share based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Capitalization and net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Capitalizationandnetlosspershare</Role>
      <ShortName>Capitalization and net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Subsequentevents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Basis of presentation and summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Accruedexpenses</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Share based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationTables</Role>
      <ShortName>Share based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Sharebasedcompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Capitalization and net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/CapitalizationandnetlosspershareTables</Role>
      <ShortName>Capitalization and net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Capitalizationandnetlosspershare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Basis of presentation and summary of significant accounting policies - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies - Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Equity Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/EquityInterestDetails</Role>
      <ShortName>Equity Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/EquityInterest</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/AccruedexpensesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1</Role>
      <ShortName>Organization, Consolidation and Presentation of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Debt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share based compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Share based compensation - Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails</Role>
      <ShortName>Share based compensation - Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Share based compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails</Role>
      <ShortName>Share based compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Share based compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationNarrativeDetails</Role>
      <ShortName>Share based compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vrna-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Capitalization and net loss per share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails</Role>
      <ShortName>Capitalization and net loss per share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="vrna-20240930.htm">vrna-20240930.htm</File>
    <File>vrna-20240930.xsd</File>
    <File>vrna-20240930_cal.xml</File>
    <File>vrna-20240930_def.xml</File>
    <File>vrna-20240930_lab.xml</File>
    <File>vrna-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vrna-20240930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="440">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="6">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vrna-20240930.htm": {
   "nsprefix": "vrna",
   "nsuri": "http://veronapharma.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "vrna-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "vrna-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "vrna-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vrna-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vrna-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrna-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 168,
   "keyCustom": 30,
   "axisStandard": 14,
   "axisCustom": 2,
   "memberStandard": 14,
   "memberCustom": 20,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://xbrl.sec.gov/ecd/2023": 2,
    "http://fasb.org/us-gaap/2023": 1
   },
   "contextCount": 127,
   "entityCount": 1,
   "segmentCount": 34,
   "elementCount": 391,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 440,
    "http://xbrl.sec.gov/dei/2023": 32,
    "http://xbrl.sec.gov/ecd/2023": 6
   },
   "report": {
    "R1": {
     "role": "http://veronapharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "gbpPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "gbpPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
     "longName": "0000005 - Statement - Consolidated Statements of Shareholders\u2019 Equity",
     "shortName": "Consolidated Statements of Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-37",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-43",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations",
     "longName": "0000007 - Disclosure - Organization and description of business operations",
     "shortName": "Organization and description of business operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies",
     "longName": "0000008 - Disclosure - Basis of presentation and summary of significant accounting policies",
     "shortName": "Basis of presentation and summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://veronapharma.com/role/EquityInterest",
     "longName": "0000009 - Disclosure - Equity Interest",
     "shortName": "Equity Interest",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://veronapharma.com/role/Accruedexpenses",
     "longName": "0000010 - Disclosure - Accrued expenses",
     "shortName": "Accrued expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://veronapharma.com/role/Ligandlicenseagreementobligations",
     "longName": "0000011 - Disclosure - Ligand license agreement obligations",
     "shortName": "Ligand license agreement obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R12": {
     "role": "http://veronapharma.com/role/Debt",
     "longName": "0000012 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://veronapharma.com/role/Sharebasedcompensation",
     "longName": "0000013 - Disclosure - Share based compensation",
     "shortName": "Share based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://veronapharma.com/role/Capitalizationandnetlosspershare",
     "longName": "0000014 - Disclosure - Capitalization and net loss per share",
     "shortName": "Capitalization and net loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://veronapharma.com/role/Subsequentevents",
     "longName": "0000015 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies",
     "longName": "9954471 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)",
     "shortName": "Basis of presentation and summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables",
     "longName": "9954472 - Disclosure - Basis of presentation and summary of significant accounting policies (Tables)",
     "shortName": "Basis of presentation and summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:UseOfEstimates",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:UseOfEstimates",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://veronapharma.com/role/AccruedexpensesTables",
     "longName": "9954473 - Disclosure - Accrued expenses (Tables)",
     "shortName": "Accrued expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://veronapharma.com/role/SharebasedcompensationTables",
     "longName": "9954474 - Disclosure - Share based compensation (Tables)",
     "shortName": "Share based compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://veronapharma.com/role/CapitalizationandnetlosspershareTables",
     "longName": "9954475 - Disclosure - Capitalization and net loss per share (Tables)",
     "shortName": "Capitalization and net loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails",
     "longName": "9954476 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails",
     "longName": "9954477 - Disclosure - Basis of presentation and summary of significant accounting policies - Segment Reporting (Details)",
     "shortName": "Basis of presentation and summary of significant accounting policies - Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://veronapharma.com/role/EquityInterestDetails",
     "longName": "9954478 - Disclosure - Equity Interest (Details)",
     "shortName": "Equity Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://veronapharma.com/role/AccruedexpensesDetails",
     "longName": "9954479 - Disclosure - Accrued expenses (Details)",
     "shortName": "Accrued expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1",
     "longName": "9954480 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Details)",
     "shortName": "Organization, Consolidation and Presentation of Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://veronapharma.com/role/DebtDetails",
     "longName": "9954481 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
     "longName": "9954482 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)",
     "shortName": "Share based compensation - Share-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails",
     "longName": "9954483 - Disclosure - Share based compensation - Share Option Activity (Details)",
     "shortName": "Share based compensation - Share Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
     "longName": "9954484 - Disclosure - Share based compensation - RSU Activity (Details)",
     "shortName": "Share based compensation - RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-112",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
     "longName": "9954485 - Disclosure - Share based compensation - Narrative (Details)",
     "shortName": "Share based compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
     "longName": "9954486 - Disclosure - Capitalization and net loss per share - Computation (Details)",
     "shortName": "Capitalization and net loss per share - Computation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "dei:EntityListingDepositoryReceiptRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrna-20240930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "vrna_A2023TermALoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "A2023TermALoanMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Term A Loan",
        "label": "2023 Term A Loan [Member]",
        "documentation": "2023 Term A Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_A2023TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "A2023TermLoanMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Term Loan",
        "label": "2023 Term Loan [Member]",
        "documentation": "2023 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_A2024TermALoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "A2024TermALoanMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Term A Loan",
        "label": "2024 Term A Loan [Member]",
        "documentation": "2024 Term A Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_A2024TermBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "A2024TermBMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Term B",
        "label": "2024 Term B [Member]",
        "documentation": "2024 Term B"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_A2024TermCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "A2024TermCMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Term C",
        "label": "2024 Term C [Member]",
        "documentation": "2024 Term C"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_A2024TermDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "A2024TermDMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Term D",
        "label": "2024 Term D [Member]",
        "documentation": "2024 Term D"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_A2024TermELoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "A2024TermELoanMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Term E Loan",
        "label": "2024 Term E Loan [Member]",
        "documentation": "2024 Term E Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_A2024TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "A2024TermLoanMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Term Loan",
        "label": "2024 Term Loan [Member]",
        "documentation": "2024 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://veronapharma.com/role/Accruedexpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r439"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194"
     ]
    },
    "us-gaap_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of RIPSA",
        "label": "Accretion Expense",
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r548"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails",
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees and general corporate costs",
        "label": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "documentation": "Accrued Professional Fees, Listing, And General Corporate Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_AccruedResearchAndDevelopmentFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "AccruedResearchAndDevelopmentFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial and other development costs",
        "label": "Accrued Research And Development Fees, Current",
        "documentation": "Accrued Research And Development Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r75",
      "r121",
      "r332",
      "r345",
      "r346"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r29",
      "r293",
      "r296",
      "r318",
      "r341",
      "r342",
      "r530",
      "r531",
      "r532",
      "r539",
      "r540",
      "r541"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r439",
      "r568"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r352",
      "r539",
      "r540",
      "r541",
      "r553",
      "r570"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common shares withheld for taxes on vested stock awards",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Equity settled share-based compensation reclassified as cash-settled",
        "label": "Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation",
        "documentation": "Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r244"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r460",
      "r471",
      "r481",
      "r506"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r463",
      "r474",
      "r484",
      "r509"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r467",
      "r475",
      "r485",
      "r502",
      "r510",
      "r514",
      "r522"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "verboseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r281"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of redemption premium on debt",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r83",
      "r231"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issue costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r231",
      "r314",
      "r536"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r119",
      "r140",
      "r170",
      "r184",
      "r188",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r288",
      "r290",
      "r301",
      "r329",
      "r376",
      "r439",
      "r451",
      "r549",
      "r550",
      "r555"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r125",
      "r140",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r288",
      "r290",
      "r301",
      "r439",
      "r549",
      "r550",
      "r555"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r288",
      "r290",
      "r301",
      "r549",
      "r550",
      "r555"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_AtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "AtTheMarketSalesAgreementMember",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Sales Agreement",
        "label": "At-The-Market Sales Agreement [Member]",
        "documentation": "At-The-Market Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://veronapharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation and summary of significant accounting policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r117",
      "r416"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r85",
      "r139"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r85"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://veronapharma.com/role/EquityInterest",
      "http://veronapharma.com/role/Ligandlicenseagreementobligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest",
        "verboseLabel": "Ligand license agreement obligations",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r104",
      "r110"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r57",
      "r330",
      "r363"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r539",
      "r540",
      "r553",
      "r567",
      "r570"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in pounds sterling per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r364",
      "r382",
      "r570",
      "r571"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary \u00a30.05 par value shares; 667,659,630 and 667,659,630 issued, and 654,649,358 and 643,536,094 outstanding, at September 30, 2024 and December 31, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r331",
      "r439"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r51",
      "r52",
      "r192",
      "r413"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r51",
      "r52",
      "r192",
      "r347",
      "r413"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r51",
      "r52",
      "r192",
      "r413",
      "r529"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r51",
      "r52",
      "r192"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r51",
      "r52",
      "r192",
      "r413"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation and consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r422"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r238",
      "r239"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties payable",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r239"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails",
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r219",
      "r234",
      "r319",
      "r419",
      "r421"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r192"
     ]
    },
    "vrna_DavidZaccardelliMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DavidZaccardelliMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "David Zaccardelli [Member]",
        "documentation": "David Zaccardelli"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum american depository shares value",
        "label": "Debt Covenant, Average Daily VWAP And American Depository Shares Value Calcualtion",
        "documentation": "Debt Covenant, Average Daily VWAP And American Depository Shares Value Calcualtion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r62",
      "r63",
      "r94",
      "r95",
      "r143",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r315",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r537"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtInstrumentCovenantDebtServiceCoverageRatioMinimum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtInstrumentCovenantDebtServiceCoverageRatioMinimum",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of aggregate principle amount",
        "label": "Debt Instrument, Covenant, Debt Service Coverage Ratio, Minimum",
        "documentation": "Debt Instrument, Covenant, Debt Service Coverage Ratio, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtInstrumentDebtDefaultInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtInstrumentDebtDefaultInterestRateStatedPercentage",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt default stated percentage",
        "label": "Debt Instrument, Debt Default, Interest Rate, Stated Percentage",
        "documentation": "Debt Instrument, Debt Default, Interest Rate, Stated Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtInstrumentEarlyRepaymentPenaltyPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtInstrumentEarlyRepaymentPenaltyPercent",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early repayment penalty",
        "label": "Debt instrument, Early Repayment Penalty, Percent",
        "documentation": "Debt instrument, Early Repayment Penalty, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtInstrumentExitFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtInstrumentExitFeePercentage",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exit fee percentage",
        "label": "Debt Instrument, Exit Fee Percentage",
        "documentation": "Debt Instrument, Exit Fee Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r216",
      "r315",
      "r431",
      "r432"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, fee amount",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r54",
      "r233",
      "r315"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance discount",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtInstrumentInterestRatePeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtInstrumentInterestRatePeriodOneMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Interest Rate, Period One",
        "label": "Debt Instrument Interest Rate, Period One [Member]",
        "documentation": "Debt Instrument Interest Rate, Period One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r143",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r315",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r537"
     ]
    },
    "vrna_DebtInstrumentPartialPrepaymentDenominationMultiple": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtInstrumentPartialPrepaymentDenominationMultiple",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denomination multiple",
        "label": "Debt Instrument, Partial Prepayment, Denomination Multiple",
        "documentation": "Debt Instrument, Partial Prepayment, Denomination Multiple"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtPrepaymentPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtPrepaymentPeriodAxis",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Prepayment Period [Axis]",
        "label": "Debt Prepayment Period [Axis]",
        "documentation": "Debt Prepayment Period"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtPrepaymentPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtPrepaymentPeriodDomain",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Prepayment Period [Domain]",
        "label": "Debt Prepayment Period [Domain]",
        "documentation": "Debt Prepayment Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtPrepaymentPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtPrepaymentPeriodFourMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Prepayment Period Four",
        "label": "Debt Prepayment Period Four [Member]",
        "documentation": "Debt Prepayment Period Four"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtPrepaymentPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtPrepaymentPeriodOneMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Prepayment Period One",
        "label": "Debt Prepayment Period One [Member]",
        "documentation": "Debt Prepayment Period One"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_DebtPrepaymentPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "DebtPrepaymentPeriodTwoMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Prepayment Period Two",
        "label": "Debt Prepayment Period Two [Member]",
        "documentation": "Debt Prepayment Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r174"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://veronapharma.com/role/Sharebasedcompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r246",
      "r274",
      "r275",
      "r277",
      "r438"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit/(loss) per share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r158",
      "r160",
      "r162",
      "r163",
      "r164",
      "r168",
      "r299",
      "r300",
      "r326",
      "r338",
      "r423"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit/(loss) per share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r160",
      "r162",
      "r163",
      "r164",
      "r168",
      "r299",
      "r300",
      "r326",
      "r338",
      "r423"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://veronapharma.com/role/Capitalizationandnetlosspershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalization and net loss per share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r165",
      "r166",
      "r167"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "People related costs",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost related to share options and PRSUs granted but not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ordinary shares per ADS",
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Major Customer [Line Items]",
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r113",
      "r128",
      "r129",
      "r130",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r169",
      "r196",
      "r197",
      "r235",
      "r278",
      "r279",
      "r280",
      "r284",
      "r285",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r318",
      "r341",
      "r342",
      "r343",
      "r352",
      "r404"
     ]
    },
    "vrna_EquityInterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "EquityInterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest receivable",
        "label": "Equity Interest Receivable",
        "documentation": "Equity Interest Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r460",
      "r471",
      "r481",
      "r506"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r457",
      "r468",
      "r478",
      "r503"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign exchange gain",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r401"
     ]
    },
    "vrna_ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange gain/(loss)",
        "label": "Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases",
        "documentation": "Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r464",
      "r475",
      "r485",
      "r510"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r464",
      "r475",
      "r485",
      "r510"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r464",
      "r475",
      "r485",
      "r510"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r464",
      "r475",
      "r485",
      "r510"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r464",
      "r475",
      "r485",
      "r510"
     ]
    },
    "vrna_GainLossFromResearchAndDevelopmentTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "GainLossFromResearchAndDevelopmentTaxCredit",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit",
        "label": "Gain (Loss) From Research And Development Tax Credit",
        "documentation": "Gain (Loss) From Research And Development Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42",
      "r43"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r386"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r200",
      "r325",
      "r428",
      "r439",
      "r545",
      "r546"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r76",
      "r97",
      "r170",
      "r183",
      "r187",
      "r189",
      "r327",
      "r336",
      "r425"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r387"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r387"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r109",
      "r155",
      "r156",
      "r175",
      "r283",
      "r286",
      "r339"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "vrna_IncreaseDecreaseInLicenseAgreementObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "IncreaseDecreaseInLicenseAgreementObligations",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties payable",
        "label": "Increase (Decrease) in License Agreement Obligations",
        "documentation": "Increase (Decrease) in License Agreement Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "documentation": "Increase (Decrease) In Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax incentive receivable",
        "label": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "documentation": "Increase (Decrease) in Tax And Tax Credit Receivables, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r467",
      "r475",
      "r485",
      "r502",
      "r510",
      "r514",
      "r522"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r456",
      "r526"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r456",
      "r526"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r456",
      "r526"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r100",
      "r131",
      "r173",
      "r313",
      "r388",
      "r449",
      "r569"
     ]
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Long-Term Debt",
        "documentation": "Aggregate amount of interest paid or due on all long-term debt."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r111",
      "r112"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r137",
      "r138"
     ]
    },
    "vrna_InterestRatePeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "InterestRatePeriodAxis",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Period [Axis]",
        "label": "Interest Rate Period [Axis]",
        "documentation": "Interest Rate Period"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_InterestRatePeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "InterestRatePeriodDomain",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Period [Domain]",
        "label": "Interest Rate Period [Domain]",
        "documentation": "Interest Rate Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest receivable",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r417",
      "r439"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r83"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r140",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r289",
      "r290",
      "r291",
      "r301",
      "r362",
      "r424",
      "r451",
      "r549",
      "r555",
      "r556"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r96",
      "r334",
      "r439",
      "r538",
      "r544",
      "r554"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r116",
      "r140",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r289",
      "r290",
      "r291",
      "r301",
      "r439",
      "r549",
      "r555",
      "r556"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r59",
      "r60",
      "r61",
      "r64",
      "r140",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r289",
      "r290",
      "r291",
      "r301",
      "r549",
      "r555",
      "r556"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_LigandUKDevelopmentLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "LigandUKDevelopmentLimitedMember",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ligand UK Development Limited",
        "label": "Ligand UK Development Limited [Member]",
        "documentation": "Ligand UK Development Limited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r537"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal outstanding",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r95",
      "r223",
      "r232",
      "r431",
      "r432",
      "r564"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://veronapharma.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r41"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r436",
      "r552",
      "r565",
      "r566"
     ]
    },
    "vrna_MarkHahnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "MarkHahnMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mark Hahn [Member]",
        "documentation": "Mark Hahn"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r241",
      "r323",
      "r340",
      "r354",
      "r355",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r415",
      "r427",
      "r435",
      "r437",
      "r440",
      "r551",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r436",
      "r552",
      "r565",
      "r566"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r87",
      "r98",
      "r114",
      "r126",
      "r127",
      "r130",
      "r140",
      "r147",
      "r149",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r161",
      "r170",
      "r183",
      "r187",
      "r189",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r300",
      "r301",
      "r337",
      "r384",
      "r402",
      "r403",
      "r425",
      "r449",
      "r549"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently adopted accounting standards and recent accounting standards not yet adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r464",
      "r475",
      "r485",
      "r502",
      "r510"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense)/income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "vrna_NuanceShanghaiPharmaCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "NuanceShanghaiPharmaCoLtdMember",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nuance (Shanghai) Pharma Co Ltd",
        "label": "Nuance (Shanghai) Pharma Co Ltd [Member]",
        "documentation": "Nuance (Shanghai) Pharma Co Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "vrna_NumberOfWhollyOwnedSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of wholly owned subsidiaries",
        "label": "Number of Wholly Owned Subsidiaries",
        "documentation": "Number of Wholly Owned Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_OaktreeFundAdministrationLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "OaktreeFundAdministrationLLCMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oaktree Fund Administration, LLC",
        "label": "Oaktree Fund Administration, LLC [Member]",
        "documentation": "Oaktree Fund Administration, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r183",
      "r187",
      "r189",
      "r425"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "vrna_OrganizationAndBusinessDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "OrganizationAndBusinessDescriptionTextBlock",
     "presentation": [
      "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and description of business operations",
        "label": "Organization And Business Description [Text Block]",
        "documentation": "Organization And Business Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r439"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income/(expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r439"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r462",
      "r473",
      "r483",
      "r508"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r465",
      "r476",
      "r486",
      "r511"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r465",
      "r476",
      "r486",
      "r511"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment cost",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "terseLabel": "Lender and third-party fees",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of withholding taxes from share-based awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of furniture and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "vrna_PerformanceRestrictedStockUnitsPRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "PerformanceRestrictedStockUnitsPRSUsMember",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance restricted stock units (PRSUs)",
        "label": "Performance Restricted Stock Units (PRSUs) [Member]",
        "documentation": "Performance Restricted Stock Units (PRSUs)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r198",
      "r199",
      "r418"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Term Loans",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r349"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds from Issuance of Long-Term Debt and Capital Securities, Net",
        "documentation": "Amount of cash inflow from long-term debt, finance lease obligation, and mandatorily redeemable capital security."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "issuance discount",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "vrna_ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Revenue Interest Purchase And Sale Agreement (\"RIPSA\u201d)",
        "label": "Proceeds From Revenue Interest Purchase And Sale Agreement (\"RIPSA\u201d)",
        "documentation": "Proceeds From Revenue Interest Purchase And Sale Agreement (\"RIPSA\u201d)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of share options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r328",
      "r335",
      "r439"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r240",
      "r241",
      "r269",
      "r270",
      "r271",
      "r322",
      "r323",
      "r340",
      "r354",
      "r355",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r415",
      "r427",
      "r435",
      "r437",
      "r440",
      "r443",
      "r547",
      "r551",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r240",
      "r241",
      "r269",
      "r270",
      "r271",
      "r322",
      "r323",
      "r340",
      "r354",
      "r355",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r415",
      "r427",
      "r435",
      "r437",
      "r440",
      "r443",
      "r547",
      "r551",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r457",
      "r468",
      "r478",
      "r503"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of 2023 Term Loans",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r350"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails",
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r219",
      "r234",
      "r319",
      "r420",
      "r421"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r282",
      "r563"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "vrna_ResearchAndDevelopmentExpenseNetOfAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "ResearchAndDevelopmentExpenseNetOfAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research And Development Expense, Net Of Adjustments",
        "documentation": "Research And Development Expense, Net Of Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r458",
      "r469",
      "r479",
      "r504"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r459",
      "r470",
      "r480",
      "r505"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r466",
      "r477",
      "r487",
      "r512"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r92",
      "r333",
      "r344",
      "r346",
      "r351",
      "r365",
      "r439"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r196",
      "r197",
      "r278",
      "r279",
      "r280",
      "r284",
      "r285",
      "r292",
      "r294",
      "r295",
      "r297",
      "r298",
      "r341",
      "r343",
      "r352",
      "r570"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales, net",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r140",
      "r171",
      "r172",
      "r182",
      "r185",
      "r186",
      "r190",
      "r191",
      "r192",
      "r195",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r301",
      "r327",
      "r549"
     ]
    },
    "vrna_RevenuesPurchaseAndSaleAgreementAdditionalFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementAdditionalFunding",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional funding",
        "label": "Revenues, Purchase and Sale Agreement, Additional Funding",
        "documentation": "Revenues, Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_RevenuesPurchaseAndSaleAgreementMultiple": {
     "xbrltype": "pureItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementMultiple",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple",
        "label": "Revenues, Purchase and Sale Agreement, Multiple",
        "documentation": "Revenues, Purchase and Sale Agreement, Multiple"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo": {
     "xbrltype": "pureItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple after year one, before year two",
        "label": "Revenues, Purchase and Sale Agreement, Multiple After Year One, Before Year Two",
        "documentation": "Revenues, Purchase and Sale Agreement, Multiple After Year One, Before Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree": {
     "xbrltype": "pureItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple after year three",
        "label": "Revenues, Purchase and Sale Agreement, Multiple After Year Three",
        "documentation": "Revenues, Purchase and Sale Agreement, Multiple After Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree": {
     "xbrltype": "pureItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple after year two, before year three",
        "label": "Revenues, Purchase and Sale Agreement, Multiple After Year Two, Before Year Three",
        "documentation": "Revenues, Purchase and Sale Agreement, Multiple After Year Two, Before Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne": {
     "xbrltype": "pureItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple before year one",
        "label": "Revenues, Purchase and Sale Agreement, Multiple Before Year One",
        "documentation": "Revenues, Purchase and Sale Agreement, Multiple Before Year One"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_RevenuesPurchaseAndSaleAgreementPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementPurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Revenues, Purchase and Sale Agreement, Purchase Price",
        "documentation": "Revenues, Purchase and Sale Agreement, Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of global net sales",
        "label": "Revenues, Purchase and Sale Agreement, Purchaser Percentage, Global Net Sales",
        "documentation": "Revenues, Purchase and Sale Agreement, Purchaser Percentage, Global Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "vrna_RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensees",
        "label": "Revenues, Purchase and Sale Agreement, Purchaser Percentage, Licensees",
        "documentation": "Revenues, Purchase and Sale Agreement, Purchaser Percentage, Licensees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r528"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://veronapharma.com/role/EquityInterestDetails",
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computation of Basic and Diluted Earning Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of Share Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Current",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r46"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "vrna_SecuritesPurchasedNoncurrentRevenueInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "SecuritesPurchasedNoncurrentRevenueInterest",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue interest purchase security agreement",
        "label": "Securites Purchased, Noncurrent Revenue Interest",
        "documentation": "Securites Purchased, Noncurrent Revenue Interest"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r191",
      "r426"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://veronapharma.com/role/OrganizationConsolidationandPresentationofFinancialStatementsDetails_1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expense",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance",
        "periodEndLabel": "Outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RSU Activity",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance outstanding",
        "periodEndLabel": "Ending balance outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "vrna_SpecialtyPharmaciesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "SpecialtyPharmaciesMember",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesSegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specialty Pharmacies",
        "label": "Specialty Pharmacies [Member]",
        "documentation": "Specialty Pharmacies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27",
      "r113",
      "r128",
      "r129",
      "r130",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r169",
      "r196",
      "r197",
      "r235",
      "r278",
      "r279",
      "r280",
      "r284",
      "r285",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r318",
      "r341",
      "r342",
      "r343",
      "r352",
      "r404"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r169",
      "r324",
      "r348",
      "r353",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r404",
      "r444"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r169",
      "r324",
      "r348",
      "r353",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r404",
      "r444"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r461",
      "r472",
      "r482",
      "r507"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r66",
      "r92",
      "r349",
      "r404",
      "r412"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r66",
      "r92",
      "r255"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r66",
      "r92",
      "r352",
      "r404",
      "r412",
      "r450"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share units vested",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r92"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options exercised",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27",
      "r92"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r90",
      "r366",
      "r382",
      "r405",
      "r406",
      "r439",
      "r451",
      "r538",
      "r544",
      "r554",
      "r570"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://veronapharma.com/role/Subsequentevents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information [Abstract]",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "vrna_TaxCreditAndIncomeTaxesReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veronapharma.com/20240930",
     "localname": "TaxCreditAndIncomeTaxesReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax incentive receivable",
        "label": "Tax Credit And Income Taxes Receivable, Current",
        "documentation": "Tax Credit And Income Taxes Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares held in treasury",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Ordinary shares held in treasury",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r44",
      "r45"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://veronapharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r103",
      "r105",
      "r106",
      "r107"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://veronapharma.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://veronapharma.com/role/CapitalizationandnetlosspershareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481639/420-10-35-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001657312-24-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001657312-24-000031-xbrl.zip
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MUGAQ]*H?O1S;QH4-M%,2Z#15>/1VNF;<2.\16%C%N23+,8DPB'-E,R(GL@(
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M<'P\E5L_O5B!0BB JRD\!C+4;GO*5WZMT7R&'XZ<^A^L_ ]02P,$%     @
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M!8"5*U4X@X@IS>-E%;*YRN<$2=<2[O)Y=\<_/&J7Z8P>$2HSTTWNKR[7F*3
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MIRJ?>?U57HLW<0?V#> _4$L#!!0    ( .1%9%EZ<X3BV@0  %L4   2
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M;XY'[_KQ%8=#P=?2\+:XT2OAB'I1&J(*%_01EZB7I2&J<'$E<8EZ52KS2KB
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M@[GZ'=:7\AT!7"\VW<?]I/^H#&!Y^HX+E"2NBY3R68CF^9^1@\8YK%./)A?
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MUW,>QF7,+<L&4JMTM#-MT?#,]<3$1V@I:&=5<KKD]*4LULB9T^O;<?J6P_B
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M3HQ6TRH=7:W7\LLBD1Q6--8DAZWEL-I"-Z_]<9B>=XZEY+"BL28Y;#V'+53
MV1^'&96.:9JJUEXT%B6/21XK$X]E8K&]GYBMF96.@4F+#?&C',=1#'%#F-S2
M<-/MZ),H+;/ALLG*/Y(\DCR2/)(\DCR2/)(\6SNW"\>%5CBW8*?=>)8_I-_
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M_Y0*J-Y'S!H03'?R^TH_8B!3(D9YD27Z9^2,<"=.1A"+.OIP3\:\I^F3W[6
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M6#IX\508\X0#M%M ;3*<ULBE;V"+>#9WY@"&EA\W]T+<E00Q_(GGH!9<Q]K
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M68+"H"LXXI 99Z;-*5>C#B:@]-&E?^,E&2GD$,'*B8B[O43"FX]!$6!+&CF
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M.6ZQMS9\H&IRUCI,VBNC")6E/>4RHUYKG3UZ^&U(OENU$3 TFXUF.6YQL(Y
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M(;HVXE2W!^[:>-A&G2?=V^\#2#VKW6"Z*__WDQ,XW)]7]XT#U6&2QK'BLO"
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M44AE<3Q 8@,%J!4E8DKB)2#M\$:Q__>E'X9_DN*M'VU8L),XG(.@=V)4"Y9
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M#*,XXY(H<Q)2+$BH(<,G7@_6!S '$BQ@-# %?X436!\^V!;9SJVK+<_&/T:
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M_B"!6R[I(<=*EJ%!>S5%]HX[3<'T\7/9/V%5(E"6ZT)6$L[5SCN>IEXB$WM
M3$TMA[+;S@0ILGS'G/VJTG20B, L"60 3*<R ^\.B0-K%RJ#!O,#T!JLY?"3
M,D\F K0+8] @X6X QG^*1)E@+DC7R!NG//0[F$8..W%3M$543JBD0,JV4U0C
M,XL-\J!:H@POX#0I)F]P45^6VG$]$W-\*5#0I](CUYQ-$)L.^=Q;T(HR4@&S
M)'8TS0S^H$U)E/+*IT39->&8TDTKLN5>UYCZE)B:81OF@"IEOI# N5+/*YIM
MQ'\LU!>+I0Y@=+&Q!3;4>M-/YE=5YT]BPA4A]+HE:I1Z4I12AJ)TQ00D[J=I
M1/=6L!>)4U0:"#FC@-1!T'0F6/C %L+U>XO"C$N5O!9@5!7QH;[^X[E^G:*]
MB,2EOOLX23'PS,GC9%R$\A:SM.?L/FOZ/JX+CH7XDSRN7DP)82:3KM &#$V_
MOKBGO[BJ@@5.WP]T9GR%C49Q %F=,$W14D/7O"\2463IJR_Y^:6\#<X\Y:TF
MU <A5'*..I@O+'XNN!*:1&FB*A30=^IC\E?*?!:#?\NL_*?FLT]Z??"99HHV
M6.@>5=UZ$SMSCN$767$)7J]1I6=D@5OQ,D[$7-:ZB"A&7Y!O1C'UARB2I6\^
MQ\1-\ZD8'.5WB"F6;_ ["HM(\Y#JY(RZ1,P[H1@ZI\:K,"TE"M:X]Y2X9X3^
M4:"[(%V75"4 'V%K&L&"WHOC5$B/K13\:'0YX_ V%R,O5_U84X>Z!$@=WI9Z
MP$\5++958$"^0M<L&XK'9.8 ]PINQ%FDIGP)K$_.TAK96:RTD".!U=N6'\+6
MILZ$*U0+/1*ZU@]\YB,\$^O@-%Q*ND"0_P(O;C3SO7_(Y??%^3/!GEWOL5KQ
MR@4=P>/D*(P+?/QXC7&^MX "=Y@[H^[0]U29K"1;+I8P?HVQA!LX \<69"D3
ME43&DD]1#0BYZC$33N[B6A:09DU18!.-KPU:Y<OU)^LCF'#6=ZK"!/!_5>+*
M^O@5\RR3I:HBMEY@+DG6R*@(JX]8UZ&KMEXVK"O05?TPID*U.\%%H9A?&X@$
M^> $,ZUE'*0QS,.1RK4(RM,P'^V0^:,Q%^@ 1&ZPC!84WE\ZW5ZCJ:,IE#9G
MY/UD!6%SP3Y?!4'#;PL_%G$2!C*<(LOZ,0V&*L!TN2$FYZH\XJ&!8:N/V!\V
M^ODCZAKMD,MV!*X.VKJ#":!&V9R)A+;RWR)J9"6Z"ZP*TAG,G,5A)M(87C^]
M*6(R^(I?6HC&&FZ<0FQL@RNQJ1R9-!S@*'"V-)I0K@'''#&Y7=4"YXCHVX>O
MWZ\RC/@FIIQL]1FT)JMO70(=C!/5*.6I.\$4ZZ5-B9\O@"]<B\Z_IN.> _<T
M4KG)QEQ?F;TJ<FGG5!X*NG#IKZP\UWT$5A>>;X0VYXF+@']C5(GCFWTGP)(V
MJ209A?;R',P9Z4.X=2Z\S\KLLW1K$+7"B1-9J^'*#)P^U1;#3] RH+"-XDW;
M[IV3)U&90\;.A$P2'X/OG Y+905[<"B6$JJU')*J9"D_)&F_R[:U>K\VGIW8
M4PC@1=\22 (98]"/2\;? *JNY-1.M/)>.\8FLHY3>'<HG55 @TE\X2Q5U0#Z
M.G*5Q=DJ84[NKZD+>'Y^C^&9^SV.NV?==548CVN7'Z32];'/5ZR-D-EF9R ,
M?ZC<].I"D_W+1QZW[N,,;N(/A!/J;68^-.SR$A_5("35-BM2,:LT6D8)%'ZN
MN^V!L&CG.[6:I0@Y%_NJBIFX4.!A/V9=#-?DN9S@@NXB@4T!N+PBJRC\4%@N
M7LX7<.>L2_R5.JI-DX\FH7X786(\P\XEQ1,RJE)Z&'D?] F-\W&]@[X!@&M%
MT0XNGRM[VZ%,9]6Y\Y4[5%/X'(IR?F0%6RJ>3S?H"KP3UK95_GX^@0BP-51%
MH^3@=EWB:EQ2 B@)ZEN^HKAAO4-W Z>EBB!"!X'+?/(G=;F"NQLVF\K\QN8]
M:&/!%A+F7?E'6W8_]S!&MSQ*1B1:\Z@76%8K1)2=HJ.=-7%,@9<GILX7+F5T
M4B.1!%MV8*?%"2G"53FSA(<4.@6=]DX(V37&*/?RX]"H?/!#T-JC2W(C*>]:
M4#A0US@.K]T=\MIE3'L:K?"[=(P@KP)YO9AA-;U,AZ,D-[#SL<\UK!Y3I3WA
M$A'1V/&1NK'=='*'52%9=@CV3E@4&>(]B*MV0M_?"?TA5[J80]/^Z#^XSYW$
M5.W'ROI@J,I5X@ZV)3SNF,-I94332 ^7#I<N $8XETY5T<)OACOH2AN+Z$_,
M;PF0D_@#=HHL;4M5N$^PY &[]U$[@RQ1_</U]ZRZ%UVR8!>#$>U1!;K:,>ZE
M1LEC0<EVX?Y[O0.@)%WQ6C1K]=:@&:#1@Z'/OAV*JKP)WARTRVCRMXM;, DN
MT>_1''6:_WO3:OQK<7.!+6C_=O%]$@&+!C6+:_\O6\U+$'.M8;O5EH_E_2+=
M5G?Q\W7^&'!GQ5%"M!W^6CH!!OWAXB=-9ZD]+J/:XW(,'I>WAL?E2F?3GX:J
MOVLW/3-K]]<MR@FK<\A/ S9K(?&^.CF>Q07FN:I6ZLC($53 UVWU#^3\J 0;
MWZE/9;\#:A>:QIEGIK*+C9UYAK@0! M.="(]^NAE^RGJURM^>K&LTW",^KT5
M:?Y2\.7Z[LB>T2M+ 63=*9V'6K<K0RGO*<BF#7 XL&HO;NY%^@=9KC#V:)2+
MFT8C;UT&5K@?5M:3B*Q.-+,V=:D2U!@VMFX]Q_KZ]IUJJ44=0LX >65C#;-)
MQ"HT,&HN*BI[$: 55<:$ZQNK?LOM!0C>+B ;J %L[F9-- @1J>21)U;(]M>R
MDZ=NGP*;3;R%+ZQ_I6!2ZF:G>4\IF?<?MB]^=W3I>[G8^E008D=._WECW>YI
M''O](;'$A/OLJ=YJY/8L.R?^S=DOF'@'3)2[N@.+P63-"37E7Z1).C=+]KAE
MN?@KQ8?-5H' :%3S:D)\ZG4F'8N:)+!UN8@XIFRX&=D19?2EEGR*DUEZS:8-
M .-.;W')EQ6$AGBBCM(<V&6WL.Y/AQDC2*:6ES0 [Y>Q-_$PMBS;<;-<*CCJ
M*!Z< (L,T8EC6\IDMH$>)Q@VGWE! +!CAU@:W0!]GX,S]#<E?G.5=$:P)<<M
MPS'VU&>97M5;)6-21<=\WAE/0%2^=0K@<]<V5Z*A;?8Y+[>HDI+9*,"F@6Y2
MZ%',0[-I9.)$)5OP2\HC((^=LZ)5"/4NI^X"AV@MP/LZB^AFKL71&=#%!VS<
MV&Y5Y$4&1BI71;LH*@W4O0=IO'"\?:>G4D\GF]\ANVIGRJ/.<[%DVH=BH;^T
M!B.=K+: ;5A1N'1\-.B( K+^AFV[L'7MUYGXH'[3-SH+[IJ @,C]%EN,O6,O
MO]2O@-'&UH?/;TU=AFNQN8R2?-Q,4-P43@5Z54G=GAU72%V"!WR*ZE(+K,*1
MRAI0R^PP4P3]3. XHJ5U&_J8=2QHF(#UB8IZ,8^&(;B(/%_.D,V_C=7^S"Q0
M296P!D)HX=U26$>=OL!:9.2$1.8!0,'F%74K5WEG63_7:]FA3$>+)9/% !4M
M.W-<72OE8F*B$3IF:XY* *+<L!M\0>\\^)G.$7 FE(%.MZ(FTYP!?_N2C92B
M1FKQ)/+&%*KRPSN;4YK5*%8+#TWWS5WH8Y63*[$HFW>R#FC&2Z1>5_QY80:&
MF\UXWF:R\XEH8RNMF&H\_"8SBX$WAS>!=R:^)S"$;T3 20DJ=UJS%DJ7-C.(
MD/W(_.I8 0*5J[N9P#QV2L:.,7%:#AC)IQ^I_/&*?K^<?POJ/<!+D D09X-*
M:)X:=RA2L7TPGBCC.<@-E9))'EXLIXA)XS]_ AZR4TCUS<_$4?.C;L!6C>'.
M+C%)WG'QIN14JVRJBHOY'I3RK6:%Y9<FA8-31(5*ML^^;B"5H7.)*')ASN12
MF>(&!2]"WV-HQ4)P9GK;NK1^<^204^Q$"/O+4E'C=$Z)/QB>,K-XRDO>+[-]
MWSSV4^<4U33U]Q5H<QJ'77NTKR6R02X0X=7+]&LE9;BRA)\#-6TB%-%(7(D-
M>03HB21'2=>JB6ZFTJK,+3)X^:7P4T>F&S9(>('Z+0<QKEA(OA66&=,K2?F?
MX=PPC-+&MB;+2(!^'Y@YZPXF>W-^..EF-) ,72IRUBVWV))L2G=24KS,1K-
M>C5<H]=(A+Q&,[Q<*PN3]1H,1;&N'"3&IM? H>GQ,0UBQSZY8:0&[_@.8(%^
M3K$6V5Q*306#I^)83I"*.9%-]\^0+$.%G G"+[RI\5IDNW!4^D8>0AWO)<>X
MU1"VK(!L[0J.+.HR9FXZV9(*&AD645MDL@SS5P_F%$WL008)A.GA\F&:8!%'
M;#!R@/)8[DO2 .M'>/+()4FC0P=:TT9#@3J3ST)Z^$>X\"96O]DGS 4X@REA
MS$-3@1P%"84WJ2SB19::DF<O/T11>=?DA#89G#%&U-6U RJ2W6Z>>23[F,6#
MG(]H5/$!JTNQ;QSG+&8LD%U_3.!&]5K#PG%"P'%M.8-.,[M(3'T]8!$+^W+B
MPV BY,0TZ1\8@NXE1\(#-)_$I_P<@W?*"<E3E>(NLZNY",A?4AFFXO(GHK:L
M#[]K\ '3#R?LFM'2:Y7FRYS2P<2:U'<BFE\84R=1Q;3UL]8-@"^0[%*5&L [
M<73(#4M2ZNPWF="-<EZF'*8;R@''4]F3-%(,$ITW&)7#G0/>W(8>C7>5 ^5N
M,&\U8&=,9-:BT94O[6R HGPM.^HH8 )/T7 8B_C!:AFL)CQ*3-$'DKZA>(V*
M@<(D6!K@4ZYOMGY,,"-D0&4)HT6H3#,Y'4_.3DDQ==@HS 45"YNC BZ$IS^*
MN]H _Z!*>F5I)&?6DTMUN56][VE 96/&/!=DRA'0-#M,UQL:Y3W:U\R&:::,
MY\=RYWMQ2N>V?#!"1X](C'G>.6\HHYQ4];)-2,+@ F.K=&D8(47\A5VF9F-H
MR6[U/4J=BC+1\W8%(WFQKG;,>_!<5 P]/:(SEI6VZN=,M.3\S>2%&F4M<4G[
M\5EYGCNN](D4G 89["0GD!>BIF"H=7BNYGR1)L;Y5*#/B2(2+JQ)(HQE5P2"
MJMQ1-LBZ.$&;F66VK (SPY;G6:4(M0H0(V>AO6&/6!U)DV"A\E_C2.0T48"A
M/;+'6O:0P1LA.X+M!-T13/LILWE0AHB0R+-B;Q8I[P!T+8S'Z.G@P+4Q@U@G
M-RE'2VGZ>X:=5 .A!B=C13]M>HX'D6@N#R.?P2XDI/NK<?42J]0(Z#D:'88-
M@A]S4!0 [TR2+2Y9F4-RM'(.J21#9S*0MDHFK@N;4W0@CX.V\57.[Z/; </E
MN$+^[9&5#5(MSAOM? KE<,9ZENQ 3'>RJD*6;^<1\$QB#SG70N74[M,0*CMZ
ML')N'AN1XC2.N=[5K:SW7 .2O#C4\[&UZLAS[C:/-QF+&Y[VK-WB14_O'\I9
M5I C2'+($K2 R[7WG@J\ 4.S7:E>&IM>Y]G"!R\7.+$^QOPC@W]DUAF^]-25
MR&HDN YC@C:!_C1.N+G]20GS)N8I#8NFC-=5@P@KD1S]K.:BVHW+Z_)7C&H\
M_1:=4^S)TD:*^2:5GI3K.&]CFAN>CG$1<'XF'-<4BO1R.?4K4W%=;G?_$52C
MP#U/Q/VVJJ4YT>YI'/D>!V2?CD9 1S80R+H7*C3+6)GI8N)/42EE#\.*5QD#
M#(J-Q1O6UQ7O4J$%+ UW(B&1$U,VX/>L4S(_SO>KAGVL>IXU7!]_PU-T60EA
MA;%X*(_W6IK19A!-?JI#[FELUNA[4IP8JJ4!%5M-.2LUX :8*!N0!S3@\A4-
M@HM=ONZ$4A-=K5=GD#$27SFF>:EEL.(I%)Y8<8?:T.14GQ5A3"-XF5/G5%88
MO'8F?58XM4:Q1FD<J"D\H&!C>Q_9GW M_JH$'=H*.4;E$F= NMG4G[74Q8 P
MQY)0@R2RO=GW9LB*0C,]H]W_5O4%:MQREN?)4X<>(!WTF&_F;:J#<0"DE"*7
M*R_(SAO-&=YZ 8;T.5\[4,T(N>GL$@.NN1XA\)!.A5!Q+EY3YIV?!EAW%,_?
M@=62 L/9-+[L2I'KB7DNDGKKL^XFM,VD]562T<[ZXA4CYE4*;6;1&)JO.?.J
M<K6L"1\U*L[W*,[U3H["*8ZWXWFD9*AY09Q&VBMBO+5P5'.\#6VPW/GO1 AE
M2\E@6J=*#E2.JG(SEK717%$782@1F?1@.P4$ >:>Y =HE7 B=SL@U6,N0LBV
MIY+&<6$,POO"O=%!(!F/9W_LE,HS\DZ$3+^PB_SUL"ST^87[6W6X_XC$X!>9
MWX3)-;^^D)SLY1DPLNJ#<09H1('NL1&$Y.<L-4L='J4:5E@0^^YQ3,2:ZZHL
MM!!7MZQ%4];Y*<S4*UMW9_V]\=^-U1HW_,X"MNJB(91K=OR?SGSQ^JWQ_9G-
M2N48.\_%U+6+ *GO<^R?@F#"9H/IW'J'5[:(/-8!UH QPAJXJ>H5*;MX&>"E
M!#K'G\CAJ:PY /O'?%R6%-2U;KID&WF=\2H;_*JT/)42YTDLD<D.=![#+PQ"
M*E5%G;2G+#6ST, ;*XZ,/%XTO:C?G-&T2/H!L2M[+MF?&HEG39,5%A9?*!>@
M,H+"B[RXT$PY]]I=RE9.BS/^<'Z>2[\*6?)O),QGB2J)/&:I8EBCK"J]5V4'
MKAH+7!A,;.FYQ%0"@^R31DE@C)]74F^E)"_G)^.^9+W,,65"/.,6:E/7VAMT
M;7J#ON>\05_RWJ#KG#?H(WJ#(B%79CH!-B"#HUIMRR+VI&]F%D7F830@= 9(
M03<B;Q)UVC&'O3&9&*[NSJ$D!1PI'7C4SHII/YQ.8]2<;QPPG!+E#$(D0H['
MLYLQ_[5<FY$FGAY @]5.&*56LS^32/9JD*D"G-' L7F 3/9>"L,KMF3,*,'Y
M!YW7YI &JM]T C93$%. G_6X\1N=O+#E)VBW]?Q4__9JU1^WZ[E_N_"FSF Z
M&#BBV9D(6,8==80[GDR%.^V[HVF_];^C[L59V0O'G5#QK2J%(IO96E8XRM6%
M1.2H69P!TT3NE T32'C^RRR\X^*WE3&*_>!EO2") \P3/HE?WF/$>R7\Y.X5
M6P$],+K$,3S.(A:OU!^O72]>^,[RE1<0-.A'^_3NHU$P3&E)!/_OJC?+KQOP
MU:_ESWNC1G?0K_RJV6CM^'F_N=LO5FVJU6JT.Z-Z4]MMJMM9N]2OA Z,$H!U
MB.)_N^A<9)R=FGN^:EJM12+7V?6Q4>FQ]N(G/OBZ)!J+B,PX?&AN,]S$>]O,
M;-9S"\T/$O?0T'N$2\D>D[R'A-\BL4C+MQ"ZKT_JNI!W;W$EFT_[;,#5.1P&
MGPE0KLG3F /+!E+,>A9?RCU.)D),I^O.C8V2'^?4F]6JYH;TU36$M.GD)LIL
M^LUV^-.T3@&:OQ2!=Z##FX>F[DQ'=>J>W6]W>0[BPYP?O]H)#JN958VY->9F
MIZ8N/NW7->[6N'MRN'N47'=GE6E*_W>D*E-)4R3 ?RFE'[W:2V<J''V3FEW_
M?LO?'TAM9];7.1IDK.8"U44Z!U+=]>_;NT&O4FP<(0?M=O;CGT<@W\_\:NZE
MF-77<[:4\]CZQ2ZAGMPP+"TWY)RPT5-,"6NN*Q8KA$H/K;FL0_R*2SD1Q&\U
M[5ZOO2/N5^/@@[&EYWL[;7O4&]:7<YR7,[![HUWMU0-=SB$M@FZ%]"@P^J,"
M^Q852+79L!-$.SV[->K7JNEQWDZK8W=ZM5UWI+?3;MG#YV([/(5O\@>/8"]Y
M*!_,0;F%KG*/4,/Q(7"W;[='K?W4F*</&-4W6B$P^G:G5=_H&=UH>V2/ALUC
MN]'SRB;:%!K#\I:GM"O."J%?=)MVOS]X>3QQWOHV[W&;+''JVSR/VVQWP>#L
M']%M/@<[I[K'0)V'<4R_?U9Y&"M;,F:-#VHWZVYVF=UO[1IIJ_UXCR7U.LW1
MSB*OOI:'IYE1>U=7QN-X5U4Q:Q &8O5=GM=3!U+$3D, ?L@W='I*A_,)$F[7
M'O3V]%B=F*?Q!"^G8W=&]>4<Z>6T[$[_B2[G61DXQ>E4M36SF\(\LH?#=JTR
M']_%=)N[NV+K:WD$>ND.'_]BGI7*_K[89A5;R_WZ D-W)<#76L@&+:0[Z-4J
MXG%>SHN6W6SM('OKBWFT?/WN<'#2NON1\/>UR8 4*M,QLE_9/_,@K5Z><1#8
M;G9[1Q0#KB_S7H&G_JY51/6%'O&%ONC8@U;GB*CS.61H4//O,?<B-QN-UYGH
M!W-<M &M=U=KGYY'U;=99:-T[7YW!R95W^8QWV9[:#?[.V1(//AM/K-8A9(W
M=;1B3_SM-6NG^/%=2[=;W\KQW4J[N7OZ=VU";#8A/HMD_SJB-6K)EE)8=OH!
M86>Y88H3&T@2/\_.F8<$S9&3,]A5H_[>=M6]0/-$>GI-$#5!;#!-ASM4']8$
M41/$61,$6/?MP0[AGB<F"-(5?Z7Y4<<^ HQ6W'Y2Z)KI%4=]S/7SD_74=CWN
M]?W;*\M9+*+P%@.Z <^6;?>-J64XXVPAH8$#:K.)ZO[2<FX=SZ>98_#;J_0&
MCF?)'S>L,@QI:%JV"USNEUY#=KQ24QYW&JS6L$[C7G9$O^KFRT=]PNW/P_?>
M;/3N<>_6W<R;S##^XZ<N+)DA%>PUG3J3)(VP6\0$7HQ37B=I%.%$:!PDF4-Z
M&[Z\%4$21DL+YSC/A./*7R'VTX8OQPY.JXW"I>/3U%@W%3BA]*-W \\@HGNX
M]] *QXGC!?A>G+"*XY8C<8/#J'%U368Y(K"M.Z%\B>K%/# 4AQ&&BO000"%.
MOA:7OI,&='2U;8"FFB4N%U)C;1=P6Z&KCW\B(VYWI)65!;($S-,X\CT."/@#
M6/]+JWDO/FHC7U\X$8_>_:73:.Z_6,?60WJ!;A!M?QD4-H<S@;TX>P8YPB+R
MX 8 ?(J\8!'XX5"/_]5/XQ!V !.J)%82>;+U)*<CE>'C((@R%F"06#:-/;D+
MK:\S7+L-MYNZ2.3,80BZ3,V).97=BUP<)A\A/X$3$D\J+ H0'7N!HV@79U=/
M85O EWBN_(V_G(2+912%^#/Z*!#CU ?4</-/PUL7L Y-(;WSDIGU^?K];^_X
M9+[/<^Z!H8XJ0;40X<(7EVIS='Z>R;P@OB69Q"X0]>-0L5Y6$.3D;;SJ=J.M
MMP'_Y@IU8ZY] 4@XH]LWYM/C^'KXR_<TW!QY,QWKW>=_7'V^?H<\\29RYE:<
M+A:^)Z+SY&M;]%<]&Q:W]5DEM^OT&NW#<;M6I]$]*+MKMQK#C?S.C>!4@<'V
MQDLDXU%CL#49$YB XDP>:<4S.)A46?"8P$F(EFR>M [[8\X&3QDO-\@2QQY/
M/>%+[<=*!-":Y(:P;V!]&2/T45U*%XJ:I6X"[] *3L.Z B,3-X 6@RW9,3\(
MZQB*$.SD3T%Z3\9\,FM#[Q 8C7?KH1YF2R9$JE+D )NR-<A<!">(CYZEK^ /
MP9QK!ELNWEBKT=<P-$"!D^1%'-/F:5?UY'<]Z[,P^]O\[UD,<3]F?@DR$F>X
M(^)/!1,"L*PYR\Q$3&8!;.1F:7 ))B>4F&&DY+C4LUA7"6"U%,DF]7PW3$F8
M(R<P*#",P-[Q_DUO.4^96]W]Z32.NL?!,J?,#H8W,'!E9K*^5S 53-$J\S.9
MPP[N)V,M64N&BW4*BQ7E*T@G/)G:YRKSPGS>*Y0ATWM&12=%04S. ,2P2Q ]
M$3 Z4)7'B35V?-!E69\W7X#/B^E43$B;T:\#[4;([=,VP:1@WUHXG<9P!M0*
M@M)"T>:N4!+JH_P!"A)?>AF(!:!]!"M(>V#FW.*7\H1@ZOB O>12V=Y0 *7!
M%]*#B*;&$O9L."6J[ ?\UR9]7QH-!5-!61JN%T_2&#4 9QP"I/-64KMXHR9D
MI\6Z1=Y77((5**4BN(&_R-DCM[U S[SE8*TCW"M^XH:^#R<F91;OHKOZU5Z^
MRXE"T@HDFSCQ3"'9:B[\_/21[FI]!+?KN7^[\*;.8#H8.*+9F0A8QAUUA#N>
M3(4[[;NC:;_UOZ/!Q5DI,:UV?GWZ]Q-(I5(>CO)L@183DZK!#7Y!K]&"(4#7
MQR9QA+25&SM_NC(:73)3X!CA'7$:"JO$L_ N)BX0)R HYN0".@"XK!=DP(4I
M;-B-C?Z6AP&?W+QB*A1_G" S7,3BE?KCM6IKY04$#/K1Z_P+>XM2^)%>R%]G
M--9H,IW)Q#7Y9OEU [[ZM?QY;]3H#OJ57S4;K1T_[S=W^\6J3;5:C79G5&]J
MNTUU.VN7VI#+N&5CTK6/C4J/521?L&!\G%2#X2;.2]+R\WIFL45BY+[ >X0[
M,7)SMDU]..[;0M:]3:[JQM,^&W!U#H?!9P*4:[)H<F YKU8%U2E5:Q)Y#E2Q
ML^DWSS-I;[?#'W=:7L_NMW<=,'D*=?LUYIX[YMYKVGF-NT=RB\\3=X^2ZSZ'
MZK@OI2&/]?B38_K]LZJXK\Z$KHOMM^*@3S40M[Z:!U7,ZNLY6\HY9)O@;@5K
MIW][@2N"Y-6H'%LYRDE7=<?@W89*].U!<U?%>0T:'7%KIQ.\G5;';H[JVSG2
MVVEW['[K#(9^G!KKWR+_O];]=^,SS:[=[^_:.;Y6,!]+2/?LSO")!NK5M[/I
M=OHCNSW<T_=X)!; D3AUUO:/+_D9ZQ:^A^+^W98]VGG([4Z0. $%]*RNM#O<
M?Q),?:/'>*.CCMWM[#FEY(@B7$>=%+0IPK5W%\AZ'$)5/[=.'Q2GX1$-1*BO
M\S[]*DGDU+=Y'K<Y'-C#>EC)8TN:RKK;.I_BF'[_K/(I5C:3R@J':T_KCD/<
MF]TG\A75E[/I<@:[!G/JFWFL4)L]&IRVB_4T&#Z-2PNQIP$:O*D7SXC=AU/J
M5E'G5NPZ\*_?VWV6UHEYV4[P8O;+IZNOY[SIYEEI]A_R'61J+7ZWB%G+;N\[
MG+=6%A\\5&)W^Z/Z<H[S<EKV8/1$E_.L-/D/A0YUM>Z^:W3*;K=W'ZY2:X</
M?S-VM[/# ,KZ8A[M8I"WMVJ]_2&!_+[8=!(;2-;:^XXJ2+O.ICW6R^GW:R?\
ML5Y-^XFHYCG$_F66,V4 Z-#_K^R=V;\359U)6:E MH=[CTVLTV*/ZC*']F#G
MNJ7Z0H_X0E^TFG:SUSPB\GP..<X4]QT+;&FO>LHGSL^G[:%R9FC=&=B]P3%E
M5-;7>9\0Y<@>M';@4O5M'O-MC@;VL'],M/G,0A5*X-3!BCTGP=O-U@Z%-+5+
M_+$NIM<>U-=R?-?2LKNG&Z@X$EY>;4A\%LF#E$EN*8KE(!B0>)8;ICA6AL1Q
MW=_WOJ Y=H(&?;RW"TD?$#9/I*W7%%%3Q!J*Z#;M=F<'Y:,FB)H@SIH@1B.[
MT]LA;^B)"8*4Q5]IRMVQSRFD%;<?F[QFR,Y1'W/]R&0UF1X'S0KO5KC6^[=7
MEK-81.$M!G8#Z[_20%CMOC%;D6?=,C1PG&\V/=M?6LZMX_DT&1%^>Y7>P/$L
M^>.&588A37;,=H'+_=)K]*NG*&\S_?$\9W;G.L1;IW'$'0Y$U]XL3BW>Y=IM
MG,,\F:F)R[&!4[#7=.I,DC3"9C@\M!D>PTG0KD6S;G,XCW/F;T60A-'2"H'/
MS83C\J]LPG[:\>78P>'+4;AT_,03>LS\1^\&GD%$QU'0.-MXG#@>#5"&_^+0
M:R"TF]1W:'E-9CDB@*,(Y5&4;\[-9I:DAQ " "XB<>D[:4!G5_L&<'[[3V>^
M>/U63_JF4:C"&$Q-YS]/:EE9_T_ /(TCW^. @#^ ]K]T^JNFT6]'4.:,^U]:
MG49K[\5PLKTQ"1QGMK<[!29?G&Y?/<X>-M)JC*RJX>([C&QW8D4.A7GP=R+C
M# ;A,0SP^>0NE)/;VW#GJ8NDSXR'8,XTCL_+]?]*G0@93&$9 .W8"QQ%PT"@
MWA2V$2$H<>,W_G(2+I91%.+/Z*- C%,?4,3-/PWO6< Z-#+YSDMFUN?K][^]
ML^DMSF02I2C$>73[+_U&1T-.LQ[X0,1)&(@\"[-QBGS+ +05SP 9)-]#U(!M
M\ %\(!*!=Q2!_A!8XR6]#0?7WP2>.N+7;]]_5[RHL#8BTD*$"U]<*C#):X)C
M_](RGC2@:+"]*OZ.:V9JB16GBX6_1!03^^+,- KG4O-!UKX4.//>C\-,XN"7
M'I ,Z#=A4'Q4(AA PH%C@%B)^6+@?#U]/OBW). ,I;0@D!A%JS&=O065C<FL
M1636+J)9)&BNO5P:/YD[":(C80K^FW&Y8[W[_(^KS]?O4+;<1,Z< >:)Z#SE
MPQ:=N,]&5&Q]5BDU6LWN?<1&7FIT>HWN(:5&?]3H;)0:D@]EP@,X4G&AUB@G
M18 NHC\%*5@9#S#XAZ(KH&WOUD.%SUZMA$OP#]IP/XLP)A;XBA6X6Y%-<\=)
M[L:O)"HULY\X8Z+>U3\IC>)]?!3C4<2]/"S,_\XBM9N%<P/B Z[@STM2NE\Y
M_IVSC-%I8!(6T) )P%5GWY\ W_S?<82.BO*.3Y*^6?R0:1 Y(+2*,D *24!Z
MP\!PK,D,I3;30J_1S(2Q%\5LGQN:P<)9DB0L: C$20J$U<LK#2!/IB*.X5^2
M\TS"($Y]HK2I0#+R F )<]8D$C&9!0"WFZ6A 3 QHD *(R6,Y498E0I@M10.
M/$X]WPU3,BO#-$>_800[]OY-;VE85ZY+%(;^"C*V9D[Y(*VA 14\2:6&@ER3
M7@QOQ3>O?JV57=0\Y0O![4\]X4N;$HX/DI>6]'W\W]*6FHUAE2YT.,U,NW=,
M)0D/A4;P)$PS'*C>>^FZXL293L]3B?BR1<W#49]WW]/MI@^@1%;8Q?IN7H+G
M% :9PXO/#1O#>VD.EBPTE(33JE(;Y".5IF8%I3B4(J"4^W*O*204?+OU0T1S
MZV/HT*]^Z13UJ14D[N'?^>IWWGVK" J#]HDXX=[@\,#](Y"QU/+*&CN^$TR8
MH(O$+*93,2'%3[\/%$$A@4+0 *N5W;GA=!K#E1=4*+E0M+G/HH1 ,W^ #-JF
M8ZO"()\YM_BE/"%8TSZ0!)EYVUMN8$R!-*NVQZ3QYN:,M^E6IA&POX!40Y!
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M=E!'YA'QXU;C')H!_R%O7JO\$5X>F2K8<05>%'L("?S/ D%K7FD@1[<(*=G
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MF<R;B=$P6R<2P:YWHH\;K0HN;K0JWUQZBY_CI2T^HT2#W_=P_;8E!=5/)8N
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M1=1265!1(C>M*"L,AI_"9&:+$'%1^&*<I_CF0+-!/*;!FZ*K%DE"/(\L)@,
MZ*OW;_BO^[>OWMRAPZ#NII7720F]GXO%SV!FFH*BL3*.B7!:T7VI:[2B:!)
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M\?__GQX- IV0W$#5T2^V]O.KLEUN:W0@M8O+J[KO%F\E:?"A;#_]-R+NCG(
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MXA]4PHG ?AWF +6I9F3&IZZ- XZA8*\+<1GBP8Y-J+ABO61U+0-Z(5F>=F4
M-E8%(O0@SI$YND8\ ^IX->[WUP7PQ[D+X&RZ11JU)@S9B4G15T48BW43N(:<
MY#//X[/)*U\LWH^ORX10G76-\26&#X1;CVP6MY&!@&3"=H'T!S2T1;N'JJ1X
M@ D&8&KIL,(S5J5V])C2K[BC=O0&P5T.S9R<OZ$+A?;(=5@./+CD7&,367VK
MD].D+U>_!+VCL0JJUJ)VA(LV#[M1MLF\;=^!]@0,W26F[UZA?W.MG2F*'\1N
M7Y7UGBGEED5O0'UE9@^TP,P<Y\/,MNBN\N4GP<[(5*"QD=+!<10#?F(*+Y,A
M=L>DHU]%C(?F\<0^.@?P&,,@'?K+KE1\ANQ\&;LA37(^*E.:C"/P+8?:$>/=
MOTG!I$>:-+'N:,:Y@)DQ(]OH>1*S<B5K%(<'>N?N280!TE)ZBT[<N\=9NP'L
M1GR5QQI8IJIMRO<-L'%_C=]T9Y7$I.,NK.%4^SC!,SK71SG9//'E_19&!S,E
M8S[Y9UNFB> DD\N#SF2BN]@6PFA.1RO@Z;^@YG60:4"")Z_7V@S,Z_O%24]!
ML#67,)TQ&%OPX99.3V_UH2GS"#Q;U<+J9CP0D45 DVN?*C+ M]>%\!]@N,:$
M4E6NA4W)D]R$Q*)2FD:6#%CO#?.S%16%K]LXTEX_+Q,8G*"C-K:\+E;]5@@Q
MC#X&S;S#V\.:7A4Q%F[[%OP!&A:C=5ZRL9F-$B2;8D,)R2O) \TW)W2##Z+/
MP\H>7^:0W;< "@'>B%HM\";.#8%G'@OE:  <@4I@>MHWA8D26"8^EWC:S2&3
MG%)PBLD1R9>HU_Q75(ZB&$G>;\J;6D@%Z9]=4XM .94F8V7@7AK%A ["#;PK
M W&>B_/GQ6($-0L;&,FJ0DXK^@>!B[@>ZN2%*#P6#&@T?$K;3QT\HU86G74C
MN#I6*GG"53P+PV,1AH22U%PNV.U<1&+>R0>YDPT3SR9'V=/7,>V.E(5U'@?2
M("\_O)M*@2Z0J6T'0P"D,JHNBJ<<"0G6JMC49AZ,MN6&AY,D8T)R9NR-CEUX
M"'?O6<@>B,?!C-6T0YRB+XI.>6)MQ"T<7,>5"OIUYJ(( B)NLM)%PZ,P.GF8
M$/X%20,'HB@;AGP^R0S3HBICO7Q?:TX[*P'3G[:'MG1^3(1$S +T(+64VANP
M591=KZF%IK@IZ5&N:I*=,.'[S8>_1.)\E)P[TC^MSE/N,+ @Y S @]'*\+QZ
M3WH,ZJ<3(FXHDUD4'J0H4,S2]"4*;:78J!!*,Z,J^$O*O3(=S*['0]A)MWF<
MO X;9MD.VR=IZ^SZ1C@/Z'1VST 5R'/0-:WPK-_/VWG>'IN0RX3'A;),F4<$
M;Z@3=S4])$,TFGJ_%S"(3K((FZU:&7_<D'N)>1:MI4YQZIN\G]MM'H0:5F9J
M2^QC'RNZZ93_/V_8 _'!F8^6A\A(;4Q(@A:KNB>S^8S<;Z[F9<(Q[O%/O-,@
MH5NR@1UC0/ALS_M\UGWN*ZFHH\H LEVI$@L]E )X8E_,[,R>=[-0-'$T>TE^
MW0^"H/#T/VK&ALB'YVT[<U]B"W)PKG8'Z(%.NI"YLE967MR4+O4A+0P#[,^\
MEP_'+CK-Z MB_\3P)R/A'YK!"9 8HI2>V=WG(M:#VFQL'4;K\7ET^O3HX5RL
M<QDN<U5@](U+@3/J*6]62A!0<L)0(5+XA0*HY@T_\X:7S>J9C""U=K3E-B]W
M2GX+?T@*'.K?CB5@ EC"M.>!3;.L?NFKI;6;=62VI;D\3$\SQ.4L"X^CU?C9
M^7N-([$^[2F(KL#>C)^?V: _;8(_TI1\W3<-"F2G&Y1G@7P W&=T55,>/#DU
MA-K&6R9RX&B\M''4&JG\9$RTW0)GO:NKXN!G@[B>5)/6#WW;EGEF$\>&2D[2
M> Q(%##<G<S0O[^NC?_\_75MS ?_7S_XT4WLZFW1V $FDT''E=L@>H;1]^UD
M8Z',: \12":P.L9V)L#.D%(7T/-DC^*Z9)N4"R OU,F,2>"J8-/R6103Q@95
MS@=64@L><#';DH?"CWJ$^E]F^"RMM6?3EROI[IUW[JP[1W&EM5P@RR!5:O0&
M,^2_KB)!<2B08O]NR$22Z1-BFCG-\*"VU"K;V@OO@] P/,T@3[5KUM6)V\=F
M=["]F()-@?Q_,&.Z5ZID;0G?H4&A<3WA,_75V:4DL-L=/,UKI"L$L EK1TMI
M+11M?T7!Z3ZT(['A5I*@KI&/U10:8OBB05W<[!Y6#IZ41F8R1U#=$^D0DBDI
M1<5K632A10@@@T'5DD=U:5M,VA6#, PSFC4:>_/A+R'[Z_!FO$VRH-*(I1FB
MX#LI;@&-,GJE5X I?A"0VLN /Z-[\Q]^$M_P;8 Q+O["0+;8ZF4H";T<.L(<
M!?94F][%XB>.^5SC'A.R<+RI\: N0ZO-&+8.^%%[0W/7F3J>\N6Q6(;5F& *
M*!E'7#>K2,9Z0MW5OJO)"LQ\5\$<"^)@XC;I6.6(0OB"17.)(>W*X_4*. <G
M2I@NF9%K#*:I%E12ZN!KV=7WT((X2V@>D(^)2^:Y)G(2G:I8EYUDI"06R+DZ
M&+^CMF74"3NXU(I6%/\(#;W,B,&/EWFBXIA>8 3EQG<\^M8+1ZW.!+G2+AQN
M8P/010C0SE-,;,]34#-O::]KGD:]IU,*KXVIDL#1L='0:BC KH>.;HJ5).7#
M%28>9D R4K8Z4!9MRB1\N>(7>V7^XI9 Y'GP7^$W6A9"0KW#X97SRE:$[+T<
M$"%+Q1G'3<LEU,'//!L^F)RR6?8[%#2613)CUK>N-@6W;;7@#PD#7-,A@PH&
MNNML'6(3^,F/R9S66@=/RUQIQWGG[QTXW'IQCO,CF[*XIB5? CI8K'CRH^1H
M\4)QB';CQO4&7KF4WL"T#MIVO^AU\-<":F+QSQY/5:MFH:MO&E>(8BB[]>:M
M%AJ>'P??L&ZS]+)KXYS2P%U;;->VQ;\4]1X8^_\J5GB/TD:,Q<':N7H)^*=B
MI#-!9/YBP'O51<*YP\I*'C2,8+B?6#P!K2!]]Y/=R0H,8$XSM2#5,.LZ:EE>
M*SE1;.N6"=_R99N^/BA998'2Z/3%]5-'K@+7R/<(#X -UO?#3M$Q=B,5,AD5
M*BW4@XQUZ#^U;^LP\%:ZFRLP&MK$>NECOEA$U8O'GV*,F]2[?!W2"FA/+C05
MUO)T=Y1V5_5M-4DA%QH#C"4-OXS'9OA"H;_-7JC-MY9RL7?5=[17)/?,T76,
M.B;Y]=S$\AQX9WU^TOI=:3'D5:,L'+BO9\&Z$I4CW>OP(\&N7%2\?$(A&;!A
MXLK>%CK3'2.1/I,"YH8L'BMW;T8RF5*+IT:YHFPF%^J.BPPFM^_B]'#S0,4N
M\#1O%OMMD<-<95YM!<FE;9%FMF9P$J=,-*^U8QW4*ZN,5'J@CA ,\LH.7^<I
M*+B7PY4"49KPJDB8,^7A8\FFIMS97I)IR!:O?UXTO1V5X; U[<>*]F_:9S<R
MHFVQ80_!9S\'3FW,?XI>8B*VV(8(_=*RO(OY(HV1N,BYLCCS=SDV_"H8MV%O
M4?NU&? =&*-TO&X((&4LP=A2*P^O+>S@+(Q$=K01ZOCQU.CV.,)%?E. X'$5
MZ'@[>MMZ-6!0WR/7! )>:ZI:_O7M>^NJDL"B))'+FT"YF\1S;EA\W(J+Q0_"
MA8(Q#.Q[-CAL="Q/-I-RFJ-J>UTXF7PI#I DO$*[P'28)).]P2MEJBZTNK:Z
MT9IS*4,[ ORPT!"8A2]NZ9U%[M=;G@*CU%7\54W..2PGTZ&N"BG65!,5F5S^
M,"DJ^!NOBPNRIUYO8MSD7U^^3[:#O+U:]7O'.G'T($H*PO<SWK% 4^+J1$?B
MG"Q\R:<#V&/&+_$\$4,%5Z0))EXI13R)%4<\JLN+S\6R#VZXWBPF(@3<SBF)
MGI[5MXS&T,831IM/L#*'0#M#S?8BUT*">\<!E "E&:C"F,[SM-FDZQ)J:0X)
M5?D(99(Q!.DC1+Y6GH01>+(E<K''1RC$!D[?P_$M'4NRV&,4U48;8[F'HZZ>
MZ3.&L5.0 ZX\WH)/,V^U*JC/>V3(O:U1&AG?7M>\4GT%&IUJ$#CR KV]%+4<
M^[J=L*SIU_FFJIGFM*6W+ZHP"$2/S9*N_Q3L;2)RNDAAN.%(HQXQAZ'PI_DV
M=MSY9$[X/<J_QS8QRD\T?HDAU=-45+F8J!^8\D52"2/BL"U=LUWF>\T;*"76
M6'7I"4%N@SO\"R:@7DF<37^(!-[RE0_A@8)E>OGQ0VSW59\6QV95[_5@7NX;
MTDXOOGG^!W4X]H6<XLE;O*(#PQP'&;WN,M\EL3C=]W^1H00UP;?/,[KFBQ>D
MY=FZW'6YQ0RF"6":/_W^P#0/1LV$3!]9W8*L.QS#@=_E<CKNF%W&8R:D9F3&
MU%EB\D<4F@JN&O",BE@MF<A,@<.XE3D$<K5:8P>)<Z%[PF0GA9[$[)HP."!1
MPKX5/CSTPT4AD6I ODV\7EA22'W#4>@JB?%Y.(0N3&OEMUW9MJ$ @,3\MDA6
M9LWDT10U/I/#E/!>XM8<O;>+=D_J4^/V';B;P]7<3:;78/3.(RZ#J97/.(#5
MW'RXV:I8EGPKN,_^X_+ 9,]I-79""D8KL]+*@ZSC):=3KY!W18:GKG@)U4-(
M/++%+W6))X^7NT* O4UNV1H RE)%3A;3;X[%:FC8PH3@Q-EQ9H?IL&\C^>7!
M/Z\N*(>C%XO7P[L%^QM6KY35[R'->@.6%]ED- ')'CI)(ZN A'H.[KY*^X:P
MI&6KB02L0L(/>4A24["\O"=F&"%<6H""5'?7Y!8] QFXH$*E;F4#0SY&QY^>
M54ZD(9?9ZQLU\08V0W4%(DX5-V;VOX2L7#GVZ>WEZGF5G!-8XZ@JOBJ_1L9>
M  Y#6ZJ!Z=V6F;[^54E7LF+ Z$)XL\$OOS663*>6;-L@W>(OK-4M]6^@Q^"D
M=2?!RT-Q35:LS<N5^P1%!^2&#![JNXO%Y9J5!Q+RDM+%:1GNR%>>8)$)4F6I
MFP!#_]IVC7G?77Y#H^8;EM\VGND/%ZA)I\,R=8^3H\3%\9#0]0@7K3+)U6GC
M'.)80@@M/><:NSJA9N7_-'A*WS!/]=+F\H!D?\MG$:<-=#)Z^'2@DVP3'=U/
MK)[Q JRBO*\=-N/USW* ^8O.OUY3S%I@#J:@ +>1<VWH8T-U-21^*RDK%I]+
M&2U PKPM-F5KWG3>1IX^*8+5<M=M?IL%^O 6<]57D%_WY:^?PBZ^BTKD^1]%
MB61QS]XBU@SS4?[&'LE21Y%("MY/%=HPDZ%Y3F__]L&Y3MN<Y..Z$&N.^]-C
MD2A8%5CT#?846VQ@(-D(MUWK,7^R!3\YK0J;I1;$*3N\Z3@G9K3"8*/EP*:L
M*OJ%Q)Y%=<TJ893V@'&ADX^W"U_<<(FUX:P )^?(TK'?5@)V('.NZUW=!=(7
M^9V,RM.!0S*T9@1M]#,F>(2G+0"JX(IG,$NUW))2!*HN[W1U5_*W52&5+:MP
MI(8P+.YH8DPX8"R<>B3!94)W;W!G8\Q=?/7ZYZ]%G?X<K%?@OL,/[P,52K5X
M@\-:K?[C[S4G?<(OL@D5;1?69Q67QC2Z[U]EMNL=%^TY260)&/&?=R*[4M82
M8667J_]<DNXG>9WZ  _6I"T9/B>9J^@+A>X56L"_QJP!2)-9%<F6W*'BX'^P
M/.:\'WD774T7PZO]C>/5*L76+&JK^K2=$.ES2H[Q6-/Y!MEO\.TWEKP:#'-[
M"OI,RM-<ZN :8N/&#.6K?"];%%%!P3",<*A,^E+O/>G+\#,AZQ3SZ2/M-'
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M.^F*1N?/:":2%NF*B4,[EZ>5@G+%3\KQ7UPS'BG :R;F<N(SDBN&END&0,
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MATU[,/I[;-\C,MEHZRT)%-L92O&$:^,MK1>7.TRY6N4[56XXL#J/;[V.*C0
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MG;$RKA"[8-V*K+\EI;N2N3GXU;:VJ012ZV82.GQ+\]LQ_9Z8-H-<ZM%:AE]
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M:!6*:R;>'$HBQX*7@1;B&G8T/63CO_%4<B_U7)'O&8?^EW\NQGFN2//-9,?
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M'ZJ27-HUOWFK:S[X:E>D.43>1,511*X_J6&-8Y50UTNH>=:D_\LBJ\&N?VC
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M>5Y&E8K#^>(]:9 P#%4MKOT5YZ?0( ,&;'>+'VFJ:B68@$T)<\Q* @K_PR7
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M@R9#L'YNNDRJU]D*>0.DY!(TX9@H/YF8^=>4'.'$&!X45L:ZW%6">AS=86(
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M?XD7CB*(L-;1L#ESHO)Q:@\!9V:5M[P;),J>!E=B<5OVZ1C+<TCN<Q\UYJB
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M4=$TH1SB#'>\KJ*Q^4<CG_$9Z.N:&@0.3@AD=#<[X]1RC5] HKZQ"3'&!#E
M$_;9ZJJ4/.2,-N_T 9=1D<\IN\IA[\_NZ-QS1TY3C2S2]#JM>]%\L:!F\EB?
M<!=VQ!! [;82390NY#C$&9D8.M@C3G]Q<Z7%3F9X,1%*); ?R\VY(X;=^;6/
MB[U!H@ETUOTVRKK%N_VJN9RH6F;C?L]II9=U76).+HWVX=A+RP_6_\SCWGL9
M/@%'*Y5G>/" %[&^Y@VNAW#)VO89\<RG4TR^[YOU:>*^0G]J@FDC-MX->B&6
MU].W<V\FG@@^*Y0[**0HC(#U^^2T70H:G2C+RVV(WI*7W%=$+UIV-3>O[<*^
M+!MNI \+Y+J^K*W=(Z^U?-R6($M'\X6/:PVX,'KZ^,#!%E6$_+B/R:,>0!GY
MIEULVC!VG8TBISF= 3R&:V"ER385,"HLGV^M>YN].CW25A'FI9 3UI6.P(D4
M[/ ^T9>(W8:\9567/N=D5D$GMT[<FF*"9BVB?&: IH\+AO\'^(P^FI^(D\62
M9H^WENN@=*55"KKWT/@L6UA:6CSA5T,%YC.9R^,XF!10Z NTL;8E]FC<5:9M
M3;0Q.IABZBF_LI"O[<!4EF %%8C;)*F1>T":VEOQ95M#'J\4'\P@A^B3452K
M$^;]S,Z*7C&6OO?]LZ1RL$6]!U?>"<:K^]B^3/IEXL^5L+ 3R]<M;IT!.5[X
MKKIGY/+P %]\'>%Q2Q6'<!S"ND_I)"%_7T:PRD$ &BWQ.>6YKW?HL,/\J9;O
MNAJ1/5RWMQ6@-,F"(-M@.UWW8-EU2)@G+;\M3^*V[:)?+5_0P_NZVL0M^\4T
M4(&[W,()3;K;'!I!=?L9?0P72#;Z^>(=J@.-R:!QJ;4;-AS8LO;P!NGP+-M_
M1)=AQI9935!!L$:V(NWVA4V#BH#O6]>E'I$Z1]>=*/K%MGY: E>TP]/J5RS*
MC#!(,5Y(#VJ/G-<MB-UMN\QVX5W(H6-H%E_.-0ORZ]%#3\!\.[H"^,&"3=B$
MF&23U/ZU"I[$C-XRQP2"'<?W#6FE)(E9*:,0.8E:A V!3<=[VC8QF<*YPQ:&
M1#Z6GB8^P@P_?C-T0'DE-[9;$HQQ4UVQ#E(T^LG-! S&R=%MVX#4X7SQ74?>
M@% N32SEZ#:4#=^E6ODX<EM5ECGN*RC+4DEU/XP(@+BAU!*4X?8?Z$M-F((-
MVJ,O;TAVL)%.]*9MSBJ@.UD[*GG09N+-^K"L4D(]?>(R8HFH@$YSO21Z'*"8
M60@MQ1:ZRBO]&;;3PC-/2&T-EYBJMS%[])[8RR@ 7KP!4 4FXZ=W;]^_*8S6
M+VSGNM]4)3<!A3'3M@6CFM)GXOQ7L(T 6D;)'5[Z]N:*,-5)9+<P&R>]^GC1
M]>DQ'>(C&AIKR6H3',WBWP-UXP*CV:92;S,@!(\[-X@,OZABIV(G4I7EX 0;
M5W5&5W(+RH^)H4*;5]PG:B\D,.)C,ANX;-PF-DX1 R!0E(?W"3/7[^7LY4I
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M-3C+UI5X7Q)GA*&1]O2F#&%#,%&Y@%'D?X3913'KQ9>+0U6J/AE1?9BX")8
MK04T+?1<.W2*(YSE&;$ZJZHQ"\>8?T8Y&I:4HY44EPAWV"'W]^++%U_&1*9D
MG-/+X_"4-DI\X_?/:=6\^/*KYXD,B)-'$$(-ZS52JY:@37Q#(JS;N/7?J/*.
M<49$=%!"UL&M$.(W %[+C:"LY] ONI+/.4Q">*FOY*6^.E_\4PJJ[C7R-R@@
M<,0ED'4BZ!$;9ITQ"/:TI$H1"')Z77EC"=>I_=S%UDD*:=/*%^Y^7?8VIZ(B
MR;O>.R\A1&OB;J\C=Z5W[;=$_:@#&W/BZC*X/Y\OOH,SA9*L$8V!GL(XQE3,
MR(5N8;JJB+<('@XE:9DF%%WWQ 8:_C=EM72,=%@5S^QSR("1RDRK+E]'>G[=
M'F<I[87\2\J':FTV*Q!9Q'*:X)A%R]MJ"DKL&*Z];C=U:V>^-!Q1DD'T@PPN
M%<_9*:G"O&70?'L])2@KC1PQI1KEL'X*AOE-I-YUNIY]9K9D(5?A@6LU(FK#
M93)P/MJV=6?PJVZX6KP%U.ZEVP TH4+9BKKZC\#^L?V^6&))/__SG[XJIJ2=
M9H[U(CG7_7$N@(]O?F(K/N<6,%5Y/#NR=Z**PPX41K1AY2#A39\1&FMFB\"E
MNJ'*GO=[TSL70\_]Y(X;ZIN,Y*KX=I[=IM?Y]M7%Q#Z6>LCYXF]*C.Z<XN!9
M(Z-8-NZ]Z@2\18_74R4DMIE[(F%?7H<1ML:_O>H,]PGMX(9KHHSV _<31093
M:3#UY*8'OTO<,$/1N]?H)^_%CRGBOC*J%@,1^M"()(:<+X*M:+FW6=!H%F:M
M4KLT!9?4+!Y6 9L,84^33R9&IFV#E9^P?: 7&*0O8MSW[V0E&&.Z*K11^& (
MD,V3T'/^3L[!%5D31TK708F;$]HIM8KU*I&#<!E\CM49@DM<82Y$6.ZI/8DR
M%7;RCNX(O3=T.%U<7M*F YB'WA.F[L*I87UQ\<.KBV<1R40[%@GFZD-<&FQ"
M]'84?9H/BWNK<F&YH8;;@Z*7>3EA=8?)#I/#276%.]'_3>VQ=_Q ?FPVE.5P
MW@+=3FSE&_+2JL5?V_8#&TWW"WRO3XEAZJ8);T-U"5S%%229CV7I*,SP"5]4
M-?!OVU=I7JT,AT177G7E[GKQ^I_I6W&UE*'Y;NXSJNRV&XG.>]+ +_IG.@Q3
M;_Z:/ZNS(WNPX<'NCSZ>GQJLSV" J<3L?$@F"C&#'A;+XHNIA?1,/QFED9W.
M-*U$^BJ6V?$G8@<),4T5E@E]F]DXJ(LJ>301CS.F#\C/:KJ+5X1$1UBI1V:)
M]N<^6-0K",E%>OKP+\R%;029%[P++<G??ZDJDK?H&.2GXP[%R XT G 7RGS"
M,8*G6/<='^CVT'N.YY=MLAX[PBK3,:V+0K) N-3KB:MZW>5B2=T-Z-=@HJWL
M)EC^]M;A^:]O2TY(G8K25I3^XZDH_6B'+3J,F547/E>]M7WNU[!!#XGE\1#A
MNWPRG2^@>NAA37P2M*;,="3V5A#=WF\P$],;Y6AS'Y8.V(T2-*QCX&**MR-3
MC\2L?C^"+@UUY0,C<Q\YG:7GLK(LY2=E>(C/Q 5[."RS:O[5DDNR.5A >%6U
M. E@ 5TF)N<>G(+]L_34LHKR54+=JA_.DNF1@F9%BY0J"'+X#Q;7WDW.2UY'
MRA3X>4S77574F/@D1X'1T)!=&F?S"L:V"7:>3_9BP<[&XJ?SOU.&U@WC6QU&
M%EC18_(N(1:^2L=\Q'0^^HIC],GE"B];::<+B^<]P;T.>,JW+]^SSOC0#_9R
MS)899O/YB['T=/9>YXN_:E$)=WOYWEXX/AGGR/B'.<4HT]QV+=SAXRGE$V/X
M'<U@.<ZQZ=78<G+5T(4<*]0 N6K4AOW!WAC?>FT,C5.%9/.E:ZCQS+S?U ,K
M2Z!>,4_#GB^^E3';J?Z+I!9C&[BSMG1SB"9)$7M<JHJD[\KGQ?40ITVGP?9=
M.QKX@'BWD2*Z.&IP$B,#-?(&; P<FU=65Y9<RJI:XHH1*7/_E2/945!HLB/-
MK*BQAHXCB[HV[*)M-[IF+20;D;[:72#:19(XPI%8[X>HZ2YLS\F"1@971R]=
M$D@PK(=>24=-7MM,B;"#%^*J*S^HP_PF5!3!0Z\_5$JEH#-5+%Z&+5PBJQ[^
M"VN&+(M+0+D%G[#;*W 9%D$^WP,!)7%.UM7#"?4-A9Z2(Q#I>;@VX7&]U,=L
M+L U0.<9H E5R.*.J/081Y:!X_G=:)*'?DQAFQ"G"A-V(4DZ53_N]YN$/F"J
MX?5\<23CPCM % (FDAF4JR^')JRP+*O19[51JCY);B,8MO!>>Q5(4^29UI]:
M;3>FI7(HXIBZ'M[,6MTH#,YP>6.[VWIQG*=PZK_,5J$V.3R4>BTAS\S]KGBF
MX4R*57A7FXESX0A-.?U#O2(^R5-HYQV#;8+!1W.;^> .&F-?HU##H:+L@>[F
M=,8CCYZ2JXI>8U42(,$4]?NNI;/-,EWN<'BO71B1"CV!?,X! ?0HT_\_F!/O
M#@JF,8=/K#6@ FR%,6%+Q#^OJVU2F?QL I?CRL.4!RIOF:9@?+@)CD3Q5,<[
M(!R_+#R'O=:D^ 8=";@:[<.5]<%D]*!2C2J4T,/K5+!R1",*D]4J0??E89&K
MR*:N%Z/CHD=$/V9DZ!@6)$_[0[^OF*_?TL?Q3$;*+=R3F)CM[XY?R7U4AI)3
M:Z@'I:+%=H@Q<BNXC5UUC^Y1OTV]+#<2WK4;%9A[8<#9L[U9Y H$&8\9N]SB
M=$W49L*[)G(SLJ'SCC +M<XI-C+:",]3/BHOU8VI=8S"6L8E2M[5:XO?CSI)
M*$Y!LR!]LLBF[P'H4_P!CWE&A*V .+W5;M@G8U;NF< ]?)PEFTU.DN,6X-:"
M1:$?F[+KVEN'MIOL[(L71)*Y1]N2[PTFWZ+]4"U&2LA:6\@)[1/,I&I/"DMR
MU(K7WB\E^->-J:3'CE>%O$7:UK=EMZI6RD=>>/L:(014?*M*ZCH,,W:^N%@N
M6Y1>B,C<STBV.(Z+^[%"7XR6C !/H>A)&T1*PVN24;'9RM&C'*.4<WRH@K[(
M/&-V]V_Y.HSC]<#4NR(UY@'9<0[//[3 2;VD:=5 K,YX>#49*-5CFT9L:LG:
M*1A AUPBT?0 \"(V-*RW2"-9P7:./^[8O#YD#!@58]'J:&)]ENO>!#1)2\FL
M8'C&8"U<#[.3HM9*)D>K^".?RTZO(^=5H<( T<\+&U6X#[ Z/2C2?V]^U8Y:
MLT>X_<FCL$ASAKY36&=#LXM2\9>%@DRE2_R, %X",7JZ2<9W::8%RY-&80CQ
M7'=P3;%PCSQEC(%FP$AH*'L:08B;D P6TB(F)Z!]4%'N),G,9$D?9*.]#^+B
M;#O*Y,"XHOJ#$ED2E2L;?_=K1S^J6-6^\IZ/JYS&%\)P:%I<#Y'<A5&4QDP&
MVV$UW7YS,..X[>K>D<+SX(V[R.SXS-/Q$43:Q^Q.QFU0W-F1])F!EO\C3(QB
M*L3YU18\$BH(J[-#NU PK*ZS")SE1DPQV0W]F8S?G7&7R*J%M1I)TC4QP+C<
M2 ]_5V=\% -5PKBCWXB[3V&U6F&:[N#+5WJG>$!M657^A=DY8U2$"<1+ME-@
MU9O-P.U2-]5?3G5^J_/_UV^OSK^C0ZNY.MM4ZS ,?YJ\(?^J1F+_+V?TH4?:
MQ)1W>O''K_6=_^<?(1NNK\[_0&/QACVKC)F2$7#4AS&0)HTQ]UG.INR]F-S]
MF(&XW4"N!/)W\@MB*22*'7IHG88IPC3%61WM*-\8G^'JZX\W]*=U].O7T?L4
M*3H6I&.'9DZA:Z03<O=Z.DWXHTYX+C$E-0)'^JA\.<M<#!(%4J/B!2'<'C!(
M@E2@OX<Y^[E:"\[?G#6/*>*%K#BQ(DGK%SL?<YU7)]OR5);: Q<84#Q3*50#
MT(W(+G6YG9;"I^*N.,3&QLKHOL^LW A$ZB;3,"3@Y,"S7B4$!_Y#*EKJ^03N
MB*U.:^-1UP8C(%3@;Q'UM>=;;SGY399"X3UIY_!I1A]W1M,V[OL>U[-MK%H@
M'F4<O%PJ.!;GI%D3FEJR&UG73*\Y&(=B.BVBQSTR\JY"> <JY1!FLBH[:$JM
M9M0C%KZ,'Q$RDJ;T,!C'5P86%24SJVD!;=GG#(:F:[0TP[I"\4XN(DJ2PQH(
M@72@A*R0D,7\*XF<M*)T6G*/' S[Z#>X"#3]$*/*=7&52D#P%B.9W(Q9.?%0
M4L*\698^%?<2?R:2,Y?R,;6;7]/"/2V<1XYT].PR[?)8%DUFWS)IBN'=?"ZU
MC@?6BEY>EXU(9VN+HD#$Y$<4@W?=L"+A"--]FJH!.AR]X(Q$P.E2\U.Z_5R*
MRE<U?$;JJ8G7'M?N%)'@BBD[&9()3,]EW>X@7[&L!F[6- A>D5"+UT3W7=[4
M1MR-_,R,NDF&EC..G3?1>H5#EAVSK$."'G+\4,'F4-F(PD:(&R["H%^[':4/
MO@E3*N(JXMK9+U&6ZM!T4'@SFCS(^,[V:+U Q@OFF($&X_;_;^]+F]M&LFS_
M"J/>](0]0<M:+*\S$Z'VTN7IVL)VO7XQ7R8@$A31(@$. $IF__J7]]PE;X*@
M%K==*K$X$3UE25@2F3=OWO4<?4)13G.!@+?TW#K5&(%LU.&IX0^@[Z9&^Z$V
M#9V\/S%4NHRZRAMISOF8+]H<D-<'3X>#P_V#@Z%8L-QRDQ0YR6Z3 DV'92+5
MC5LAS:6K;>$O)C'$SHV1Q#"?+/19"[,_*) ?82K*+!X-XQ2U=1@.UDD 5@8X
M8<)'@!NFK1Y1S F_.W@E,RF$9:/"=9HP-&TSU18>[?^P*H]+LBO;RPH.2U7W
MA['H6."NIM.5 ]!3@P2)%H4P0#K'XEM[@Q,7NY?Z-<%IZ(N@:CWNQU\^_3RT
M3C'J.*#8"F5\I$MGJ?9*JWL(^2:N ^Q'?K%!27RF\5SUTTR02I-HL+ZM:+$%
M<(&LIOLJ:3>WYA:#A09:XC^RTCK-L5$9X\Q>P?%#:^3M:P&D[V;PR@8(HOKM
M6A^^%+0D(FI9M#/MI^M=2P?C7&Y-N=/)G!H!&J')HYF6WA\[Z_LV(V"N5#^1
MD'%M$GMDNA*YE)11B#>"U_G:9:I:5:Q9 7&(8*J*7[M6(AO;D.C@3[,,?A>(
M<&$-I;@V5@-Z:*@AB[,TRO'S1'Q3->-8-DC@9M4E(6A>,(Q6Q@ 0Y9@8B\,X
M,(8.XUXXC@7W"65<F^ZDL4WR,9E%C-/0I$2^L3[9[5=2)4."+7=*0X1=ZW2X
M,@2!&'[W"/YKMC;6A)51.V%Q37@[ 7=H<YF%9W0&N<-=^PGT)=8(27QAOD_#
M?8DEGDFO2%,OQ01*.1N%.+<8M8)=P12Z6[$)?=UMNH+ MF_#&;502F.W&%BP
M\;+.F\Y<NL)TSYW.RY"F8WRMNTU\A ;N4=H<>./&C(SWW*:UD5XXE!A0N"5H
M"#K"M=;<(3*05D$(&".3WKC8+-VIY'=08*:2R'3C4MD9M(LG$C9&TQ8L9IY?
M4QL(FR#S-4K2#5)(NX#C^V_4<P;TZ#!11$N=]CBM\_^L=90(DD2$Q?WB5Z;Q
M\ZW8)N: SU;.XONX7% EZN U)(\Z;:EC"?9V0S(2&XS)8X)G0J!QX6<&O,L+
MG'C<V6'&V.9.S(@\ZE <4B.#$#7R[#PW"B_EE;#G,6NY?T)L9TZ\#2%8)O%%
MAZP)[TKK70D&2PM_G+><8,]U&"*'C$(2#J33HK0=EK,GLROELU*^YW^\4K[?
MS6ZGC3P")=*X3^JMRKLOKB38MMK"NS=XX]NNR=/CWNUPN+T.]F^-\EALC]3J
M4A4M7I5U17:;(;FNWH<_A )2/=KP!4%)49\$% ?)!Q_)?!TKBPT[&!BVL;VO
MTV-E@:]UKEE';X5,BSROPQ7[D?/TJE([H1<_\V%^WRXI+)2E 4" &U"[NQZS
MXZZ.[8F?=)\DGGBA//3((Y)-$28P&O;MBK5R%B%.+?P*-I[(Z^".[SW@M,Y6
M\.X%N;#9L)3"E@Q_YOKU2.9RX/&I-[?L;,-1_*Z04SCX#L%7([_$@>3\2D&L
M?!Q1;^A@?O#K+Z\?ZC*#+ME,-188E@C:H/^U+//! ?E<AT?BQ=&D$U[(G)U*
M\0PZMIS.=$_,.,8&^_I6M6W&9R=M1,3(KC@^X1N&<",[XMM)3;;9.6_).KJD
M=&=$P4Z<3:#Y@#LD<RB#XH_;FV0V?\E&YTB44T0IGV24_LZ606"R5K!")C3
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M^6$)_,\=C).B8VT'3]A3M2KL34]9?YX0@B63P;8LW&<!48NVK)I @@QB+\;
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MH50PBH52H3=:)N)@+GT[A7'._@UPP$@](]X@92^+AJE6BU+0SE%:2)T+2X'
MT4%PJ3C%,FEH05J50020RHQ2B_K?1'83LEH"8)?^."QC'_-)V -NOFAH43<*
MHXM6F/+HD_5R37Q)_T3D0B^XPK1@ZA:N$@K?%$RU9CV7+N%: ]U,0Y$_I=M5
MR@Y=.=3U(\^N'+=X VRI2OB) BX5PSF#V07@T4K^P$1+E'\9U<4I':@DT8BB
MB-_F5G.B&5_W=+8I"?F 8L9TKH+!A90E"H#FX6TJIIM1AC?6]!J-6PR=.92O
M6/&U 4/G>@BOGK@80K<.B8Z36^TT\K1*AQN'7Y?UYOB; S[O!Q^[ MLY$NC=
MHM/SIJK^X##5]?CY#I1]_YG^H6C.F\$'\C/8QGOO7.%/9K/=CV/MMO;,M?G%
MH53F5#'"F7#Z#(-4H?6G]EF[3C>1A":6#"<L^  #RL(2]Y." 6@0 1FYN$-9
M6P\%.+N8*0T)G3>:*B7W:#3M8B2;68HPGW8Y2 @<#4;CL.HK Y3?C(V!C17W
MBP2B#<<B(L3V!LL=-FPZB$E!I@7I2)D3TM3;8$"]E\X2:K>AT(.D:=:8(BYS
M,TFOE*IO(4_T&ZU9;%JJ9&MR]+1>Y)+QC]&N#>&P4?ARQ#E;@N*6NPBO)'P
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M1O!-96]9TG)H!AU 3RX0>'$(]EY]:\$Q2J0SQ6QEOADKIVRX((W;VX!(7S+
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MT=E#]'(D9-#%T+1\)+AL;-]0_!3J6$8HW>D]+S7R<3_4T5<\&733^21(L\'
MZFYL?\1"H$#P)&($ADC>B0+2+-T@E)_6#MMY=I[SQ1&KBI7*5A G?TJWM3+?
MB%YN&$AR+&![RMK97:F66<03!\Y5!+M5*UKEMD;AW;C(2EW?C4L:'\7CS*W^
M%RDH,!2/"=.)\67"UC5D%8;-SC=H=6Q E2X.@W9&BW)WTI:N@SG-#W8'ZY2#
MB:+#5M\ TH.TEJ1\FAPI_IB0E,^.F)X,H0((Z3 F>TA<1E\WL"P9E'N3:&=I
MFCD1\IZU]@[0H#J=*8P:30X>5RHJ469]WPN*!,MYZ-_E'COL3N30 3.&9[8X
MS/-9LWE<H'=B*"0<IU=I?[?HG25'.O \OT(6G1I!S7JB1ZZ;[?47KFL5\E4!
M.<9,J)8'9#/)C ZK ];#D*7%*.QL9NZ'EOI*!T:*'.OW%?.TE,V$-Z\S^>['
M!%U-::K6B'ZB8BJBMJNJSHUS*6J)#OFM.P60R$#%-&E3FS5^CF1E&*NM[FG<
M *%]V Z$<\_,!>."2PW7@(CA7CNH$.I*:*D394-!6V>,=3X1\(=Q/BN4^$:6
MN ;/6P.P*?DE)@%3);D<IMN1( O/4GW5E''ACS1?"""ESD4QB>#$_A:>!A3/
M7A2-=?57 W0W1AKP<N51!D'NDUWB\.,_1J@[Y+H\\-UI-6;/@?LQZ&H#J.M\
MA*<,$X,ZJFS&W-QT2 D,YX;'J=K:M.5V&JS'\HITOMT,N]1U(,BEYXPQS*T6
MPM!7T=_9/$MN1FL[2(TU?[(ES7=2>U>4EA<:B]"[(#27U<2Y]9; >LQH&+,X
M0]^KUFYZ!MLK- S>A.QI)$'P-'WFP"+EN:^U]'1P$N3^<'__*8<%U&.A0K)9
MSF]K@'<AE5]L&?"H1#H<];-M+&&%:-9$IYNR)A.3I6E-7)J.-UU8B+/8:!M=
M$=&+2*Q<*N4C>RL!_].0[30;R^N8T;-'EL7<RU9BKJD-,$.8G$N,)4[4,'*W
MC+Z'[>4/I'1>2[/61&8T^&NS3>U'1B$TB_0S5Q70_/%*%@YW)0N_]Y/@8T*^
M0]$UV>-$S"(%^+.*T6:J90O0'-('M#WX'-&BB-B_W"UI@^9>*X ;<#-*SU-3
MM=KZ/6<1X4E5.XUK%:G6/:W0Q8VASNKSN>F"*3XDD%PE;-]_7X[/&%4[<I25
MJF&9KCS23LP'PLP1C[1X/[..\=1;CU2B4E8]AQ_>I 3I+I)#;<3W1.M>&U+#
M-VJ-RZ][?]W3M*WDS&=F#+<$WB/3A.F=<"$Q =Y$Y"S7%AMF,:[  XWY$UY*
M?5IHQ0NP_PE5H)0%Z> SSKE!D@C-I7:F919N*KZ>V0N$=XHAB\\*0J@))DK&
M<C)P0C<T6D7 J+=>-"C12_@R)"&8E\Z:#^7T1S(J(:!."90)B<(=2?;VO^YU
M/$7/-8^67[8S*ALC%D1DG=^-8T1XQ8HSS(&".I\BX=+Z][GC4,&7X[:O^E1$
MWT[I3$.R/<0M8T0Q-\]<]\B+),7W85LV0"E2%I1D\2B9%BX'8,5R'G>\^X+.
MYK]4Z %(9J2?EC_;*&D:2)%%#]9(R8(/G\\FG/E?ZB?CXG%^V@Z8K3*,%QYN
M4W&\KD0]1,U->'@'<.?=@(PA9QBYL;G16]8NH0P@S3[/6T)>-\+/#I*_7C-(
MB=2R.(6GP/BZK7);$_"H/#W[*#8I@Y6E!#9RD$&'0S0N!7!"FL](;W K/(5Z
M&V1:::XL/\;[<\[L\7B,%N>A-RU<KX<D7WF&^'LB.)#0(#%A]V.[26B!/U"O
MY*B,/LON-VI4MUV)039\>C7VP9<8_.174DYT61/5@_HZZ_>X:'+Z$81U$21(
M@\X*PNZ3BV&NG2K=AL,FL26P-M%JZ,MUB@VPKL!Z*-)Z;!I"DY#-QJAZS:#,
MB,V27&BD;AFN3AMQ4WT!+(HEM2F3NQA/KC:>F*L;F"?7'&K]M@K+[Y;8'[?T
M^AS=5D+Q73IH)\&U "Z,H 0EK1.^*PL9,>I4ZV^>HAJ^FA'J^%IN&_-M74%<
M&U=IRP"<'<NX4\4//LH*&+X>Y25]=.S(E29>/UA/,Z LKTEI72O,J4!RZ];L
MWA/1N%);O'5(7NDB-QM7F8L<C)PN=A\KS3(@+J'#.S=K>$W;1ABH4R$6'321
MC<%P]02EK(LYV!67M-HD-CL:H5697VHJ+GS?V"$55IT66>N<97TCY83Z1(^2
MY&%E;$_EN6'_R+3%Y&@WDX&40<Y(-*<$O.@@4'N2)!_EAR?[3X9F& :WELUV
M_R2&H3(.6DN 4+VM]+2/\)7P,XIZ/I0TRD4.8")F'5:F'G[:C<7$@42"WY@K
M["PD>9EGYR7P$CE'8OB8S-%#U%T+D4TX0.%M$L+C GRC+7?-J60=SQ7F4G S
M+?V,SML)D'YJ_DVKW?=1(H3ULF$ZM-C(BK2%-3-E_I315M))-9M5EQKC???F
M)!8\NYX&:[T?WG8^.9N)WBBT+3%5SN<T?JDXM!IG/G4@XS=;SP1P@ 35-NCZ
MM8)Y1;B<"CKN(A0;E#-_4=+7F_!FIN%8^,2&[90FAOYIU7S/NDL_99\Q1_?C
MX+EM)%IVM=*D9Y\'->.K+<LN7+Z:G'31B#SI5MJM9T4^P3^#,<I'"0!RK>>:
M;O#1[8KC?DW#6D/D.2*W<?V_H:@!96&)UY$3'!XF,,=XV!K'5/I>"9NP#@HB
MRX6=17!FML&2H,=0['6>"Y8%,X1;$2I-/%Q?4M)+K*O0CPDBAB:".(M$K5L1
M]#"XMC@,77I]:/B5"T)1(9A2"%#XQ[P:<U\]K>Z"H4LC+E\0B&4CR&B3Z['[
MS!Z\$9'-0+% +*H7.PTXY-.:Q\\$E"+U\) KLI/91BHF@Z9B;YKLD3GTKX #
MI3T@@'] #>QG,'7A)$V>W56B\3EI'-?AA]#4*&24BYYI<[ ^F=-M?* +4'><
M1(=E%.EOXK21B2/VC]G_DW7.HN#-3\*QNA5[Y&^Y*X"^ 8)37)O@>R];N%4*
M>$%HZG(7H],[P"]2,$J,2!7W(S>C4AACP9<UZ!A8/B:^IWD9K(8TV&DYY.]_
M#*=3L+^7C"/T&M");$I__^.'UV&OSU&^3(730?:7\T&#P&W.V[9H4)^[81I8
MF>-A'W]\._CPK]E\\>H-'8?XM6Q<&Z@X'XW<9P$-C/AU3!33(;H-LO3G8 Z/
M*42_/CD,1(O9;2\K8MG N3,</,@>4L:+C52&'T&C6'A$PT53P(#*PK];ME8/
MGC_5MOBB]K>@D#;LWV4=RQ[#%:L<8#=\;$(.^^9?8WK-X &7#HV7(R4SBDD%
M'6B6G*0TH'C#8K;D:N-E0STEE!Z-?WTXU.HK/T<G\5EO[#FD<Q^</B3=#$
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MSW7X,]HLP!3X,!F$/$UY.RF<P\HKO'U*/$\6%F&N(-Y0P\[@]P;OJ+ IC9R
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M^2RW-6-:T0J;$4L6,F-YQ<W)12*@23@NHE"">S#D#U4/6)Z*L%A<_U(D]>=
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M[OO^%3X^KZ?:=;]T[-X3OO4>QW';#MO=>^:\$'7)DIA&+ T@VYI??[( 61=
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M/YU__=O"][^*Z;>9<^[9]-/O7QWWEWT1+\N>_<=O;S_%4SCSI#\<3_PP7M\
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MG3_#EY]'?CCVL<CWBO8M$':435B/[D"IA3KJO$N2;G31@9_9!BG$Y,%DPM"
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MU]X&5T>[2E=A.LR6TEUU=B\%=A3X/@DA8W&3,(+'"7/:G0&(5;Z41E(!4<9
MJW?2V2\1UFP@W1</-I%S]?-$BPH^P^CL;>.'\R#;6Z9\UHH(1LL@-1 '($CB
MPB5CC44?ME7^8LG%]Q\[U!%[4U%F%4/*VWB>WP3D =T9H,1DC3&N+$<)Q("
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M 9F7PWI]*6Y%_U%I1IBF#H(/UK!6I\JMZY=U=</C\*"WEV'% N'O(*[*S5O
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M*#&2PLG[W>^<,\YW[SCCWOOKCKO(^I6]UYYSS3F?^3P[BY/%$PQ X)JEC26
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M"SD@G_F3%M(0OF<"&7I._C0OJVWW[1^-A@D+)9M D>HR0%:^-_OYRD#C-YN
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M:^FYS<<)<7&"/A97'=]5,MV^R[0#3CL!M&5_@%/LX/TVOQ$ICZM>U*;41S2
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M:<>7\JWSA><E;Y_,3:%983S"W PH&S^%(C@YI!TG9^!L'00]$*D(@8BSO_>
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M373VM>4C;E$/ZX0I(Z*97,Y_.?7,CD6DFIZBVO?\>YS, OLF7IK\D7H!)=P
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MYGVN4B@/\PS"=LGLF4J+$Z'56S8"MY\;K?.BH/#J&XTO>J7*[%..APR5ES'
M:?SFS &(3_8]0DX?%H\2(]N_?S<4>JR>8E] U8]XO;8;RV@_][U0!IS%&<'[
MG#KRK8B@_8JFCQHQDB,/9V!<$(7ZY7,U35.)1^I:P]OO*"H*\4885)9G-( B
M2)&&T\]76[PHYSM8POR]!=*!U K&"5X8Z"];/SNGS+LDWX<SF'3G JH(J0GY
MOJR2,NDQ@E!@LV1O9M>4?,ONWD38RZW4GDB]SZ<J?'I@PD@(>;5[A[5,N3C.
M/KY#*L#%YOD4N^ KUV9^<T[VDG?\.6TW &E6^)4 !YH)\M:X 3M15;]KI]3_
MQLB9[XNS)GPURB)6"D%&P8&7" 'VRTF$$)BI+UJ@!BR.@#"%\'SK=2CY4<]8
MOW=ME6\]8X,EO0(J-/@E):W?'\'*8 E)*$D][)9EN7\%MFD<J15RO/YCNO5A
M?[T#4.C'WS^-(76:-V J*#RDKCQK,Y'\=T'SV_%)>GB%2MI/L9M[(MP%X)"S
MV\_-V1Y7R]QG%V#[E9I@X/8>T&['P_\.Y[^?]8'X3584U*<R_S[@")$3!1AD
M7*_SQ\<^L4P%P+)+[V4<E\\G>&;]>1WW^'2AQW(+I7M@:A@CTB"8%O233'<'
MUI86_*55/24U:;Z5,]6X/$7;XZ\)\0>@0Y\%S.1/*4!M_[-7TI&N#[!3JG'Y
M BWZ))B OVI!^-><P/KE:W)F,21^N0M+/0LK<0/A[!O&$+\Q4YMIK:WSN+K4
MT,_KVCE>9;[C!C,99>:?"U2Z7T>"9#+F(M7'7,-P!Z D=PZ@ZF1A'@\%E4C"
M%;Z>IM2X_-C./$2K"_141,Y#9/9JIM[JD(J>_LX70-_Q8ZJ/!M6V5K!Z3]W<
M&R'7+6.>?%7'.A'!C!2-4^S%'QJ2U9>R<,DAW1!R\D^L@(%J,2(QV'HST<U_
MSJ455[QK-[A&KNC9W>4SFG;)+5FJJT\(L] <%A3@_YC1+L*F);KVUWJ+AUSM
M/IUE-F%T H#>F'J])2:6\[NL.N/%N96RF.:4A8W14Z *Y1Z\=)LL4FOJ[H2!
MV](.#^!P,T<P1#:OOFS>Z2M%S$OH<-KD*Y44'0_)F_I26W#R$I-;)9!Y ?7=
MR&@B0(:1T6DDAQQX)V/F=W?FP:'S!R##MQ.4(1!J#&';*P<&JMXM+"!\NJ0@
M2367=KQ"M#,B^'[7,2);U,:JU1XUI1=5IYR%OXPC[G2@9ZGZJ>(FQ'PVNE:*
MIM@$O/^.UR<.,Z]#VF_.W#[/\<=B.6H+)HKN$$3>RLH_BE( [AEY3OS^%BIV
M+86CNR$)TKL9MUN")53*05LHHO4X<-3<X>;?&-'UL45K[BI)-Z;IE[.R=BMI
M(]-LQI!@P')I!P>&P&_X+DH J41UP?7=4H/'J(P*YP57O>)!09D'8O+\%KVB
MBPXD'[J0]<7Z:D;=[UQ'STS$PR'QFP(#ZZ*O54:[)",5>6-_YA65HV9'V4SO
M+RH#&^3Y]L=9U+ $U#&$ ZXI-ICJYN)<5YL%W38G,%]-_9A;?4LRU)8UL9A4
M#;7DBOU14;;J]"%XO>SC,T *U&H#<S<K^O;=[:I$]^$ Y2W)"S86O2M6D[7*
M5G(]$?.TXGOW"&Z[WUW[%%*T9"W/R;-MPP=:;&D7Z;H4SBBD;YXD$$-,#K.=
M^ 6?SZH;#XV ]R_-\E2=U'QD$&#8;,/Y]M_NI1OJL=B:_:Z?2#!A0:&;J]C4
MZ^2[F:97;UNTVVZ*\/6]S=?_>"/Y[9-&S#5@B&:'/,7(U^+3QI$XDS;IAD^*
M^::IY2+5 _UO@CP39#YX"K9&NH,-I.C_!HQ  #MU(P565S^=)*G).#-QW>E"
MG[BP030*Z@EY%8:M=]B$@GMWYI[.=U71[Y"M8U5^G]IZN-&J[SKY%#;?EWN7
M*XC3PE*HX5)?&!0YRODS,[?$>4,OH/"]1[#LPJM)"P-Q0>WE=&V;@8&(IT<5
M-NSAPNU,P2H 3<"" 9@EO^:0L'7]1,#E.-45$ZF>;*/F6_;BB49Z2&TR'^4+
M!=H%X08>_+H?\#O ?V[ZX@&(+:WC'3^I!=V!KUWKV(F'B%08R0!AK&:)69*X
M]NXG]>=IAW-//1U73Z^8WU(6$NSOS/@VX[UXFMS;90WR#VO2>5XS/\2]/NW(
M7_\);ZHI>.2:N%"IZ$ L)^83ZA&J T:VSE6/0==84&)+*98=B^<:R0/7J%+6
M,4',":.?H@1AM].@+I'S](*PH=3<%1P(]>Z&:R/PB5!%\FVY@(2]2Q484KXH
ME\$H L\MFO(Z'7:ISV23>7'$V/:'?WV2D0:"G;CP2]O]_V VX=J\C_[V8(+\
M%-8*I](ZH#&@1YIV3Z VM5-EMUNJ&F-WAQ\*F08'R2.6;VI(.MZ_^%MD8[!/
MD^84&%B4,K=X8D%QXL)E8[UT:Y#-X4F'_)_0&O7.H0AG-\@U((O ,+/WJ'%T
MAD]_&;YNW)OY16Q;/PQC_/\P8_'_9:O6PO#^8"K Q:9J<F5OE 5R3!6XSROV
M+-X^*F36()O"?O;[V?O6Y7YC_^5L7HDV-;)U'$K>%U, %!F/TRT_-I<EWRF=
M[0UEUWA3*K%\LY'S?:\HYU.4+&!+K,C2SB6"63\F.E'X^KNEWP='4Q^> ;M;
M??U2Q2IVMSR3B,9;;GS_Q<C=_]/88#836Z%PGESI#=^@>Q4??'WJ&I(L9*HJ
MCZ6]) ]<E'_6<:2*#B'3.O'@>\Z#G6U28W0M[U[5H()OIGZ2?\O\.1[^CX,V
M_V_,%=^%$1HD8.-8_/;P4<5<B_$*S)CUI;%+PYRKM>/VUHE(W8 E,/>&'A_1
MJV9*I;#J-<8FO:>/13FE0'1[5K6: (_PO?EUIJOU9=7NZU)78IZ4=6OB];4&
MAW@Y^@VIW_M"-F#UOP$>FCKR$I81A0[@4D4&!YWX5!X] 43 =I>\E0..W52Z
M./5" W>V_<2+^US'L6%(Y:41?L02C@)ODYNIV0JZD@[5"BH+3'=\M*2K4L2>
MTOCS.2BC)W-L$8"ZU6>'X;2B*4W+227)49)R4X X[1!JQ!FSI4]Q<21?=C^)
M)??&K(SG;'0)^PTEJ)6G^U*-V?Y8^#F!OQZ5YNIH%Z5%4$I)_*G@31I%OTO*
MN\2C9/ZGWI'"\7X?O6LE*H\J>L[75C6_^F/!N2I7^V>()2UUQ^@[HDC7J> #
MD-RT<T!="*M1N1.;T/-2()HRU8T5DPBZ'B,#&?H9*.IL2FDN71>?ALRNSVV.
M#@0LJ<E2)4A)7L^5;KP0QYS$7C@ $?*<>=W_'2=*7_"_<3?BB=J&Z^14Y,"+
M3D>[IL?#'Q^NB=+L2(9WH?Q Q*TI+\GG/=,N12/[-W@@*[#4?++I$S4K%VH2
M91$;W.070-=1M%*X3=]S:^_ZN_S':F)R](@U711/11V 8L(HC\$)#NZGF9.M
ME*W)-O<4S3V!ZN?CBW/':#M:+<-24()[[1:V*H@NM-"B6H94 D:* ;KK0!T5
M)1_$=P"Z&_!MMUW1/+GCS6[,9,;*KD.2CT(LRVN"F_D!2*!-;%Z85ORKN5_$
M \CQ[6 (PG_M$5,3Z(:03A9&]@>4.O'(FEA6)UX/R].B66_;^A?R2U;-AAA#
M7J+)+OJO<ZE19,.&^]ZI.!X%I?OE8?=%F"=<=C$U4#AF[CCZ6RKU,OEM2IR0
M>F*%)@T&_K%Q_&E=N>B7!"5/A<-7/I]MZ%F]EN3IT 4EVY[.(''21?0[F3+R
M7^7KQVH>I3YCUCW*"E*024PMTOHWG<<5#<:[^D*/:O61O"?N;8=:GO[4.Y#^
M-7-$BN$4L (E<X,(4$\8H.2VMI5&=&*JTSTI1?&1,Q4GM.'PX]+S-9=LAO>N
M?>&P(KZR4;K<)R\(0Z &T%6P9]"[LP9!Q3^<J>]+G#8LV/N-ZE?",U^TGU"4
M%+0S-[JCN 5K,CQ31!<N(!7%(L-I"@ __NJD"G/^G5]IX?HCY>,) 5[1KU2/
MKYV189-7*D;^G<J?6R+EQ9!V9M67TA'Z7?9-0],9!:Z.^/Y/UTXZ2DX(71YN
M=%MTT5[A/ .^\ X<;V!%,Z'?9MV0--2H Y8/)0*D;+1C>;<,^KVQM7B>UAR!
M6-+*B[@'RY$OCMS8 RU(QF6@.RY![ZH?0?4R1<F:?ZT30D<$@(PN'8=+JU86
M[QV=+]S4^)KV.9#S86G_HPU@IOX U"$0:G5D8(VT*2Y^OZ.B7^ZMAIGF\[+I
M$NK;S<B]&&^WM7<##B.L&-]"S[E8,=ZU&5Z\0VS^B"7G1V_AK6K:HK>?;Q/S
M0[]6U5-.V@D(OD"6M[_HC(1>:Y.Z;"3$6EUC4\WS!F\FA&]U<DY;VCS=4KQA
M[F+O5^=KM_<O8#+0A#@]'HO/2+?I[+-5)H6S/<"Z6X5;Y-][UE\=IK!UF9\@
MN%1 R?KY^X178E!^1S_!^)[1RQB.-M"(507BUY$6:^;1U(*C1MSTBU-UMQ<0
M,:IAFSW(4M]YZ>:EX9_S1K_8_AK"HEG.WRAW7B/5TT6$;<D+]%T3#[^03P!J
M-BLS5CSEY /.:W\R!O#QF(7G]"NL6%?3%:;;Q%!37!2Q?J]$2\JM1_O36<4:
ME8OSO3(WS=[<QPVF7'_\)T[V* A2.W<]P^?=3_M_4_UD/\6\.1T0%"30:2IU
MZI:-(0B$$@ULT:?:,<J0TC0;I/ZX5H"20U5B5\\LM+8&?($G5S\2VR+GI)\4
M?K@TZJEA!_M,5K?4>7AB 9]SUP:?]%5-RH-\WU,?CP2IZU=R25Y8.AX)U<,&
M[<QG])ZC.U<#G.1+X?(4J\DJQW7G\M='EEV'ZKUJF_,4CCF*9WS.B'2 2^V!
MY\297.\+D<<8.70/BC5)IPLM@*COG7OR)D0\Q4ZL<-6B(.'&HE>XE]NXA_Z+
MO 99Y?X#D,=6B#4,.*/X.#51_7#($,DP1'CQK'&0HN4GXQ5L?/-M_N:!YW\]
MF#SB-*N?-L#)0<)T3(0H%1,>(LIL73X;['/8Y^'91DCHHA4FY;V'I$2PL2R$
M+JB#.]E+4$_16DWU\#=2H)VI<A4S5_UPVTPF:1B'L8$34F=9F-E632F@]LRT
MR2'"8$TL;'@?\=G%WX%Z#]DUD6ZFT:/;ORCJT7%!O^U>TK._ 2S,+DB9Q\$J
MM[,^?[4[EGX NMGV]B7(V,*)2\G@;14_*N\5)9\N6#$,$V!.+:K-J!W:CL,Y
MV&H/@S)=F@,77^/_VG!^QU>/T(6MB6&;.(K>#.E(0AGPS&Y2Y5YAK-9,43WB
M79A-N<9K8E()5VNXXITA5@.#Q/_;#%^"K_D]$JD)%; @8F/^AKT-DS'621-]
MJ2*^E='[:L_[D2>W!)$WDO?.:R8.H%DU3"-Y2(9&8P:#I>7:JT<S:,-C&L7T
M/DP[^AN, ,,%I<*DU.BB%#/8)/ULNI/^3^S=IMBQHA8+ 0G)PN2>J^+'C ^_
M,J#*RU73'J"ZL>P'(._\6&I8FR!0$%Z.(%9\2/@E/3_HDI6CP?_G\/T/-<>"
MWS3>1NW8PC["R%8+(=W,XXQ4 YZ()=W ;:TC%N/C)* J!ZZ5'=-\SB"M$O3Q
MMW&1DFZ%T""5A\$*H7>7%;H[<RZ8=G8Q2TY[FKTK?&E?Q5X7S EZ_Q/FZ1LV
M[9R76+3H%W,]-SA(IF[>XUSJZ9<BG2^XDS_>-^[]!')-OQRKG7[EEBE']FL"
M2"\=3LFE@D<=J!\8I5!?-Q1!,]/].'F[*7ZGPZ38]<P571DV87/]A[+5L")\
M[4PJ&&<]&T<*BR_(Z&^L'0TLJ,NX,&]0?)=5OOA^H3815F7* C:]!71'BG+%
MY;V??Q^JIN2*^2E*CJ UU!9:?[!_11,2\]2R<-@:]63DB0>\[/:C.;;29"3-
M;Y2CMV+V$[VT#N!#X6M9,  CB?=8/%H =(B;0H.%FLFTS-TT8O5:Y=UJ5]I9
M3#9*%9%"HUHR&MO4!HN":E^T-7)@7NHFA/+HYLS&T9*#>=#MRK]LJ:K &6SU
M/EUXS7T*$Z"]L:@PBFDQ0Y4U>QZ=+@L@*>Z>$WK?\6/<$(0,9R7KK0-01B'%
MFI&0!?OKY@$S17?8H0/ PLBS+1-&@DB#UGRKF=]PNZ:I4'VASG4)S[MI+IVX
M5V%S75_H[??8=Z3^##*/8C3,:+<0V6Y3SM:<;I^/7%!!S7O>-[S.!HTJ P-G
M"N-$4[<F0HS:ZL6:Y#YY%5[?FX]:E;9)%*G(/AQX1!=$V*UAVWH,HPMAB+ H
ME$1=/06[Q-$;9^"@BIVK2!*?KG2>,Q]LZ+D\,'*_/6W@E<IC?E,6"2*;+GAT
MV]!]*:MQ16X+,"34ZG11DXIDP/2FM=1\GPBC7PZJG_+IUIH^QQ-! @0XD;K9
MT@:IH1Q?_XM-0D(U[_KN[-0"W37%X9Q?Z\UCST8(PLR0IQ.)H:DXB"A+GL&H
MH)KQ\0@?.9EY1>7'=T^8#&3O*:X\"#O/S[9E#,D\ $&8IX$E)K<)S;6#7-\I
M5?T-$%O\:VEY]-FY6H&.AJ'BX<^H1\<<WUUH/U?<H6*-08U"R!8[<;##:)\#
MD!ABR9+2^SR_"P497VD5<M5JJ&T(M=T].B[_0UH?/2WCTXJPI@MQ]DA!GAV
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M^@ E[M_,()SX7$8_$?W\<47BW>NF;:4?>U&$QT$6=PY H_!%J <84'*/HT$
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M9V.+3KG!TJJ\O /X'(+P)8RTYKE#$,]JX2&HU_80Q'T(HMU&CTW-H0GM$QW
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M[?^?LTO_DOY+^C\!:13PD3)R#?A"Z>AAL$]Q6!NYOLL9L+1[.)H#S;23FI6
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M7J%DG<\ROE!]TK&L>;KZ@:KNWAQ*?^,TWGW>KM:_P38S:6L*.OE?&4+=R&O
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MMU?5?L0ZB=U5?T9MT&@,Y 3=?L<FLK2(U^\W$FH$QZ"XK<W 7(CIGM;:#^5
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M)LI.S&\(W_?^!WOVPC>A7\3-FSW$S5R>IK?P1([5C; )+4L+'F#;M8F]%%>
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M<^X-RO%Y/L]-/EQ+/:ZAQ+V\X@(QHCB8'RDR46V;8[SQ+4^V"Q62(-@MY*V
MREE3]_L0",_@Q:[VXA7O!&NE^Q92CCTO'DC6AQ5V;(U4(,+:PPC6/H2C,+@]
M_ V0[#())T-^=20XB+O%JS;]&E'(0M]O&=,*YTZI?Q'@LU#RP.&>!T@*FV1X
M;F-!Y*!%[9&RA)$ HFO@)V&X\'=NW*^SMJ_].AIK<ZRPB\-"C3Z#[&_,,ZQ
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M76\V#T'9D^C[2.M#T&OS+C1P>QZ]V]K6JL@<PY@!C@SAY?1_6DU4MAZ"5D+
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MG;,EBLY+Y#DV;4=%XG0X%\!COWQE: $;6S]E[]O(VO;4O;%JK$UZWQ<JQ!H
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M\!J0K1+?VW8+YZ-@ :H%H<BQ\CRCADP=D12-1[%9@T\5GWU+XM2L[4 STF0
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M0.,W9]K(3B5'H)]:H$#_?^#] ^\?>/_ ^P?>/_#^@?</O'_@_0/O_TMXH@4
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M5UHJ@ :3]\HYLFS3DD'%$:)B8KQI)URA2P_%S/@+7<SN^2[2D9WB,98'-[W
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M^'F0 -K'8NT!YP,=74+5W&@/6 @3&%KFZ"'0&"=716A(3N[RW/=LM6-13KA
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MXF*RA$O+P><<696,QKQEKZ\'JG7DNM0K&/558PRN(7O29I0YJMU9(A##>OI
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M11W%G@*AE1G%\Q&BM=7/'L1<,1:_?!'D\@(A9%PV]6]\B,':ZN.2[;"WWYE
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MLCG_/^VJE4@%H)X(30H66JDBLEH?V/:,['LK?LM>M N,6;_ D*;YY%USS=<
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MMG454O^-O#99@QQW/4>RO[_LL])K'["5O?'^7W38!*P64J,5^$1VZLD[,QD
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M>/&T=-JN#(EADJ)'L6J#:)"DE%NRWK%A79)!Z5-%'=;^%'/V3YJZ]5N[O[Z
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M;WT2_I>:PZ24%-]B"(NPYYL?2\&7681YL2IO._]7GTUGWQO<.B9Z6@,BQZ(
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MIFR?L5'K=-?PFO7)7PTX2W)FZ/-9ZSW\R0X:&IS)]AL<5%]:EC>]IC3>E)'
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M37#Q:POY4>,.T^&'^8Z2A5WA/!]TMA9-[G+1&5O5.3)$W6?S;K4)4D!1D%D
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M2%B.71AD6)^[_&![Y(57I$_I)*7H#?'D><^1.FD0<@K"H"J,<"+J=S"*6X9
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ME)S+$P/=;&=%S &C"V-;Z2&41<@KLFR;(3BXUE'W27*;0X'P0]%P94P! ]_
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M@ZL19L=!ROQ!_J8<>^>@#J:9&I3)R#RR]7XEP2RJ"*D)\<K?@,Z<@]S,1F-
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M#@N>;;F;W>>_G*IF4FQTH_M!XH[\8^HNV\KL[O[ H'/0=RM!)>)I3>I'[*#
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M'KZH;6Z5H/?XN2[<_BO'>NSN<Z:2__XNP_^=10RP/(RWECJL'E&C.0>UJSG
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M24*:#M_[]#XK7,#+4YRXX(S8G1<81]8F:DXM>C1&EWA22<8-^DB1X:/,WB=
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M*__YS$KJ.^SR Y/9AMM/H!&!]K(17+PVB78%5JYO[7W31F<L165]Y7X>5Z:
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MA8NO^*#$OP=,8\>0FW;0:R*]O<W =T.E,DTC&P_JRAK19Z"(VY))H=7:_9<
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MF7:=U_>I#)>3(DP]<##9,R.HZ$Z_%ONLAAT6?@NJ[C#OY>WS/5DU0:I!H[7
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M^!@DL0#P*1O\Q^;:AP/=#$M^@?( **5;HBG>8 %6K?)CK]\1LKR,]P2_9=U
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MZY.N6P;F:D^??!*>U(K5":\(Q_2%X#T[3K0O %?^F?"+%6322B:\J:_1+/<
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MA].FY#:R55F\:99'M<HD6Y]*?2=TQ1.*6)V57?K6^BY;WO?'PW1T^V'Z!4
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MC[=//!P'"$9(N] O+G2QQU,T5LNG\D%"U4YAU+T/T"C!SP:7* 9H3KE8>W^
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M7_QT/'7BU2 U]U137_P-KF/<4],PHRS^ICQG&,R0RV<PTQG%9.JCG[K'LEX
MPD5N,+3J K\3EX?E$_,%YH,.&[95-=028<T@DWO*6TN98?^QF=PKW'#7" U0
MUZ61LU?,Y)8(P821;8:=I.>;+P#Q?%>XN?+9R=PI0<5S\BK\JMSD[<I6&[6
M\+RM1"YC7IC]79QMZX'_%/^E>HJV#!5,2!>(A I"'ZFE5FX7&75ZM*%NA3W=
M(SPINIPBF$SG</>N2-Q5=H=_YZ;9$7++_;B6KJW"$GL>IPUPZL/M.M=,+D:.
M"83[B6Z.[64)-OBT9CG-\+_>])S,O-?YH9A[OB"I<0@:6C4E,3=]M1:E\$K&
M25;3!/7YY>3.K>R]#.;U*E6],9M3JQ,+GPU>#+FV',F2+20\$P1RO/R)J&4
MJ0L2-/B^E_\PV4A6PN-5>#4\Z,Y#8.L1X<U;NN*E"X#[!2 N7WP^<^+QW''8
MZ&G[AW:T&=M.I/>":/8$GG,/#_DIS\YJ4"C'IV^E6WF9[.A90HKIU\#$!YTQ
M[1K_5%X/WI>OV^16DN[JE[FOGJE+(&9H3S-(&SRI,J@N5E.^U&=[ZDNF2];Q
MJDO0EHEDPE,E!S4$TS[>!$UH%J=^2UK^E$2\% :%R62<[BB)7U,;$26\U5-+
MIU91TLCK=7O;E1 N>UP?.=(XV5P-7=\<A=,$:>KL7RI7I@5^D(S:(_;>KY+]
M 6")Z_XX'\']0P,>':1#W[#8HL5NF>3M5[04U+EN$"KV5M6HP+LMYYN5]&N
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MK)9>^4=1]X)$U&8T? ^O@NU-2#OHN3UJK\ '!&UW_ -XTJ%>'#3,1(AJJ\#
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M;6^4[$W>U-=_*>=J<=VJ5F#VBM%>(QI':_!:AG81^&]KHV>,C!40T<XZ.IC
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ME!>(5:6GSGQT/9 *0+:51VZR_V0>.H#878\=LLPB#K::2]]CD7]=*1"/BZ6
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M.I^_W-)" !(T![:9P&S6*8V?U/^OGV6EYQSO^\<=.DCC T[D'.+1\ V.0_;
MA,LM9T#7.H8T6]WP#.T]V66/(9&[]SZF2RZM8W^C2P58J5.HGN7N9=[U0FA;
M_\ROE6)1WP9OSMSV@C).9"ZHI#CW/'5.IKZ'4QE1G-$XDY+R4":@ A7W*(ZL
M7O;0W(NUZ4Z,N_]^T_1&7GZA"[2_Z,)2=V?OTM 5>-4W!--P$[R<"ZKA7?//
M>7&\,P1?J5;>-8//E\X[AV399EXNVY;7.C]JEM$\#V(6X5B*#). <9SY88Z#
M.$\E)Q%)M \#:"V_NSM(K<+;R:]KW8!=X_?H)RSQ>$92G(2IIQPYR3"37H;]
M6+(PYU$N(@:K_+/FP$7U?I?P("0^C9*0XS0($O4-Y RGB?2P3*4O@YB*S*R9
MPN7?@(7E[H!^LS/-FBJ@P:T(6@\&^-C4PEXOEU7!5DLM^VA9*D/;;4+C2<)<
M#0C8VWO:H0"GR#H:!'#R(5?]%6924,8B%N,\T*797IC@C(5*NPB1>DD<1VE
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M&!.6ACCS9(:#),@$C7R?A:"T+3@*(^L,C0W*Y^77&NFWJ4[&#A-$-ZC\%:9
M+-ALID_&91Y,O2A<4,.[-39Z9-6/&B'%PI_0!B>T16J4BRE[GCA2018(3*J1
M[!ETJ* NV D>)/BPJ!602KD\M^6\X&I3!9=_*I?7HGQJ4CJ $WN--QS= 6GP
M0&O'>HU-<TYKE*18Z903A1GJ4#,/,)AS;3C<, K#H*X+F%<CS/T%,\(J(&$.
M9;+P!)CPW6 %?+%E<MMB68ABOE*Z1VY#(^^^\?E**:GWBB"=)[):=K5[[VBU
M4)]2?2O;3)(V5C5C*6.9B'WL!3H]W1,49VGH8>4@^0FGC!@V_W.*U=BAS!T<
MU^T3M'#)#LO6(.);/'62Z+RL:_2D9++)C$,_%NL<N9^ J6].7IN9W33YRX!I
MN;WWL!-:?;?W'M[LOX<UDOK"HQT5ZNZ:8Q2^N<J/<X+3M)ER+MEXE#/G='-+
M%:Q37^_5VJ9J)9 DB0A/<2K]$)-0J5*:,(FS,*$D]FF4!3E(E>[N/K9*;&9=
M:F!6Q3S[C#!43K;D 96,,65P-7&* E?BOK?WM&)[BJPC\3OY$'RBX-LN7>1_
MK6BUU(-6[^1366F[A%(O)"%N@C#Z&D;W)H]Q[NL[F2#W>2A-!PN>@3&R2*VA
MH@U8U,(U'S-XCCG] N:(9)B8P:D%S1X<H,=J!.&Y/2>;1#A U.Y PJ%'793Q
MO_NF@QFKHOZB?]A65PM?)BSS$TP#'F 21:$^TRA._5 &69@E 07=E0Q"'%DH
M=WI Z[+]2\K03['+[.1SR@28F*ZK3G1]25.2O@\=K7^\PZ<W?7RZL%2]A_91
M"M9/P7O%LO4>\ON+U_L6VB9"M,F"W;7++,FD)_R,XXRD2O YSW%*9( C/TRC
MQ$_R/"96TTCWP!A]Z!>7M&VR2F4+%9H!L<\9,QFW(=0R5-@1]VZ .(N<AI,D
M.,MBV-]]XKR%DZ0=9RJ<?LQ.Q/Y&BT7]L:QK6=\L]B6XE>J9H%$NF3)Z(R\@
MZK1-(YQ&?HZSF(8TC*.,Q2 /<A#BR*>M!JWK1>7!(=-VT(&)X3#W?$;SU$LH
M%I2F2F71!*=>SC!-94Z#/ AC+[!066Z8>+$2FY:79DK.Z?<%4WL:-/I1P_Y)
M<^70C&D;[KC3A<:4.M*.P_ FU9?&Y!]J4/.%ECI5+F1%Y[KN4#P6BT)?O^J(
MX'[6DE*?*:%>AEG&,TQBKKP8F00XH"P.@I#(V/=!>M4$ZLBZ];.<JP<?KM!#
MBTQS-4CWT $J!2-6&BH&UPP"*H<=ENPC,&(2&(AF5VK"".:TJ@+"AB-U 5IL
M4X'1W*=?5U43J#8NNMA=-;)<GZ@[,$S#.D%@O[1>1AM,)$^0Y2P>?YX.RPJ)
MO:TF+(HX1<)^'<3))RQ*B#>U@<H:;:=U==UD,Y\D69:E^M:*8T(3@K,H]; O
M?"^/",T"S[R$^!R4T3.-UE6DNCRGF_4&Z[K;SZ1^L7)&NF4@8"RJ03/2+Z?>
M=ARZ#1>@<\_[J1L8<7YF\933S/OQ/QA</O"PG>'^6RUO\G?ULGA4^]:S)!!^
M*J(0^S357;\]?<5  IPRFGDDS:B?@[I[[&\_LKY1P+3'*=?@8';W 2?,#&Q[
M^F!*I2-M ^FJ345\07]T_QQEX-1IZAS9S >;3VH<GR;LT H^\Q3<W+V5Y35?
MKNA\_G)+BZ9O%*#6^/3JL2_HWMV@-52DP:+=;E?@\OTS'!BVBR\G'B9HE]$-
M,I7[2;,RF<]L.9GIW$_2K@D]\*1EJ]AR\:"^]4<=T-(Y,9W!Y/LLRZ2?X]3S
M TQR&>)4^ 2KOPA?YFDL!&B*Q6DPH\?P%P]80VTBJE==)I75"(LS;#([\2XG
M'B:0#=WW4+KAK6%[R7+5%_8TD&F;PO82>M01MO]I>)[9N\6R6+Z\+^;RTZH)
M9+(T),0/0^R)6(^I$ RG49S@, A%RC+/5_)JFF!VN/G((MF"0QH>:@&:IY0=
M\:%?^BZE#B9S ,) V6/G*+!*&SO:;+)\L7-D[":*G7W&[F2[>9(Z KMX^*@K
M]3\6E#7-F=^T$^=F:1)E1$B"I<B5$-$HPFD>!CCF(9&$9$+X1L,VS<"-+%8=
M%%2ND4#SIGW$O$.CKV&$#?/,SCUW+(')X@8N:@!?H0WH*]0!=W<*FA'IZ#0<
M #;IJ6A&^.'I:+C*,BE4I_X5HKMR67^L69@F>=@.+TDQB4(/9T$NL.>)D(?4
MCT,*"M"<A#*V;]G"7*>!08<0G>2+F1!?3"W0F>P([>"-(+"]!+E*W3P)8]IT
MS3XRCU(T>Q^V-5D_?Y'SN793Z>)E%B19)O(\QWD:2G7>ALJWC$6*,X\*3KR8
MI<2H(=7I[:<Q6QN(J ,)-5SWN&%JNMK2:&6\FI%G8;Z>HN(" W9ONXE-V%.D
M'!NQ)Y^R;0#S]9IS'4)3A^9M52[47WES"5VW<>SVSVV7@-0/?#\/,NQ%(L(D
MIAY.B<B5H"593CQ/'7F@LF@H B.+HFX)NUC.7Q#MF@?0#7*H7M*%T",]FO29
MJGGR].\7Y1*]R.5Z$VBS&. K,3MIQV0T3!\H3- 6%;2/RS3W*+;,<-8A!@A^
MXOXP=LPY[@YCN0_\/N=.UNM!9V^E#H\5B^9ZX*WZH>FM3M\>HVN=#6BT!QMI
MX.:7.KUL&+[:<<4!F#JP)!YTLV-"F=7]3N_&D]WRF)"W>]=C]+Q%\E0SXD0*
M)>NYK&NU(9V_E[+^6+3=H!:B2V-\4U9/I7+4VQFC:X\Q\M(LRD6(PYB&NK)9
M%WE(9=*'4<)C1AGSC$R+RU$9W=W>(M4,_6T,BG6Z,E]C!)F?[(#]_?IA6J;"
M-$B'%MKCJT9,Q^8:U*Z00@ZMLY\WZ+7CAH>C *Y9#4@8FXSE=EEEH[,>EH#F
MA%N]66J709@NE<T))_;RW=SLZ*H;^7Y,:<8$]2EE(<[21&#BJ3]H3'2)F^^G
M89@$068SE'((KI& 75SA=EEX=I!W9OZC$U:X;%=^$,L=LV7Y:4I'ZUI^ .Z5
M&Y>?)GZX=_F9=39FI5;#.N/DW<>2+KIZJXBD0>YY!*N_9'K"M![I1:16 'D8
M9@G)S9J5GX4PLA&H(:(FC>8=TD AQL<I?IB8;Q=2"1/;0P*'*\L,*8583Q=2
M;&<4&;]:H''30TR_S7)JX82F2 _>^Q9&WX,PO5%72^7E/JD7]$4IH^N'2LJV
M(<A*9^T_T6KY\HD^KA/MI#(>>*[S$6G$,0F9,AQ8E.(X#7D6"S\/ F:B2T!0
MQT[:V &*-%1@;B*,@_W:9S2^P#22!4N,)=2*Q#X+0FVX8SVH?]M:#C!8DPBZ
M%?EKX;=;;!$E7LVE[['(UW6"[=7,^SE], X0GUX^=FQ8044:+/;W:D3!G<#/
M46\0%[Z<<&!(N)]F](<&[Z@^=H XNZCPF3VG"PCW$[47"QYXU,YAUV,!]/_U
MP,UG.I?- /=Z615<[:]_<;T0^S_8>7*6DR DB0AP&.<1)DG",<LBAD66Y5&>
M4)HP?_;4U-Q]7BKU8.;,7X03Y&,_Q,S\@-+C,W0LF.N_R"UT1)>(R8=BH5OU
MZKJSY1>)6C"P8,!E[\67GI=&28AC+G2$/D]PFL8>]H1DN0Q\(97/U:+U;B&^
MR[>RQLO-.Y'JYZ_V-LSB-I/Q%VB+*4!7[;R8'7A7:(L*:A_1K#_XX>X*=V$?
M)XQR%!.Z#)=) T9.V'8837*SJ6UF81?2?BN?RKK0DR&;0=%/NM*[*&=Y&% >
MYB%6QY!R%A//QUDB<LR4/LQ(F@3<CV"IAKWP1C8OVV((K<04CXH%K5ZZZ0W-
M2(?KMY^AB8C]S.O762.P!*:5NE3%S=75%C[J$$ -!B[3%XU(O2"?L7__B1,<
MC8@]SG@T6P;W"#\O_[RM^$UU7U==67E1+GZ5RR\E?)R4R5XC"_/GI8*!;I56
ME+IA\?WG.[1%!;6XF#N,1LP9]AY=\P4FT28L&6%"%(1H*Q?3",!D_B:$W%WG
M$[3.SA/]NRP>OB@CX?I95O2A*_Z[R9M9)_7-:MED[6K=HD>F2/&VJ/F\U"/M
M/RSEXW8>8Y K[X80IAP>/\>$T 0S+TVQYU/?YS$5:61TZKM%:V1]\E8NRB8W
MK*R $R\=<=W,Q9F>ES =M,8/=0BBK='5XHAVD-2&AA*X8EZT*FJ,$9EN&>;(
MYW&$U*3.CUM&'GI!CG>WC.25CX_EHCE&6\ ?ZGHEQ8QYD2>C,,52_0T31D.<
MQCS"<>1G'B.!^A6H[O$,G-%OR3145&NP5ZAH0-J/L#O'*\-(S>4<@-Z'-<1_
M;HEO85ZA%JK#N$H_6:XB)F>@3!L+Z2?U*,HQ\+B=P#9;_4)K*78;)>U<H_SR
MLGVDFY[1#*W2(93ERX>%4ANK=J3&\HNL[K_0Q<V3WJ+^7=9+/=^W[78W"[),
MT#@1V!.)Q$1$#&=2QCC+(\:2),DSMLFY,],!4Z%ND;8'4RLM.)CRF.R]F6FC
M[^I=V+E^&CW<X'?0,VSG2I&]H-WGUF. &DJN4$L+VB$&-=2@I2('=?1<H9:B
M)BFQ_Q8 K#RG?@N.M/%D:$^JWJ=^&8?GQ>3PX0'T)F=#A^<>=&Z>QX/(ERS'
M?D(%)@GWU>&01CC)><IX%@J6!*:A\KV=I\B=:F*^&IAY!'R?^N%8MS5-4#O/
MB!Q0[/HDZE91ZOV=)HM'GR1@-_)\^@&+].4[^2P7*UG?KA.<%N(SG6_SG'Y=
MS9?%TUS^(O.RDO\N:76SD#,_RE.1T #GL1(@DC&"4^EYF/D137TO2EB6&.<W
M6Z$PLI"M82+6 $4O"BHJ%X;EKA=PME\NI^$73(#7Z%RA-4+-M;A&"6UPND(;
MCK9H(8T7NIF HX",[-$Y:Y>R/1:'81G>%S&G-P7<;N?I<L0OHGPOB?RRG6QC
M9(LFU/;W8OGES:I>EH^R.NIJ%WM-@Y0,)UG,,6%!AEG".0XSCX0YE3P)0!-C
M38".G9M:OM"Y;O^'GN@+97/@8"4CMIG&SMPR VI@M=#15P4>K>&/VQD00K&S
M&)L!R(D#;N9,.(Z^ =;"/:'/DJ\JM=.[;TH-*?],9[#/9!:F7L!S'"1QC(D(
M ATRRW&:2\)C*47D>:8.T2D 8^<7="#1&F9316'N'YWDR;";="FEP+ 1C$B0
MU]1'B97S='+#R7RH/G)V7:G>Y^P[R]]W?;!GQ ^)\'*AQ"KS]-'JXTPH*>,1
M"?+83VF>AM!^\NO-1Q:IVZI8\.*)SE&YO="#=X_?L,+LN+0E$"9)^YWBW;:&
M/\3>84/XS=:3MX$_).I4\_>C9RQOB=HIF0-S!6=ASKCD2K)DS@@FQ$LPDZF'
M U_]E,B ^CFHC[49V-&/L<$)H783T0V9:G@!XYQ5T'.PX]+PT%"']QT@HEW=
M5I@!G?:N <2(HYL"V&H[%7+-^>IQ-=>WH\U]@KZ4J.07M;,"\6'!E4&M!QQ_
MDLN;_)Y^F_$X)*$7YLKC#3-,PB3"F2]3+&F0)GF:>SSC$%T"A#^R4MG!!I7-
M'2'?Q0?-%2HP;0+EKYE:&9%K,/VRR[#V4G4/%=3BTHTROT(*(9TPIU!RIVTL
M>>%([4"A3ZI_+%ESJ(ALM[&-P\W5OY:MDMNY%]UFQFT3U[,\3D/&,AQRHGR&
MG(<X]2."/::=")[YN0#Y# #8(VNB+FFAZ.930F-RYBP,LR 05(0X3Z,<$\%3
M91QF/D[S)!-"*?@LSV;/LF+E*S-Q%P=S[Z5XT!;/O.#-7'2Z#B"CDLW5KYI[
M\_%X:QKV'(5?T.CG#A)[R35;-!R76%Q O[-8J#GDB4.B8)8<1T;A6]@I['>/
M3_/R1<HF![+-1>F:/ $T[]E-QM:S'=PV@;;+!H-IA//TF\F_$]*!;N&I;+GM
M-W+5\6&XVQ=8V >)=23:Y^%,*LB#Y!Z*[?"""X545L_J,#R=A?:I7#PW261-
MPEE]7R[I?/?WNAGHIW+Y[W*IZUL>%L5_2M%FF[TOJ^Y'^CE_)G0!@<Q3[">>
M4(:9^ALE(L"1Y &5@I,@]JW4PR3HCZUSE.?>]$%HVTV@O*ST)(HU>$OM,\V+
M!:JT[^YU.=:3&QK6R<8::?73=G3(%N^K+JFX>==W!N_:7K%.RG+7VGH:Y%_G
M")CTQ9P]5Z;%XCL[K&8I9U%$)<<BR0-,"",X([KT+4N%EU,:$K,18Z-C.O(1
MU*BI2K:!NV795LJALDTD;RX);N\^_U:C!Z7K]"-LM=P,1*HV2'XG)]5K'TK_
M$.?/]:-.A?X'.&_^48Z6_Y^<(I,?&)9G0Y,7>D/_7%92OE_M7X:5BX\?WW0^
MMR_#*/*8Q$D@"28L9)@FQ,<!B86065/8;)QR/PQO9#W=(8 T!F@?A2NDD !D
MA1OPKE^/CL 1F#8<8H9-<W(#K@ 2X]URQRX+WOJ3@:6YFY/:F]-NL,UT">SF
M-.UEJP.6P5-0WW8?P;U:.N.9$((0Q4B9ZM33+,,L##W,O3#+O#C-4FYT^WZX
M\<A:; T*:5CFF:9[I/?KIDL(@BDA,UI ":6G$+=*)-W;:+($TE/H[R:.GOS]
MB"5X,R^*DBB4%"<)Y9A(EF"F1$-'(+G//64 I$8)VB"H(XO0&LP(96 N:^G&
MDSM@<=<8?!JA0FY\<\ 5W\8I@C.R$8PW^_Y*W4[:"^#%\)Z8]Y2MYK32+3?O
M=4T7N!'FV0U&UG,=W*9[ZQ6Z-Z]'ZZ>Z7\4Y(QBFTG9I17\T4-U.RC:BRZIS
MY?E=)VM7.4C8;H_*X8<M#)(/77+6'5W*-@Q^_:VH9V&H9]TF!/.,)I@$N8^I
M;JJ6^CEEF3))PMA\!.YI&",+X1JH[I,LUS=7?VC $-?Z#'L,K(W+B88)XJCT
M JR&R^FVLQ%.T>_($.@GJ??8/[-TND.^'_>](WW@42MOIY9JA6Z2_U;9"_/R
M2;_7+NF_2;6]%O^QJI=-*Z"9C#/?"_(0,T)]'1A(<!8G##/*>!*'7A"E1DUZ
MX*!'5D5K7!JC56RQ =GW$$X:.4,C\0?J$76LT;.9=Q!9%_2TZ?8W.=K!9C2V
M@7RCD=AGZR Y9"/42[+@Q("K!-EQ2G_)@M(#I\EF!]OI(=="J$^F[O[QL5A(
M?^:'>4[SD&"1*D5+HCS#:>P'.!:$TCSB04*-Z_[/0AD[]:R=C=%!O%K_!6G8
MYEV&^ODT'*EU0CU,65H3;C$,I(>P"T: G-IUXL$?/80=C_OH>WB$Z._ZYY4R
MO[@^!![DQ[;J0]8S3WM=$:.8T"3&)%&BRXAD6/#<XUZ0AIQ"S"-[3$86[PT<
MA^'/7L8Z"!V[8M<HX>0-<FB+G6X)-#&;'4:>7;%[U&BT+=O=!JE-6'51X+H7
MP/<3S#;A RC ;;2A7>KHMKSI)M_-1+IK<QUU0E)]U%^WW@:*@]1+$C]G6(;:
MD299C#,J/,P23Q F0BG-3@I'^(Q\7C20$6OR"_D.=K#$SDMYWG^(O (G84?)
M0)+F2%63CMCA*,OR4FPFS:5TQ+K#C$E7V]HIOGOZ32G<MH/CNNVB9-)C+ AQ
M*D-E]D:A+H^G*4ZHS'/"19XFH&Z5)V",?AWXS;8QY2F&F&F:"\F$7@)J"CMH
M([28["'&D>R?@C"I//>0>"BC?8]:MJOHNDZ^T;@NNL2_NZ+^L\L>Y9R() @\
MG.3*JB!"QIAY'L>ZO4(L?3^0L5$+<$-X(\OC&CK: X\T?& ;A0&VF4FJ0V;
MI+:'#R,431N2Z:HKP@"T:3LAF)%^U/W <)F=S#==<-9M9@M9;[I#2U_PQ,\P
M\[FN>LZTK#.&J><Q/TR4"^%1B*R?@3.RC+=]G'@+"\VWX&$2?HY)9I+M@'28
M1+=4[T <X2P>(,J1_)Z#,JG<#I!Z**]#C]O)Z>^T*O1)KV_EFUR,)(Q2/^8>
M#D)*=&H.Q9D72LPSSH7@:2(YJ%_4(8"1)7,-KLW3@"2HG.6(F31>0B=,#$$D
M@@7P'!V.).]H^TE%[AQQA[)V]CD[(6L;P'U>JMV:656PL;]G5H^9Z]5T)-Q
M'&4V[P!5CCZW<U F_>H&2#W\^(8>MVR$K+OEM(,WWZZJ8O'0YF"U SD_R:_-
MK^I9RO,\T/5209PJ^XQ[&::AX%CI?B^2<4:#'*3^S<".?"AH(%2]*MU8DW>3
M<-N!U-8C< W9:2;A[ID$#,\VC;U:!%"+09?BN!V7J]!HGW!PM61'MZLNR&9
MI^V"#&+$41=DV.J)Q^UVHQ??EU4NB^5*C_]=3V@E@A$9RAS+@.1*V; (TS3+
M<>X+G^0Y\95'N)ZL>P_0.>Y1-9*]_4FZ]W ]U0&>;*)NSZLQ5%ROQ.G7FI.[
MF82[@_AW-0YWF*^O/?FV!\-_C"&WPRQV-L_6 )3]P"8_8/?%<BYG/N&$19[
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MJ-8J2$Q5A<W* :K/)^HR<Z^EWTQZ.>/ I'*KXS6FZ0HD%U9[=2%T;0#@78U
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M=ERGS'>!5IK8_%9JEN<O\@5@QJMAYI /4@]Q.7'NG%@_?*#V^9K[&^>26^?
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M>[Q3'G[:^[)E93JCYDART C"-5350,(,E//C"<J@->(* \!FA!>N5UPXRC
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MQY[54\;+]GUU!X[OSR7'[-OF[[@LY'WT/=YQ;Y4'+LTQ29$;IUQFT7@(^T&
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M%F!Z#I"JFN+;D17,$AQXD(UM6RZ< QLW3LW(3=.R8%)H8/, QV_(7@ (+VI
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M/0P0QE&./#_@W,U"GKN@SG-CQ&SGJIR1EOFC3)X^"CD$1&?$\:C4%(VJ(5D
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MK;$ON,*3#<+F9%O[2O>0,F[.SU!FIX'8.T#/'1S($B)#L>ER0(=PHD AIL)
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MLJVA>@2YHQ<H/AEHGTJGXQ?<;]]A+MG]M+@G=>X#IEE8K:9EFC9\UB87]TC
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M\7[@Z" 9J4J1*I(4A@QG&_$Q;H+/$Z-X="!TL!GVZ%0^23H(*16'Z)@#Q3!
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M6X[[:#D^\_[Z=Z^^BD<=41%L>;V/U36%R @)#"EZB3Y19-$Z >Y>8L;.BVZ
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M#C !PTVS'00 Q\BO&_U?!; IDJEL)6!]\%8L.P@F%DCT1SHS979"[0> ?4W
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M>#FLX]X^RNLBM6&GKH87%W0;@:X^+=9A=O7O:U#[=K'^W[B^['DX*5$6Q46
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M)N#Q9Y([[[?K1[>@3/D2BW>OL.<3R<'$'_D*0DN=)9F>;):X>.L[6!SW?_%
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M %!+ 0(4 Q0    ( .1%9%DP;3MQN <  (TB   2              "  0
M  !E>&AI8FET,S$Q<3,R-"YH=&U02P$"% ,4    " #D1619L3E5L; '  "W
M(@  $@              @ 'H!P  97AH:6)I=#,Q,G$S,C0N:'1M4$L! A0#
M%     @ Y$5D65XF" ?5!   "!0  !(              ( !R \  &5X:&EB
M:70S,C%Q,S(T+FAT;5!+ 0(4 Q0    ( .1%9%EZ<X3BV@0  %L4   2
M          "  <T4  !E>&AI8FET,S(R<3,R-"YH=&U02P$"% ,4    " #D
M1619X?KCYFT9 @"Z^1( $0              @ '7&0  =G)N82TR,#(T,#DS
M,"YH=&U02P$"% ,4    " #D1619D7>^LN@+  !M=   $0
M@ %S,P( =G)N82TR,#(T,#DS,"YX<V102P$"% ,4    " #D1619H'4?JX05
M   :Q   %0              @ &*/P( =G)N82TR,#(T,#DS,%]C86PN>&UL
M4$L! A0#%     @ Y$5D61+XKCQW(P  7&\! !4              ( !054"
M '9R;F$M,C R-# Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( .1%9%D?M9L#_ ,"
M .%F @ 4              "  >MX @!V<FYA+3(P,C0P.3,P7V<Q+FIP9U!+
M 0(4 Q0    ( .1%9%EC[H#L3)X  ,%-!@ 5              "  1E]! !V
M<FYA+3(P,C0P.3,P7VQA8BYX;6Q02P$"% ,4    " #D1619X(6WM:%5  !4
M 00 %0              @ &8&P4 =G)N82TR,#(T,#DS,%]P<F4N>&UL4$L%
3!@     +  L S (  &QQ!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>vrna-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:vrna="http://veronapharma.com/20240930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vrna-20240930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vrna:SpecialtyPharmaciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vrna:SpecialtyPharmaciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-09</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-27</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-27</startDate>
            <endDate>2023-12-27</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermELoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermELoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:DebtPrepaymentPeriodAxis">vrna:DebtPrepaymentPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:A2024TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:OaktreeFundAdministrationLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:OaktreeFundAdministrationLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">vrna:DavidZaccardelliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">vrna:MarkHahnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>vrna:subsidiary</measure>
    </unit>
    <unit id="segment">
        <measure>vrna:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2024</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-30">0001657312</dei:EntityCentralIndexKey>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-527">Subsequent events&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"&gt;[OPEN]&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:TrdArrDuration contextRef="c-126" id="f-532">P357D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-127" id="f-533">P359D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38067</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Verona Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">98-1489389</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3 More London Riverside</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">SE1 2RE</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c-1" id="f-12">GB</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="c-1" id="f-13">44</dei:CountryRegion>
    <dei:CityAreaCode contextRef="c-1" id="f-14">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">283 4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Ordinary shares, nominal value &#xa3;0.05 per share*</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">VRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">654649358</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">336040000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">271772000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">6904000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">7964000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">3617000</us-gaap:PrepaidExpenseCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">5587000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">10954000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">4315000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">3443000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">3365000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">364253000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">289708000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">40000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">24000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">1980000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">2847000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">17565000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">18416000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">381818000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">308124000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">6831000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">3492000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">18143000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">3585000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">169000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">952000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">1180000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">1011000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">844000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">435000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">27950000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">8692000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">120009000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">48374000</us-gaap:LongTermDebtNoncurrent>
    <vrna:SecuritesPurchasedNoncurrentRevenueInterest contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">102019000</vrna:SecuritesPurchasedNoncurrentRevenueInterest>
    <vrna:SecuritesPurchasedNoncurrentRevenueInterest contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">0</vrna:SecuritesPurchasedNoncurrentRevenueInterest>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">1349000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">1775000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">223377000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">50149000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-79" unitRef="usd">251327000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">58841000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-81" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-82" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-83"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-84"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-85" unitRef="shares">667659630</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-86" unitRef="shares">667659630</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-87" unitRef="shares">654649358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-88" unitRef="shares">643536094</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">42771000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">42771000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">621628000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">601063000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">828000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">1517000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-95" unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-97" unitRef="usd">-528479000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">-388433000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-99" unitRef="usd">130491000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">249283000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-101" unitRef="usd">381818000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">308124000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">5624000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-3" id="f-104" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">5624000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-3" id="f-106" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">543000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-6" decimals="-3" id="f-108" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">543000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-7" decimals="-3" id="f-110" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <vrna:ResearchAndDevelopmentExpenseNetOfAdjustments contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">10552000</vrna:ResearchAndDevelopmentExpenseNetOfAdjustments>
    <vrna:ResearchAndDevelopmentExpenseNetOfAdjustments contextRef="c-6" decimals="-3" id="f-112" unitRef="usd">2958000</vrna:ResearchAndDevelopmentExpenseNetOfAdjustments>
    <vrna:ResearchAndDevelopmentExpenseNetOfAdjustments contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">36704000</vrna:ResearchAndDevelopmentExpenseNetOfAdjustments>
    <vrna:ResearchAndDevelopmentExpenseNetOfAdjustments contextRef="c-7" decimals="-3" id="f-114" unitRef="usd">13094000</vrna:ResearchAndDevelopmentExpenseNetOfAdjustments>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">35196000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-116" unitRef="usd">13353000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">104665000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-118" unitRef="usd">35381000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">46291000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-120" unitRef="usd">16311000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">141912000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-122" unitRef="usd">48475000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">-40667000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-124" unitRef="usd">-16311000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">-136288000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">-48475000</us-gaap:OperatingIncomeLoss>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">1612000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit contextRef="c-6" decimals="-3" id="f-128" unitRef="usd">-309000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">3044000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit contextRef="c-7" decimals="-3" id="f-130" unitRef="usd">70000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-5" decimals="-3" id="f-131" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-6" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">-3653000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-7" decimals="-3" id="f-134" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-135" unitRef="usd">4750000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-6" decimals="-3" id="f-136" unitRef="usd">3390000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">11268000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">9469000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense contextRef="c-5" decimals="-3" id="f-139" unitRef="usd">9882000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-3" id="f-140" unitRef="usd">401000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">13225000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-3" id="f-142" unitRef="usd">1434000</us-gaap:InterestExpense>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases contextRef="c-5" decimals="-3" id="f-143" unitRef="usd">1475000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases contextRef="c-6" decimals="-3" id="f-144" unitRef="usd">-1012000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">1281000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases contextRef="c-7" decimals="-3" id="f-146" unitRef="usd">660000</vrna:ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-147" unitRef="usd">-2045000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-148" unitRef="usd">1668000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-149" unitRef="usd">-1285000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-150" unitRef="usd">8765000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-151" unitRef="usd">-42712000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-152" unitRef="usd">-14643000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">-137573000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-154" unitRef="usd">-39710000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-155" unitRef="usd">250000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-156" unitRef="usd">44000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">2018000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-158" unitRef="usd">527000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-159" unitRef="usd">-42962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-160" unitRef="usd">-14687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">-139591000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-162" unitRef="usd">-40237000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-163"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-164"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-167"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-171" unitRef="shares">651944000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-172" unitRef="shares">651944000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-173" unitRef="shares">638239000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-174" unitRef="shares">638239000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-175" unitRef="shares">638239000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-176" unitRef="shares">638239000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-177" unitRef="shares">648633000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-178" unitRef="shares">648633000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-179" unitRef="shares">631448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-180" unitRef="shares">631448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-181" unitRef="shares">631448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-182" unitRef="shares">631448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="0" id="f-183" unitRef="shares">667659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-184" unitRef="usd">42771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-185" unitRef="usd">601063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-186" unitRef="usd">-1517000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-187" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-188" unitRef="usd">-388433000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-189" unitRef="usd">249283000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-190" unitRef="usd">-25794000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-191" unitRef="usd">-25794000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-15" decimals="-3" id="f-192" unitRef="usd">170000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-193" unitRef="usd">-170000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-194" unitRef="usd">751000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-3" id="f-195" unitRef="usd">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-196" unitRef="usd">816000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-16" decimals="-3" id="f-197" unitRef="usd">3338000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-14" decimals="-3" id="f-198" unitRef="usd">3338000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation contextRef="c-16" decimals="-3" id="f-199" unitRef="usd">237000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation contextRef="c-14" decimals="-3" id="f-200" unitRef="usd">237000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-201" unitRef="usd">4258000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-202" unitRef="usd">4258000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-17" decimals="0" id="f-203" unitRef="shares">667659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-204" unitRef="usd">42771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-205" unitRef="usd">602497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-206" unitRef="usd">-1282000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-207" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-208" unitRef="usd">-414397000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-209" unitRef="usd">224988000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-23" decimals="0" id="f-210" unitRef="shares">667659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-211" unitRef="usd">42771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-212" unitRef="usd">616618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-213" unitRef="usd">-1203000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-214" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-215" unitRef="usd">-485311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-216" unitRef="usd">168274000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-217" unitRef="usd">-42962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">-42962000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-30" decimals="-3" id="f-219" unitRef="usd">206000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-29" decimals="-3" id="f-220" unitRef="usd">-206000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-31" decimals="-3" id="f-221" unitRef="usd">3499000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-3" id="f-222" unitRef="usd">169000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-223" unitRef="usd">3668000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-31" decimals="-3" id="f-224" unitRef="usd">5600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-225" unitRef="usd">5600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation contextRef="c-31" decimals="-3" id="f-226" unitRef="usd">543000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation contextRef="c-5" decimals="-3" id="f-227" unitRef="usd">543000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-31" decimals="-3" id="f-228" unitRef="usd">7654000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-229" unitRef="usd">7654000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-32" decimals="0" id="f-230" unitRef="shares">667659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-231" unitRef="usd">42771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-232" unitRef="usd">621628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-233" unitRef="usd">-828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-234" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-235" unitRef="usd">-528479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-236" unitRef="usd">130491000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-37" decimals="0" id="f-237" unitRef="shares">631338246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-238" unitRef="usd">40526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-239" unitRef="usd">529187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-240" unitRef="usd">-1549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-241" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-242" unitRef="usd">-333097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-243" unitRef="usd">230466000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-43" decimals="-3" id="f-244" unitRef="usd">-16743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-44" decimals="-3" id="f-245" unitRef="usd">-16743000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-45" decimals="0" id="f-246" unitRef="shares">20321384</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-45" decimals="-3" id="f-247" unitRef="usd">1227000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-46" decimals="-3" id="f-248" unitRef="usd">55682000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-47" decimals="-3" id="f-249" unitRef="usd">56909000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-48" decimals="-3" id="f-250" unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-43" decimals="-3" id="f-251" unitRef="usd">-270000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-49" decimals="-3" id="f-252" unitRef="usd">1756000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-48" decimals="-3" id="f-253" unitRef="usd">71000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-44" decimals="-3" id="f-254" unitRef="usd">1827000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-3" id="f-255" unitRef="usd">4290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-44" decimals="-3" id="f-256" unitRef="usd">4290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-50" decimals="0" id="f-257" unitRef="shares">651659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-258" unitRef="usd">41753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-259" unitRef="usd">590915000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-260" unitRef="usd">-1208000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-261" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-262" unitRef="usd">-350110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-263" unitRef="usd">276749000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-56" decimals="-3" id="f-264" unitRef="usd">-8807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-57" decimals="-3" id="f-265" unitRef="usd">-8807000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-58" decimals="-3" id="f-266" unitRef="usd">226000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-56" decimals="-3" id="f-267" unitRef="usd">-226000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-59" decimals="-3" id="f-268" unitRef="usd">70000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-58" decimals="-3" id="f-269" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-57" decimals="-3" id="f-270" unitRef="usd">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-59" decimals="-3" id="f-271" unitRef="usd">5074000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-57" decimals="-3" id="f-272" unitRef="usd">5074000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-60" decimals="0" id="f-273" unitRef="shares">651659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-274" unitRef="usd">41753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-3" id="f-275" unitRef="usd">596059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-3" id="f-276" unitRef="usd">-975000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-277" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-3" id="f-278" unitRef="usd">-359143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-65" decimals="-3" id="f-279" unitRef="usd">273093000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-66" decimals="-3" id="f-280" unitRef="usd">-14687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-281" unitRef="usd">-14687000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-67" decimals="-3" id="f-282" unitRef="usd">223000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-66" decimals="-3" id="f-283" unitRef="usd">-223000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-68" decimals="-3" id="f-284" unitRef="usd">42000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-67" decimals="-3" id="f-285" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-286" unitRef="usd">48000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-68" decimals="-3" id="f-287" unitRef="usd">5079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-288" unitRef="usd">5079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-69" decimals="0" id="f-289" unitRef="shares">651659630</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-3" id="f-290" unitRef="usd">41753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-70" decimals="-3" id="f-291" unitRef="usd">601180000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-71" decimals="-3" id="f-292" unitRef="usd">-746000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-3" id="f-293" unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-73" decimals="-3" id="f-294" unitRef="usd">-374053000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-74" decimals="-3" id="f-295" unitRef="usd">263533000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">-139591000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-297" unitRef="usd">-40237000</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">1281000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-7" decimals="-3" id="f-299" unitRef="usd">660000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">777000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-7" decimals="-3" id="f-301" unitRef="usd">103000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AccretionExpense contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">5511000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="c-7" decimals="-3" id="f-303" unitRef="usd">0</us-gaap:AccretionExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">120000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-7" decimals="-3" id="f-305" unitRef="usd">84000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">-3653000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-7" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">27506000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-309" unitRef="usd">14443000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">799000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-311" unitRef="usd">469000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">6904000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">4347000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-7" decimals="-3" id="f-315" unitRef="usd">833000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-5590000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent contextRef="c-7" decimals="-3" id="f-317" unitRef="usd">70000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">4315000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-7" decimals="-3" id="f-319" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">832000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-7" decimals="-3" id="f-321" unitRef="usd">2260000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">3435000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-323" unitRef="usd">-2087000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">14742000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-325" unitRef="usd">-6355000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <vrna:IncreaseDecreaseInLicenseAgreementObligations contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">169000</vrna:IncreaseDecreaseInLicenseAgreementObligations>
    <vrna:IncreaseDecreaseInLicenseAgreementObligations contextRef="c-7" decimals="-3" id="f-327" unitRef="usd">0</vrna:IncreaseDecreaseInLicenseAgreementObligations>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">-573000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-7" decimals="-3" id="f-329" unitRef="usd">-484000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">1765000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c-7" decimals="-3" id="f-331" unitRef="usd">-954000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">409000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-7" decimals="-3" id="f-333" unitRef="usd">-979000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">-93367000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-335" unitRef="usd">-39820000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">45000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">-45000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-339" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-341" unitRef="usd">56909000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">122500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-7" decimals="-3" id="f-343" unitRef="usd">9996000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <vrna:ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">100000000</vrna:ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA>
    <vrna:ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA contextRef="c-7" decimals="-3" id="f-345" unitRef="usd">0</vrna:ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">6915000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-7" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">52256000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-7" decimals="-3" id="f-349" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">11191000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-7" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">4484000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-353" unitRef="usd">1952000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">156622000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-355" unitRef="usd">68857000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">1058000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-357" unitRef="usd">502000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">64268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-359" unitRef="usd">29539000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">271772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-42" decimals="-3" id="f-361" unitRef="usd">227827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-362" unitRef="usd">336040000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-74" decimals="-3" id="f-363" unitRef="usd">257366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">249000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-3" id="f-365" unitRef="usd">1215000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">6452000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-7" decimals="-3" id="f-367" unitRef="usd">1228000</us-gaap:InterestPaidNet>
    <vrna:OrganizationAndBusinessDescriptionTextBlock contextRef="c-1" id="f-368">Organization and description of business operations &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Verona Pharma plc is incorporated and domiciled in the United Kingdom. Verona Pharma plc has one wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation (together with Verona Pharma plc, the &#x201c;Company&#x201d;). The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is a biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) are listed on the Nasdaq Global Market (&#x201c;Nasdaq&#x201d;) and trade under the symbol &#x201c;VRNA&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On June 26, 2024, the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (&#x201c;COPD&#x201d;) in adult patients and the Company launched Ohtuvayre in the U.S. through an exclusive network of accredited specialty pharmacies in August 2024. Ohtuvayre is the Company&#x2019;s first commercial product and the first inhaled therapy with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;Pipeline&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is developing a fixed-dose combination formulation with ensifentrine and glycopyrrolate, a Long-Acting Muscarinic Antagonist (&#x201c;LAMA&#x201d;), for the maintenance treatment of patients with COPD via delivery in a nebulizer. The Company has filed patent applications in multiple jurisdictions including the U.S. In the third quarter of 2024, the Company initiated a Phase 2 dose-ranging trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Additionally, based on the clinical results of ensifentrine observed in patients with COPD, including improvements in lung function and symptoms of cough and sputum, the Company believes ensifentrine could potentially be an effective treatment for non-cystic fibrosis bronchiectasis (&#x201c;NCFBE&#x201d;). In the third quarter of 2024, the Company commenced a Phase 2 clinical trial to assess the efficacy and safety of nebulized ensifentrine in patients with NCFBE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception, and has an accumulated deficit of $528.5&#160;million as of September 30, 2024. The Company expects to incur additional losses and negative cash flows from operations until its products reach commercial profitability, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company expects that its cash and cash equivalents as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Additionally, the Company may enter into out-licensing transactions from time to time but there can be no assurance that the Company can secure such transactions in the future. Accordingly, the Company may need to obtain substantial additional funds to achieve its business objectives including to further advance clinical and regulatory activities, to fund launch related costs and to create an effective sales and marketing organization to commercialize Ohtuvayre. Any such funding will need to be obtained through public or private financings, debt financing, collaboration or licensing arrangements or other arrangements. However, there is no guarantee the Company will be successful in securing additional capital on acceptable terms, or at all.&lt;/span&gt;&lt;/div&gt;</vrna:OrganizationAndBusinessDescriptionTextBlock>
    <vrna:NumberOfWhollyOwnedSubsidiaries
      contextRef="c-1"
      decimals="INF"
      id="f-369"
      unitRef="subsidiary">1</vrna:NumberOfWhollyOwnedSubsidiaries>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-370" unitRef="usd">-528500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-371">Basis of presentation and summary of significant accounting policies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K filed on February 29, 2024 (the &#x201c;2023 Form 10-K&#x201d;). The Consolidated Balance Sheet as of December 31, 2023, was derived from audited consolidated financial statements included in the 2023 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#x2019;s significant accounting policies are described in Note 2 to those consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and reportable segment, the development and commercialization of ensifentrine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;For the three and nine months ended September 30, 2024 the Company relied on four specialty pharmacies to purchase and supply Ohtuvayre to patients. These four specialty pharmacies accounted for 100% of all Ohtuvayre net product sales in the three and nine months ended September 30, 2024 and accounted for all of the Company's outstanding accounts receivable from product sales as of September 30, 2024. The loss, or a significant change in the buying patterns, of any one of these specialty pharmacies as a customer could negatively impact the sales of Ohtuvayre.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, gross-to-net revenue adjustments, amortization and carrying value of the revenue interest purchase and sale agreement (&#x201c;RIPSA&#x201d;), and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Inventory, including Pre-Launch Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company values its inventories at the lower of actual cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. When the Company expects to utilize the inventory beyond one year we record it in inventories, long-term on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Prior to obtaining initial regulatory approval for Ohtuvayre, the Company expensed costs relating to production of pre-launch inventory as research and development (&#x201c;R&amp;amp;D&#x201d;) expense in its consolidated statements of operations and comprehensive loss in the period incurred. Inventory acquired and the related costs after June 26, 2024, the date of the FDA&#x2019;s approval of Ohtuvayre, are capitalized. Products used in clinical trials are expensed as research and development expense in the statement of operations and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess or obsolete inventory to its net realizable value in the period in which the impairment is identified through cost of product and other revenue in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Additionally, the Company&#x2019;s product is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of sales in the consolidated statements of operations and comprehensive loss. No inventory was written down as a result of excess, obsolescence, scrap, or other reasons during the three or nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Revenue Interest Purchase and Sale Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The RIPSA is eligible to be repaid based on royalties from net sales of Ohtuvayre (ensifentrine) and any other future products. Interest expense is calculated using the effective interest method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the RIPSA and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of the liability, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s revenues consist of product sales of Ohtuvayre. The Company accounts for contracts with its customers in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Pursuant to ASC 606, for arrangements or transactions between participants determined to be within the scope of the contracts with customers guidance, the Company performs the following five steps to determine the appropriate amount of revenue to be recognized as the Company fulfills its obligations: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s revenue from net product sales was generated in the United States following the FDA&#x2019;s approval for marketing of Ohtuvayre for the treatment of COPD in June 2024. The Company sells Ohtuvayre principally through arrangements with specialty pharmacies (&#x201c;SPs&#x201d;), who are the Company&#x2019;s customers. The customers subsequently resell the product to patients and health care providers. The Company applies the ASC 606 five step process discussed above to the contracts with SPs. The Company provides limited right of return to the customers in cases of shipment errors or expiring or defective products. Product revenues are recognized when the customers take control of the product, which occurs upon delivery to the customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company recognizes revenue from product sales at the net sales price which includes estimates of variable consideration for which reserves are established and reflects each of these as a reduction to revenue. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;results in the future vary from estimates, the Company may need to adjust its estimates, which would affect net revenue in the period of adjustment. The following are the Company&#x2019;s significant categories of variable consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Distribution Fees: The Company pays distribution fees to SPs in connection with the sales of its product. These distributor fees are based on a contractually determined fixed percentage of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Government rebates and chargebacks: The Company contracts with Medicaid, Medicare, and other government agencies (&#x201c;Government Payors&#x201d;) so that Ohtuvayre will be eligible for purchase by, or partial or full reimbursement from, such Government Payors. The Company estimates the rebates, chargebacks and discounts it will provide to Government Payors and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates these reserves based upon its contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Commercial Chargebacks: Chargebacks are discounts and fees related to contracts with various third-party payers and programs that purchase from SPs at a discounted price. SPs charge back to the Company the difference between the price initially paid by SPs and the discounted price paid to SPs by these entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Product Returns: Consistent with industry practice, the Company offers SPs limited product return rights for shipment errors or expiring or defective products. The Company makes a reasonable estimate of future potential product returns based on inventory reports from SPs, visibility into the inventory distribution channel, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Co-pay assistance: Other incentives which the Company offers include voluntary patient assistance and assurance programs, such as a co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other fees: Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;License Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s revenue may also at times consist of revenue from the Company&#x2019;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements may include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently issued accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-372">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The unaudited condensed consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiary Verona Pharma, Inc. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;) and should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K filed on February 29, 2024 (the &#x201c;2023 Form 10-K&#x201d;). The Consolidated Balance Sheet as of December 31, 2023, was derived from audited consolidated financial statements included in the 2023 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company&#x2019;s significant accounting policies are described in Note 2 to those consolidated financial statements.&lt;/span&gt;&lt;/div&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and shareholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-373">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and reportable segment, the development and commercialization of ensifentrine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;For the three and nine months ended September 30, 2024 the Company relied on four specialty pharmacies to purchase and supply Ohtuvayre to patients. These four specialty pharmacies accounted for 100% of all Ohtuvayre net product sales in the three and nine months ended September 30, 2024 and accounted for all of the Company's outstanding accounts receivable from product sales as of September 30, 2024. The loss, or a significant change in the buying patterns, of any one of these specialty pharmacies as a customer could negatively impact the sales of Ohtuvayre.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-374"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-375"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-376" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-377" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-378">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, gross-to-net revenue adjustments, amortization and carrying value of the revenue interest purchase and sale agreement (&#x201c;RIPSA&#x201d;), and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Inventory, including Pre-Launch Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company values its inventories at the lower of actual cost or net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. When the Company expects to utilize the inventory beyond one year we record it in inventories, long-term on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Prior to obtaining initial regulatory approval for Ohtuvayre, the Company expensed costs relating to production of pre-launch inventory as research and development (&#x201c;R&amp;amp;D&#x201d;) expense in its consolidated statements of operations and comprehensive loss in the period incurred. Inventory acquired and the related costs after June 26, 2024, the date of the FDA&#x2019;s approval of Ohtuvayre, are capitalized. Products used in clinical trials are expensed as research and development expense in the statement of operations and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and writes down any excess or obsolete inventory to its net realizable value in the period in which the impairment is identified through cost of product and other revenue in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Additionally, the Company&#x2019;s product is subject to strict quality control and monitoring that is performed throughout the manufacturing process, including release of work-in-process to finished goods. In the event that certain batches or units of product do not meet quality specifications, the Company will record a write-down of any potential unmarketable inventory to its estimated net realizable value and record the expense as cost of sales in the consolidated statements of operations and comprehensive loss. No inventory was written down as a result of excess, obsolescence, scrap, or other reasons during the three or nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Revenue Interest Purchase and Sale Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The RIPSA is eligible to be repaid based on royalties from net sales of Ohtuvayre (ensifentrine) and any other future products. Interest expense is calculated using the effective interest method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the RIPSA and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of the liability, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s revenues consist of product sales of Ohtuvayre. The Company accounts for contracts with its customers in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Pursuant to ASC 606, for arrangements or transactions between participants determined to be within the scope of the contracts with customers guidance, the Company performs the following five steps to determine the appropriate amount of revenue to be recognized as the Company fulfills its obligations: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s revenue from net product sales was generated in the United States following the FDA&#x2019;s approval for marketing of Ohtuvayre for the treatment of COPD in June 2024. The Company sells Ohtuvayre principally through arrangements with specialty pharmacies (&#x201c;SPs&#x201d;), who are the Company&#x2019;s customers. The customers subsequently resell the product to patients and health care providers. The Company applies the ASC 606 five step process discussed above to the contracts with SPs. The Company provides limited right of return to the customers in cases of shipment errors or expiring or defective products. Product revenues are recognized when the customers take control of the product, which occurs upon delivery to the customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company recognizes revenue from product sales at the net sales price which includes estimates of variable consideration for which reserves are established and reflects each of these as a reduction to revenue. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates. If actual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;results in the future vary from estimates, the Company may need to adjust its estimates, which would affect net revenue in the period of adjustment. The following are the Company&#x2019;s significant categories of variable consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Distribution Fees: The Company pays distribution fees to SPs in connection with the sales of its product. These distributor fees are based on a contractually determined fixed percentage of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Government rebates and chargebacks: The Company contracts with Medicaid, Medicare, and other government agencies (&#x201c;Government Payors&#x201d;) so that Ohtuvayre will be eligible for purchase by, or partial or full reimbursement from, such Government Payors. The Company estimates the rebates, chargebacks and discounts it will provide to Government Payors and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates these reserves based upon its contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix, resulting in a reduction of product revenue and the establishment of a current liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Commercial Chargebacks: Chargebacks are discounts and fees related to contracts with various third-party payers and programs that purchase from SPs at a discounted price. SPs charge back to the Company the difference between the price initially paid by SPs and the discounted price paid to SPs by these entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Product Returns: Consistent with industry practice, the Company offers SPs limited product return rights for shipment errors or expiring or defective products. The Company makes a reasonable estimate of future potential product returns based on inventory reports from SPs, visibility into the inventory distribution channel, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Co-pay assistance: Other incentives which the Company offers include voluntary patient assistance and assurance programs, such as a co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug co-payments required by payers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other fees: Fees payable to third party payers and healthcare providers, along with fees to our direct customers that are settled via cash payments, including certain patient assistance programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;License Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s revenue may also at times consist of revenue from the Company&#x2019;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements may include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently issued accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-379">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-380" unitRef="usd">4315000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-381" unitRef="usd">4315000</us-gaap:InventoryNet>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently issued accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-383">Equity interest &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company entered into a collaboration and license agreement (the &#x201c;Nuance Agreement&#x201d;) with Nuance Pharma Limited (&#x201c;Nuance Pharma&#x201d;) effective June 9, 2021 (the &#x201c;Effective Date&#x201d;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The equity interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company evaluates this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;Ligand license agreement obligations&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In 2006, the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#x201c;Ligand&#x201d;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#x201c;Ligand Patents&#x201d;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#x201c;Ligand Licensed Products&#x201d;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The contingent liability assumed included a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Due to the FDA approval of Ohtuvayre on June 26, 2024, the Company has recognized the following in the nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt"&gt;$6.3&#160;million in research and development costs related to a milestone payment for first regulatory approval of ensifentrine; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt"&gt;$15.0&#160;million related to a milestone payment for first commercial sale of ensifentrine. The Company has classified this as selling, general and administrative expense as it relates to the resolution of the 2021 dispute with Ligand. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is obligated to pay low single digit royalties based on the net sales of all Ligand Licensed Products and expenses all costs related to royalty amounts as a cost of sales within the income statement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-77" decimals="-5" id="f-384" unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-77" decimals="-5" id="f-385" unitRef="usd">25000000</us-gaap:AccountsReceivableNetCurrent>
    <vrna:EquityInterestReceivable contextRef="c-77" decimals="-5" id="f-386" unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-387">Accrued expenses&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.617%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-388">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.617%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent contextRef="c-3" decimals="-3" id="f-389" unitRef="usd">6414000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent contextRef="c-4" decimals="-3" id="f-390" unitRef="usd">752000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent contextRef="c-3" decimals="-3" id="f-391" unitRef="usd">4463000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent contextRef="c-4" decimals="-3" id="f-392" unitRef="usd">2039000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-393" unitRef="usd">7266000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-394" unitRef="usd">794000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-395" unitRef="usd">18143000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-396" unitRef="usd">3585000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-78" decimals="-3" id="f-397" unitRef="usd">6300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-79" decimals="-3" id="f-398" unitRef="usd">6300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-78" decimals="-3" id="f-399" unitRef="usd">15000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-79" decimals="-3" id="f-400" unitRef="usd">15000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-401">Debt&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"&gt;2023 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On December 27, 2023 (the &#x201c;2023 Effective Date&#x201d;), Verona Pharma, Inc. entered into a term loan facility of up to $400.0&#160;million (the &#x201c;2023 Term Loan&#x201d; or &#x201c;Loan Agreement&#x201d;), consisting of a term loan advance in an aggregate amount of $50.0&#160;million funded on the 2023 Effective Date (the &#x201c;Term A Loan&#x201d;) and four additional term loan advances subject to certain terms and conditions. The 2023 Term Loan was repaid in full as of May 9, 2024. Verona Pharma, Inc. and the Company did not incur any penalties, but did incur a prepayment fee and final payment fee in the aggregate amount of $2.3&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"&gt;2024 Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On May 9, 2024 (the &#x201c;2024 Effective Date&#x201d;), Verona Pharma, Inc. (the &#x201c;Borrower&#x201d;) entered into a term loan facility of up to $400.0&#160;million (the &#x201c;2024 Term Loans&#x201d; or &#x201c;2024 Loan Agreement&#x201d;), consisting of a term loan advance in an aggregate amount of $55.0&#160;million funded on the 2024 Effective Date (the &#x201c;Tranche A Term Loan&#x201d;) and four additional term loan advances subject to certain terms and conditions, as discussed below, in the amounts of $70.0&#160;million (the &#x201c;Tranche B Term Loan&#x201d;), $75.0&#160;million (the &#x201c;Tranche C Term Loan&#x201d;), $100.0&#160;million (the &#x201c;Tranche D Term Loan&#x201d;) and $100.0&#160;million (the &#x201c;Tranche E Term Loan&#x201d;) with each tranche issued subject to an original issue discount of 2.0%. The 2024 Loan Agreement was entered into with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agent (in such capacity, the &#x201c;Agent&#x201d;), and certain funds managed by each of Oaktree Capital Management, L.P. (&#x201c;Oaktree&#x201d;) and OCM Life Sciences Portfolio LP (&#x201c;OMERS&#x201d;) party thereto (collectively, the &#x201c;2024 Lenders&#x201d;). The net proceeds of the 2024 Term Loans will be used for general corporate and working capital purposes and a portion of the proceeds from the Tranche A Term Loan was used by the Borrower on the 2024 Effective Date to repay, in full, the existing outstanding indebtedness owed under the 2023 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Tranche B Term Loan was available, subject to customary terms and conditions, during the period commencing on the date the Company received approval from the FDA for its new drug application for ensifentrine through and including the earliest of (i) the date that is 30 days immediately following the date the Company receives such approval and (ii) September 30, 2024. The Tranche C Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche B Term Loan), during the period commencing on the first business day following the achievement of a specified net sales milestone for ensifentrine and ending on December 31, 2025. The Tranche D Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche C Term Loan), during the period commencing on the first business day following the achievement of a specified net sales milestone for ensifentrine and ending on June 30, 2026. The Tranche E Term Loan will be available, subject to customary terms and conditions (including the prior borrowing of the Tranche D Term Loan) at the 2024 Lenders sole discretion and upon the Company&#x2019;s request. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company received $52.8&#160;million in net proceeds at closing of the 2024 Loan Agreement and draw of the Tranche A Term Loan, which consisted of the Tranche A Term Loan face value of $55.0&#160;million less the original issue discount of $1.1&#160;million and lender and third-party fees related to the 2024 Loan Agreement and RIPSA, as defined and discussed below, of $1.1&#160;million. $52.4&#160;million of the net cash proceeds from the Tranche A Term Loan were used for the repayment in full of the existing outstanding indebtedness owed by the Company under the 2023 Term Loan of $52.3&#160;million and interest amounts related to the 2023 Term Loan of $0.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On June 28, 2024, the Company received $68.6&#160;million in net proceeds related to the Tranche B Term Loan, which was available upon FDA approval for Ohtuvayre. The amount received consisted of the Tranche B Term Loan face value of $70.0&#160;million less the original issue discount of $1.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The 2024 Term Loans will mature on May 9, 2029 and each advance under the 2024 Loan Agreement accrues interest at a fixed per annum rate of 11.00%. The 2024 Loan Agreement provides for interest-only payments on a quarterly basis until maturity. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrower shall pay an exit fee to the 2024 Lenders in the amount of 2.50% of the aggregate principal amount of the 2024 Term Loans to be paid (the &#x201c;Exit Fee&#x201d;). The Borrower may prepay the 2024 Term Loans in full or in part provided that the Borrower (i) provides at least two (2) business days&#x2019; prior written notice to the Agent, (ii) pays on the date of such prepayment (A) all outstanding principal to be prepaid plus accrued and unpaid interest, (B) a prepayment fee of 7.00% of the 2024 Term Loans so prepaid if paid on or before the first anniversary of the 2024 Effective Date; 5.00% of the 2024 Term Loans so prepaid if paid after the first anniversary of the 2024 Effective Date and on or before the second anniversary of the 2024 Effective Date; 2.00% of the 2024 Term Loans so prepaid &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;if paid after the second anniversary of the 2024 Effective Date and on or before the third anniversary of the 2024 Effective Date or 1.00% of the 2024 Term Loans so prepaid if paid after the third anniversary of the 2024 Effective Date and on or before the fourth anniversary of the 2024 Effective Date, (C) the Exit Fee and (D) all other sums, if any, that shall become due and payable under the 2024 Loan Agreement, including interest at the default rate with respect to any past due amounts. Amounts outstanding during an event of default are due upon the Majority Lenders&#x2019; (as defined in the 2024 Loan Agreement) demand (except during a payment or bankruptcy event of default, whereupon such default interest is automatically imposed) and shall accrue interest at an additional rate of 2.00% per annum, which interest shall be payable on demand in cash and (iii) any partial prepayment of the 2024 Term Loans shall be an aggregate amount at least equal to $5.0&#160;million in a denomination that is a whole number multiple of $1.0&#160;million in excess thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The 2024 Term Loans are secured by a lien on substantially all of the assets of the Borrower and the Company, including intellectual property, subject to customary exclusions and exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The 2024 Loan Agreement contains customary representations and warranties, covenants and events of default, including two financial covenants: (i) commencing on the 2024 Effective Date, the Borrower is required to maintain certain levels of cash, and, after the Account Control Agreement Completion Date (as defined in the Loan Agreement) subject to control agreements in favor of the Agent, and (ii) commencing on the fiscal quarter of Company ending on September 30, 2025, the Borrower and the Company are required to maintain quarterly trailing twelve-month net sales from the sale of ensifentrine in the United States; provided that such revenue covenant will be waived at any time (x) the Borrower and the Company&#x2019;s unrestricted cash balance subject to control agreements in favor of the Agent on the last business day of the applicable fiscal quarter is equal to or greater than the product of 1.25 multiplied by the aggregate principal amount of outstanding 2024 Term Loans on such date or (y) the average daily closing price of the Company&#x2019;s American Depositary Shares for each of the thirty (30) trading days preceding the last trading day of such fiscal quarter multiplied by the total number of issued and outstanding American Depositary Shares of the Company is at least $1.0&#160;billion. The 2024 Loan Agreement also contains other customary provisions, such as expense reimbursement, as well as indemnification rights for the benefit of the Agent and the 2024 Lenders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As of September 30, 2024, the effective interest rate was approximately 13% per annum and there was no material difference between the carrying value and the estimated fair value of the 2024 Term Loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"&gt;Revenue Interest Purchase and Sale Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On May 9, 2024, the Company and Verona Pharma, Inc. (collectively the &#x201c;Sellers&#x201d;) entered into the RIPSA with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agent and certain funds managed by each of Oaktree and OMERS (collectively, the &#x201c;Purchasers&#x201d;). Under the terms of the RIPSA, in exchange for each of the Purchaser&#x2019;s payment to the Sellers of a purchase price of $100&#160;million, in the aggregate, upon approval of ensifentrine by the FDA by a specified date and subject to certain labeling conditions (the &#x201c;Tranche A Purchase Price&#x201d;), the Sellers agreed to a true sale of assigned interests to the Purchasers, including a right for the Purchasers to receive 6.50% on the global net sales of ensifentrine by the Sellers (the &#x201c;Royalty Interest Payments&#x201d;) and 5% on certain proceeds the Sellers receive from licensees engaged during the term of the RIPSA outside of the U.S. (the &#x201c;Ex-U.S. Payments&#x201d;). The Sellers will begin payment of the Royalty Interest Payments and Ex-U.S. Payments in the first fiscal quarter after receipt of the Tranche A Purchase Price. The Sellers will also have a right to receive an additional funding tranche equal to $150&#160;million (the &#x201c;Tranche B Purchase Price&#x201d;) upon achievement of a specified net sales milestone in any trailing six-month period after receipt of the Tranche A Purchase Price and subject to certain terms and conditions. The Royalty Interest Payments and Ex-U.S. Payments will cease upon reaching a multiple of 1.75 times the amounts actually funded by the Purchasers. The RIPSA includes a buy-out option, which provides the Sellers with the right to settle all outstanding liabilities at any time by paying a buy-out amount under various terms and conditions. As of any date of determination, the aggregate amount of payments received by the Purchasers under the RIPSA, divided by the amount funded as of such date (the &#x201c;MOIC&#x201d;) equals 1.20x, if such date is on or before the one-year anniversary of the funding of the first tranche of the RIPSA, the MOIC equals 1.40x if such date is after the one-year anniversary of the Tranche A Funding Date and on or before the two-year anniversary of the Tranche A Funding Date, the MOIC equals 1.55x if such date is after the two-year anniversary of the Tranche A Funding Date and on or before the three-year anniversary of the Tranche A Funding Date, and the MOIC equals 1.75x if such date is after the three-year anniversary of the Tranche A Funding Date. The Purchasers have the right to terminate the RIPSA under certain conditions, including the Company&#x2019;s insolvency, and the Company&#x2019;s divestment of ensifentrine, in which case the Sellers must pay the Purchasers up to 1.75 times the amounts actually funded by the Purchasers as of such default determination date. Pursuant to a security agreement signed in connection with the RIPSA, the Sellers granted to the Purchasers a security interest in certain assets to secure obligations under the RIPSA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On June 28, 2024, the Company received the Tranche A Purchase Price of $100.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As of September 30, 2024, the effective interest rate was approximately 25% per annum and there was no material difference between the carrying value and the estimated fair value of the RIPSA.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-80" decimals="-5" id="f-402" unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-81" decimals="-5" id="f-403" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-82" decimals="-5" id="f-404" unitRef="usd">2300000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-83" decimals="-5" id="f-405" unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-84" decimals="-5" id="f-406" unitRef="usd">55000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-85" decimals="-5" id="f-407" unitRef="usd">70000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-86" decimals="-5" id="f-408" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-87" decimals="-5" id="f-409" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-88" decimals="-5" id="f-410" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c-89" decimals="4" id="f-411" unitRef="number">0.020</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="c-90" decimals="-5" id="f-412" unitRef="usd">52800000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-84" decimals="-5" id="f-413" unitRef="usd">55000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="c-91" decimals="-5" id="f-414" unitRef="usd">1100000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-90" decimals="-5" id="f-415" unitRef="usd">1100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="c-84" decimals="-5" id="f-416" unitRef="usd">52400000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
    <us-gaap:LongTermDebt contextRef="c-82" decimals="-5" id="f-417" unitRef="usd">52300000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt contextRef="c-92" decimals="-5" id="f-418" unitRef="usd">100000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="c-93" decimals="-5" id="f-419" unitRef="usd">68600000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-93" decimals="-5" id="f-420" unitRef="usd">70000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-93" decimals="-5" id="f-421" unitRef="usd">1400000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-94" decimals="4" id="f-422" unitRef="number">0.1100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <vrna:DebtInstrumentExitFeePercentage contextRef="c-95" decimals="4" id="f-423" unitRef="number">0.0250</vrna:DebtInstrumentExitFeePercentage>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyPercent contextRef="c-96" decimals="3" id="f-424" unitRef="number">0.0700</vrna:DebtInstrumentEarlyRepaymentPenaltyPercent>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyPercent contextRef="c-97" decimals="3" id="f-425" unitRef="number">0.0500</vrna:DebtInstrumentEarlyRepaymentPenaltyPercent>
    <vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage contextRef="c-83" decimals="3" id="f-426" unitRef="number">0.0200</vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage>
    <vrna:DebtInstrumentEarlyRepaymentPenaltyPercent contextRef="c-98" decimals="3" id="f-427" unitRef="number">0.0100</vrna:DebtInstrumentEarlyRepaymentPenaltyPercent>
    <vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage contextRef="c-83" decimals="3" id="f-428" unitRef="number">0.0200</vrna:DebtInstrumentDebtDefaultInterestRateStatedPercentage>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-90" decimals="-5" id="f-429" unitRef="usd">5000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <vrna:DebtInstrumentPartialPrepaymentDenominationMultiple contextRef="c-90" decimals="-5" id="f-430" unitRef="usd">1000000</vrna:DebtInstrumentPartialPrepaymentDenominationMultiple>
    <vrna:DebtInstrumentCovenantDebtServiceCoverageRatioMinimum contextRef="c-83" decimals="2" id="f-431" unitRef="number">1.25</vrna:DebtInstrumentCovenantDebtServiceCoverageRatioMinimum>
    <vrna:DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion contextRef="c-99" decimals="-8" id="f-432" unitRef="usd">1000000000</vrna:DebtCovenantAverageDailyVWAPAndAmericanDepositorySharesValueCalcualtion>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-100" decimals="2" id="f-433" unitRef="number">0.13</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <vrna:RevenuesPurchaseAndSaleAgreementPurchasePrice contextRef="c-101" decimals="-5" id="f-434" unitRef="usd">100000000</vrna:RevenuesPurchaseAndSaleAgreementPurchasePrice>
    <vrna:RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales contextRef="c-102" decimals="3" id="f-435" unitRef="number">0.0650</vrna:RevenuesPurchaseAndSaleAgreementPurchaserPercentageGlobalNetSales>
    <vrna:RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees contextRef="c-102" decimals="2" id="f-436" unitRef="number">0.05</vrna:RevenuesPurchaseAndSaleAgreementPurchaserPercentageLicensees>
    <vrna:RevenuesPurchaseAndSaleAgreementAdditionalFunding contextRef="c-101" decimals="-5" id="f-437" unitRef="usd">150000000</vrna:RevenuesPurchaseAndSaleAgreementAdditionalFunding>
    <vrna:RevenuesPurchaseAndSaleAgreementMultiple contextRef="c-102" decimals="2" id="f-438" unitRef="number">1.75</vrna:RevenuesPurchaseAndSaleAgreementMultiple>
    <vrna:RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne contextRef="c-102" decimals="2" id="f-439" unitRef="number">1.20</vrna:RevenuesPurchaseAndSaleAgreementMultipleBeforeYearOne>
    <vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo contextRef="c-102" decimals="2" id="f-440" unitRef="number">1.40</vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearOneBeforeYearTwo>
    <vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree contextRef="c-102" decimals="2" id="f-441" unitRef="number">1.55</vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearTwoBeforeYearThree>
    <vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree contextRef="c-102" decimals="2" id="f-442" unitRef="number">1.75</vrna:RevenuesPurchaseAndSaleAgreementMultipleAfterYearThree>
    <vrna:RevenuesPurchaseAndSaleAgreementMultiple contextRef="c-102" decimals="2" id="f-443" unitRef="number">1.75</vrna:RevenuesPurchaseAndSaleAgreementMultiple>
    <vrna:RevenuesPurchaseAndSaleAgreementPurchasePrice contextRef="c-101" decimals="-5" id="f-444" unitRef="usd">100000000</vrna:RevenuesPurchaseAndSaleAgreementPurchasePrice>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-3" decimals="2" id="f-445" unitRef="number">0.25</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-446">Share-based compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following tables show the activity of each type of share-based compensation and are presented in ordinary shares. The Company&#x2019;s ADSs that are listed on Nasdaq each represent eight ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share options activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,689,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,432,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,037,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,020,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,924,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,712,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,056,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,654,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,005,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Restricted stock units (&#x201c;RSU&#x201d;) activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,502,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,357,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,143,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,045,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,098,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,045,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,486,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Performance restricted stock units (&#x201c;PRSU&#x201d;) activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;PRSUs will begin to vest upon achievement of certain performance conditions and are subject to continued service. The fair value of PRSUs will be recognized over the remaining service period using the graded-vesting method once the performance conditions are determined to be probable of occurring. As of June 30, 2024, the performance conditions were assessed by the Company and considered probable of being met under the applicable accounting framework, and accordingly the Company recognized $2.2&#160;million and $12.1&#160;million in share-based compensation expense related to the PRSUs in the three and nine months ended September 30, 2024. The total compensation cost not yet recognized as of September 30, 2024 related to PRSUs was $5.0 million, which will be recognized over a weighted-average period of approximately one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A summary of the Company&#x2019;s PRSU activity for the period ended September 30, 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of PRSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,730,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,724,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,724,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(420,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,569,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,734,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-447">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-103" decimals="-3" id="f-448" unitRef="usd">790000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-104" decimals="-3" id="f-449" unitRef="usd">1110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-105" decimals="-3" id="f-450" unitRef="usd">5470000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-106" decimals="-3" id="f-451" unitRef="usd">3336000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-107" decimals="-3" id="f-452" unitRef="usd">6864000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-108" decimals="-3" id="f-453" unitRef="usd">3969000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-109" decimals="-3" id="f-454" unitRef="usd">22036000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-110" decimals="-3" id="f-455" unitRef="usd">11107000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-456" unitRef="usd">7654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-457" unitRef="usd">5079000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-458" unitRef="usd">27506000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-459" unitRef="usd">14443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <dei:EntityListingDepositoryReceiptRatio contextRef="c-3" decimals="0" id="f-460" unitRef="number">8</dei:EntityListingDepositoryReceiptRatio>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-461">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,689,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,432,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,037,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,020,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,924,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,712,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,056,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,654,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,005,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="0" id="f-462" unitRef="shares">24689624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-14" decimals="0" id="f-463" unitRef="shares">2432000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-14" decimals="0" id="f-464" unitRef="shares">64000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-14" decimals="0" id="f-465" unitRef="shares">1037424</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-22" decimals="0" id="f-466" unitRef="shares">26020200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-111" decimals="0" id="f-467" unitRef="shares">7924000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-111" decimals="0" id="f-468" unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-111" decimals="0" id="f-469" unitRef="shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-28" decimals="0" id="f-470" unitRef="shares">33712200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-5" decimals="0" id="f-471" unitRef="shares">2056000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-5" decimals="0" id="f-472" unitRef="shares">107632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-5" decimals="0" id="f-473" unitRef="shares">2654960</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="0" id="f-474" unitRef="shares">33005608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-475">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,502,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,357,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,143,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,045,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,098,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,045,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,486,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A summary of the Company&#x2019;s PRSU activity for the period ended September 30, 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of PRSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,730,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,724,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,724,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(420,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,569,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,734,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-112" decimals="0" id="f-476" unitRef="shares">19502624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-113" decimals="0" id="f-477" unitRef="shares">1752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-113" decimals="0" id="f-478" unitRef="shares">4357208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-114" decimals="0" id="f-479" unitRef="shares">15143664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-115" decimals="0" id="f-480" unitRef="shares">2045384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-116" decimals="0" id="f-481" unitRef="shares">13098280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-117" decimals="0" id="f-482" unitRef="shares">566824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-117" decimals="0" id="f-483" unitRef="shares">2045376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-118" decimals="0" id="f-484" unitRef="shares">10486080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-5" id="f-485" unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-5" id="f-486" unitRef="usd">12100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-121" decimals="-3" id="f-487" unitRef="usd">5000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-120" id="f-488">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-122" decimals="0" id="f-489" unitRef="shares">10730144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-123" decimals="0" id="f-490" unitRef="shares">5248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-124" decimals="0" id="f-491" unitRef="shares">10724896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-125" decimals="0" id="f-492" unitRef="shares">10724896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-119" decimals="0" id="f-493" unitRef="shares">420864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-119" decimals="0" id="f-494" unitRef="shares">3569696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-121" decimals="0" id="f-495" unitRef="shares">6734336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-496">et loss per share &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Net loss per share is calculated on an ordinary share basis. The Company&#x2019;s ADSs that are listed on Nasdaq each represent eight ordinary shares. The following table shows the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.258%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;During the three and nine months ended September 30, 2024 and 2023, outstanding share options, RSUs and PRSUs over 50.2 million and 45.9&#160;million ordinary shares, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <dei:EntityListingDepositoryReceiptRatio contextRef="c-3" decimals="0" id="f-497" unitRef="number">8</dei:EntityListingDepositoryReceiptRatio>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-498">The following table shows the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands except per share amounts):&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.258%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-499" unitRef="usd">-42962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-500" unitRef="usd">-14687000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-501" unitRef="usd">-139591000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-502" unitRef="usd">-40237000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-503" unitRef="shares">651944000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-504" unitRef="shares">651944000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-505" unitRef="shares">638239000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-506" unitRef="shares">638239000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-507" unitRef="shares">638239000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-508" unitRef="shares">638239000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-509" unitRef="shares">648633000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-510" unitRef="shares">648633000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-511" unitRef="shares">631448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-512" unitRef="shares">631448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-513" unitRef="shares">631448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-514" unitRef="shares">631448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-515"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-516"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-517"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-518"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-519"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-520"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-521"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-522"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-523" unitRef="shares">50200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-5" id="f-524" unitRef="shares">50200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-5" id="f-525" unitRef="shares">45900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-5" id="f-526" unitRef="shares">45900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-528">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-529">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-530">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-531">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
